Cognition through the (st-)ages by Reichel, Judith
 
Cognition through the (st-)ages: consequences of 
immuno-toxic lesions, protein accumulation and 
environmental stressors 
Judith M. Reichel 
aus  
 Berlin, Deutschland 
München, 09.10.2014 
Dissertation der Fakultät für Biologie der Ludwig-
Maximilians-Universität München zur Erlangung  
des akademischen Grades des Doktors der 
Naturwissenschaften (Dr. rer. nat.)  
Erarbeitet am 
Max-Planck-Institut für Psychiatrie, 
Research Group “Neuronal Plasticity“ 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Erstgutachter: PD Dr. C. T. Wotjak 
Zweitgutachter: Prof. Dr. W. Enard 
Dissertation eingereicht am: 09.10.2014 
Tag der mündlichen Prüfung: 02.03.2015 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
i 
 
Eidesstattliche Erklärung 
 
 
 
Ich versichere hiermit an Eides statt, dass die vorgelegte Dissertation von mir 
selbständig und ohne unerlaubte Hilfe angefertigt worden ist. Des Weiteren 
wurde die hier vorliegende Arbeit gemäß der „Promotionsordnung der Ludwig-
Maximilians-Universität München für die Fakultät für Biologie vom 27. 
November 1991“  von PD Dr. rer. nat. C. T. Wotjak als Mitglied der Fakultät für 
Biologie betreut.  
 
 
 
München, den 09.10.2014         ................................................  
(Unterschrift)  
 
 
 
 
 
 
 
 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
 
 
 “In theory, theory and practice are the same. In practice, they 
are not.” 
- Albert Einstein - 
  
 
 
 
 
 
 
 
 
 
 
 
 
To my family. 
 
iv 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
 
Zusammenfassung 
 
Die Fähigkeit zur Kognition, d.h. des Erlernens und des bewussten Anwendens des Gelernten, steht 
schon seit Jahrhunderten im Zentrum philosophischer, psychologischer und neurobiologischer 
Studien. Die spezifischen zu Grunde liegenden Mechanismen sind jedoch auch heute noch nicht 
vollständig bekannt. 
Bekannt hingegen ist, dass mit zunehmendem Alter die kognitiven Fähigkeiten abnehmen, und dass 
die Anzahl neurodegenerativer Erkrankungen mit zunehmendem Alter in exponentiellem Maße 
ansteigen. Diese neurodegenerativen Erkrankungen, wie z.B. die Alzheimer- oder die Parkinson- 
Erkrankungen, führen zusätzlich zu erheblichen kognitiven Einbußen, so dass die Patienten auf 
externe Hilfe angewiesen sind. Da die Lebenserwartung in unserer Gesellschaft immer weiter 
ansteigt und kognitive Defizite zu enormen persönlichen und ökonomischen Belastungen führen, 
besteht ein großes Interesse an der Aufklärung der neurobiologischen Mechanismen kognitiver 
Prozesse.  
Es gibt mittlerweile viele verschiedene Methoden, um die Grundlagen kognitiver Fähigkeiten zu 
untersuchen; sie reichen von In vitro- Untersuchungen in Zellkulturen, zu In vivo- Untersuchungen in 
Nagetieren und höheren Säugetieren, bis hin zu Untersuchungen am Menschen. Die Studien am 
Menschen sind allerdings oftmals auf non-invasive bildgebende Verfahren wie z. B. die funktionelle 
Magnetresonanztomographie (fMRT) oder Positronen-Emissions-Tomographie (PET) beschränkt. 
Tierstudien hingegen bieten ideale Möglichkeiten, unterschiedliche kognitive Aspekte mittels 
Verhaltensuntersuchungen zu analysieren. Im Besonderen für Nager-Tiermodelle sind eine Reihe von 
kognitiven Tests etabliert, die z.B. speziell das kontextuelle oder räumliche Lernen untersuchen.  
Obwohl viele Erkrankungen kognitive Defizite zur Folge haben können, schädigen neurodegenerative 
Erkrankungen, fortgeschrittenes Alter oder Unfälle das zentrale Nervensystem (ZNS) auf vollkommen 
unterschiedliche (neurophysiologische) Art und Weise. So werden z.B. selektive Fehlfunktionen 
bestimmter neuronaler Subpopulationen für die Entstehung spezifischer Symptome impliziert. Des 
Weiteren treten die mit neurodegenerativen Erkrankungen assoziierten Proteinakkumulationen 
ebenfalls primär in bestimmten neuronalen Subpopulationen auf. Daher haben wir uns für drei 
verschiedene Manipulationsmöglichkeiten des ZNS in Mäusen entschieden, und das folglich 
geänderte (kognitive) Verhalten der Tiere untersucht. Alle Mäuse basierten auf demselben C57Bl/6 
genetischen Hintergrund und ihr ZNS wurde entweder lokal mittels immuno-toxischen Injektionen 
oder exogener Protein-Expression manipuliert, oder aber der gesamte Maus-Organismus wurde 
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extremem Stress ausgesetzt. Alle Mäuse wurden in umfangreichen Verhaltenstest charakterisiert 
und bezüglich ihrer kognitiven Fähigkeiten analysiert. 
Das erste Projekt (i) untersuchte die Konsequenzen lokaler selektiver GABAerger immuno-toxischer 
Läsionen mittels Saporin-konjugierter anti-vesikulärer GABA-Transporter Antikörper (SAVAs). Wo 
immer SAVAs appliziert werden, werden sie selektiv von GABAergen Interneuronen aufgenommen, 
welche sie folglich abtöten. Wurden SAVAs im dorsalen Hippokampus (dHPC) appliziert, verursachte 
dies schwere kognitive Defizite bezüglich des räumlichen Lernens sowie einen vorübergehenden 
hyperaktiven Phänotyp. GABAerge Läsionen mit kürzerer Inkubationsdauer offenbarten zudem eine 
bisher unbekannte funktionelle Differenzierung: GABAerge Interneuronen im dHPC sind absolut 
notwendig für das räumliche Erlernen einer bestimmten Position, nicht aber, um eine bereits 
erlernte räumliche Information wieder abzurufen. SAVA- Applikation im prälimbischen Kortex (PrL) 
hingegen führte zu reduziertem sensorimotor-gating und eingeschränkter kognitiver Flexibilität.   
Basierend auf diesen Ergebnissen untersuchten wir daraufhin, ob eine zelltyp-spezifische 
Manipulation, die weniger lokal begrenzt ist, ähnliche Effekte hervorrufen würde. Daher analysierte 
das zweite Projekt (ii) die Konsequenzen der transgenen Co- Expression eines Reporter-Gens (lacZ), 
welches üblicherweise als Indikator für transgene Modifikationen eingesetzt wird. Diese Mäuse 
wurden sowohl mittels umfangreicher Verhaltenstests, als auch strukturellen (Mangan-verstärktes 
MRI; MEMRI) und molekularen (Proteomics/ Western Blot) Verfahren bezüglich der lacZ- Expression 
charakterisiert. Da, wie bereits erwähnt, das Alter ein wichtiger Faktor für kognitive Fähigkeiten ist, 
unterliefen ausgewählte Mauslinien zudem wiederholten Testungen bis zu einem Alter von 24 
Monaten, um mögliche additive Effekte der Proteinexpression und des Alterungsprozesses zu 
untersuchen. Unter der Kontrolle verschiedener expressionsbestimmender Promotoren verursachte 
die lacZ- Expression sowohl spezifische verhaltensbiologische als auch strukturelle Veränderungen. 
So bewirkte z.B. die lacZ- Expression in glutamatergen Neuronen erhebliche kognitive Defizite und 
deutliche strukturelle Veränderungen, während GABAerge lacZ-Expression Veränderungen des 
akustischen Startle-Reflexes und des Angstverhalten verursachte. Diese Veränderungen waren zwar 
abgeschwächt, wenn die lacZ- Expression erst im adulten Stadium der Tiere induziert wurde, stellen 
aber dennoch eine eindeutige Veränderung des verhaltensbiologischen und strukturellen Phänotyps 
dar, und müssen daher berücksichtigt bzw. nach Möglichkeit vermieden werden.  
Das fortschreitende Alter der Tiere und die lacZ- Expression interagierten miteinander und 
beeinflussten so weiterhin den Phänotyp. Das Alter selbst hatte jedoch keinen direkten (negativen) 
Einfluss auf die kognitiven Fähigkeiten der Tiere. 
Aufgrund dieser überraschenden Ergebnisse fragten wir anschließend, ob eine Manipulation des 
gesamten Organismus mit dem fortgeschrittenen Alter interagieren und kognitive Defizite 
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verursachen würde. Daher untersuchte das dritte Projekt (iii) das Angstverhalten und die kognitiven 
Fähigkeiten in einem Mausmodell der posttraumatischen Belastungsstörung (PTBS/ PTSD) bis zu zehn 
Monate nach dem „Trauma“-induzierenden Geschehen, d.h. die Mäuse waren zu diesem Zeitpunkt 
bereits 15 Monate alt. Die Tiere zeigten ein eindeutiges Angstverhalten selbst neun Monate nach 
dem „Trauma“, aber keine offensichtlichen kognitiven Defizite bezüglich räumlichen Lernens oder 
des Kurzzeitgedächtnisses. Allerdings konnten wir eine inverse Korrelation zwischen dem 
anfänglichen Angstverhalten ein Monat nach Trauma-Applikation und der kognitiven Leistung im 
Alter feststellen. Dieses könnte eine mögliche Verbindung zwischen Stressanfälligkeit und kognitiven 
Fähigkeiten im Alter darstellen. 
Zusammengefasst unterstreichen die hier präsentierten Ergebnisse abermals die Komplexität 
kognitiver Mechanismen. Eine lokal begrenzte und hochkonzentrierte Läsion einer neuronalen 
Subpopulation führte zu klar definierten spezifischen Verhaltensänderungen, abhängig von deren 
Lokalisation. Im Gegensatz dazu verursachte die exogene Expression von lacZ eine Vielzahl von 
Verhaltensveränderungen, die zum Teil auf entwicklungsbedingte Mechanismen zurückzuführen 
sind. Diese Verhaltensänderungen wurden zwar mit fortschreitendem Alter weitergehend  
modifiziert, dieses hatte jedoch keine weiteren negativen Konsequenzen auf die kognitiven 
Fähigkeiten. In ähnlicher Weise wurden kognitive Leistungen im Alter auch nicht direkt negativ von 
stressvollen, traumatischen Ereignissen beeinflusst. Vielmehr scheint die Intensität der anfänglichen 
Angstantwort bereits die kognitiven Fähigkeiten im Alter vorauszudeuten.  
Dementsprechend hebt diese Arbeit die vielen verschiedenen Faktoren hervor, die die Kognition 
beeinflussen können und die bei Erkrankungsprozessen zu kognitiven Defiziten führen können. 
Außerdem kann diese Arbeit neue Hinweise bieten, wie kognitive Fähigkeiten auch im Alter erhalten 
bleiben können. 
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Abstract 
 
Cognition has been at the center of philosophical, psychological and neurobiological studies for 
centuries. Yet, the neurobiological mechanisms underlying cognitive processes remain to be one of 
the last frontiers of modern neuroscience. 
In an ever aging society and considering the inherent decline of cognitive abilities with age, the 
efforts to understand the neurobiological basis of cognition are further increasing. However, 
cognitive abilities not only decline with progressed age; indeed, neurodegenerative diseases often 
lead to severe cognitive impairments even in middle-aged patients. Furthermore, single-insult events 
such as infections or traumatic brain injuries can lead to cognitive decline, and even non-physical 
stressful life events have been shown to affect cognitive abilities.  
There are a number of different approaches to investigate cognition, beginning at the molecular level 
in vitro and ranging to animal- and human studies in vivo. While the human studies focus mostly on 
imaging approaches via functional magnetic resonance imaging (fMRI) or positron emission 
tomography (PET), animal studies are ideally suited to analyze the cognitive performances on a 
behavioral level. Particularly for rodent models a variety of cognitive tests are available, ranging from 
specific contextual learning paradigms to place-learning tasks as well as short-term memory 
assessments. In parallel to the varying disease- and cognitive deficits- triggering mechanisms, we 
chose to investigate the general behavioral and cognitive consequences of three distinct 
manipulations of mice on a C57Bl/6 genetic background. Throughout these three projects we either 
manipulated the neuronal integrity of the mice on a molecular level via immuno-toxic insults or 
exogenous protein-expression, or, on a whole-system level, via environmental stressors. All mice 
underwent in-depth behavioral screens in order to assess the cognitive and general behavioral 
effects of the respective manipulations.  
Project one (i) involved selective GABAergic immuno-toxic lesioning via saporin-conjugated anti-
vesicular GABA transporter antibodies (SAVAs). Wherever present, SAVAs are taken up by GABAergic 
interneurons and ultimately destroy the affected neurons. This treatment resulted in severe spatial 
learning impairments and transient locomotor hyperactivity when applied at the level of the dorsal 
hippocampus (dHPC). Short-term GABAergic depletion in the dHPC furthermore revealed a 
previously unrecognized functional distinction: we found that GABAergic interneurons of the dHPC 
are necessary for the acquisition, but not for the recall of a spatial memory. GABAergic lesioning of 
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the prelimbic cortex (PrL), in contrast, resulted in diminished sensorimotor-gating responses and 
impaired cognitive flexibility. 
Based on these results we subsequently asked whether a less locally defined but nonetheless cell-
type specific manipulation would result in similar effects. Therefore, Project two (ii) analyzed the 
consequences of a transgenic reporter-gene expression (lacZ) under the control of several different 
promoters. In addition to the extensive behavioral screens, these mice also underwent structural 
(manganese-enhanced MRI) and molecular (proteomics/ western blot) analyses. Furthermore, based 
on previous reports regarding additive effects of age and protein-accumulation, selected mouse lines 
also underwent repeated behavioral and structural testing until the age of 24 months. The lacZ 
reporter sequence is commonly employed to assess transgenic modification efficacy and it’s 
expression is believed to be inert to the phenotype. However, we found that depending on the 
driving promoter lacZ expression resulted in severe cognitive impairments accompanied by marked 
structural alterations in the CNS or changes in hyper-arousal and anxiety-related behavior. While 
these effects were attenuated when lacZ expression was induced in adulthood instead of 
embryogenesis, they nonetheless significantly influenced the entire phenotype of the mouse and 
have to be controlled for. In addition, lacZ expression itself and the duration of expression/ age of 
the animals further interacted to modify the behavioral responses and the morphology of the CNS. 
Interestingly, age itself did not negatively affect the cognitive capabilities of lacZ-expressing mice. 
Given these unexpected results, we furthermore asked whether a less specific, whole-system 
challenge would interact with progressed age and consequently diminish the cognitive abilities of 
aged mice. Therefore, Project three (iii) investigated cognitive and anxiety-related behavior in a 
mouse model of PTSD up to 10 months after “PTSD-induction” (i.e. at the age of 15 months). This 
project revealed that a strong PTSD-like phenotype cannot only be observed one month after 
trauma-application, but, in fact, persists even 9 months later. Although this strong anxiety-related 
phenotype did not directly affect the cognitive performance of aged traumatized mice, we found an 
inverse correlation between the initial fear responses after trauma and the cognitive performance in 
aged traumatized mice- indicating a possible relationship between stress-susceptibility and cognitive 
abilities in age.  
Taken together, these results once more underline the complexity of cognition. A locally restricted 
and near-total depletion of a distinct neuronal sub-population resulted in clearly defined and specific 
effects depending on the affected area. In contrast, exogenous lacZ expression caused a variety of 
behavioral alterations, including strong developmentally-related as well as adult-inducible cognitive 
impairments, particularly regarding contextual fear memory. While these behavioral changes were 
further modified by the duration of expression and the age of the animals, they were not necessarily 
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negatively affected by it. Lastly, environmental challenges do not directly affect cognitive abilities in 
aged mice either. Rather, initial stress responsiveness may be indicative of cognitive abilities in age. 
Thus, this work highlights the multitude of factors affecting cognition and elucidates several disease-
related mechanisms inducing cognitive deficits. Additionally, this work provides new insights 
regarding the preservation of successful cognition even in aged individuals. 
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1 Introduction 
 
1.1. Cognitive Neuroscience  
Cogito ergo sum – René Descartes (1641) 
Scholarly reflections regarding cognition and consciousness have been at the center of philosophical, 
psychological and, more recently, neurobiological investigations for centuries, most likely beginning 
even before Aristotle (ca. 350 BC) and Descartes in the 17th century. However, even today, there are 
still a lot of unanswered questions and disagreement, beginning with the precise definition of 
cognition within a philosophical, psychological or neurobiological context (Kandel et al., 2013). At the 
core of the debate resides the question, whether cognition is a purely conscious process or whether 
most of the cognitive processing is in fact done at an un-conscious level. At the turn of the last 
century, Sigmund Freud highlighted the influence of the unconscious mind as the driving force 
behind human behavior, and while the extent of the influence of the sub-conscious has been 
somewhat revised in recent years, the unconscious mind is nonetheless still recognized to be an 
important part of cognitive processing (Power and Brewin, 1991; Bargh and Morsella, 2008). 
For the sake of this work I will refer to cognition as defined by the Oxford English Dictionary as “The 
mental action or process of acquiring knowledge and understanding through thought, experience, 
and the senses”.  
Today cognitive neuroscience constitutes a combination of five sub-fields: perception, action, 
emotion, language and memory (Adolphs, 2001; Kandel et al., 2013).  Its origins can be traced as far 
back as Iwan Petrowitsch Pawlow, Edward Lee Thorndike and Burrhus Frederic Skinner, who are 
viewed as the “original behaviorists” and the “founding fathers” of cognitive neuroscience, beginning 
in the second half of the 19th century until the middle of the 20th century. These pioneers of the field 
gained insight into learning and memory-related behavior of animals from purely empirical 
observations. In the beginning and middle of the 20th century, however, a new generation of neuro-
cognitive investigators, including e.g. Edward Tolman, added a new layer of complexity to the 
behavioral studies: individual perception and an inherent motivational state. Soon thereafter first 
computational models of neural processing were achieved and through a number of groundbreaking 
studies, which revealed for instance the similarities of neural mechanisms on a cellular level across 
species, as well as the arrival and combination of new methodologies, the modern field of cognitive 
neuroscience arose (Kandel et al., 2013). While this field now employs in vivo imaging as well as 
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cellular- and molecular interventions with the goal to study the mechanisms of cognition, subsequent 
behavioral testing of animal models in order to assess the actual behavioral and cognitive 
consequences, is still very much at the center of modern cognitive neuroscience approaches, just as 
it was for Pawlow, Tolman and many more “original” cognitive neuroscientists.  
 
1.2. Why study cognitive neuroscience? 
Given the complexity of cognition as underlined by the ongoing dispute regarding its definition, one 
might ask why to focus on cognition or cognitive abilities in the first place. One particular 
characteristic of cognition, both adding to its comlpexity and explaining the hightened research 
interest, is that cognitive abilities are not only guided by genetic predispositions (Robinson et al., 
2014), but are also vulnerable to external influences throughout an individuals life span. 
Furthermore, cognitive abilities are often particularly negatively affected by the aging process 
(Grady, 2012; Morrison and Baxter, 2012; Fjell et al., 2014). Thus, in an ever-aging society with the 
associated increasing economical burden regarding healthcare and care-taking of the elderly, it is of 
the utmost importance to understand the basic mechanims of cognition under healthy as well as 
diseased and/ or aged conditions in order to alleviate individual suffering and the economical 
burden. 
 
1.2.1. Neurodegenerative diseases and cognition 
Nonetheless, age is not only a major risk factor for declining cognitive abilities, age is also the main 
risk factor for neurodegenerative diseases, which in turn negatively affect cognition. However, while 
age is a strong confounding factor, neurodegenerative diseases often entail additional components, 
e.g. genetic mutations and environmental factors (Brown et al., 2005; Lill and Bertram, 2011).  
 
1.2.1.1. Alzheimer’s Disease and other types of Dementia 
Possibly the most notorious and most-referred-to neurodegenerative disease is Alzheimer’s Disease 
(AD), which severly impacts the overall life-quality and in particular the cognitive abilitites of the 
afflicted individuals (Abdul et al., 2009; Kilgore et al., 2010; Chang et al., 2014). AD is also the most 
common type of dementia, affecting approximately 11% of people age 65 and older and about 32% 
of people age 85 and older in the U.S. in 2013, whereby females had a nearly two-fold increased life-
time risk to develop AD compared to men (Ferri et al., 2005; Thies and Bleiler, 2013). Familiar AD 
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cases present with a high number of genetic risk factors, usually involving amyloid-beta or the 
amyloid-precursor protein (APP), and an earlier disease onset compared to sporadic AD cases, which  
typically present with a later disease-onset age (i.e. > 60-65 years; (Hardy and Selkoe, 2002; Arlt et 
al., 2013; Guerreiro and Hardy, 2014)).  
AD is clinically defined by a progressive loss of cognitive abilities, including increasing memory loss 
(recent conversations, names, words), decreased working memory and, particularly in later stages, 
desorientation of the patients even in previously familiar surroundings (Dubois et al., 2010; Thies and 
Bleiler, 2013). These behavioral and cognitive changes are accompanied by equally progressive 
functional, structural and molecular alterations throughout the CNS (Braak and Braak, 1991; Liu et 
al., 2005; Abdul et al., 2009; Dubois et al., 2010; Lopes and Agostinho, 2011; Fjell et al., 2012; Cohen 
et al., 2013; Talantova et al., 2013; Thies and Bleiler, 2013; Orr et al., 2014). In particular the extra-
cellular accumulation of beta-amyloid protein depositions (a-beta plaques) and intra-cellular protein 
fibrilles (neurofibrillary tangles, NFTs; tau tangles) have been at the focus of AD-related 
investigations. These plaques and NFTs are typically first observed throughout the entorhinal cortex 
and the hippocampal formation, before spreading throughout the cortex and subsequently through 
the entire CNS. One of the main difficulties of this disease, however, is the fact that it entailes a long 
so called “pre-clinical phase” (i.e. prodromal phase), during which the a-beta plaques, tau tangles and 
other biomarkes such as changes in the composition of the cerebrospinal fluid (CSF) proliferate, but 
do not yet cause significant behavioral alterations and therefore remain unrecognized for a long 
period of time (Price and Morris, 1999). Once the behavioral alterations are obvious and the patients 
are diagnosed, there is often very little that can be done to alleviate the disease burden. Only very 
few animal studies have successfully demonstrated the reversal of cognitive decline in animal models 
of AD  (Kiyota et al., 2011; Xu et al., 2014). Therefore many studies now focus on enabling earlier 
diagnoses, in order to increase the time-span to try and prevent or at least slow the severe 
consequences of AD (Sperling et al., 2013). Interestingly, while Braak & Braak (1991) have first 
described the pathological extent of tau tangles and amyloid plaques throughout disease 
progression, it has since been found that tangles and plaques do not necessarily appear to the same 
extent at the same time or place during (initial) disease stages (Arnold et al., 1991; Price and Morris, 
1999), indicating somewhat indepent disease mechanisms or at least independent accumualtion-
inititations for these two pathological hallmarks of AD. 
However, while being the most common type of dementia, AD is certanly not the only one 
presenting with cognitive decline. In fact, e.g. Vascular Dementia also often presents with severe 
cognitive impairments and accounts for approximately 10% of all dementia cases. The abundance 
and precise location of the vascular damage (i.e. mini-strokes) throughout the CNS determine the 
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exact behavioral and cognitive consequences indiviually for each patient (Thies and Bleiler, 2013). 
Another fairly common type of dementia is the frontotemporal lobar degeneration (FTLD). As 
indicated by the name, frontal and temporal lobes are particulalry affected (i.e. atrophied) by FTLD. 
However, unlike for patients suffering from AD, memory impairment only occurs throughout later 
stages of the disease (Thies and Bleiler, 2013).  
All of these types of dementias are not completely separate entities, but rather overlap in 
symptomatology and pathology, e.g. intra-neuronal tau tangles. If a patient presents with 
pathologies of more than one dementia, he is considererd a “Mixed Dementia” patient, most 
commonly observed for patients with AD and vascular dementia (Thies and Bleiler, 2013). Lastly, all 
types of dementia not only affect cognitive abilities, but additionally have a high comorbidity with 
depressive symptoms. The cause- and effect relationship of dementia and depression, however, has 
not yet been conclusively resolved (Gualtieri and Johnson, 2008; Diniz et al., 2013; Bennett and 
Thomas, 2014). 
 
1.2.1.2. Parkinson’s Disease 
Furthermore, there are additional neurodegenerative diseases, which are also characterized by intra-
cellular protein accumulation and the decline of cognitive abilities, for instance Parkinson’s Disease 
(PD), the second most common neurodegenerative disease (de Lau and Breteler, 2006; Schumacher-
Schuh et al., 2014). PD is also a highly degenerative disease, severly impairing overall quality of life 
and particularly at later stages also causing cognitive impairments (Balzer-Geldsetzer et al., 2011; 
Barker and Williams-Gray, 2014; de la Riva et al., 2014). PD affects about 2% of the population and its 
core symptoms are motor impairments, such as bradykinesia, rigidity and rest tremors which are 
attributed to the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and 
subsequent dopaminergic lesions in the striatum of PD patients (Schumacher-Schuh et al., 2014). In 
contrast to AD, however, there is a relatively useful treatment available for PD patients: levodopa (L-
DOPA), a precursor to dopamine. At least throughout the first few years of the disease L-DOPA is 
often able to mask the dopaminergic neuronal loss by artificially increasing dopamine levels and 
thereby minimizing the motor deficits. After this initial phase, however, the dopaminergic loss either 
becomes too much to mask, or the patients build up a tolerance, requiring larger doses of L-DOPA, 
which in turn increases the negative side-effects including dyskinesia as well as hallucinations (Foster 
and Hoffer, 2004). The exact cause of PD is still a matter of debate, with genetic mutations only 
accounting for a relatively small number of cases. Nonetheless, whenever genetic factors are 
involved in the disease etiology, they are so-called “dopaminergic” genes such as DAT1 (dopamine 
(active) transporter 1), DRD2 (dopamine receptor D2) and COMT (catechol-O-methyltransferase; 
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involved in dopamine degradation), all of which are involved in dopaminergic signaling throughout 
the nigrostriatal pathways (Ruottinen and Rinne, 1998; de Lau and Breteler, 2006; Schumacher-Schuh 
et al., 2014). Whether caused by genetic mutations, toxins or other environmental factors, another 
pathological hallmark of PD are lewy body inclusions (LB; intracellular accumulations of α-synuclein) 
throughout the substantia nigra pars compacta (SNpc) that are ultimately leading to dopaminergic 
neuronal loss. In addition, LB inclusions have also been described throughout telencephalic and 
limbic regions, affecting not only dopaminergic, but also glutamatergic, cholinergic and GABAergic 
projection neurons (Braak and Braak, 2000).  
The above mentioned cognitive impairments of PD are particularly severe when LBs are present. If 
LBs are present without obvious dopaminergic loss and therefore without obvious motor deficits but 
with cognitive decline, the disease is no longer called PD but lewy body dementia instead (Thies and 
Bleiler, 2013). Because of these overlapping pathologies, the disease-definition of PD as a primarily 
motor-dysfunction disease is currently undergoing some dispute (Berg et al., 2014). Furthermore, by 
now it has been established, that the “PD-typical” motor-impairments are by far neither the first nor 
the only severe symptoms of PD (Barker and Williams-Gray, 2014). In fact, in many cases the patients 
experience a variety of neuro-psychiatric symptoms, such as depression, during the prodromal phase 
of the disease, e.g. after cellular and molecular changes in the CNS have begun, but before 
experiencing the first clinical motor-dysfunction symptoms (Lieberman, 2006; de la Riva et al., 2014).  
There are of course a number of other neurodegenerative diseases, such as Huntington’s Disease 
(HD) or amyotrophic lateral sclerosis (ALS) that are equally devastating and complex, but wil not be 
further discussed throughout this work (Kiernan et al., 2011; Ross and Tabrizi, 2011).  
 
1.2.2. Psychiatric disorders and cognition 
While the psychiatric symptoms of PD (and AD) are only concomitant to the main motoric and 
cognitive symptoms, many primarily psychiatric disorders have also been shown to negatively affect 
the cognitive abilities of the patients (McIntyre et al., 2013; Musso et al., 2014). 
 
1.2.2.1. Schizophrenia 
One of these psychiatric disorders that affect cognition is also one of the most complex disorders 
known today: Schizophrenia (Tamminga and Holcomb, 2005). Schizophrenia is clinically defined by 
three classes of symptoms: (1) positive symptoms, represented by e.g. hallucinations, delusions or 
movement disorders, (2) negative symptoms such as depression or anhedonia and (3) cognitive 
dysfunction such as deficits in working memory (Walker et al., 2004; Tamminga and Holcomb, 2005; 
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American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 2013; 
Foussias et al., 2014). The life-time prevalence for schizophrenia is approximately 1% (Perälä et al., 
2007), the precise cause and underlying mechanisms, however, are still not entirely clear. There are 
several hypotheses regarding the etiology of this disorder, involving the dysfunction of distinct 
neuronal sub-classes (e.g. dopamine, glutamate or GABA) based on an interplay of genetic 
predispositions, developmental factors and environmental triggers (e.g. extreme stress). These 
alterations are often correlated to decreased cortical volumes in particular for the prefrontal cortex 
and the hippocampal formation (Lewis, 2000; Blum and Mann, 2002; Walker et al., 2004; Ross et al., 
2006; Meyer, 2014). Schizophrenia typically manifests in early adulthood (between 20 and 30 years 
of age) and affects slightly more men than women. So far, no single genetic, developmental or 
environmental manipulation could conclusively recapitulate the schizophrenic phenotype in an 
animal model, thus further supporting an interaction of multiple factors in the etiology of 
schizophrenia.  
The above mentioned cognitive deficits observed in schizophrenic patients are quite pronounced but 
can vary from slowed processing of visual and auditory stimuli to incoherent speech, deficits in 
attention as well as executive functions and up to impaired cognitive flexibility (task-switching) and 
spatial memory (Kuperberg and Heckers, 2000; Walker et al., 2004). However, until recently most of 
the research efforts were directed towards the positive symptoms including hallucinations. While 
antipsychotic drugs can now drastically reduce the burden of this symptom class, schizophrenia-
related cognitive deficits remain under-studied. Consequently, even well-medicated schizophrenic 
patients (with regards to positive and negative symptoms) suffer from marked cognitive impairments 
and often rely on (public) financial support (Goff et al., 2011; Ibrahim and Tamminga, 2012). 
 
1.2.2.2. Major Depressive Disorder (MDD) 
Besides schizophrenia, other psychiatric disorders, such as major depressive disorder (MDD), have 
also been shown to negatively affect cognitive abilities (Konstantine et al., 1998; Chamberlain and 
Sahakian, 2006; McIntyre et al., 2013). Similar to schizophrenia, MDD is also a complex trait disorder 
attributed to a number of genetic predispositions as well as environmental triggers, with a life-time 
prevalence of 10 – 15 % for men, and a markedly increased prevalence for women (Kessler et al., 
2003; Hasin et al., 2005; Levinson, 2006). In particular genetic polymorphisms for neurotransmitter 
sequences (e.g. serotonin) have been in the focus of MDD-etiology related studies (Levinson, 2006). 
The cognitive impairments associated with the disorder, however, have again long been under-
studied, and only recently the importance of this symptom class and its alleviation has been put at 
the center of investigations. Again similar to schizophrenia, the cognitive deficits associated with 
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MDD are very diverse. Impairments ranging from emotional image- and face processing to attention 
and memory deficits have been reported, thereby spanning both declarative (explicit) and non-
declarative (implicit) cognitive aspects (Clark et al., 2009; Elliott et al., 2011). Structural and 
functional analyses using (functional) magnetic resonance imaging (f-MRI) have reported decreased 
activity in the prefrontal cortex (PFC) of MDD patients during cognitive tasks, as well as decreased 
activity and size of the hippocampal formation, which could explain the observed cognitive deficits 
(Bremner et al., 2004; Campbell et al., 2004; Videbech and Ravnkilde, 2004; Clark et al., 2009). 
Whether the decrease in hippocampal volume is cause or consequence of MDD has not been 
resolved.  
Proven to be involved in the etiology of MDD however, is stress-exposure. The more prolonged and 
severe the stress exposure of an individual is, the higher the likelihood that he will develop MDD (de 
Kloet et al., 2005; Holsboer and Ising, 2010; Oglodek et al., 2014). Stress (-hormone) levels are 
controlled by the hypothalamus-pituitary-adrenal (HPA) axis. The HPA axis is a common feature 
among vertebrates whereby the hypothalamus modulates the levels of corticotropin-releasing 
hormone (CRH), which then acts at the anterior pituitary and stimulates the release of 
adrenocorticotropic hormone (ACTH), which in turn induces the release of glucocorticoids (cortisol in 
humans and corticosterone in rodents) from the adrenal glands (Sapolsky et al., 2000; Miller et al., 
2007). MDD patients often present with increased cortisol levels (Oglodek et al., 2014), and 
glucocorticoids themselves have been shown to be involved in a number of physiological and 
neurobiological processes, including learning and memory (Liston et al., 2013). HPA axis activity is 
controlled by a negative feedback loop, monitoring and mediating glucocorticoid levels via their 
binding on glucocorticoid receptors (GR) throughout hypothalamus, pituitary and hippocampus 
(HPC). The HPC displays a particularly high density of GRs, and plays therefore a crucial part with 
regards to HPA activity and feedback-monitoring (Reichel, 2011; Wingenfeld and Wolf, 2011).  
As briefly mentioned above, MDD patients, as well as (aged) individuals suffering from prolonged 
stress, often present with hippocampal volume loss and decreased HPC-activity. While the volume 
loss used to be  ascribed to de facto neuronal loss, it is now believed that prolonged high levels of 
glucocorticoids induce dendritic and synaptic atrophy in the hippocampus, while enhancing dendritic 
arborization in the amygdala (Magarinos and McEwen, 1995; McEwen and Magarinos, 1997; Vyas et 
al., 2002). This atrophy in turn interferes with the negative feedback mechanism of the HPA axis and 
thereby prolongs increased glucocorticoid levels. This particular vicious cycle regarding disturbed 
HPA function has led to the glucocorticoid cascade theory now believed to be involved in many 
stress-related disorders such as MDD (Sapolsky et al., 1986; Sapolsky et al., 2000). Volume and 
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activity decrease in the PFC of MDD patients or of stressed individuals has also been ascribed to 
dendritic spine loss due to prolonged increased glucocorticoid levels (Anderson et al., 2014). 
Furthermore, given the close relationship between HPC and HPA axis regulation as well as HPC and 
cognition, this mechanism could not only explain the decrease in hippocampal volume and -activity, 
but also the declarative cognitive deficits associated with MDD and prolonged exposure to high levels 
of glucocorticoids (Sweatt, 2004; Barkus et al., 2010). The impairment of the PFC structure in turn 
could explain in particular the deficits related to attention and task-switching (Euston et al., 2012; 
Bissonette et al., 2013). 
An additional environmental factor that has been shown to increase the probability to develop MDD 
are infections or immuno-toxic insults leading to prolonged increased immune activity and 
inflammation. However, once again, the cause-consequence relationship between infection and 
MDD has not been conclusively resolved (Dantzer et al., 2008). 
 
1.2.2.3. Post-traumatic stress disorder (PTSD) 
A further psychiatric disorder affecting cognition that is highly comorbid with MDD and closely linked 
to stress exposure as well as alterations in immune-system functions, is post-traumatic stress 
disorder (Post et al., 2011; Gola et al., 2013). Under the new Diagnostic and Statistical Manual of 
Mental Disorders (APA; Vth edition, 2013) PTSD is now defined as a Trauma- and/or Stress-related 
Disorder which can develop after a single exposure to a life-threatening (traumatic) event, serious 
injury or sexual violation or after experiencing repeated exposures to aversive (traumatic) events. 
PTSD is now clinically defined by four diagnostic clusters: re-experiencing (intrusive memories), 
avoidance, negative cognitions and -mood as well as (hyper-) arousal. The term “negative cognition” 
hereby refers to an impaired memory directly related to key aspects of the PTSD-initiating traumatic 
event. Furthermore, a distinction is made between acute reactions to an intense stressful event and 
a chronic phase of PTSD whereby the symptoms are present for more than a month after the event 
(American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 2013). 
PTSD has a life-time prevalence of 5 – 15 % depending on population cohort and study design, and 
approximately 10 % of trauma-exposed people develop PTSD (Kessler et al., 1995; Nemeroff et al., 
2006; McLaughlin et al., 2013; Santiago et al., 2013; Stein et al., 2014). Since 90 % of trauma-exposed 
individuals do not develop chronic PTSD, the environmental trigger (i.e. trauma exposure) cannot be 
the sole factor causing the disorder. In fact, life style choices as well as genetic predispositions and 
single nucleotide polymorphisms (SNPs) have been associated with the likelihood to develop PTSD 
after trauma-exposure (LeardMann et al., 2011; Ressler et al., 2011). Additionally, personality-traits 
such as novelty-seeking or trait-anxiety have been correlated with the risk to develop PTSD after 
Introduction 
 
- 9 - 
 
trauma exposure and therefore underlined the existence of inherent vulnerability- and resilience 
markers that warrant further investigations (Jakšić et al., 2012). 
PTSD is clearly a stress-related disorder and similar to MDD, CNS structural alterations including HPC 
volume reductions have been reported in the context of PTSD (Bremner et al., 2007; Golub et al., 
2011). However, HPA axis (dys-)regulation related to PTSD remains unresolved, with several studies 
reporting contradictory findings ranging from increased to decreased to un-affected cortisol levels in 
PTSD patients (Gilbertson et al., 2002; de Kloet et al., 2006; Jatzko et al., 2006; van Zuiden et al., 
2011). Furthermore, the cognitive deficits described for PTSD patients, aside from the symptom 
classification, also appear to be more closely related to PFC dysfunction, rather than HPC-based 
deficits, with particular impairments reported regarding attention and cognitive flexibility (Brandes et 
al., 2002; McNally, 2006; Rauch et al., 2006; Qureshi et al., 2011).  
 
1.2.3. Life-time cumulative effects modulating cognition in age 
While the aging process itself is associated with a gradual decline of cognitive abilities, life-time 
events such as exposure to stress or psychiatric disorders and their effects on HPA axis activity 
closely interact with each other and additionally modulate cognitive abilities in age (Grady, 2012; 
Anderson et al., 2014). Furthermore, psychiatric disorders themselves have been associated with 
accelerated cognitive decline in age and an increased prevalence of dementias among psychiatric 
patients has also been previously reported (Potter and Steffens, 2007). Moreover, psychiatric 
symptoms such as depression have in fact been shown to not only be among the first symptoms to 
present, but also to increase the risk to develop neurodegenerative diseases, including their inherent 
devastating cognitive impairments (Gualtieri and Johnson, 2008; Yaffe et al., 2010; Jakobsson et al., 
2012; Kohler et al., 2013).  
The gradual cognitive decline with age has been reported across species, in particular for mammals, 
and is therefore well worth studying in animal models (Samson and Barnes, 2013). 
Taken together, cognitive abilities are affected by many neurodegenerative and neuropsychiatric 
diseases and their underlying neuropahtological mechanisms, and are furthermore modulated by 
life-time stress-exposure and by the aging process itself. Vice versa, deficits in cognitive abilities are a 
major symptom-class across almost all neurological afflictions and it is therefore paramount to 
investigate the underlying mechanims of cognition in health and disease in order to find new 
therapeutic approaches and thereby alleviate individual suffering as well as the economic disease 
burden. 
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While many molecular and electrophysiological questions regarding the underlying functional 
mechanisms of cognition in health and disease can very well be studied in vitro and with 
computational models, or in humans using non-invasive in vivo imaging techniques, the ultimate 
physiological assessment, particularly regarding learning and memory-related behavior, has to be 
done in living organisms, specifically in animal models (Levin and Buccafusco, 2006).  
 
1.3. From mice to men 
There are a multitude of animal models in use to investigate many research aspects, including 
learning and memory. These models range from invertebrates such as the nematode Caenorhabditis 
elegans (Ohno et al., 2014), the marine snail Aplysia (Roberts and Glanzman, 2003), the common 
fruit fly Drosophila melanogaster (van der Voet et al., 2014) up to non-human primates such as the 
rhesus monkey Macaca mulatta (Avdagic et al., 2014). However, perhaps the largest class of animal 
models is constituted by the rodent models, including gerbils, rats and mice (Teixeira et al., 2006; 
Castellano et al., 2014; Thurley et al., 2014). In particular mice are incredibly well suited as a 
neurobiological model organisms due to their almost 99% genetic congruency, their short generation 
time and cost-effectiveness (Peters et al., 2007). However, even given all the similarities between 
humans and model organisms, and also when acknowledging the near-optimal conditions featured in 
mice, one has to concede that they will still always remain model organisms.  
 
1.3.1. Criteria for animal models 
Therefore, a number of criteria have been defined in order to assess the translational applications of 
a given animal model. These criteria are necessary in order to validate a disease model in terms of 
underlying physiological mechanism as well as possible therapeutic interventions. There are three 
validation criteria commonly used: Face validity, Construct validity and Predictive validity (Willner, 
1984; Belzung and Lemoine, 2011).  
Face validity constitutes the symptomatic similarity between model organism and human disease. 
For instance, a mouse model of PTSD should portray the defining symptoms such as e.g. generalized 
fear and increased hyper-arousal (Siegmund and Wotjak, 2007). Construct validity, in contrast, 
describes the correlation of disease underlying (neuro-)biological mechanisms between model 
organism and human patients. Therefore, a mouse model of PD, for example, should present with 
loss of dopaminergic neurons, whereas a mouse model of AD should present with a-beta plaques and 
NFTs. In order to determine whether a model organism would also be useful in terms of therapeutic 
Introduction 
 
- 11 - 
 
treatments, the Predictive validity was defined. In this case, a known therapeutic intervention in 
humans should work in the respective animal model, and vice versa. For instance, L-DOPA should 
reduce the behavioral symptoms of a mouse model of PD, and a subsequently successfully tested 
anti-PD treatment in this mouse model then has a high predictive validity to be successful in human 
patients. Lastly, one additional criterion is sometimes employed: Etiological validity. This criterion 
describes the compatibility between events causing a given disease for humans and the model 
organism. Thus, a mouse model of PTSD should develop its hallmark-symptoms after an etiological 
relevant, i.e. highly stressful, event (Willner, 1984; Belzung and Lemoine, 2011; Reichel, 2011). In 
order to model particularly complex psychiatric disorders such as Schizophrenia, an additional 
distinction is used: animal models representing endophenotypes with little face but high predictive 
validity (e.g. hyperlocomotion) are considered an animal model of schizophrenia even in the absence 
of additonal overlapping symptoms, if they respond appropriatly to antipsychotic drugs, i.e. if 
hyperlocomotion is decreased after treatment. There are, however, also animal models of 
schizophrenia who encompass face-, construct- and predictive validity, e.g. endophenotypes 
presenting with altered sensorimotor gating abilities (Swerdlow and Geyer, 1998; Powell and Geyer, 
2007). 
 
1.3.2. Genetically modified animal models 
The mouse genome was sequenced shortly after the human genome (Waterston et al., 2002) and 
given the genetic similarities between mice and humans, the idea to manipulate specific genes in 
mice that are known to be involved in certain disease etiologies in humans, seems obvious now. 
However, the methodology to do so appeared unattainable for a long time and the final 
accomplishment gained its inventors the Nobel Prize in Physiology or Medicine in 2007 (Mak, 2007).  
The groundbreaking work was done by Mario Capecchi, Martin Evans and Oliver Smithies in the 
1980s (Evans and Kaufman, 1981; Thomas and Capecchi, 1987; Koller et al., 1989). Their work 
combined homologous recombination and pluripotent embryonic stem cells, which enabled nearly 
any previously envisioned genetic manipulation in a mouse model (Deussing, 2013). 
Today, a number of genetically modified mouse models are available, ranging from straight-forward 
knockout models to assess the function of a single gene, to minute receptor manipulations as e.g. 
applied in the field of optogenetics (see chapter 1.5.5.). As mentioned above, most psychiatric 
disorders and neurodegenerative diseases are not caused by a single gene-malfunction as it would be 
modeled by a complete gene-knockout. Therefore, more specific technologies to manipulate the 
genome have been established. Hereby a distinction is made between constitutive, conditional and 
inducible (-conditional) manipulations. Constitutively genetically modified mice entail manipulations 
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that are not only applied during embryonic stages, i.e. the insertion of targeting vectors into 
embryonic stem cells in order to induce homologous recombination and thereby either exert a 
specific gene sequence or add a gene sequence of interest; but “constitutive” also refers to the 
activity of the manipulation, i.e. immediately after insertion and thus also during embryogenesis. This 
of course implies that effects based on developmental involvement of the targeted gene sequence 
and effects occurring during adulthood cannot be distinguished (Deussing, 2013). Furthermore, 
depending on the targeted gene, a manipulation can have numerous consequences throughout the 
whole body instead of being limited to a distinct tissue or organ, thereby again hindering the specific 
characterization of its function. Moreover, the manipulation of a gene beginning during 
embryogenesis can cause compensatory mechanisms that can, once again, not be distinguished from 
de facto gene-effects (Deussing, 2013). Therefore, in order to enable the spatial and temporal control 
of genetic manipulations, additional methodologies have since been developed that entail naturally 
occurring DNA site-specific recombinases (SSRs) and are referred to as conditional manipulations. 
Perhaps the most commonly used variant of SSRs is the Cre/loxP system (Hoess et al., 1982; Argos et 
al., 1986; Akagi et al., 1997). The DNA recombinase “Cre” (Cyclization REcombination) recognizes the 
loxP site of the bacteriophage P1 genome and enables the recombination between two pairs of loxP 
sites. Cre not only recognizes these loxP sites but also their orientation. If the loxP sites are oriented 
in the same direction, Cre will excise the DNA sequence between the two sites and will leave behind 
one loxP site. If the loxP sites are inverted to each other, the floxed (i.e. flanked by two loxP sites) 
DNA sequence will be inverted (see also chapter 2.1.2.1. and Figures M-1 and M-2). Due to this 
distinction Cre can be employed for numerous inserting, exerting and inverting approaches of target 
sequences in order to silence or activate a specific gene (Mills and Bradley, 2001; Branda and 
Dymecki, 2004; Deussing, 2013).  
The target-sequences, consisting of the gene of interest and the loxP sites, are generated via 
homologous recombination-based gene targeting. Hereby the loxP sites are inserted into introns 
adjacent to the target sequence of the gene of interest and should therefore not affect gene 
expression themselves (Gu et al., 1994; Deussing, 2013). In order to activate this manipulation, i.e. in 
order to induce Cre-mediated recombination, mice carrying the floxed target sequence are bred to 
mice expressing the Cre recombinase (i.e. Cre-driver mice). These mice express Cre under the control 
of a specific gene-promoter. Thus, when bred to the “floxed” mice, Cre is only present and therefore 
only recognizes the loxP sites in those cells where the chosen (i.e. “Cre-driving”) gene-promoter is 
active. Hence, the Cre-driver line ultimately determines the “conditions”, i.e. the temporal and 
spatial pattern of the genetic conditional manipulation (Deussing, 2013; Harris et al., 2014). 
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However, in particular the temporal specificity is still not always given with this approach. 
Furthermore, opposing effects during development and in adulthood cannot be assessed in this 
model and especially during development ectopic gene expression or toxic side-effects due to 
increased levels of Cre recombinase have been reported (Schmidt et al., 2000; Deussing, 2013). 
Consequently, additional approaches have since been developed to enable better temporal control 
of Cre expression and thereby of the genetic manipulation. Two main systems are employed towards 
this goal: the “tet-off” or “tet-on” system and the tamoxifen-inducible Cre system. The tet-system is 
based on the control element of the Escherichia coli tetracycline-resistance gene and encompasses 
two parts: a hybrid transactivator sequence (tTA) and a minimal promoter fused to the tetracycline 
operator (tetO) sequence. As long as tetracycline is administered, Cre expression under the control of 
tetO is suppressed. Once the administration is stopped, tTA binds to tetO and Cre expression is 
induced (Gossen and Bujard, 1992; St-Onge et al., 1996; Schenkel, 2006; Deussing, 2013). Instead of 
tetracycline, doxycycline can be administered, which displays a higher lipophilicity and therefore 
penetrates the blood-brain barrier more easily and can thus be administered in lower concentrations 
(Bastos et al., 2012). However, since both tetracycline and doxycycline are only removed relatively 
slowly from the organism, this approach also lacks a precise temporal definition (Kistner et al., 1996). 
Therefore, the modified “tet-on” system has been developed, which enables Cre-recombination 
shortly after tetracycline/ doxycycline administration (Hasan et al., 2001; Schönig et al., 2002). 
Nonetheless, both tet-variants require the presence of the tTA sequence, a tetO-driven Cre 
recombinase as well as the actual floxed sequence of interest, making it a rather difficult system with 
many variables and possible side-effects or inefficiencies. 
In contrast, the tamoxifen-inducible Cre system employs a ligand-dependent SSR that is selectively 
activated in the presence of a synthetic compound. Today the ligand-binding domain (LBD) of the 
human estrogen receptor (ER) fused to the Cre recombinase (CreERT) is most commonly used. The 
inert binding capacity of tamoxifen (TAM) by this fusion product has been artificially heightened and 
yielded the CreERT2 fusion product. Upon TAM administration the Cre recombinase translocates into 
the cell nucleus where it recognizes and subsequently acts on the loxP sites (Picard, 1994; Logie and 
Stewart, 1995; Feil et al., 1996; Feil et al., 1997). TAM can be either i.p. injected or fed to the mice 
and is converted to 4-OH-TAM in the liver of the animals; 4-OH-TAM then binds to CreERT2. TAM-
treatment as well as Cre-translocation are proposed to have only minimal effects on the behavioral 
phenotype of mice (Vasioukhin et al., 1999; Vogt et al., 2008; Deussing, 2013).  
In order to assess the efficacy of a given genetic manipulation, the bacterial lacZ gene coding for β-
Galactosidase (β-Gal) is often added to the sequence of the original viral vector that is inserted to the 
embryonic stem cells via homologous recombination (see above). Alternatively, the lacZ sequence 
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can be introduced into a so-called reporter mouse via gene-trap in the ROSA26 locus (i.e. R26R mice). 
Hereby the lacZ sequence is preceded by a floxed STOP sequence, which will be conditionally excised 
upon Cre-introduction. In either case lacZ transcription leads to β-Gal expression, which in turn can 
be readily visualized via immuno-histochemical staining protocols (i.e. X-Gal staining) and thus 
enables the visualization of the Cre-activity pattern and thereby highlights the specific localization of 
the genetic manipulation (Weiss et al., 1997; Soriano, 1999). 
Given the recent advances in mouse-genetic-tailoring and the increasing number of modified gene 
sequences, several transgenic mouse consortia have been established in order to sort through 
available alleles and their reported functionalities and to enable the exchange of sequences with the 
ultimate goal to target and analyze every protein coding gene (Austin et al., 2004; Ringwald et al., 
2011; Skarnes et al., 2011; White et al., 2013). 
While genetic manipulations in mice have been possible and available since the 1980s, genetic 
manipulations of rats remained elusive and near-impossible for a long time. However, over the last 
few years methodological approaches have been refined and genetic tailoring of rats has become 
possible and feasible as well (Li et al., 2008; Tong et al., 2010; Schönig et al., 2012). Particularly in the 
field of cognition these breakthroughs will undoubtedly improve and enhance the possibilities of 
investigations, since rats can be trained in even more complex cognitive tasks than mice.  
 
 
1.4. How to study cognition in animal models 
As mentioned in the description of neurodegenerative and neuropsychiatric diseases, the 
hippocampal formation (HPC) and the prefrontal cortex (PFC) are often affected by structural and 
molecular changes caused by the respective disease, and the behavioral deficits can also often be 
traced back to a malfunction of these structures. Both HPC and PFC are essential to successfully solve 
a variety of cognitive tasks. Moreover, the Amygdala (Amy) is an important part in the network that 
is also frequently referred to as the limbic system. Although there are additional structures involved 
in the limbic system, cognitive aspects are commonly ascribed to an interplay of HPC – Amy – and 
PFC. Fortunately, these structures are highly conserved across mammals and can thus be studied in 
rodent models. 
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1.4.1. The “cognitive network”: Hippocampus – Amygdala – Prefrontal Cortex  
While the structures HPC, Amy and PFC themselves are conserved across species, their specific 
location varies somewhat between species due to the increased cortical folding in higher mammals. 
Thus, Figure I-1 (below) represents a schematic outline of the approximate locations of HPC, Amy and 
PFC in a sagittal view of the rodent brain (Fig. I-1). One additional structure that strongly modulates 
the activity of this network is the nucleus accumbens (NAcc), which is located ventral and slightly 
caudal to the PFC. The NAcc itself has been described as an integration node that is bilaterally 
interconnected with HPC, Amy and PFC. A distinction is made regarding the core and the shell of the 
NAcc with respect to its morphology and involvement in distinct behaviors. Depending on the 
excitation level of either core or shell, the NAcc then further modulates the activity of HPC, Amy and 
PFC via the differential release of dopamine (Goto and Grace, 2008). 
 
  
Fig. I-1: Schematic localizations of PFC, HPC and Amy in a mouse brain (sagittal view): PFC, HPC and Amy constitute a basic 
cognitive network and are conserved across mammals. Network activity is closely mediated by NAcc activity. Amy = 
amygdala; HPC = hippocampus; NAcc = nucleus accumbens; PFC = prefrontal cortex. Modified after Paxinos and Franklin 
(2004). 
 
Today it is known that the HPC, and in particular the dorsal HPC, are extremely important concerning 
cognition in general and the spatial learning abilities of rodents in particular (Morris et al., 1982; 
Sweatt, 2004; Woollett and Maguire, 2011; Schlesiger et al., 2013). In fact, John O’Keefe, May-Britt 
Moser and Edvard Moser have just been awarded the Nobel Prize in Physiology or Medicine 2014 
“for their discoveries of cells that constitute a positioning system in the brain” 
(http://www.nobelprize.org/nobel_prizes/medicine/laureates/2014/press.html). In their 
groundbreaking studies they found that the activity of so-called “place cells” in the HPC is specific to 
distinct locations in a maze. Moreover, the activity of certain neurons in the entorhinal cortex 
(adjacent to the HPC) is also dependent on the spatial localization of the animal in a maze. These 
activity patterns form a hexagonal grid and “grid cells” and “place cells” represent the coordinates by 
rostral caudal 
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which the animal orients itself (O'Keefe and Dostrovsky, 1971; O'Keefe, 1976; Fyhn et al., 2004; 
Hafting et al., 2005; Sargolini et al., 2006).  
The hippocampal formation consists of the dentate gyrus (DG) and three cornu ammonis regions 
(CA1 - CA3). The last part of the CA3, reaching between the two blades of the DG, is also sometimes 
referred to as CA4 region. The DG contains three layers, receives its input from the entorhinal cortex 
(immediately adjacent to the HPC), and does not project outside of the HPC itself, but to the CA 
regions instead. The top layer (closest to the CA regions) is called the molecular layer, underneath it 
lays the granule cell layer and lastly the polymorphic cell layer or sub-granular zone (SGZ). The SGZ is 
also the place for adult born neurons to emerge (i.e. neurogenesis). While neurogenesis continues in 
adult rodents, the number of granule cells does not increase and only major environmental 
influences, such as prolonged environmental enrichment and physical activity beginning already in 
adolescence, cause a neurogenesis-related volume increase in the DG. Furthermore, the relative 
composition of the DG also varies along a septo-temporal axis, whereby the septal part contains 
more granule cells than the temporal part of the HPC. The two main neurotransmitter classes found 
throughout the hippocampal formation are the excitatory glutamate and the inhibitory GABA. Both 
transmitter classes are represented by a variety of distinct neuronal subclasses such as pyramidal 
basket cells, mossy fibers or granule cells, some of which have been shown to entail both 
glutamatergic and GABAergic markers (Freund and Buzsaki, 1996; Rapp and Gallagher, 1996; 
Kempermann et al., 1997; Kempermann et al., 1998; Anderson et al., 2007).   
Many studies have focused on either the glutamatergic or GABAergic importance for a functioning 
hippocampal formation and subsequently for a successful cognitive performance. In particular 
glutamatergic signaling via the N-methyl-D-aspartate receptor (NMDAR) or the metabotropic 
glutamate receptor 5 (mGluR5) has been shown to be important for hippocampus-dependent spatial 
or contextual learning in rodents, and has additionally been connected to cognitive deficits in 
neurodegenerative diseases (Andre et al., 2014; Kaur et al., 2014; Zhang et al., 2014; Zhang and 
Manahan-Vaughan, 2014). A malfunction of GABAergic interneurons, particular for the HPC, on the 
other hand, has been more closely associated to dis-inhibition in epilepsy or the hallucinatory aspects 
of schizophrenia (Takechi et al., 2009; Gill and Grace, 2014). However, the feed-forward inhibition by 
fast spiking GABAergic interneurons in the CA3 region has also been shown to be necessary for 
spatial learning capabilities. Overall, GABAergic interneurons represent an important counterpart to 
the excitatory neurons throughout the CNS. And although GABAergic interneurons represent only a 
minor percentage of total cortical neurons, a disruption of their equilibrium-maintaining qualities has 
detrimental physiological consequences, as seen in a number of neurological and neuropsychiatric 
disorders, such as depression, schizophrenia or epilepsy (Sanacora et al., 2000; Wong et al., 2003; 
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Markram et al., 2004; Fatemi et al., 2005; Jinno and Kosaka, 2010; Ruediger et al., 2011; Kullmann et 
al., 2012; Lehmann et al., 2012; Inan et al., 2013; Gilani et al., 2014; Reichel et al., 2015b). 
GABAergic interneurons can be divided into subclasses based on their morphology, their expression 
of calcium-binding proteins (e.g. parvalbumin, calbindin or calretinin), the co-expression of 
neuropeptides (e.g. somatostatin, cholecystokinin or vasointestinal peptide) and electrophysiological 
properties. Each of these subclasses has been linked to particular functions and/ or distributions 
throughout the forebrain, whereby Parvalbumin-positive (PV+) interneurons represent the largest 
subclass and have been especially implicated in learning and memory related neuronal plasticity 
(Freund and Buzsaki, 1996; Caillard et al., 2000; Markram et al., 2004; Lee and Soltesz, 2011; Donato 
et al., 2013; Kubota, 2014). 
Besides the previously mentioned septo-temporal distribution-axis of granule cells in the DG and 
reports that the ventral HPC contains approximately twice as many GABAergic neurons than the 
dorsal HPC, recent studies have also elucidated distinct behavioral functions of the dorsal and ventral 
HPC. The dorsal HPC is proposed to be more closely linked to declarative or explicit cognitive 
functions such as spatial learning abilities, whereas the ventral HPC is more closely associated to 
“emotional learning” and anxiety-related behavior (Bannerman et al., 2003; Ferbinteanu et al., 2003; 
Barkus et al., 2010; Fanselow and Dong, 2010; Jinno and Kosaka, 2010; Strange et al., 2014). 
Anxiety-related behavior as well as emotional and associative learning is additionally often linked to 
the amygdala (Amy). The Amy can be subdivided into multiple structurally and functionally distinct 
sub-regions including the central amygdala, the lateral amygdala and the basolateral amygdala. The 
central amygdala is widely regarded as an inhibitory node, due to its high percentage of GABAergic 
neurons. Sensory inputs from cortical or thalamic circuits enter the amygdala formation 
predominantly through the lateral subdivision. Subsequently the information is computed within the 
entire amygdala formation via feed-forward and feed-back inhibition before the final output is 
released from the central amygdala (Swanson and Petrovich, 1998; Ehrlich et al., 2009). 
The prefrontal cortex (PFC) on the other hand, is closely associated with impulse control and 
cognitive flexibility and is implicated in the cognitive deficits observed in e.g. PTSD or Schizophrenia 
patients. The PFC consists of the anterior cingulate-, prelimbic and infralimbic cortex (ACC/ PrL/ IL), 
and recent studies have investigated the specific contributions of ACC, PrL and IL in the context of 
cognitive flexibility. Remarkably, these studies have revealed opposing effects of PrL and IL. 
Specifically, activation of the PrL is reported to enhance central amygdala output and thereby 
enhance fear responses, whereas the IL is proposed to inhibit amygdala activity and thus decreases 
subsequent fear responses (Vidal-Gonzalez et al., 2006; Van De Werd et al., 2010; Ashwell and Ito, 
2014).  
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1.4.2. Behavioral tests to assess cognition in rodents 
Admittedly, no cognitive task requires the sole activation of only one of the above described 
structures. Typically HPC, Amy and PFC are all involved in the successful acquisition of a cognitive 
task, and depending on the circumstances and the specific nature of the task, one structure might be 
preferentially required compared to the others. In order to assess distinct deficits in HPC, Amygdala 
or PFC, specific tasks have been developed that usually require a weighted involvement of one of 
these structures compared to the others in order to successfully solve the task.  
 
1.4.2.1.  Spatial learning and cognitive flexibility 
One of the first examples for a spatial learning task in rodents was the cross-maze for rats by Tolman, 
Ritchie and Kalish, who studied both the spatial- and the response-learning abilities of rats (Tolman 
et al., 1946). This (dry) maze consisted of four arms, at the end of two of which a food reward could 
be located; the other two arms could be used as starting positions. Using extra-maze (allocentric) 
cues, the rats were trained to learn the food-position, even when alternating the starting positions 
(i.e. spatial learning). The animals could also be trained in this maze via intra-maze (egocentric) cues 
in a response-based learning protocol. For this, the food-position was changed in accordance to the 
start-position, requiring the animals to always use the same “body-turn” (e.g. always “go left”) to 
reach the target.   
Today it is known that spatial learning heavily depends on an intact hippocampus (Morris et al., 1982; 
Morris, 1984), whereas successful egocentric response-learning relies on the dorsolateral striatum 
(Featherstone and McDonald, 2004). While Tolman used a dry cross maze, Morris established the 
Morris water maze (MWM), a round basin filled with water and subdivided into four virtual 
quadrants. A (hidden) platform is located in one of the quadrants and test-animals are trained to find 
it. Due to their inherent aversion to water, mice and rats are motivated to locate the platform and 
swim directly to it. The latency to reach the platform and the path length are recorded and function 
as learning parameters to assess cognitive abilities (Morris et al., 1982; Morris, 1984).  
The water cross maze (WCM) constitutes a combination of both of these mazes. Hereby a four-
armed maze is filled with water and a platform can be positioned at the end of one of two arms, 
while the other two arms serve as alternating starting positions. If the platform is always placed in 
one arm, but the starting positions are alternated, spatial learning abilities can be assessed; if the 
platform position is always moved in tandem with the starting position, an egocentric response-
based learning is enforced (Kleinknecht et al., 2012). 
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Tolman’s maze, the MWM and the WCM can all be used to assess hippocampus-dependent spatial 
learning capabilities of rodents over the course of multiple days (usually 4 – 7 days, depending on the 
protocol). However, for instance PTSD- or schizophrenic patients typically don’t present with 
cognitive deficits primarily related to hippocampus-dependent learning tasks, but rather display 
short-term memory-, attention- or cognitive flexibility deficits. Therefore, additional protocols have 
been devised which enable the investigation of cognitive flexibility via MWM or WCM, i.e. reversal 
learning. Hereby a previously acquired platform position is moved, causing the test-animals to re-
learn the new position and thus adjust their previous swimming strategy. Intact cognitive flexibility, 
or set-shifting, has been ascribed to the PFC (Jones, 2002; Bissonette et al., 2013; Reichel et al., 
2015b). Additionally, increased neurogenesis has also been shown to be beneficial for cognitive 
flexibility as well as pattern separation (Burghardt et al., 2012; Niibori et al., 2012).  
 
1.4.2.2. Short-term memory and attention deficits 
Attention- or short-term-/ working memory deficits can be assessed using for instance a T- or Y-maze 
task and analyzing “spontaneous alternation”. This refers to the fact, that a mouse (or a rat) will 
explore a different arm/ part of the maze, if put back a second time in a previously explored maze 
within minutes of the first exploration (Deacon and Rawlins, 2006). Furthermore, the object 
recognition task can be employed to investigate either long-term or short-term memory deficits of 
rodents, depending on the time interval between initial sample (i.e. exploration) phase and the 
subsequent choice phase. During the sample phase the animals are allowed to explore two objects, 
one of which is later replaced by a novel object (i.e. choice phase; for more details please see chapter 
2.2.6.). If the short-term memory of the animal is intact, it should remember the initial exploration 
and the natural tendency for rodents would be to explore the novel object more, than the familiar 
one (Bevins and Besheer, 2006; Ennaceur, 2010; Leger et al., 2013). Furthermore the surrounding 
conditions, such as spatial positions of the objects or light intensity and interval between exploration 
sessions can be adjusted according to the question of interest. Especially the light conditions can 
interfere with experimental results, as for instance mice are active in the dark and exhibit heightened 
anxiety behavior under light conditions (Kulesskaya and Voikar, 2014). Heightened anxiety as well as 
other emotional components have been shown to negatively affect the cognitive performance of 
rodents (Zurkovsky et al., 2007; Wingard and Packard, 2008; Packard, 2009). Therefore anxiety-
inducing factors have to be controlled for when assessing cognitive abilities of rodents- unless of 
course their effects are at the center of the investigation. 
 
 
Introduction 
 
- 20 - 
 
1.4.2.3. Fear conditioning and extinction training 
Fear conditioning (FC) is a widely used paradigm to investigate learning and memory related 
questions in rodents. In general the animals are hereby exposed to an aversive stimulus such as an 
air-puff or a foot-shock and their ensuing fear-response (e.g. freezing behavior, i.e. total lack of 
movement) is assessed by varying protocols. For instance, for contextual fear conditioning animals 
are placed in a distinct conditioning-context where they are exposed to the aversive stimulus, e.g. a 
mild inescapable foot-shock. If the animals are put in the same context again, they display increased 
freezing behavior. The foot shock (unconditioned stimulus, US) can also be coupled to an explicit 
conditioned stimulus (CS; cued fear conditioning), e.g. a tone. If CS and US are paired, both 
hippocampus-dependent contextual-fear memory, as well as amygdala-related tone-fear memory 
can be assessed individually. If then the tone is presented to the animals again after cued FC- even in 
the absence of the US and in a different (i.e. novel) environment, the animals also display increased 
freezing behavior. Increased freezing behavior in a novel environment in the absence of the CS is 
referred to as “generalized fear” and is of particular interest in the context of PTSD-related 
investigations. Furthermore the CS can be presented at different time-points with respect to the US. 
For instance, the CS can co-terminate with the US, or the CS can be presented as a precursor to the 
US (i.e. trace-fear conditioning), whereby CS and US are separated by a short time-interval. However, 
trace-fear conditioning typically requires more than one trial for the animals to acquire the CS-US 
pairing. Depending on the FC protocol and its inherent emphasis on context or cue (e.g. tone), the 
specific deficits of HPC or amygdala can be assessed (Kim and Jung, 2006; Siegmund and Wotjak, 
2007; Herry et al., 2008; Wingard and Packard, 2008; Curzon et al., 2009; Raybuck and Lattal, 2011; 
Catani et al., 2013; Lugo et al., 2014).  
Moreover, once animals have acquired a distinct fear memory, they can undergo extinction training. 
Hereby the CS is repeatedly presented to the animals in the absence of the US and the animals learn 
that the CS is no longer predicting the aversive stimulus. Thus, their fear response to the CS 
decreases. This re-learning process is again largely ascribed to the PFC, and in particular to IL-activity. 
The IL is proposed to inhibit amygdala activity und therefore decrease the fear response. However, 
spontaneous recovery of the fear response has been observed in rodents as well as in humans after 
extinction training. This has been shown to be mediated by e.g. increased stress-levels, i.e. increased 
glucocorticoid levels, which in turn decreases IL activity and subsequently (re-)activates amygdala 
and thereby enables the re-occurrence of the fear response (Golub et al., 2009; Plendl and Wotjak, 
2010; Bissonette et al., 2014; Cruz et al., 2014; Maren, 2014).  
Lastly, as mentioned above, neurogenesis has been shown to be beneficial for the re-learning of a 
spatial learning strategy in the MWM and in particular for pattern separation with respect to 
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swimming to the correct platform. However, it has also recently been reported that increased 
neurogenesis “induces forgetting” and thus decreases contextual freezing levels and generalized fear 
responses after fear conditioning. These seemingly contradictory consequences of increased 
neurogenesis, i.e. improved spatial learning but decreased contextual fear memory, are currently 
undergoing in-depth investigations (Kheirbek et al., 2012; Frankland et al., 2013; Akers et al., 2014).  
 
As mentioned at the beginning of this chapter, due to the closely interconnected network of dorsal 
HPC – ventral HPC – Amygdala and PFC (as well as the mediation by NAcc), the behavior that can be 
assessed in the described cognitive task is of course a result of a (differentially weighted) combined 
network-function and modulation, as opposed to a linear effect of the dysfunction of one structure. 
Furthermore, one should always keep in mind that all behavioral assessments are easily influenced 
by the emotional state of the test animals (e.g. long- and short-term stress/ anxiety; see above) as 
well as the age of these animals. Moreover, physical activity (e.g. latency in a swimming task) or age-
dependent physiological deficits (e.g. hearing loss) can strongly influence and bias behavioral read-
outs. Therefore the appropriate tests have to be chosen, depending on test-animals and research 
question. 
 
 
1.5. Animal models of Disease 
As described above, each disease and disorder has their own physiological hallmarks affecting e.g. in 
particular HPC or PFC; therefore specific animal models have been developed in order to represent 
the physiological basis found in human patients.  
 
1.5.1. Animal models of Alzheimer’s Disease 
As previously mentioned, AD has genetic as well as environmental risk factors, and while mice do 
develop age-dependent cognitive deficits, they do not naturally develop AD-defining a-beta plaques 
or tau-tangles. Therefore, a number of transgenic mice have been generated that (over-) express 
protein-members of the amyloid-precursor protein (APP) to amyloid-beta-pathway, or are involved in 
the generation of tau-tangles. The first AD related transgenic mouse model was the PDAPP mouse 
and expressed high levels of the human mutant APP (Games et al., 1995; Bryan et al., 2009). This 
model developed a-beta deposits and synaptic loss and showed memory impairments in the MWM 
learning task, but not for contextual fear conditioning (Gerlai et al., 2002). The cognitive 
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impairments, however, have been observed for this model even at a younger age, before structural 
deficits or a-beta plaques are apparent (Kobayashi and Chen, 2005), thereby infringing on construct 
and face validity.   
Shortly after the PDAPP transgenic AD-mice, the generation of another model, the Tg2576 mice, was 
reported. These mice over-express the Swedish double mutant form of APP695 and develop 
cognitive deficits at the age of approximately 10 months (Hsiao et al., 1996). Similarly to PDAPP mice, 
these cognitive impairments extend in particular to spatial learning tasks, but do not affect cued-fear 
conditioning paradigms (Corcoran et al., 2002).  
The formation of a-beta plaques not only involves members of the APP family, but additionally 
requires distinct β- and γ-secretase enzyme activity. One of the human mutations known to cause 
familiar AD is a mutation in the enzyme presenilin (PS), which modulates γ-secretase activity. PS1 
constitutive knockout mice die soon after birth, but adult-inducible PS1 and PS2 knockout mice are 
viable and develop cognitive impairments, albeit less severe than Tg2576 mice. PS1 over-expressing 
animals have also been generated, but they do not develop a-beta plaques or cognitive deficits 
(Kobayashi and Chen, 2005; Spires and Hyman, 2005; Bryan et al., 2009).  
In order to model the human situation more closely, animals carrying multiple AD related transgenic 
modifications have also been generated. The first model involved APP and PS1 (APP+PS1) and 
developed spatial learning deficits at the age of approximately 15 months, even though a-beta levels 
are reportedly markedly increased already at an age of 6 months (Holcomb et al., 1998; Bryan et al., 
2009). There are a few additional transgenic a-beta related AD animal models available today, mostly 
combining some of the above mentioned mutations or refining them. Some of these models even 
present with a-beta plaques at the age of nine weeks (Chishti et al., 2001), but all of them only 
present specific aspects of the disease and are not able to recapitulate the entire spectrum of 
symptoms observed in human patients. By now, most of these models are only cognitively assessed 
via spatial learning tasks, whereas other aspects of cognitive decline in AD are often under-
represented in animal studies (Bryan et al., 2009; Edwards et al., 2014). 
In addition to the a-beta related AD mouse models, tau-tangle-models have also been developed. 
These mice present with neurofibrillary tangles throughout the HPC and neocortex and cognitive 
decline has been observed in the MWM at 4 months of age (Götz et al., 2001). 
Lastly, in an attempt to model the human situation even more closely, mouse models combining APP, 
PS1 and NFT pathologies have been developed: the 3xTg-AD mice. These mice develop a-beta 
plaques and shortly thereafter also NFTs, both of which begin in the HPC and subsequently spread 
throughout the cortex. Once again, these mice display impairments for the MWM task, but not for 
instance for the object recognition task (Oddo et al., 2003; Bryan et al., 2009). 
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1.5.2. Animal models of Parkinson’s Disease 
PD is defined by the loss of dopaminergic neurons in predominantly the substantia nigra pars 
compacta (SNpc), but also affecting e.g. amygdala, entorhinal cortex and HPC (Braak and Braak, 
2000). This dopaminergic loss ultimately also causes striatal lesions and pronounced motor 
impairments. Treatment with Levodopa (L-DOPA), a biochemical precursor in the synthesis of 
dopamine, can transiently mask the loss of dopaminergic neurons, but does not halt or stop disease 
progression. Approximately 10 % of PD cases are based on genetic mutations; the remaining 90 % of 
occurrences are proposed to be a combination of genetic predisposition, life-style choices (e.g. 
alcohol intake) and the exposure to environmental toxins, particularly those that are increasing the 
amount of reactive oxygen species (ROS). Therefore, both genetic and toxic-insult animal models of 
PD are established, whereby the toxin-based models are most commonly used. 
The two most common toxin-based models are the 6-Hydroxydopamine (6-OHDA) and the MPTP (1-
Methyl-4-phenyl-1,2,3,6-tetrahydropyridin) model, both of which do not cause alpha-synuclein 
plaques (i.e. lewy bodies; LB). Although 6-OHDA is a product of the endogenous dopamine 
biosynthesis, it is also neurotoxic and if it accumulates in the cytosol of neurons, it kills the affected 
cells. 6-OHDA can be taken up by the norepinephrine transporter (NET), but has a high affinity for 
monoaminergic neurons, is thus preferentially transported via e.g. the dopaminergic (active) 
transporter (DAT) and can spread across neurons. However, 6-OHDA does not cross the blood-brain 
barrier and is therefore administered locally in the SNpc or the striatum. Affected neurons in the 
SNpc show signs of degeneration within 24 hours and die soon thereafter, whereas application in the 
striatum causes a slower (retrograde) degeneration lasting up to three weeks. Injections are usually 
done unilaterally, since bilateral application has been shown to be lethal or cause severe side effect 
such as seizures. Furthermore, comparisons between the lesioned and the un-treated side are useful 
when assessing novel therapeutic approaches such as neuronal transplantation. Although 6-OHDA 
injections are typically done unilateral and dopaminergic lesions occurring during PD are bilateral, 
the 6-OHDA disease model nonetheless causes well-defined motoric deficits on the contralateral side 
to the injection. However, this model is most commonly used to assess the molecular mechanisms 
associated with the loss of dopaminergic neurons, rather than the behavioral effects (Dauer and 
Przedborski, 2003; Jackson-Lewis et al., 2012; Torres and Dunnett, 2012).  
In contrast to the 6-OHDA-model, MPTP does cross the blood-brain barrier and can therefore be 
administered either directly to the CNS via stereotactic surgery or via acute, sub-chronic or chronic 
i.p. injection regiments. MPTP is the most commonly used PD model to date, and was first discovered 
by serendipity as a PD-like symptom-inducing substance. Illegal intravenous drug use had caused 
Parkinson-like symptoms including postural instability and tremors for a number of young-adult 
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humans. It had later been found that the responsible substance in the drug was MPTP, which has 
since been shown to induce PD-like symptoms in mice and monkeys that are attenuated by L-DOPA 
administration, similar to the effects seen in human PD patients. Moreover, these behavioral findings 
appear to be due to similar mechanisms both in MPTP toxicity and in PD: preferential loss of 
dopaminergic neurons in the SNpc. Interestingly, once MPTP crosses the blood-brain barrier, it does 
not directly affect dopaminergic neurons, but is first taken up by glia cells or serotonergic neurons, 
which convert MPTP to its active state of MPP+ via monoamine oxidase-B (MAO-B), before releasing 
it to the extracellular space. MPP+, similar to 6-OHDA, has a high affinity for DAT, and deletions of 
this transporter have indeed been shown to be protective against MPP+ toxicity. Also similar to 6-
OHDA, MPP+ affects all monoaminergic neurons, but is particularly toxic, i.e. induces relatively more 
and faster degeneration, for dopaminergic neurons. The underlying mechanisms of this distinction 
have not been conclusively resolved (Sedelis et al., 2001; Dauer and Przedborski, 2003; Jackson-Lewis 
and Przedborski, 2007; Antzoulatos et al., 2010; Jackson-Lewis et al., 2012). 
In order to assess the MPTP-lesion efficacy or to test novel therapeutic approaches animals often 
undergo behavioral testing to determine their impairment. Two very common tests are the Open 
Field test, assessing basic activity such as distance moved or number of rearings; and the rotarod 
test, which assesses motor abilities and motor learning. Additional test can be used to asses e.g. grip 
strength or gait-alterations of the animals (e.g. by recording foot-prints), and even nest-building has 
been reported to be affected by MPTP lesioning (Sedelis et al., 2001). 
 
1.5.3. Animal models of Schizophrenia 
Given the complexity and variety of symptoms presented by schizophrenic patients (i.e. positive- and 
negative symptoms as well as cognitive deficits; see above), animal models of Schizophrenia often 
represent only distinct features of the disease, as for instance hallucinations cannot be sufficiently 
modeled in animals. Most of the models therefore focus on construct and predictive validity, rather 
than on face validity. In other words, distinct symptoms of Schizophrenia, such as anhedonia, 
impaired sensorimotor gating or deficits in working memory are reproduced in animal models and 
their neurobiological mechanisms are investigated. These findings are then commonly cross-
compared to the alterations observed in schizophrenic patients. Additionally, although not a 
symptom of schizophrenia, hyper-locomotion in rodents is often used to assess anti-psychotic drug-
efficacy and in particular their effects on the dopaminergic system.  
A core feature of schizophrenic patients is the apparent inability to filter or “gate” sensory input. This 
can be modeled in animals via so-called pre-pulse inhibition or –facilitation tests. Hereby an acoustic 
stimulus that would provoke the acoustic startle reflex is preceded by a less intensive pre-pulse, 
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which modulates (i.e. gates) the startle reflex. Depending on the intensity of the pre-pulse and the 
interval between pre-pulse and actual startle impulse, the resulting (combined) startle response is 
either decreased (i.e. pre-pulse inhibition; PPI) or increased (i.e. pre-pulse facilitation; PPF) in relation 
to the basal startle response only to the main startle impulse. Typically, schizophrenic patients 
present with deficits regarding pre-pulse inhibition.  
The cognitive deficits ascribed to schizophrenic patients vary and are often even worsened by anti-
psychotic treatments (e.g. haloperidol). However, these deficits are rarely generalized and are mostly 
related to working memory or cognitive flexibility. In rodents this can be assessed for instance in the 
MWM or WCM, employing the reversal learning protocols described above.  
In order to induce schizophrenia-like symptoms in animal models several approaches are used: 
pharmacological models, developmental models and genetically modified models. Pharmacological 
models display drug-induced schizophrenia-like symptoms that have also been observed in non-
schizophrenic humans after the ingestion of these specific compounds. For instance, both dopamine-
agonists and antagonists have been used to induce and block hyperactive (i.e. psychosis-related) 
phenotypes. Additionally, serotonin-agonists such as LSD (lysergic acid diethylamide) and glutamate 
receptor antagonists such as PCP (phencyclidine; “angel dust”) have been used to induce psychosis-
like states in animal models. While these models usually have high “pharmacological isomorphisms”, 
meaning they respond well to antipsychotic drugs (i.e. predictive validity), they do not provide 
additional insight to disease etiology or underlying mechanisms.  
Pre- and perinatal events, such as infection during pregnancy, have also been associated with an 
increased risk to develop Schizophrenia; therefore a number of developmental models are 
established. For instance neonatal excitotoxic lesioning of the ventral hippocampus has been shown 
to induce a number of disease-related behavioral alterations as well as molecular similarities that are 
attenuated by antipsychotic drugs. 
Lastly, human twin studies have clearly demonstrated a genetic component in the disease etiology; 
therefore genetically modified models have also been established. For instance, knockout mice of 
distinct dopamine receptor subtypes have been used to assess their implication in the disrupted PPI 
response and it has been shown, that the D2 subtype is predominantly involved in the amphetamine 
induced PPI deficit. Furthermore, since the discovery of the “Disrupted in schizophrenia-1” (DISC1) 
gene, a number of genetically modified mice have been generated and a down-regulation of DISC1 
has been found to cause schizophrenia-like phenotypes in the animals. Ongoing studies are further 
investigating the specific neurobiological mechanisms as well as potential predictive validity of these 
new models (Swerdlow and Geyer, 1998; Geyer et al., 2002; Tamminga and Holcomb, 2005; Powell 
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and Geyer, 2007; Goff et al., 2011; Ibrahim and Tamminga, 2012; Holley et al., 2013; Barnes et al., 
2014; Gòmez-Sintes et al., 2014; Meyer, 2014; O'Tuathaigh et al., 2014). 
 
1.5.4. Animal models of PTSD 
PTSD develops as a result to a (life-threatening) traumatic event in humans. For ethical reasons a 
truly life-threatening event, e.g. real-life exposure to a predator, can hardly be modeled in animals. 
This has to be taken into account when interpreting the findings of PTSD-related studies in animal 
models. Nonetheless, a number of “trauma-like” stressors have been established that reproduce 
several key findings of human PTSD-patients. For instance, animals can be exposed to a predator 
odor (e.g. rats and mice can be exposed to cat or fox urine), prolonged stress (e.g. animals are 
(repeatedly) restrained for > 10 min) or even a single inescapable foot shock. However, for PTSD-
related studies, as opposed to purely learning and memory related fear conditioning studies, the foot 
shock is usually more intense (e.g. 1.5 mA opposed to 0.7 mA). Furthermore, with respect to face 
validity, animal models of PTSD should present with a heightened generalized fear response after 
prolonged fear-incubation. Meaning, the fear response of animal models of PTSD is often not 
assessed 24 hours after the “traumatic event”, but after a “fear-incubation-interval”, e.g. one month 
later, in order to mimic the delayed PTSD-symptom onset in human patients. The most commonly 
used animal (rodent) models of PTSD have all been shown to reproduce one or more of the following 
hallmarks of PTSD: altered glucocorticoid levels including structural effects on hippocampal and 
amygdala dendritic arborization, hippocampal volume decrease, sleep disturbances, increased 
contextual and generalized fear responses as well as hyper-arousal and generalized avoidance (Vyas 
et al., 2002; Siegmund and Wotjak, 2007; Glover et al., 2011; Golub et al., 2011; Pamplona et al., 
2011; Daskalakis et al., 2013; Polta et al., 2013). These molecular, structural and behavioral effects 
can subsequently be assessed and modulated via biochemical therapeutic intervention, e.g. 
fluoxetine or valproate. Furthermore, a CS-US coupled PTSD model is particularly useful to study the 
effects of exposure based extinction training and spontaneous recovery of the fear response (Golub 
et al., 2009; Heinrichs et al., 2013; Schmidt et al., 2013). The findings of these studies can then, in 
turn, be applied for the treatment of human PTSD patients. 
Since only about 10 % of trauma exposed people will consequently develop PTSD, additional factors 
aside from the trauma itself have to be taken into account. Therefore, several lines of investigation 
related to the development of PTSD also focus on the effects of genetic predispositions and early-life-
events, which are associated with epigenetic changes and have been shown to increase the 
vulnerability to develop PTSD or PTSD-like symptoms in animal models. Seemingly contradictory 
results with regard to stress exposure in early life and the likelihood to develop psychiatric symptoms 
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has furthermore led to the “mismatch” hypothesis. This hypothesis states that when stress levels 
stay the same throughout life, psychiatric incidences are decreased, but if early-life minor stress 
levels coincide with late-life heightened stress levels, the development of psychiatric symptoms is 
more frequent. This “match/mismatch” hypothesis extends to several stress-related disorders such 
as PTSD or MDD (Uddin et al., 2010; Schmidt, 2011; Schmidt et al., 2011; Holmes and Singewald, 
2013).  
 
1.5.5. Additional approaches to study cognition in animal models  
It is of course impossible to generate a specific mouse model for every disease, and even if one exists 
it often does not encompass every hallmark of the human condition (see above). Consequently, 
additional approaches have been developed which often focus on the function of specific neuronal 
populations or receptors, e.g. as mentioned above for mGluR5 and spatial learning. However, the 
genetic ablation of an entire receptor class is often either lethal or causes a plethora of symptoms, 
compensatory mechanisms and side-effects. Thankfully, recent advances now enable the targeted 
(transient) activation or inactivation of a defined population of receptors at distinct time points: the 
optogenetic tool box (Fenno et al., 2011; Yizhar et al., 2011). This methodological approach combines 
the Cre-dependent (conditional) expression of light-sensitive channel-proteins (-opsins), that can be 
activated by distinct light wave-lengths. This activation then, depending on the expression site, 
causes activation or inactivation of the targeted neuronal receptor and thereby facilitates the 
investigation into the signal transduction mediated by these specific receptors and ultimately their 
effect on the behavior of the animal. This approach has since been extended from mice to rats and 
even primates (Diester et al., 2011; Witten et al., 2011; Madisen et al., 2012).  
Another recently established approach to investigate distinct signal transduction pathways is the 
conditional transgenic expression of DREADDS (Designer Receptor Exclusively Activated by Designer 
Drug), which are activated by clozapine-N-oxide (CNO) and can also be used to activate or silence a 
specific pathway (Armbruster et al., 2007; Nair et al., 2013).  
While the optogenetics- and DREADD approaches are both very sophisticated and enable the 
manipulation and functional investigation of distinct neuronal populations and pathways, most 
cognitive deficits observed in psychiatric or neurodegenerative diseases are the result of global 
impairments rather than single malfunctioning receptors. Vice versa, due to technical limitations 
both approaches are (so far) not feasible to manipulate entire large brain structures (such as e.g. the 
hippocampus). However, one appoach to do so, are for instance exitotoxic lesions administered 
through stereotactic surgery. Hereby even large brain structures, such as the HPC, can be 
manipulated via e.g. ibotenic acid infusion and subsequently behavioral and structural consequences 
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can be assessed without the additional confounding factor of a genetic manipulation (Kleinknecht et 
al., 2012). 
Similarly, the application of toxin-conjugated anitibodies has been established in order to affect 
entire brain structures. This method introduces e.g. saporin-conjugated antibodies into a distinct CNS 
structure via stereotactic surgery. These antibodies are then taken up by selected neurons, 
depending on the antibody target. For instance, saporin-conjugated anti-vesicular GABA transporter 
antibodies (SAVAs) are selectively taken up by GABAergic interneurons (Antonucci et al., 2012). This 
specificity is achieved because SAVAs are directed against the intravesicular epitopes of the vesicular 
GABA transporter (VGAT). When the vesicles fuse with the presynaptic membrane, the transporter-
epitopes become accessible to the extracellular milieu and thus to the conjugated antibodies 
(Martens et al., 2008). Subsequently, the vesicles and the attached SAVAs are internalized and SAVAs 
accumulate in the GABAergic nerve terminals (Antonucci et al., 2012). Since saporin is toxic to the 
ribosomes, SAVA accumulation ultimately abolishes affected GABAergic neurons (Wiley, 1992; 
Reichel et al., 2015b). 
Lastly, a number of in vivo imaging techniques for small animals are also available. While imaging 
approaches have been mostly limited to purely structural comparisons for many years, recent 
methodological advances now also allow for physiological measurements via positron emission 
tomography (PET) of e.g. the expression pattern of a specific receptor in rats over time (Verdurand et 
al., 2014). Moreover, magnetic resonance imaging (MRI) is also no longer limited to structural 
observations, and can even provide non-invasive insight into the protease activity in a rat brain (Haris 
et al., 2014).   
These in vivo imaging approaches are particularly useful for aging-related investigations, since they 
can be repeated within subject and therefore provide a timeline of age-related structural and 
functional changes (Cabeza, 2001; Small et al., 2004; Fjell and Walhovd, 2010; Grady, 2012; Callaert 
et al., 2014). Ex vivo analyses of aged brain tissue on the other hand can be done via immuno-
histochemical staining for senescence-associated beta-galactosidase (SA-β-Gal), a mammalian 
inherent analog to the bacterial β-Gal based on the lacZ gene. The expression of SA-β-Gal has been 
shown to be increased in aged animals, particularly the HPC, and can thus also be correlated to 
cognitive deficits in age (Geng et al., 2010). 
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1.6. Cognition through this thesis 
 
1.6.1. Factors governing cognition 
In summary, cognition is a highly versatile and highly susceptible trait that is negatively affected by 
most neuropsychiatric and neurodegenerative diseases. The underlying mechanisms of cognitive 
abilities have been intensively investigated on a behavioral, genetic and molecular basis across 
species- yet there are many questions left unanswered.  
For instance, one major factor affecting cognitive abilities is the age of the individual. Age itself, on 
the other hand, is a major risk factor to develop neurodegenerative diseases, which in turn often 
severely impair an individuals’ cognitive abilities. Additionally, cumulative environmental triggers, 
such as stress or physical and immunological insults are also more likely to cause cognitive deficits in 
age than in the acute phase of the insult. The increased life-expectancy and therefore the increasing 
incidences of neurodegenerative- and life-time-event-related cognitive decline and the resulting 
individual and economic burden therefore necessitate further investigations into the interplay 
between disease, life-time stressful events and age as well as their respective consequences on 
cognitive abilities. 
 
 
Fig. I-2: Factors governing cognitive abilities: Cognition can be modulated by cell-type specific manipulations, structure-
specific manipulations, protein accumulation, the ageing process and environmental stressors. Varying combinations of all 
of these factors are investigated via the three projects reported in this thesis: (i) SAVA, (ii) lacZ and (iii) PTSD & Age. 
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Analogous to the numerous factors influencing cognition, the work presented in this thesis followed 
three main lines of investigation regarding the manipulation of cognitive abilities in mice: In order to 
span as many cognition-governing factors as possible, we employed three different approaches to 
either investigate the consequences of cell-type specific manipulations (e.g. GABAergic 
interneurons), structure specific manipulations (e.g. dorsal HPC), protein accumulation (a hallmark of 
neurodegenerative diseases) and environmental (traumatic) stressors with or without progressed 
age (see Fig. I-2). 
 
The three different projects are termed (i) SAVA, (ii) lacZ and (iii) PTSD & Age and are described in 
detail below. 
 
1.6.2. Project (i): SAVA 
The first project (i) SAVA investigated the consequences of the depletion of GABAergic interneurons 
in distinct brain regions of C57Bl/6N mice. To achieve this selective depletion we locally administered 
saporin-conjugated anti-vesicular GABA transporter antibodies (SAVAs; see above), which are 
selectively taken up by GABAergic interneurons (Antonucci et al., 2012). Although many genetic and 
in particular optogenetic approaches are available today to specifically ablate or silence distinct 
neuronal sub-classes, in particular the optogenetic methodology has its own drawbacks. For instance, 
it requires genetically manipulated mice, surgery to place a cannula or a fiber optic implant and the 
actual light application (Ung and Arenkiel, 2012). Genetic modifications as well as optical surgeries 
have their own limitations (e.g. compensatory mechanisms) and side-effects (e.g. off-target 
activation or local “burning” of neurons due to light-intensity) and are furthermore not practical in 
terms of silencing GABAergic interneurons throughout the entire dorsal HPC. Therefore, we chose to 
apply the SAVA-method and locally deplete GABAergic interneurons via toxin-injections. This method 
allowed for the time- and region-specific investigation of GABAergic modulations on mouse basal 
behavior and cognitive function. We investigated this cell-type specific modulation for two distinct 
structures: the dorsal hippocampus (dHPC) and the prelimbic cortex (PrL). While the PrL 
investigations only took place > 14 days after SAVA administration (i.e. long-term GABAergic 
depletion), we analyzed the long- and the short term effects (i.e. < 10 days) of GABAergic depletion in 
the dHPC. Regarding the short-term depletion we particularly focused on the consequences for the 
acquisition and the recall of a spatial memory. These manipulations were done in C57Bl/6N mice and 
following the behavioral analyses GABAergic loss was quantified via parvalbumin staining by our 
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collaboration partners Prof. Wolfgang Härtig et al. at the Paul-Flechsig Institute for Brain Research 
and the University of Leipzig, Germany (Reichel et al., 2015b). 
 Since GABAergic interneurons play a major role in the functioning equilibrium of the neuronal 
network and are closely associated to the disease etiology and cognitive deficits in schizophrenia, we 
expected severe behavioral alterations in particular after long-term (i.e. > 14 days) GABAergic 
depletion for PrL and dHPC. Specifically, regarding dHPC depletion we expected major cognitive 
deficits presenting as decreased contextual fear responses and impaired spatial learning abilities. 
Additionally, a disinhibition of the dHPC has been reported to cause hyperlocomotion, thus we 
expected an increased horizontal movement observable in the open field test. We did not expect any 
changes with respect to anxiety-related behavior or acoustic startle response following long-term 
dHPC GABAergic depletion. In contrast, SAVA administration in the PrL was hypothesized to decrease 
anxiety-related behavior as well as pre-pulse inhibition, as the PrL GABAergic network has been 
shown to be involved in the sensorimotor-gating deficits of schizophrenic patients and mouse-
models. Furthermore, we expected deficits in cognitive flexibility (i.e. reversal learning of a platform 
position), but not for the initial acquisition of a spatial memory following long-term GABAergic 
depletion in the PrL. 
Antonucci et al. (2012) previously reported the integrity of the glutamatergic neuronal network 
within 12 days of SAVA administration. Thus, in order to distinguish short-term consequences of 
GABAergic loss from long-term effects and a possible connected network dysfunction including 
secondary loss of glutamatergic neurons, we additionally assessed the short-term (i.e. < 10 days) 
consequences of GABAergic depletion in the dHPC. We tested the cognitive abilities (i.e. spatial 
learning performance) of these mice beginning already 3 days after SAVA administration. We 
analyzed both the specific involvement of dHPC GABAergic interneurons in the acquisition and the 
recall of a spatial memory and expected performance deficits following both treatments, due to the 
overall importance of the dHPC regarding spatial memories. 
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1.6.3. Project (ii): lacZ  
The second project (ii) lacZ analyzed the consequences of protein accumulation within distinct 
neuronal populations and brain structures and the interaction between protein accumulation and 
progressed age. Specifically, we investigated the consequences of lacZ expression under the 
expressional control of several different Cre-driver lines, either active beginning during 
embryogenesis (i.e. constitutive lacZ expression) or induced in adulthood.  The mice used for this 
project were kept on a C57Bl/6N genetic background for at least 10 generations. 
We chose to investigate lacZ expression, as it is a common reporter protein and widely used to assess 
transgenic manipulation efficacy. We did not generate any of the mouse lines ourselves but bred the 
lacZ reporter mice to several Cre-driver lines, and assessed the presence of the lacZ- and/or Cre-
sequences via genotyping (PCR) and X-Gal staining. Although lacZ has not been previously associated 
with neurodegenerative diseases, its lasting expression and thus accumulation once the preceding 
STOP-sequences is excised by the Cre-recombinase, constitutes one of the main hallmarks of 
neurodegenerative diseases: protein accumulation. Additionally, the Cre-driver lines enable us to 
affect distinct neuronal subpopulations, e.g. glutamatergic, GABAergic or DAT-positive neurons, thus 
allowing us to mimic the selective vulnerability of neuronal sub-populations to neurodegenerative 
diseases. Moreover, β-Gal, the protein coded for by the lacZ-sequence, is an analogue to senescence-
associated β-Gal (SA- β-Gal), which is a marker of senescent cells across mammals and has been 
shown to accumulate in neurons of aged rodents; age in turn is associated with cognitive decline 
(Dimri et al., 1995; Geng et al., 2010). 
Aside from its probable connection to a senescent cellular (and thus possibly impaired cognitive-) 
phenotype, given the vast application of lacZ-reporter mice and the proposed expansion of it, we 
thought it essential to thoroughly analyze the detailed consequences lacZ-expression and lacZ-
accumulation might have on the cognitive and general behavioral phenotype of these mice. 
Moreover, although several studies have reported un-wanted Cre-mediated side effects for 
transgenic mice, to the best of our knowledge, no one has specifically analyzed the consequences of 
lacZ expression. This is particularly surprising considering the recent efforts of several consortia (e.g. 
EUCOMM) to bundle genetic resources and generate repositories entailing transgenic lines targeting 
every protein-coding gene. Without the detailed analyses of lacZ-expression effects, it will not be 
possible to reliably interpret any results obtained in those studies (Skarnes et al., 2011; White et al., 
2013; Giusti et al., 2014; Reichel et al., 2015a).  
Therefore, we first analyzed the effects of constitutive lacZ expression under the control of a 
glutamatergic Cre-driver line. Given the widespread distribution of glutamatergic neurons and their 
involvement in many neurological diseases (e.g. AD or Schizophrenia), we expected performance 
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deficits across exploratory, anxiety-related, sensorimotor-gating and cognitive tasks; the extend of 
which possibly mimicking the deficits observed in aged rodents.  
In order to control for the specificity of the lacZ effects we also tested the glutamatergic Cre-driver 
line without lacZ expression and GFP expression under the control of the same glutamatergic Cre-
driver line, both of which were not expected to reveal behavioral alterations compared to Cre-
negative littermates. 
In order to compare the consequences of lacZ-expression for two diverging neuronal sub-populations 
we also investigated the effects of constitutive lacZ expression under the control of a GABAergic Cre-
driver line. Here we expected again hyper locomotion due to hippocampal disinhibition, 
sensorimotor gating deficits and possibly minor cognitive impairments.  
Since the accumulation of proteins related to neurodegenerative diseases does not start in utero, we 
additionally analyzed the consequences of lacZ expression when expression is induced in adulthood 
(via tamoxifen-treatment). Consequently, we first investigated the effects of adult-induced 
expression under the same glutamatergic Cre-driver line as above, thus enabling a direct comparison 
and distinction of constitutive and inducible lacZ expression effects. Here, we expected similar but 
attenuated behavioral consequences, due to a shortened expression- and accumulation period 
compared to the constitutive glutamatergic lacZ expression. 
Given that the neurodegenerative disease-characteristic protein accumulation occurs over decades 
in the human patients, we additionally investigated the consequences of long-term adult-induced 
lacZ expression under the control of two distinct Cre-driver lines (CamKIIα and DAT) and its 
interaction with age (mice were 24 months old at the end of testing). Since CamKIIα is reportedly 
predominantly expressed throughout the cortex and the hippocampus we again expected minor 
cognitive deficits which are exponentially worsened by age compared to non-lacZ expressing 
littermates (Burgin et al., 1990). 
In contrast, long-term lacZ expression in DAT positive neurons was expected to induce worsening 
motor deficits reminiscent of Parkinson-like rodent-models.  
Lastly, the adult-inducible Cre/loxP system entails a translocation of the Cre-recombinase from the 
cytosol to the nucleus upon tamoxifen administration. This was controlled for via the adult-inducible 
DAT-driven Cre-line without being bred to R26R mice, and was not expected to reveal any 
phenotypic consequences. 
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1.6.4. Project (iii): PTSD & Age 
The third project (iii) PTSD & Age investigated the consequences of one or two traumatic events in 
middle age on the cognitive abilities in age of a mouse model of PTSD. Therefore, C57Bl/6N mice 
were exposed to an inescapable foot-shock at the age of five months, which results in a PTSD-like 
phenotype one month later (Siegmund and Wotjak, 2007). Additionally, half of these mice 
underwent a second stressor via an etiologically-relevant “earthquake-like” procedure at the age of 
12 months. Subsequently, the anxiety-related behavior and cognitive abilities regarding short-term 
memory and spatial learning were tested at the age of 14 to 16 months. We expected single-stressed 
mice to display cognitive impairments in age that would be worsened in mice that underwent 
multiple stressors.   
 
In summary, the work presented in this thesis aims to investigate and analyze the specific 
consequences of cell-type and CNS-structure specific manipulations, protein accumulations and 
environmental stressors in conjunction with progressed age on the cognitive and general behavioral 
phenotype of mice. These above described manipulations were chosen as each of them has been 
reported as a major factor for many neurological diseases that commonly present with cognitive 
impairments. 
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2 Materials and Methods 
 
All experimental procedures were approved by the Committee on Animal Health and Welfare of the 
State of Bavaria (Regierung von Oberbayern, Munich, Germany) and were performed in compliance 
with the European Economic Community (EEC) recommendations for the care and use of laboratory 
animals (2010/ 63/ EU). The projects were approved under the following file numbers: AZ 55.2-1-54-
2532-142-12, AZ 55.2-1-54-2532-141-12 and AZ 55.2-1-54-2532-41-09. Every effort was done to 
minimize animal suffering and the number of animals used. 
 
2.1. Projects of this thesis – general conditions for mice  
This thesis consists of three main projects: (i) SAVA, (ii) lacZ and (iii) PTSD & Age. For all projects we 
employed exclusively male mice, for (i) + (iii) we employed wild-type C57Bl/6N mice, either from the 
MPI breeding facility in Martinsried, Germany (i), or the commercial vendor Charles River, Germany 
(iii). The transgenic mice for the (ii) lacZ project were bred in the MPI breeding facility in Martinsried 
on a C57Bl/6N genetic background for at least 10 generations. All mice were housed in type II 
standard Makrolon cages at an inverse light/dark cycle (lights ON 9:00 p.m. - 9:00 a.m.), and were 
provided with food and water ad libitum starting at least 10 days prior to behavioral testing. All 
behavioral experiments were performed during the lights-off phase (= activity phase of mice). For a 
complete overview of all mice used, please see tables M-1 through M-3. 
 
2.1.1. Project (i): SAVA 
Animals for the SAVA project (C57Bl/6N mice; Martinsried) arrived at the age of 10 weeks and were 
allowed to acclimatize to the new environment for at least 10 days. Following surgery, animals were 
single-housed throughout the experiments.  
The Saporin-conjugated anti-vesicular GABA transporter antibodies (SAVAs) were provided by 
Synaptic Systems GmbH (Dr. Henrik Martens) and were prepared as previously described (Antonucci 
et al., 2012).   Briefly, 1 mg reduced rabbit anti-VGAT-C (131 103, Synaptic Systems) was coupled to 2 
mg of saporin (Sigma-Aldrich) with the bifunctional cross-linker sulfosuccinimidyl 6-[α-methyl-α-
(pyridyldithio) toluamido] hexanoate (sulfo-LC-SMPT, Thermo Scientific). Free saporin was removed 
by affinity purification of SAVA against VGAT-C immunogen immobilized on sulfo-link-Sepharose 
(protocol provided by Dr. H. Martens; (Reichel et al., 2015b)). For further details regarding 
application-timelines etc. please see below (chapter 2.5.1).  
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Table M-1: Animals used for project (i): SAVA  
SAVA group strain sex # n/ Group 
I (dHPC) C57Bl/6N (M) male 24 
8 x PBS (1†) 
8 x ucAB 
8 x SAVA 
II (PrL) C57Bl/6N (M) male 20 
10 x PBS 
10 x SAVA 
III (dHPC – acq) C57Bl/6N (M) male 30 
14 x PBS (1†) 
16 x SAVA (2†) 
IV (dHPC – rec) C57Bl/6N (M) male 26 
10 x PBS 
16 x SAVA (2†) 
TOTAL N   100 94 
 
acq = acquisition; dHPC = dorsal hippocampus; M = Martinsried; PBS = phosphate buffered saline; PrL = prelimbic cortex; 
rec = recall; SAVA = Saporin- conjugated anti-vesicular GABA transporter antibodies; ucAB = unconjugated antibody; † = 
died before behavioral screen was completed. 
 
2.1.2. Project (ii): lacZ 
 
2.1.2.1. Generation of mouse-lines for the lacZ project 
The mice for the lacZ project were bred in the MPI breeding facility in Martinsried, Germany, under 
the guidance of Dr. J. M. Deussing (Research Group leader “Molecular Neurogenetics” at the Max 
Planck Institute of Psychiatry) and A. Varga (Coordinator of animal facilities for the Max Planck 
Institute of Psychiatry).  All of these mice were bred on a C57Bl/6N genetic background for at least 10 
generations. Reporter-gene expression (i.e. lacZ expression) in the CNS was achieved via conditional 
mutagenesis by employing the Cre/loxP system (Hoess et al., 1982; Deussing, 2013). Mouse lines 
expressing lacZ were generated by breeding homozygous lacZ/lacZ ROSA26 reporter (R26R) mice 
(Soriano, 1999) to different heterozygous Cre-driver lines (i.e. Cre+/-). The lacZ sequence in the R26R 
mice is preceded by a floxed (i.e. flanked by two loxP sites) STOP sequence that prevents lacZ 
expression. The loxP sites are recognized and subsequently excised by Cre-recombinase, thereby 
enabling lacZ expression in all cells expressing the Cre-recombinase (for further details please see 
chapter 1.3.2. or Fig. M-1).   
In order to investigate the consequences of lacZ expression in cortical principal glutamatergic 
neurons, the Nex-Cre driver line (Schwab et al., 1998; Goebbels et al., 2006) was bred to R26R mice 
(henceforth R26R:Nex-Cre). The Nex-Cre driver line itself was originally generated by a knock-in of 
Cre into the Nex-gene locus.  Therefore the Nex-Cre driver line itself (without breeding to a reporter 
Materials and Methods 
 
- 37 - 
 
mouse) was additionally analyzed in order to control whether the heterozygously disrupted Nex-gene 
itself causes any behavioral or structural consequences (Nex-Cre). 
  
 
Fig. M-1: Basic breeding schema to achieve lacZ expression: Generation of mice expressing lacZ in a neuronal sub-
population specific manner by breeding a “floxed” reporter mouse to a neuronal sub-population specific Cre-driver mouse. 
 
In order to distinguish the lacZ-specificity for any observed effects, we additionally analyzed the 
consequences of GFP expression in cortical glutamatergic neurons by breeding homozygous CAG-
CAT-EGFP reporter mice to the above mentioned Nex-Cre driver line (CAG-CAT-EGFP:Nex-Cre). These 
mice contained a floxed CAT gene upstream of the EGFP sequence, which was again excised upon Cre 
introduction and thus enabled GFP expression in glutamatergic principal neurons (Nakamura et al., 
2006). 
To investigate the extent of the involvement of the chosen Cre-driver line, we subsequently analyzed 
mice expressing lacZ in GABAergic forebrain neurons by breeding homozygous R26R mice to Dlx
5/6
-
Cre driver mice (R26R:Dlx
5/6
-Cre (Liu et al., 1997; Stühmer et al., 2002; Monory et al., 2006; Reichel 
et al., 2015a)).  
R26R:Nex-Cre, Nex-Cre, CAG-CAT-EGFP:Nex-Cre and R26R:Dlx
5/6
-Cre mice underwent behavioral 
testing and subsequent manganese-enhanced magnetic resonance imaging (MEMRI, chapter 2.3.3.) 
at the age of 4 – 6 months. All test groups consisted of Cre-negative (i.e. no reporter-gene 
expression) and Cre-positive (i.e. with reporter-gene expression) littermates and were handled and 
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tested blind to their genotype. For detailed time-lines for each test group please see chapter 2.5.2 
and Fig. M-10. 
Additionally, we asked whether lacZ expression induced in adulthood would yield similar 
consequences as constitutive lacZ expression. Therefore, we first induced lacZ expression in 
adulthood via Cre-coding adeno-associated virus (AAV) injections into the HPC of homozygous R26R 
mice, thereby locally excising the preceding STOP sequence and inducing lacZ expression in the 
absence of a Cre-driver mouse line. AAV injection was performed at the age of 10 weeks and mice 
underwent MEMRI 4 months later. For a detailed description of AAVs and the surgery procedure 
please see below (chapter 2.3.2; Fig. M-7). 
lacZ expression induced in adulthood can also be achieved genetically, by employing a fusion product 
of a promoter-of-choice driven Cre and a ligand binding domain, in this case a variant of the human 
estrogen receptor (ERT2; (Feil et al., 1997)). Only after tamoxifen (TAM) administration the Cre-fusion 
product translocates from the cytosol into the cell nucleus, excises the STOP sequence and induces 
lacZ expression (Feil et al., 1997; Erdmann et al., 2007) (for further details please see chapter 1.3.2. 
or Fig. M-2).  
 
 
Fig. M-2: Basic breeding schema to achieve adult-inducible lacZ expression: Generation of mice expressing lacZ in a 
neuronal sub-population specific manner that is inducible in adulthood upon tamoxifen administration. 
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Mice containing the Cre-ER
T2
 fusion product received exclusively tamoxifen containing food 
(LASCRdietTM CreActive TAM400; LASvendi) for 3 weeks at the age of 4 months in order to reliably 
induce lacZ expression. 
Inducible lacZ expression in cortical glutamatergic neurons was achieved by breeding homologous 
R26R mice to the modified Nex-Cre driver line containing the CreERT2 fusion product (R26R:Nex-
CreERT2 = i-R26R:Nex-Cre (Agarwal et al., 2012)). In order to analyze the effects of adult-induced lacZ 
expression in a larger neuronal subpopulation, we subsequently also bred homologous R26R mice to 
the CamKIIα- CreERT2 driver line, thereby enabling tamoxifen-controlled lacZ expression in CamKIIα-
positive neurons (i-R26R:CamKIIα-Cre) throughout the forebrain (Burgin et al., 1990; Mayford et al., 
1996; Schönig et al., 2012). Lastly, in order to investigate adult-induced lacZ-driven effects in a 
completely different neuronal population we also bred homologous R26R mice to the DAT-CreERT2 
driver line (i-R26R:DAT-Cre). This Cre driver line allows for the tamoxifen-inducible lacZ expression in 
neurons containing the dopaminergic active transporter (DAT; (Backman et al., 2006)). In order to 
control for any effects caused directly by the translocation of the CreERT2 fusion product from the 
cytosol into the nucleus, we also screened the DAT- CreERT2 driver line without cross-breeding to a 
reporter mouse line (i-DAT-Cre). All CreERT2 containing mouse lines additionally underwent basal 
behavioral testing at the age of 3.5 months (i.e. before tamoxifen-treatment). For detailed timelines 
of experimental sequences please see chapter 2.5.2. 
Each test group of CreERT2 containing mice also consisted of Cre-positive (Cre+) and Cre-negative 
(Cre-) littermates. All constitutively expressing lacZ mice were single housed at least one week prior 
to behavioral testing; all CreERT2 containing mice were single housed at least one week before 
behavioral testing after tamoxifen treatment. The experimenter was blind to the respective 
genotypes during behavioral testing and subsequent analyses.  
An overview of the mice used for project (ii) lacZ is provided in table M-2. 
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Table M-2: Animals used for project (ii): lacZ 
lacZ group strain sex # n/ Group 
glut- lacZ R26R:Nex-Cre male 120 
61 x cre+ 
59 x cre- 
Nex-gene control Nex-Cre male 22 
7 x cre+ 
15 x cre- 
glut- GFP 
CAG-CAT-
EGFP:Nex-Cre 
male 55 
28 x cre+ 
27 x cre- 
GABA- lacZ R26R:Dlx5/6-Cre male 86 
36 x cre+ 
50 x cre- 
AAV- Cre R26R male 18 
6 x Cre- AAV 
6 x GFP- AAV 
6 x no AAV 
adult glut- lacZ 
R26R:Nex-Cre-
ERT2 
(i-R26R:Nex-Cre) 
male 51 
30 x cre+ (1†) 
21 x cre- 
adult CaMK- lacZ 
R26R:CaMKIIα-
Cre-ERT2 
(i-R26R:CaMKIIα-
Cre) 
male 90 
44 x cre+ 
46 x cre- 
adult DAT- lacZ 
R26R:DAT-Cre-
ERT2 
(i-R26R:DAT-Cre) 
male 83 
44 x cre+ (4†) 
39 x cre- (1†) 
Cre translocation 
DAT-Cre-ERT2 
(i- DAT-Cre) 
male 19 
8 x cre+ (1†) 
11 x cre- 
TOTAL N   544 537 
AAV = adeno-associated virus; DAT = dopaminergic active transporter; GABA = γ-amino-butyric acid; GFP = green 
fluorescent protein; glut = glutamatergic; † = died before first behavioral screen was completed. 
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2.1.3. Project (iii) PTSD & Age 
The C57Bl6/N mice for the (iii) PTSD & Age project were purchased from Charles River, Germany, 
and arrived at the MPI-P animal facility at the age of 4 weeks. These animals were group housed (3-4 
mice per cage) throughout the experiment, and all animals in one cage were treated the same, e.g. 
either all or none of the animals of one cage received a foot-shock. Mice received a foot-shock at the 
age of five months, i.e. after having been sufficiently habituated to the environment for four months. 
The last behavioral test was done at the age of 16 – 17 months, and animals were sacrificed at the 
age of 18 months. For detailed timelines of experimental sequences please see chapter 2.5.3. 
 
Table M-3: Animals used for project (iii): PTSD & Age  
PTSD group strain sex n 
Home cage C57Bl/6N (ChR) male 16 
No Shock C57Bl/6N (ChR) male 16 (1†) 
No Shock + MSS C57Bl/6N (ChR) male 16 (1†) 
Shock C57Bl/6N (ChR) male 16 
Shock + MSS C57Bl/6N (ChR) male 16 
TOTAL N   80 (-2) 
ChR = Charles River; MSS = Mouse Shaker Stress; † = died before behavioral screen was completed. 
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2.2. Behavioral Methods 
 
2.2.1. Open Field 
The Open Field (OF) test is widely used to assess basic locomotor activity, but can – under bright light 
conditions – also serve as a test for anxiety related behavior (Carola et al., 2002). For this work the 
OF test was performed exclusively under red-light conditions in order to observe pure locomotor 
effects, rather than anxiety related behavior. We employed the Tru Scan
©
99 set-up, which consist of 
a clear Plexiglas arena (26 × 26 × 38 cm, Coulbourn Instruments, Allentown, PA, USA) that is 
surrounded by three levels of infrared photo beams to enable horizontal and vertical tracking of the 
mice. The infrared upper two sensors were located 2 and 5 cm above the floor, respectively; spaced 
apart by 1.52 cm and connected to a computer running the Tru Scan Software Version 1.1 (Coulbourn 
Instruments) with a sampling rate of 4 Hz. Tracking of the animal only by the lowest photo beam 
would be interpreted as a nose poke, but was not used for this work. Tracking only by the middle 
beam was scored as horizontal movements (i.e. moving distance), tracking only by the top photo 
beam equaled jumping movements and tracking by the middle and top photo beams simultaneously 
was registered as vertical (i.e. rearing-) behavior (Tru Scan©99 User’s guide to Software, Copyright 
2000- Version 1.011-00- 12/28/2000). The photo beams and the arena were surrounded by a further, 
opaque Plexiglas box (47 × 47 × 38 cm) in order to prevent external visual stimuli. The arena was 
cleaned with water and dried between animals to minimize olfactory cues.  OF testing was 
performed as described previously (Jacob et al., 2009; Yen et al., 2013). Briefly, animals were placed 
in the center of the OF arena and allowed to explore freely for 15 or 30 min.  
Total horizontal movement (i.e. distance), frequency of vertical movements (i.e. rearing) and 
duration of vertical movements were subsequently analyzed as total amounts and for 5 min bins 
(Carola et al., 2002; Reichel, 2011; Reichel et al., 2015b). 
 
 
2.2.2. Dark-Light Box 
Dark-light box testing (DL) was performed as previously described (Jacob et al., 2009). 
The DL box used for this work consisted of a dark compartment (15 x 20 x 25 cm) and an illuminated 
(600 lux) compartment (30 x 20 x 25 cm), which were connected by a 4 cm-long tunnel. Duration of 
testing was 5 min, except for animals from (ii) lacZ that were tested at the age of 24 months.  
Testing-duration for these mice was 6 min due to progressed aged and decreased mobility. At the 
beginning of testing each animal was placed in the dark compartment. The entire box was thoroughly 
cleaned with water containing detergent and dried between animals. After testing, Latency to enter 
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the light compartment, Frequency to enter the light compartment and relative time (Duration) spent 
in the light compartments were scored by a trained observer blind to the animals’ treatment or 
genotype by means of the EVENTLOG software (© Henderson, 1986; (Reichel, 2011; Reichel et al., 
2015b)). 
    
2.2.3. Acoustic Startle Response 
The acoustic startle response (ASR) is an inherent fear response in mammals and is governed by a 
distinct reflexive circuit, and – among others – is widely used to measure hyperarousal (Davis et al., 
1982; Plappert et al., 2004; Glover et al., 2011). For the present work the SR- LAB set up (San Diego 
Instruments SDI, San Diego, CA, USA) was used and the ASR was assessed essentially as previously 
described (Golub et al., 2009). Mice were placed in a non- restrictive Plexiglas cylinder (4 cm by 8 
cm), which was mounted to a plastic platform located in a sound attenuated chamber. This set-up 
quantifies changes in the conductance (i.e. movements of the mice in the cylinder) as a response to 
varying acoustic stimuli. These changes in conductance were detected by a piezoelectric sensor 
located underneath each cylinder, and were subsequently amplified and digitized with a sampling 
rate of 1 kHz via a computer interface provided by the set up (SD-Instruments, 2007; Golub et al., 
2009). In accordance with the set-up manual, prior to testing all cylinders were calibrated to 700 – 
710 mV output, by mounting the corresponding vibration-standardization device provided by San 
Diego Instruments on top of each cylinder (SD-Instruments, 2007).  
During testing, the startle amplitude was defined as the peak voltage output within the first 50 ms 
after stimulus onset. The startle stimuli consisted of 20 ms white noise bursts at 75, 90, 105 and 115 
dB SPL against a constant background noise of 50 dB SPL. Startle response Input/ Output (I/O) curve 
was assessed via a protocol consisting of 136 pseudo randomized trials of aforementioned white 
noise bursts. All cylinders were thoroughly cleaned with water containing detergent between 
animals. Mean startle amplitude per stimulus intensity was later analyzed and presented as the I/O 
curve.  
Pre-pulse inhibition/ -facilitation (PPI/PPF) was assessed within the same set-up as I/O, but with a 
different stimulus protocol. During the PPI/PPF protocol animals were presented with a brief pre-
pulse white noise burst of 55, 65 or 75 dB SPL intensity at varying inter-pulse intervals (IPI) of either 
5, 10, 25, 50 or 100 ms before the main acoustic stimulus, i.e. a 50 ms white noise burst of 115 dB 
SPL. This protocol consisted of 270 pseudo randomized trials and mean startle amplitude per pre-
pulse intensity and - interval was later calculated for each animal. This was done by subtracting the 
startle amplitude following the 115 dB reference pulse from the combined startle amplitude 
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following pre-pulse and main stimulus for each pre-pulse intensity and - interval, and dividing this by 
the reference startle amplitude following  115 dB times 100:                                                           
=
(		
								)(					)
(					)
  
(modified after Golub et al., 2009; Reichel JM, 2011 and (Reichel et al., 2015b)).
 
 
2.2.4. Fear Conditioning 
Fear conditioning (FC) was performed as previously described (Kamprath and Wotjak, 2004). Mice 
were placed in conditioning chambers (ENV-307A, MED Associates) with elongated Plexiglas walls 
and a grid floor for shock application. The grid floor was placed above bedding identical to the home 
cage bedding, and the conditioning context was thoroughly cleaned and sprayed with 70% Ethanol 
(EtOH) between animals. On d0 of the FC protocol the mice were placed in the conditioning context 
and left to explore it for 3 min under house light conditions (0.6 Lux; Fig M-3a). Subsequently a 20 s 
tone (9 kHz at 80 dB SPL) was presented, the last 2 s of which co-terminated with a 0.7 mA foot shock 
for (i) SAVA and (ii) lacZ. After shock application mice remained in the conditioning context for an 
additional 60 s without tone presentation before being placed back to their home cages. The 
protocol was slightly altered for mice of the (iii) PTSD & Age-project to accommodate a second foot-
shock application: mice were also presented with a 20 s tone (9 kHz at 80 dB SPL), but received a 1.5 
mA foot shock which again co-terminated with the tone (s 198-200), then remained in the shock 
context for 60 seconds under house light conditions before a second 20 s tone (9 kHz at 80 dB SPL) 
was presented, which once again co- terminated with a 2 s 1.5 mA foot shock. After the second shock 
application these mice also remained in the conditioning context for an additional 60 s under house 
light conditions (without tone presentation) before being placed back to their home cages.  
On d1 a.m. mice of (i) SAVA or (ii) lacZ were placed back in the conditioning context for 3 min under 
house light conditions without tone or shock presentations and contextual fear memory was 
assessed via the freezing response (Fig. M-3b). On d1 p.m. the associative- or tone-fear memory of 
these mice (i.e. SAVA and lacZ) was assessed by placing them in a novel context with different 
contextual features (i.e. cylinder instead of cubicle, bedding without grid, 1% acetic acid (CH3COOH) 
instead of EtOH) under house light conditions for 3 min without tone presentation followed directly 
by 3 min house light with tone presentation (Fig. M-3c).  
The conditioning context and the novel context were additionally placed in separate sound 
attenuating isolation boxes. CCD cameras inside each isolation box enabled video recording of the 
experiments and behavioral analyses after testing. The freezing behavior (i.e. immobility except for 
*100 
Materials and Methods 
 
- 45 - 
 
breathing) was scored via the EVENTLOG software (Henderson, 1986) by a trained observer blind to 
the animals’ treatments or genotype (Golub et al., 2009; Reichel, 2011; Reichel et al., 2015b). 
Additionally, mice of (ii) lacZ also underwent extinction training after fear conditioning. For this, mice 
were first shocked and their fear memory assessed on d1 post Shock as described above. 
Subsequently, these mice were placed back in the novel context (cylinder, bedding without grid, 1% 
acetic acid (CH3COOH)) on d2, d3, d4 and d11 post Shock and were exposed to ten 20 s tone 
sequences (9 kHz at 80 dB SPL ) over the course of 21 min per day. The first tone sequence always 
occurred at 180 s, but the following tone sequences were presented in a semi-random fashion 
distributed over the remaining 18 min (Fig. M-3d). The freezing response to the first 20 s tone was 
analyzed per day and animal as a measure of between-session extinction (Plendl and Wotjak, 2010).  
 
 
Fig. M-3: Fear Conditioning Schema: basic Fear Conditioning protocol: (a) Shock application: foot shock application in Shock 
context co-terminating with 20 s tone presentation; (b) assessment of contextual fear memory in shock context with light-, 
but without tone or shock presentation; (c) assessment of tone fear memory in a novel context with light and light + tone 
presentation; (d) extinction training protocol in the novel context: first 20 s tone presentation always occurred at 180 s, 
additional nine tone presentations were distributed over remaining 18 min in a semi-random fashion. 
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In order to induce a PTSD-like phenotype in project (iii) PTSD & Age, mice were placed back in the 
conditioning chamber on d32 post Shock (rather than d1 post Shock) in order to facilitate fear-
generalization (Pamplona et al., 2011). This was followed by exposure to the novel context (and tone) 
on the next day (d33). Duration of re-exposure and the light-/ tone protocols were the same as for (i) 
and (ii) (Fig. M-3b+c).  PTSD & Age mice did not undergo extinction training and repeatedly tested 
mice of (ii) lacZ only underwent extinction training once during the first behavioral screen 4 months 
after TAM application in order to exclude age-dependent hearing loss as a confounding factor. 
 
2.2.5. Water Cross Maze 
Water Cross Maze (WCM) training was performed using the hippocampus-dependent place learning 
protocol as previously described by Kleinknecht, Bedenk et al. (2012) with mice of all project-groups. 
The WCM was located in an indirectly lit room (10 – 12 Lux directly above the water surface) and 
consisted of four arms termed N, E, S, W made of clear Plexiglas. Each arm was 30 cm high, 10 cm 
wide and 50 cm long. The WCM was filled with water (22°C ± 1°C) up to a height of 12 cm and 
contained an invisible platform (also made of clear Plexiglas), which was 10 cm high, entailed an 8 x 8 
cm surface area and was positioned either at the end of the E or the W arm (Fig. M-4). Each mouse 
had to perform 6 trials per day, alternating between N and S as a starting position in a semi-random 
fashion (if mice were started from N, the S arm was closed off, if mice were started from S, the N arm 
was closed off, thus turning the set-up into a functioning T- maze; modeled after Tolman et al., 
1946). Mice were tested in groups of six (except for project (iii) PTSD & Age during which mice were 
tested in groups of four) to ensure equal inter-trial intervals of approximately ten to six minutes, 
respectively. During the inter trial intervals mice were placed in front of an infrared lamp to prevent 
hypothermia, feces were removed from the WCM, the water was exchanged between arms and the 
walls of the maze were dried of water splashes in order to minimize intra-maze cues, and to 
maximize the view onto extra maze cues (i.e. spatial cues).  
Based on previous studies we could conclude that mice do not display a priori side-biases to the W or 
the E arm, thus, for the initial spatial memory acquisition training (=week 1) the platform was always 
located at the end of the W arm. In case of reversal learning (= week 2), the platform was located at 
the end of the E arm (Fig. M-4a). Latency to reach the platform, wrong arm entries and wrong 
platform visits (WPV; entering the outer third of the arm opposite the platform containing arm) were 
manually recorded during training and later translated into performance scores per animal and 
experimental group (mean ± SEM). Latency cut-off to reach the platform was 31 seconds, at which 
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point the animal was guided to the platform and remained there for 5-10 s before being placed back 
to its home cage. 
 
 
 
 
Fig. M-4: Water Cross Maze set-up: (a) overview for Place learning protocol; week 1 = platform in W arm; week 
2 = platform in E arm; (b) photographs of water cross maze set-up and accessories; E = east-arm; N = north-
arm; P = platform; S = south-arm; W = west-arm; modified with permission after (Reichel, 2011; Kleinknecht et 
al., 2012). 
 
A trial was deemed “accurate” if the animal swam directly to the platform without entering the 
wrong arm or returning to the start arm. An animal was deemed “accurate” if it performed at least 5 
(out of 6) accurate trials per day (≥ 83.3%). The number of Learners was calculated as the percentage 
of accurate animals per experimental group per day. In order to assess the performance of a single 
animal throughout the training week, an additional learning score was calculated. The Learning Score 
(LS) was defined as the mean-accuracy divided by the number of training days per animal. Lastly, for 
R26R:Nex-Cre mice an additional start-bias was calculated, in order to further discern the swimming 
strategy of these mice. The start-bias was calculated by subtracting the number of accurate trials 
starting from N from the number of accurate trials starting from S (i.e. if the animal swims 100 % 
accurate  3 – 3 = 0; if an animal swims at 83 %  3 – 2 = 1) and taking the absolute value of this 
subtraction. An absolute value of ≥ 2 was defined as a start-bias and indicates a response-based swim 
strategy, meaning animals either always turn left or always turn right after the start-arm. While the 
Platform 
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place-learning protocol is hippocampus-dependent, the response-based strategy relies heavily on the 
dorsolateral striatum (Reichel, 2011; Kleinknecht et al., 2012). 
 
2.2.6. Novel object recognition task  
The “Novel object recognition task” (NOR) was performed with the animals of the (iii) PTSD & Age 
project in order to assess their short-term memory performances. The protocol was formed on the 
basis of previously published work (Bevins and Besheer, 2006; Ennaceur, 2010; Heyser and Chemero, 
2012; Leger et al., 2013), and the following objects were chosen due to their diverse individual 
features but overall comparable size (Fig. M-5a): calf figurine made of hard rubber (length x width x 
height = 7.0 x 2.0 x 5.0 cm), clothes peg made of hard plastic (7.0 x 3.0 x 1.5 cm) and smurf figurine 
made of hard rubber (5.0 x 5.0 x 6.0 cm). The NOR protocol consisted of a 10 min sampling-phase of 
two identical objects at A and B in the exploration arena (i.e. empty standard type II Makrolon cage; 
Fig. M-5b) and 90 min later of a 10 min choice-phase, during which one object (either at A or B) was 
replaced by a novel one. Sampling- and choice-phase were done at approx. 10 Lux. Objects were 
counter-balanced for the objects (calf, clothes peg or smurf) and locations (A or B) to avoid side- or 
object biases. Each mouse was placed in a freshly cleaned arena for the sampling-phase and was 
placed back in the same arena for the choice-phase (i.e. one arena per animal). Mice were not 
habituated to “their” arenas prior to the sampling phase (see chapter 4 Discussion). Sampling- and 
choice-phase were video-recorded via CCD cameras and later scored regarding exploration time for A 
and B during sampling and choice. 
 
 
Fig. M-5: Objects and exploration arena used for novel object recognition task: (a) left: calf figurine made of hard rubber (l 
x w x h = 7.0 x 2.0 x 5.0 cm); middle: clothes peg made of hard plastic (7.0 x 3.0 x 1.5 cm); right: smurf figurine made of hard 
rubber (5.0 x 5.0 x 6.0 cm); (b) exploration arena, i.e. empty and clean type II Makrolon cage; A + B represent the object 
locations. h = height; l = length; w = width. 
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2.2.7. Mouse shaker stress 
Mouse shaker stress (MSS) is an etiologically relevant environmental stressor that has been shown to 
significantly and lastingly affect the stress response of exposed animals (Nakata et al., 1993; 
Hashiguchi et al., 1997; Mantella et al., 2004; Pace and Spencer, 2005). Based on these studies a 
slightly modified MSS-protocol was devised and applied to two sub-groups of the PTSD & Age project 
(see chapter 2.5.3). Mice were transferred into a room adjacent to-, but separate from their holding 
room, and “basal” blood was taken immediately thereafter via tail-vein tap. Subsequently, mice were 
placed in an opaque plastic beaker (diameter = 14.5 cm; height = 18.5 cm) on a “Dual-Action Shaker” 
(KL2; Edmund Bühler) which was shaking at a frequency of 200/min for 10 min. 30 min after 
termination of MSS (i.e. 40 min after begin of MSS) “stressed” blood samples were taken via a 
second tail-vein tap below the first cut (i.e. closer to the base of the tail). Samples were kept on ice 
during MSS procedure and afterwards immediately processed for Corticosterone-level analyses (see 
chapter 2.4.5.).  
 
2.2.8. Rotarod testing 
Rotarod testing was performed with i-R26R:DAT-Cre mice in order to assess inherent motor- and 
motor-learning skills and was done here on the basis of previously published work (Carter et al., 
2001; Rustay et al., 2003). We employed the ROTA-ROD for Mice from Ugo Basile (Cat. No. 47600; 
Fig. M-6). In principle, a rotarod consists of several divisions separated by circular plates and one 
mouse can be tested per division. Through all of these divisions a movable and grooved (to ensure 
better grip for the mice) cylinder (i.e. rod) is installed, which is turning at a predetermined or 
accelerating speed. The mice are placed on the rod and under “normal” conditions are motivated by 
the turning rod to walk in order to stay on it (Rustay et al., 2003). However, especially employing an 
accelerating speed, sooner or later animals will lose their balance and are no longer able to walk fast 
enough to counteract the rod and therefore fall off it. The time-point of falling-off (i.e. latency to fall) 
is then recorded per mouse as an indicator for motor skills. If this test is done repeatedly over a 
number of days or weeks it can also be used to assess motor-learning abilities.  
The Ugo Basile ROTA-ROD for mice consists of five cylinder division and therefore would theoretically 
allow the testing of five mice in parallel (Fig. M-6). However, for the testing of i-R26R:DAT-Cre mice, 
only three animals were tested at once. Furthermore, the rotarod was equipped with magnetic 
sensors that were triggered each time a mouse fell off the rod. Subsequently the timer of the 
respective division was stopped and the latency to fall could be recorded for this particular mouse, 
whereas the rod kept turning and the timers kept counting for the other mice. Animals were tested 
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under red-light conditions three times per day (with a 30 min inter-trial-interval) for six consecutive 
days and then again 20, 40 and 130 days later to assess motor memory. The average latency to fall 
per animal and day was subsequently analyzed. The speed of the rod was always adjusted to the 
accelerating modus from 5 to 50 rpm (rounds per minute) within 5 min. Mice were placed on the 
moving rod at 5 rpm and only then acceleration was started. In between test runs the rod, the plates 
and also the floor beneath the rod was cleaned with water containing detergent.  
 
 
Fig. M-6: Rotarod (Ugo Basile): ROTA-ROD for mice; picture modified after the instruction manual of the
 
ROTA-ROD for 
MICE (Cat. No. 47600), provided by Ugo Basile. 
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2.3. Structural Methods 
Animals of the (i) SAVA project as well as of the (ii) lacZ-AAV sub-group underwent stereotactic 
surgery. Almost all of the (ii) lacZ mice underwent manganese-enhanced magnetic resonance 
imaging (except for groups of i-R26R:DAT-Cre and i-R26R:CamKIIα mice that underwent testing 
already two months after TAM-treatment), whereas only R26R:Nex-Cre mice (constitutive and 
inducible glutamatergic lacZ expression) underwent micro-punch dissection for subsequent 
proteomic and western blot analyses, respectively. The surgeries for (i) SAVA were performed by 
Anna Mederer, technician in the research group “Neuronal Plasticity” (PI: PD Dr. C. T. Wotjak) at the 
Max Planck Institute of Psychiatry. The (ii) lacZ-AAV surgeries were performed by Caitlin Riebe, 
technician in the research group “Neuronal Plasticity” (PI: PD Dr. C. T. Wotjak) at the Max Planck 
Institute of Psychiatry. Animals were anesthetized with isoflurane during the surgery and given 
Metacam (0.5 mg/kg meloxicam) intraperitoneally before the surgery and in the drinking water for 
three days after the surgery for perisurgical analgesia. Animals were allowed to recover for at least 
12 days after surgery before behavioral testing began and weight and general physical condition was 
closely monitored. 
 
2.3.1. SAVA- surgeries                        
Mice of the (i) SAVA project received SAVA- or PBS administration either directly during surgery 
(SAVA-1+2) or cannulas were implanted and SAVA treatment was applied after recovery (for detailed 
timelines please see chapter 2.5.1. and Fig. M-9). Injections for SAVA-1 were done at the level of the 
dorsal hippocampus (dHPC) with bilateral injections at: lateral (l) 1.3 mm (from midline); anterior- 
posterior (a-p) -1.8 mm (from bregma) and ventral (v) 2.0 mm (from the surface of the skull). The 
target of SAVA-2 was the prelimbic cortex (PrL), therefore mice received bilateral SAVA injections at l 
0.5 mm; a-p +1.9 mm; v 2.5 mm. Lastly, SAVA-3+4 targeted once again the dHPC, therefor these mice 
received guide cannulas at l 1.3 mm; a-p -1.8 mm; v 1.0 mm. The injection cannulas for SAVA-3+4 
protruded the guide cannulas by 1 mm, enabling a precisely localized injection at v 2.0 mm (Reichel 
et al., 2015b). 
 
2.3.2. lacZ- AAV surgeries                
A sub-group of (ii) lacZ-mice underwent stereotactic surgery in order to induce lacZ expression in 
adulthood and exclude developmentally driven consequences thereof. To investigate this we 
employed R26R mice (Soriano, 1999), which contain a floxed STOP codon up-stream of the lacZ 
sequence (see chapter 1.3.2. and 2.1.2.). We injected adeno-associated viruses (AAV) or PBS 
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unilaterally in the left dorsal (a-p -1.8 mm, l -1.3 mm and v -1.2 mm) and ventral (a-p -2.8 mm, l -3.0 
mm and v -4.0 mm; 1 µl per injection site) hippocampus of 10 weeks old R26R mice and 4 months 
later performed MEMRI scan analyses (chapter 2.3.3.) in order to compare the volume of left and 
right hippocampus within each mouse.   
We used two different AAVs (which were provided by S. Michalakis, LMU Munich). The first AAV 
(pAAV2.1-CMV-Cre-2A-GFP M4) entailed a Cre sequence (Fig. M-7) and thus (locally) induced lacZ 
expression. The second AAV (pAAV2.1-sc-GFP-pACG-2-M4) caused local GFP-expression to control for 
a general protein expression effect. Lastly, for a third cohort we unilaterally injected PBS to control 
for a general surgery effect. lacZ- and GFP-expression could be detected via immuno-labeling four 
weeks (but not one week) after surgery (Reichel et al., 2015a). Initial injections and staining 
procedures one and four weeks after surgery were carried out prior to this PhD work and have been 
previously reported in my Diploma Thesis (Reichel, 2011; LMU Munich).  
 
     
 
 
 
 
 
 
 
Fig. M-7: Cloning map of pAAV2.1-CMV-Cre-
2A-GFP M4 (provided by Michalakis & Koch, 
LMU Munich); 1 µl of this AAV was 
unilaterally injected (per injection side) in the 
dorsal and ventral hippocampus of R26R 
mice in order to excise the lacZ-preceding 
STOP-codon and induce lacZ expression; AAV 
= adeno-associated virus. 
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2.3.3. Manganese-enhanced Magnetic Resonance Imaging (MEMRI) 
MEMRI procedure was performed essentially as previously described (Grünecker et al., 2010; 
Kleinknecht et al., 2012; Grünecker et al., 2013). MnCl2 injections, scanning-procedure, parts of the 
template-fitting and final statistics (i.e. group comparisons) were performed by myself, main analyses 
of the scans were done by Benedikt Bedenk (PhD student in the research group Neuronal Plasticity; 
PI: PD Dr. C. T. Wotjak) at the Max Planck Institute of Psychiatry and with the support of Dr. M. 
Czisch, Head of Neuroimaging at the Max Planck Institute of Psychiatry.  
MEMRI itself is a very useful tool for morphological- (i.e. volumetric; region of interest, ROI) and 
activity-related analyses (intensity of Mn2+ signal) in the living (albeit anesthetized) animal. The 
paramagnetic properties of manganese (Mn2+) and the resulting distinct accumulation patterns 
throughout the CNS enable the visualization of pre-determined ROIs and the differentiation between 
Mn2+-signal-intensities within and between these ROIs via T1 and T2 weighted scans (Grünecker et al., 
2010). 
MEMRI was performed for all mouse lines of the (ii) lacZ project (chapter 2.5.2; Fig. M-10). 
Constitutively lacZ/Cre expressing mice (i.e. R26R:Nex-Cre, Nex-Cre, CAG-CAT-EGFP:Nex-Cre and 
R26R:Dlx
5/6
-Cre mice) were i.p. injected 8 times with 30 mg/kg of a 50 mM MnCl2 x 4H2O in 0.9 % 
NaCl solution (pH = 7.0) in 24 h intervals. Scanning of the animals was done approximately 24 h after 
the last injection. Afterwards the mice were returned to their home cages in order to wash-out the 
MnCl2 solution for ca. 6 weeks (Grünecker et al., 2013) before being sacrificed and processed for e.g. 
subsequent X- Gal staining (chapter 2.4.4.1.). 
Mouse lines enabling inducible lacZ expression (i.e. i-R26R:Nex-Cre, i-R26R:CamKIIα-Cre, i-
R26R:DAT-Cre and i-DAT-Cre mice) were injected 7 times with 20 mg/kg of a 50 mM MnCl2 x 4H2O in 
0.9 % NaCl solution (pH = 7.0) in 24 h intervals. This reduced injection schedule was chosen due to its 
decreased toxicity and increased survival rate for repeated testing, as i-R26R:CamKIIα-Cre and i-
R26R:DAT-Cre underwent the MEMRI procedure three times (chapter 2.5.2). 
Scanning was done with a 7T Avance Biospec scanner (Bruker BioSpin, Ettlingen, Germany). 
Throughout the image acquisition animals were anaesthetized using inhalation anesthesia with an 
isoflurane–oxygen mixture (1.5–1.9 vol.% isoflurane with an oxygen flow of 1.2–1.4 l/min) and their 
heads were fixed in a prone position. Total measurement duration was approximately 2 h and the 
acquired 3D T1-weighted and T2-weighted images were analyzed regarding volumetric-, and also 
signal intensity-differences for several ROIs, e.g. hippocampus, dorsal cortex, lateral ventricles or 
VTA.  
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The 3D MRI images had a spatial resolution of 125 x 125 x 140.6 mm3 and the images were 
reconstructed using Paravision software (Bruker BioSpin). Further post-processing was done using 
SPM (www.fil.ion.ucl.ac.uk/spm).  
Every acquired image was fitted to a general template image (average of approx. 150 brain scans) 
and adjusted for spatial orientation/ coordinates. Template-fitting generated a set of meta-data per 
brain. After every scan was fitted to the template the required ROI could be mapped for all scans at 
once (Grünecker et al., 2010). Subsequently, each scan underwent back transformation based on the 
individual meta-data-set and the actual analyses were performed: Volumetric analyses were done by 
comparing the number of voxels per ROI using an in-house software written with IDL (Grünecker et 
al., 2013). All initial volume data-sets were normalized to their respective whole brain volume and 
subsequently the Cre-negative (i.e. normalized values of the test group without lacZ/ GFP expression) 
mean volume per ROI was defined as 100% and Cre-positive ROI values were calculated in relation to 
them.  
For signal-intensity analyses, ROI intensities were normalized to whole brain or muscle signal-
intensity, as it has been shown that muscle tissue does not significantly accumulate manganese 
(Sepúlveda et al., 2012; Grünecker et al., 2013). For further details regarding image analyses please 
see (Grünecker et al., 2010; Kaltwasser, 2012; Kleinknecht et al., 2012; Reichel et al., 2015a). 
 
2.3.4. Micro-punch dissection for proteomic and western blot analyses 
In order to analyze the protein composition of distinct brain areas of some of the (ii) lacZ project 
mouse lines, selected mice were transcardially perfused (see below), brains were dissected out and 
micro-punches were retrieved ex vivo. Tissue samples were taken from the prelimbic cortex (PrL), 
dorsolateral striatum (Strt), basolateral amygdala (BlA), dorsal hippocampus (dHPC), ventral 
hippocampus (vHPC), ventral tegmental area (VTA) and the cerebellum (Cb) of Cre+ and Cre- 
littermates of several “lacZ”-mouse lines (Fig. M-8). However, at this time, only dHPC samples of 
R26R:Nex-Cre and i-R26R:Nex-Cre mice underwent further processing, therefore the sampling 
procedure will be described in detail only for dHPC.   
Animals were deeply anesthetized with isoflurane, then transcardially perfused with 0.9% NaCl 
solution and afterwards the brains were carefully dissected out, flash frozen with methylbutane 
(Isopentane) on dry ice and stored at -80°C.  In order to obtain the specific tissue samples, the brains 
were subsequently cut with a Cryostat (Microm HM-500) until the designated area was reached (e.g. 
dHPC) and there the tissue samples were obtained bilaterally with a 0.8 mm diameter (for dHPC) 
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sample corer (Fine Science Tools, F-S-T®) at a-p -1.5 mm, l ± 0.5 mm, v 2 mm in relation to Bregma 
and with a depth of approximately 0.6 mm. Samples were bilaterally pooled per brain and 
immediately frozen in liquid nitrogen and stored at -80°C until further processing. In order to validate 
the locations of the punch-areas, selected brain sections were collected and later underwent Nissl 
staining (chapter 2.4.4.5.). 
 
  
Fig. M-8: Locations for micro-punch tissue sampling: left: sagittal overview for all tissue sample-regions; right: coronal 
location for dHPC tissue collection (a-p -1.5 mm, l ± 0.5 mm, v 2 mm, punch-diameter: 0.8 mm). a-p = anterior-posterior; BlA 
= basolateral amygdala; Cb = cerebellum; dHPC = dorsal hippocampus; l = lateral; PrL = prelimbic cortex; Strt = striatum; v = 
ventral; vHPC = ventral hippocampus; VTA = ventral tegmental area. Schemata and locations modeled after “The Mouse 
Brain in Stereotaxic Coordinates”, Elsevier Academic Press (Paxinos and Franklin, 2004).  
 
The coordinates of the designated punch-areas were based on the coordinates described in “The 
Mouse Brain in Stereotaxic Coordinates”, Elsevier Academic Press (Paxinos and Franklin, 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
 
- 56 - 
 
2.4. Molecular analyses 
 
Table M-4: Chemicals used for molecular analyses: 
Product Name 
Chemical Name/ Molecular 
Formula 
Supplier Charge/ Lot# 
Acetic acid Acetic Acid 
Städt. Klinikum München 
GmbH, Klinikum 
Schwabing Apotheke 
--- 
Agarose Ultra Pure
TM
 Agarose invitrogen
TM
 0000174605 
Dimethylformamid N,N- Dimethylformamide Sigma- Aldrich BCBD5158V 
DPX DPX mountant Sigma BCBB 2651 
EDTA Ethylenediaminetetraacetic acid Roth 49468769 
EGTA Ethylene glycol tetraacetic acid Roth 470164860 
EtOH (60 %, 70 %, 80 % 96 
%, 98 %, 100 %) 
Ethanol, 60, 70, 80, 96, 98, 100 % 
Städt. Klinikum München 
GmbH, Klinikum 
Schwabing Apotheke 
--- 
HCL Hydrochloric acid Sigma- Aldrich BCBD3530 
Immobilon Western HRP 
Substrate solution 
--- Millipore, Germany WBKLS0500 
Isoflurane Forene ® 100 % (V/V) Abbott 6010251 
Isopropanol 2- Propanol Roth 021166669 
Metacam Metacam ® (Meloxicam) Boehringer Ingelheim z20811-A 
Methylbutane 2- Methylbutane Roth 370159439 
MgCl2 Magnesium- Chloride solution Sigma- Aldrich BCBD1526 
MnCl2 Manganese Chloride; cristaline 
neoLab Migge 
Germany 
--- 
NaCl Sodium Chloride Merck K35518404601 
NaOH Sodium hydroxide solution Sigma- Aldrich --- 
NP40 Nonidet Nonidet P40 Roche 12241900 
Nuclear Fast Red 
Counterstain 
 Vector® Laboratories H-3403 
PFA Paraformaldehyde Roth 129103678 
PhosStop Phosphatase inhibitor Roche 04906845001 
Potassium Ferricyanide Potassium hexacyanoferrate (III) Sigma- Aldrich MKBF2914V 
Potassium Ferrocyanide 
Potassium hexacyanoferrate (II) 
trihydrate 
Sigma- Aldrich 060M0115V 
Rothi- histol Rothi- histol Roth 150103005 
SDS Sodium lauryl sulfate Roth 46467343 
Sodium deoxycholate Sodium deoxycholate Sigma- Aldrich 050M0141V 
Sucrose D-Saccharose Roth 469110566 
Tris 
Tris- (hydroxymethyl) 
aminomethane 
Roth 48467791 
Triton X100 Triton X100 Sigma- Aldrich 118K01602 
VECTASHIELD® Hard Set 
Mounting Medium with 
DAPI 
--- Linaris H-1500 
VECTASHIELD® Mounting 
Medium with DAPI 
--- Linaris H-1200 
X- Gal 
5- Bromo-4-chloro-3-indolyl β-D-
galactopyranoside 
Sigma- Aldrich 070M1353V 
Xylol Xylol (Isomere) Roth 488101402 
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2.4.1. Genotyping 
Genotyping via polymerase chain reaction (PCR) was done on a tail biopsy for all mice involved in the 
(ii) lacZ project and was performed as previously described (Refojo et al., 2011) by experienced 
technicians in the group “Molecular Neurogenetics” (PI: Dr. J. M. Deussing) in the “Department of 
Stress Neurobiology and Neurogenetics” (Director: Prof. Dr. A. Chen) at the Max Planck Institute of 
Psychiatry. The following genotyping protocol and the corresponding primers have also been 
described in (Reichel et al., 2015a). 
Mouse lines containing reporter sequences (i.e. for lacZ or GFP) were first genotyped for the 
respective reporter sequence and then for the specific Cre-driver line.  
Following primers were used for R26R (lacZ ): ROSA-1: 5´ AAA GTC GCT CTG AGT TGT TAT 3´, ROSA-2: 
5´ GCG AAG AGT TTG TCC TCA ACC 3´, ROSA-5: 5´ TAG AGC TGG TTC GTG GTG TG 3´, ROSA-6: 5´ GCT 
CAT TAA AAC CCC AGA TG 3´. These primers resulted in a 398-bp (base pair) lacZ-negative and a 320-
bp lacZ-positive product at standard PCR conditions. A deletion of R26R would have been detected 
by the presence of a 505-bp product. 
The presence of Nex-specific Cre was determined by a PCR using the following primers: NexCre 4: 5´ 
GAG TCC TGG AAT CAG TCT TTT TC 3´, NexCre 5: 5´ AGA ATG TGG AGT AGG GTG AC 3´ and NexCre 6: 
5´ CCG CAT AAC CAG TGA AAC AG 3´. Under standard conditions the PCR resulted in a Cre-negative 
product of 770-bp and a Nex-Cre-positive product of 525 bp. 
To assess the presence of Dlx-specific Cre, a PCR was performed using the following primers: Dlx-
fwd: 5´ CAC GTT GTC ATT GGT GTT AG 3´, Dlx-rev: 5´ CCG GTC ATG ATG TTT TAT CT 3´, Thy1-F1: 5´ 
TCT GAG TGG CAA AGG ACC TTA GG 3´, Thy1-R1:   5´ CCA CTG GTG AGG TTG AGG 3´. This resulted in 
a 313 bp product for Dlx-Cre-positive samples and a 372 bp control product (Thy1) for Dlx-Cre-
negative samples.  
CAG-CAT-EGFP:Nex-Cre mice were first genotyped for their GFP reporter sequence with the 
following primers: EGFP-fwd: 5´ CCT ACG GCG TGC AGT GCT TCA GC 3´, EGFP-rev:  5´ CGG CGA GCT 
GCA CGC TGC GTC CTC 3´. The presence of the CAG-CAT-EGFP sequence resulted in a 345 bp product. 
Subsequently these mice were also genotyped regarding the presence of the Nex-specific Cre 
recombinase (see above). 
R26R:Nex-Cre-ERT2 (i-R26R:Nex-Cre) mice were again first genotyped for lacZ (see above) and the 
presence of the Nex-Cre-ERT2 fusion product was examined using the following primers: Nex-ORF-as: 
5´ AGA ATG TGG AGT AGG GTG AC 3´, Cre-as:5´ CCG CAT AAC CAG TGA AAC AG 3´ and Exon1-s:  5´ 
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GAG TCC TGG AAT CAG TCT TTT TC 3´. Under standard PCR conditions this resulted in a product of ca. 
500 bp for Cre-ERT2 positive samples and a ca. 800 bp product for Cre-ERT2 negative samples. 
R26R:CamKIIα-CreERT2 (i-R26R:CamKIIα-Cre) mice were also first genotyped for lacZ and the 
presence of the CamKIIα-CreERT2 fusion product was analyzed using the following primers: i-Cre 1:    
5´ GGT TCT CCG TTT GCA CTC AGG A 3´; i-Cre 2: 5´ CTG CAT GCA CGG GAC AGC TCT 3´ and i-Cre 3: 5´  
GCT TGC AGG TAC AGG AGG TAG T 3´. The transgenic samples revealed a 375 bp product, whereas 
Cre-negative samples resulted in a 290 bp product.  
R26R:DAT-CreERT2 (i-R26R:DAT-Cre) mice were again first genotyped for lacZ and the presence of 
the DAT-CreERT2 fusion product was analyzed using the following primers: Dat-cre fwd: 5´ GGC TGG 
TGT GTC CAT CCC TGA A3´; Dat-cre rev: 5´ GGT CAA ATC CAC AAA GCC TGG CA3´; CTSQ-up: 5´  ACA 
AGG TCT GTG AAT CAT GC 3´ and CTSQ-dn: 5´ TTA CAA TGT GGA TTT TGT GGG 3´. DAT-CreERT2-
positive samples caused a 405 bp product and Cre-negative samples could be detected with a 1098 
bp product. DAT-CreERT2 (i-DAT-Cre) mice were genotyped using the same primers as for i-
R26R:DAT-Cre mice (excluding the lacZ specific PCR). 
At the time point of brain harvesting a final tail biopsy was taken again and re-genotyped to exclude 
a possible mix-up of animals during testing which would result in a falsification of experimental data 
(Reichel et al., 2015a). 
 
2.4.2. Proteomic Analyses 
Proteomic analysis was performed by Chi-Ya Kao, PhD student in the research group “Proteomics and 
Biomarkers” lead by Prof. C. Turck in the “Department of Translational Research in Psychiatry” 
(Director: Dr. E. Binder) at Max Planck Institute of Psychiatry. Micro-punch samples (chapter 2.3.4.) 
were essentially processed as previously described (Jastorff et al., 2009; Maccarrone et al., 2013). For 
isoelectric focusing (IEF) samples were homogenized and subsequently mixed with IEF buffer, 0.2 % 
Biolyte and Bromophenol Blue (BPB) and then centrifuged for 20 min. Subsequently, 200 µg of 
protein per sample-mix were loaded on an 11 cm IPG (immobilized pH gradient) strip at pH 3 – 10 
and incubated for one hour. Afterwards samples were rehydrated for 12 hours and IEF and 
subsequent electrophoresis carried out as in Jastorff et al. (2009). Finally, the gels were fixed in 30% 
EtOH – 2% phosphoric acid overnight, washed in ddH2O and stained with a 17% ammonium sulphate 
– 2% phosphoric acid – 34% methanol and Colloidal Coomassie solution. Evaluation of the gels was 
done via mass spectrometry and MASCOT search engine as previously described (Maccarrone et al., 
2013; Reichel et al., 2015a). 
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2.4.3. Western Blot Analyses 
Protein composition and –ratio was assessed via Western Blot (WB) analysis for dHPC micro punches 
(chapter 2.3.4.) of R26R:Nex-Cre and i-R26R:Nex-Cre mice ((ii) lacZ project). Tissue samples were 
pooled bilaterally per animal and stored at -80°C until processing. Samples were homogenized on ice 
with 33 µl homogenization buffer (HB) per animal. HB consisted of 50 mM Tris (pH 7.5), 150 mM NaCl 
and 5 mM EDTA in ddH2O. For 5 ml HB ½ tablet of phosphatase inhibitor PhosStop (Roche, 
#04906845001) was added immediately before use. After homogenization, 33 µl of extraction buffer 
(EB) were added per animal. EB consisted of 50 mM Tris (pH 7.5), 150 mM NaCl, 1% NP-40 and 2% 
SDS in ddH2O; immediately before use 5 µl protease inhibitor were added to 5 ml EB. Samples were 
then sonicated for 15 peaks at 3/30%. Subsequently samples were boiled for 10 min at 95°C and then 
centrifuged for 5 min at 14000 g at RT. Thereafter the protein content was determined via BCA 
(bicinchoninic acid) assay. Standards and samples were distributed in triplicates (5µl each) on a 96 
well plate and 100 µl BCA solution mix was added per well. The 96 well-plate was incubated at 60°C 
for 30 min and afterwards protein concentration was assessed with a spectrophotometer. Based on 
these results samples were adjusted to a 1 µg / µl concentration in 50 µl final volume (including 10 µl 
LAP-mix); e.g. sample xy: photometer concentration = 1998  (1/1998) * 50 = 0.025  25 µl sample 
+ 10 µl LAP + 15 µl lysis buffer. LAP-mix consisted of: 2.5 ml 5 % SDS, 4.59 ml 40 % glycerin, 1.6 ml 
160 mM Tris pH 6.8, 0.5 ml 5 % β-mercaptho-ethanol, 0.5 g BPB and 0.81 ml dH2O for a volume of 10 
ml. 100 ml Lysis buffer consisted of: 0.75 ml Tris-HCl pH 6.8 (62.5 mM final concentration), 6 g SDS 
and 30 g D-saccharose in dH2O. Adjusted sample solutions were stored at -20 °C overnight and boiled 
for 5 min at 95°C the next morning in order to destroy the di-sulfide bands. 12% SDS-gels were 
loaded with 20 µl of samples and 5 µl of a standard protein ladder (PEQLAB Biotechnologie GmbH). 
Electrophoresis was run at 100 – 150 mV for ca. 80 min. Proteins were then transferred from the 
SDS-gel to a PVDF membrane (Whatman™ #10401396/ 10600030) via wet-blot. The gel was stacked 
on top of three Whatman-filter-papers on top of wet sponges (soaked in transfer buffer; see below) 
and the membrane was placed on top of the gel, followed by three further filter papers and another 
wet sponge. The membrane was previously activated by the transfer buffer: 100ml 10x wet-blot 
buffer + 200 ml methanol + 700 ml dH2O. Transfer was run at 100 V for 90 min at 4°C. After the 
transfer membranes were briefly stained with Ponceau to visualize and fix proteins on the 
membrane. Subsequently Ponceau was rinsed off with dH2O and the membranes washed with TBS-
Triton (TBS-T) 3 x 5 min before non-specific protein binding sites were blocked with 5% milk in TBS-T 
for 60 min. Thereafter membranes were washed with TBS-T 3 x 5 min and then incubated with the 
primary antibody (e.g. rabbit-anti Vinculin, Cell Signaling #4650; 1:500) in TBS-T (antibody 
concentration varied across antibodies; see Tables M-5 and M-6) overnight at 4°C. The next day the 
membranes were washed 3 x 5 min with TBS-T and then incubated in the secondary antibody (e.g. 
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anti-rabbit HRP-linked, Cell Signaling #7074; 1 : 1000; HRP = horseradish peroxidase) in TBS-T for 2-3 
h at room temperature (RT; 22°C ± 1°C). Subsequently membranes were washed again 3 x 5 min with 
TBS-T. Protein bands were visualized with 1 ml (per membrane) of Immobilon Western HRP 
Substrate solution (Millipore, Germany; A : B = 1 : 1) and the BioRad ChemiDoc MP Imaging system. 
Upon adding the HRP Substrate solution the primary-secondary-HRP antibody complex at the target 
protein emits a chemiluminescent signal that can be visualized and recorded with the BioRad 
ChemiDoc MP Imaging system. Protein concentration (i.e. signal intensity) per band and lane was 
later calculated using the corresponding Image Lab™ software (BioRad) and was set in relation to the 
respective housekeeper signal (e.g. Vinculin). 
Table M-5: Primary antibodies & concentrations used for Western Blot analyses   
Antigen Source Supplier Concentration 
Actin goat Santa Cruz Biotechnology, Inc.; sc-1616 1 : 1000 
AIF rabbit Cell Signaling; #5318 1 : 500 
CDK5 rabbit Cell Signaling; #2506 1 : 1000 
PP1β goat Santa Cruz Biotechnology, Inc.; sc-6106 1 : 200 
PP2B-A rabbit Cell Signaling; #2614 1 : 1000 
Vinculin rabbit Cell Signaling; #4650 1 : 500 
 
Table M-6: Secondary antibodies & concentrations used for Western Blot analyses (HRP-linked) 
Antigen Source Supplier Concentration 
goat donkey Santa Cruz Biotechnology, Inc.; sc-2056 1 : 1000 
rabbit goat Cell Signaling; #7074 1 : 1000 
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2.4.4. Histochemical stainings 
 
2.4.4.1. X- Gal: enzymatic staining 
X- Gal staining (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside staining) was performed for 
sample brains of all (ii) lacZ-project mouse lines (containing a lacZ sequence) in order to detect the 
expression pattern of lacZ driven by the respective Cre-driver mouse line or induced by AAV injection 
(chapter 2.3.2). For these exogenous expression patterns an alkaline pH is necessary (Weiss et al., 
1997), and pHs from 7.8 – 8.0 were used. The pH values of the staining solutions were adjusted 
under the control of a pH- meter by either adding hydrochloric acid (HCl) or sodium hydroxide 
solution (NaOH). To that end mice destined to undergo X- Gal staining first received an overdose of 
isoflurane and were then transcardially perfused with 10 ml ice-cold PBS, approximately 60 ml ice-
cold 5 mM EGTA + 1 mM MgCl2 in 4 % PFA-PBS (= lacZ-Fix Solution), followed once again by 10 ml 
ice-cold PBS. The pH of the lacZ-Fix Solution had to be adjusted to suit exogenous β- Gal expression 
(i.e. pH 7.8 – 8.0). After perfusions the brains were carefully dissected out and stored in a 20 % 
sucrose-solution (PBS + 5 mM EGTA + 1 mM MgCl2 + Sucrose) overnight at 4°C. The next day the 
brains were shock-frozen in methylbutane (Isopentane) on dry ice and afterwards cut into 50 µm 
cryostat sections (Microm HM-500) and mounted on gelatine coated object slides. The sections were 
again stored overnight at 4°C in PBS + 5 mM EGTA + 1 mM MgCl2. On the following day the sections 
were first briefly immersed in lacZ-Wash Buffer (2 mM MgCl2 +  0.01 % Sodium deoxycholate + 0.02 
% Nonidet-P40 in PBS) and then incubated in lacZ-Staining Solution (5 mM potassium- ferrocyanide + 
5 mM potassium- ferricyanide + 0.1 % X- Gal in dimethylformamid in lacZ-Wash Buffer) at 37°C for 2 
– 12 h, depending on the extent of lacZ expression. The pH of the lacZ-Fix Solution, lacZ-Wash Buffer 
and lacZ-Staining Solution had to be the same (e.g. always pH = 7.85) throughout one staining 
procedure. After incubation in the lacZ-Staining Solution the sections were washed 3 x 5 min in PBS 
and post fixed in 4 % PFA-PBS for at least one hour. Due to the relatively weaker expression pattern 
and to ensure better visibility for subsequent image acquisition, sections of the inducible lacZ-lines  
(i-R26R:Nex-Cre, i-R26R:CamKIIα-Cre and i-R26R:DAT-Cre) mice underwent one additional staining-
step: after post-fixation of X-Gal precipitation, these sections were briefly rinsed in dH2O and then 
immersed in 250 µl Nuclear Fast Red Counterstain (Vector® Laboratories; H-3403) per object slide for 
2 – 3 min and were then washed again in dH2O. To complete the staining procedure sections of all 
mouse lines were immersed in 70 %, 80 % 98 % and 100 % EtOH for five minutes each, incubated in 
Xylol for 10 min and then covered with cover slips on DPX mounting medium.Image acquisition was 
done with the Leica- MZ Apo Stereomicroscope and the Zeiss- Axio Cam MRc5 (including the 
corresponding software; modified after (Reichel, 2011; Reichel et al., 2015a). 
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2.4.4.2. X-Gal: immunofluorescent staining 
Prior to X-Gal immunofluorescence staining (IF) sample mice of the (ii) lacZ project were perfused 
and brains harvested and sectioned identical to chapter 2.4.4.1. (X-Gal: enzymatic staining). 
Subsequently, sections were fixed once more with lacZ-Fix Solution 1 x 5 min, washed with 1% PBS-
Triton (PBS-T) 6 x 5 min, and non-specific binding sites of the sections were blocked in 10 % normal 
goat serum (NGS) in 1 % PBS-T for 90-100 min at room temperature (RT; 22°C ± 1°C). Afterwards the 
sections were incubated with the primary antibody (chicken-anti β-Gal; Abcam #9361) 1:1000 in 1 % 
NGS in 0.3 % PBS-T overnight at 4°C. 
The next day the sections were washed 3 x 5 min with PBS before being incubated with the 
secondary antibody (goat-anti chicken; Invitrogen A-11042) 1:1000 in 1 % NGS  in 0.3 % PBS-T for 2-3 
h at RT (light protected). Lastly, the sections were washed again 3 x 5 min PBS before being covered 
with mounting medium containing DAPI to counterstain the nuclei (VECTASHIELD® Mounting 
Medium with DAPI; Linaris, H-1200).  
Image acquisition was done with the Zeiss- Axioplan 2 imaging Light/ Fluorescence Microscope and 
the Zeiss-Axio Cam MRm (including the corresponding software). 
 
2.4.4.3. GFP: immunofluorescent staining 
For the GFP (green fluorescent protein) immunofluorescence staining animals underwent 
transcardial perfusion with 4 % PFA-PBS, brains were carefully dissected out and were post-fixed in 
4% PFA-PBS for 1 – 2 h at 4°C. Subsequently brains were stored in 0.5% PFA-PBS over night at 4°C. In 
order to process the brains on a vibratome (Thermo Scientific Mircom HM 650V) they were 
embedded in 6 % agarose before being cut into 40 – 50 µm thick sections. Sections were collected in 
PBS and stored at 4°C overnight. The next day the sections were washed 3 x 10 min in PBS before 
unspecific binding sites were blocked with 10 % NGS in 1% PBS-T for 1-2 h at RT. Afterwards the 
sections were incubated with the primary antibody (chicken-anti GFP; Abcam #13970) 1:5000 in 1 % 
NGS in 0.3 % PBS-T overnight at 4°C. The following day the sections were again washed 3 x 10 min in 
PBS and then incubated with the secondary antibody (Alexa Fluor 594 goat-anti chicken; Invitrogen 
A-11042) 1:1000 in 1 % NGS in 0.3 % PBS-T for 2 h at RT (light protected). Subsequently the sections 
were washed once more 3 x 10 min in PBS and then mounted onto superfrost object slides, dried and 
covered with mounting medium containing DAPI to counterstain the nuclei (VECTASHIELD® Hard Set 
Mounting Medium with DAPI; Linaris, H-1500). Image acquisition was done with the Zeiss- Axioplan 2 
imaging Light/ Fluorescence Microscope and the Zeiss-Axio Cam MRm (including the corresponding 
software). 
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2.4.4.4. Parvalbumin and vesicular glutamate transporter staining (immunofluorescent staining) 
Mice of project (i) SAVA were perfused with 4 % PFA-PBS + 0.1 % Glutaraldehyde (GA). Afterwards 
brains were carefully dissected out, stored overnight in 4 % PFA-PBS at 4°C and then transferred into 
30 % sucrose in PBS + 0.2 % sodium azide (NaN3) at RT. Perfusions and brain harvesting was done at 
the MPI-P by myself and with the support of K. Hagl and G. Rogel-Salazar (both former postdoctoral 
fellows in the research group “Neuronal Plasticity” of PD Dr. C. T. Wotjak), sectioning of brains and 
staining was performed by Sabine Nissel under the supervision of Prof. Dr. Wolfgang Härtig 
(University Leipzig, Paul-Flechsig Institute for Brain Research). The following protocol was provided 
by Prof. W. Härtig: 
Brains were cut into 30 µm-thick coronal sections with a freezing microtome resulting in a series 
comprising each 10th section. The sections were collected in 0.1 M TBS (pH 7.4) containing sodium 
azide and were subsequently stored at 4°C. 
A first series of free-floating sections from all animals was subjected to the concomitant 
immunofluorescence labelling of parvalbumin-positive GABAergic neurons (PV+) and the vesicular 
glutamate transporter 1 (VGLUT1). After washing of the tissues with TBS, sections were blocked with 
5 % normal donkey serum in TBS containing 0.3 % Triton X-100 (NDS-TBS-T) for 1 h. The sections 
were then incubated overnight with a mixture of guinea pig-anti-parvalbumin (Synaptic Systems, 
Göttingen, Germany; 1:300 in NDS-TBS-T) and rabbit-anti-VGLUT1 (Synaptic Systems; 1:500) solution. 
Following 3 wash-steps with TBS, immunoreactivities were visualised with a mixture of carbocyanine 
(Cy)2-conjugated donkey-anti-guinea pig IgG and Cy2-tagged donkey-anti-rabbit IgG (both from 
Dianova, Hamburg, Germany; 20 µg/ml TBS containing 2% bovine serum albumin = TBS-BSA) for 1 h. 
All sections were extensively rinsed with TBS, briefly washed with distilled water, mounted onto glass 
slides, air-dried and cover-slipped with Entellan in toluene (Merck, Darmstadt, Germany). 
Pictures of immunofluorescence labelling were obtained with a confocal laser-scanning microscope 
510 Meta (Zeiss), using an argon laser (488 nm) for the excitation of Cy2 and AlexaFluor488, and two 
helium-neon lasers exciting Cy3 (543 nm) as well as Cy5 (633 nm). The following band-pass (BP) 
filters were applied: BP 500-530 nm (Cy2, AlexaFluor488), and BP 565-615 nm (Cy3) (Reichel et al., 
2015b) 
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2.4.4.5. Nissl staining 
Nissl staining via cresyl-violet solution was applied for mice of the (ii) lacZ project with or without 
lacZ expression to visualize and compare the basic brain structures and in order to verify AAV 
injection coordinates and micro punch locations. This staining is named due to its ability to stain the 
Nissl-bodies in the cytoplasm of neurons (i.e. the rough endoplasmic reticulum), whereby the basic 
neuronal architecture is visualized (Palay and Palade, 1955). The cresyl violet solution employed here 
contained 0.5 g cresyl violet and 5 ml 1 M acetic acid in 95 ml ddH2O. Brains were first cut into 50 µm 
cryostat sections (Microm HM-500) and mounted on gelatine coated object slides. After sections 
were dried, the slides were briefly rinsed in dH2O and then incubated in the cresyl solution for 2 min. 
Subsequently sections were briefly immersed first in 70 % EtOH and then in 96 % EtOH. Afterwards 
the slides were incubated in isopropanol for 5 min and lastly in Rothi- Histol for 10 min. Thereafter 
the slides were covered with Rothi- Histol and cover slips. Image acquisition was done with the Leica- 
MZ Apo Stereomicroscope and the Zeiss-Axio Cam MRc5 (including the corresponding software; 
(Reichel, 2011)). 
 
2.4.5. Plasma corticosterone analysis 
Plasma corticosterone (Cort) levels were analyzed for (iii) PTSD & Age mice that underwent MSS 
(chapter 2.2.7). Tail-blood samples were taken immediately before (basal) and 30 min after (stress) 
MSS, and were stored on ice until further processing. Afterwards samples were centrifuged for 10 
min at 4°C and 4000 rcf (relative centrifugal force) and the supernatant (i.e. plasma) was transferred 
into clean Eppendorf-tubes. Basal plasma samples were diluted 1 : 25 (i.e. 10 µl plasma + 250 µl 
buffer from a commercially available Radio Immune Assay (RIA)-kit; MP Biomedicals, Eschwege, 
Germany), and stressed samples were diluted 1 : 200 (i.e. 5 µl plasma + 1 ml buffer). Solutions were 
stored at -20°C until Cort assessment. The Cort analysis itself was performed by Marcel Schieven, 
technician in the department of Stress Neurobiology and Neurogentics (Director: Prof. Dr. A. Chen) at 
the Max Planck Institute of Psychiatry. Analyses were done in duplicates and according to the manual 
of the manufacturers of the RIA kit (MP Biomedicals, Eschwege, Germany). 
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2.5. Project timelines 
 
2.5.1. Project (i): SAVA timelines 
The effect of GABAergic neuronal depletion was analyzed in four different experimental groups: 
SAVA-1 to SAVA-4 (Fig. M-9): 
SAVA-1 targeted the dorsal Hippocampus (dHPC) via bilateral injections at lateral (l) 1.3 mm (from 
midline); anterior- posterior (a-p) -1.8 mm (from bregma) and ventral (v) 2.0 mm (from the surface of 
the skull) with a volume of 2 µl each side. We injected 8 mice with PBS, 8 mice with un-conjugated 
SAVAs (i.e. anti-vesicular GABA transporter antibodies without Saporin; ucAB) and 8 mice with 
conjugated SAVAs (SAVA). All three groups were allowed to recover from surgery for 14 days before 
behavioral testing. On days 15 to 21 after surgery, mice underwent basal testing in the open field 
(OF), dark-light box (DL) and acoustic startle response test, both for direct Input-output 
measurements as well as pre-pulse Inhibition/ -facilitation (PPI/PPF). On days 22 to 36 after surgery 
mice underwent cognitive testing in the Water Cross Maze (WCM) and fear conditioning (FC). On day 
37 after surgery mice were perfused transcardially and the brains harvested for histological 
processing.  
SAVA-2 analyzed the consequences of SAVA injections into the Prelimbic Cortex (PrL) bilaterally at l 
0.5 mm; a-p +1.9 mm and v 2.5 mm with a volume of 0.5 µl per side. We injected 10 mice with PBS 
and 10 mice with SAVA. Behavioral testing and final brain dissection was done in parallel to the 
timeline of SAVA-1.    
SAVA-3 investigated the short-term effects of SAVA injections into the dHPC on spatial memory 
ACQUISITION. We implanted guide cannulas bilaterally at l 1.3 mm; a-p -1.8 mm and v 1.0 mm, 
allowed the animals to recover for 12 days and then injected 0.5 µl of either PBS (n= 14) or SAVA 
(n=16) per cannula. On d2 post Injection (pi) animals underwent testing in the OF and on d3pi to d9pi 
animals were trained in the WCM before being tested in the OF once more on d10pi. Animals were 
sacrificed and brains harvested on d11pi. 
SAVA-4 examined the short-term effects of SAVA injection in the dHPC on spatial memory RECALL. 
We implanted cannulas (as described for SAVA-3) and allowed the animals to recover for 12 days. 
Afterwards mice were tested in the OF on d13, trained in the WCM on d14 – d20 and only then 
injected with 0.5 µl of either PBS (n= 10) or SAVA (n=16). On d2pi and d8pi mice were tested in the 
OF whereas on d3+4pi and d9+10pi spatial memory recall in the WCM was assessed. Animals were 
sacrificed and brains recovered on d11pi. 
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Survival times post injection were 37 days (SAVA-1+2) or 11 days (SAVA-3+4). For SAVA-1 one SAVA- 
treated animal did not survive until the end, leaving 8 PBS : 8 ucAB : 7 SAVA. For SAVA-2 all animals 
survived the treatment (10 PBS : 10 SAVA). Concerning SAVA-3 two SAVA-treated and one PBS-
treated animal did not survive until the end, leaving 13 PBS : 14 SAVA. And for SAVA-4 two SAVA- 
treated animals did not survive until the end, leaving 10 PBS : 14 SAVA (modified after (Reichel et al., 
2015b)). 
 
 
Fig. M-9: Timelines for project (i): SAVA: (SAVA-1) SAVA injections into dHPC; (SAVA-2) SAVA injections into PrL; (SAVA-3) 
SAVA injections into dHPC after cannula implantation (focus on spatial memory ACQUISITION); (SAVA-4) SAVA injections 
into dHPC after cannula implantation (focus on spatial memory RECALL); a-p = anterior-posterior; dHPC = dorsal 
hippocampus; l = lateral; OF = open field; pi = post injection; PrL = prelimbic cortex; v = ventral; V = Volume; WCM = water 
cross maze; modified after (Reichel et al., 2015b). 
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2.5.2. Project (ii): lacZ timelines 
In order compare the results throughout the (ii) lacZ project not only between littermates but also 
across the different lacZ expressing mouse lines as well as the Cre-driver lines, several distinct 
timelines were established (Fig. M-10 a + b). Timeline (a) was used when testing mice constitutively 
expressing mice (i.e. R26R:Nex-Cre, Nex-Cre, CAG-CAT-EGFP:Nex-Cre and R26R:Dlx
5/6
-Cre mice). 
This timeline entailed an extensive behavioral screen at the age of 4 months including OF, DL, ASR, FC 
+ Extinction training as well as WCM testing, followed by the MEMRI procedure at the age of 5-6 
months. After ca. 6 weeks of MnCl2 wash-out (Grünecker et al., 2013) mice were anesthetized with 
an overdose of isoflurane and brains were carefully dissected out to be processed for e.g. X-Gal 
staining. Tissue undergoing proteomic or western blot analysis was not previously subjected to MnCl2 
injections and imaging. 
The second timeline (Fig. M-10b) was applied when testing inducible lacZ-mouse lines, i.e. mice 
expressing lacZ after tamoxifen treatment (i-R26R:Nex-Cre, i-R26R:CamKIIα-Cre, i-R26R:DAT-Cre, i-
DAT-Cre). These mice underwent a short basal behavior screen (OF + ASR) at the age of 3,5 months 
before receiving any TAM (i.e. before lacZ expression was induced). Subsequently, at the age of 4 
months, these mice received exclusively TAM-containing food for 3 weeks (lacZ expression could be 
detected via X-Gal staining approximately 4 weeks after TAM began) and at the age of 8 months 
these mice underwent the same extensive behavioral screen as the constitutively lacZ-expressing 
mice (OF, DL, ASR, FC + Extinction training  and WCM) as well as the MEMRI procedure. Furthermore, 
one cohort of i-R26R:CamKIIα-Cre and i-R26R:DAT-Cre mice, respectively, were additionally 
repeatedly tested at the age of 16 months and once more at the age of 24 months in order to 
investigate a possible cumulative effect of lacZ expression and age. A separate cohort of 
R26R:CamKIIα-Cre and i-R26R:DAT-Cre mice also underwent a condensed behavioral screen (OF + 
ASR-I/O + ASR-PPI/PPF) already two months after receiving TAM-food. 
In contrast, i-R26R:Nex-Cre and i-DAT-Cre mice only underwent testing at the first time-point (age = 
8 months, i.e. 4 months after lacZ induction) and did not undergo repeated testing. Tissue 
undergoing western blot assessment (i-R26R:Nex-Cre mice) was collected after a wash-out phase of 
5 weeks after the last MEMRI scan (Grünecker et al., 2013). 
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Fig. M-10: Timelines for project (ii): lacZ: (a): timeline for constitutive mouse lines (i.e. Cre/lacZ/GFP expression beginning 
during embryogenesis); (b): timeline for adult-inducible mouse lines (i.e. lacZ expression beginning after tamoxifen-
treatment); ASR = acoustic startle response; DL = dark-light box; Extct = extinction training; FC = fear conditioning; I/O = 
input/ output curve; MEMRI = manganese-enhanced magnetic resonance imaging; OF = open field; PPI/PPF = pre-pulse 
inhibition/ pre-pulse facilitation; TAM = tamoxifen-food; WCM = water cross maze. 
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2.5.3. Project (iii): PTSD & Age timeline 
For the PTSD & Age project we employed C57Bl6/N mice and divided them into 5 groups à 16 mice. 
Group 1 (= home-cage, HC) was not tested until the OF/ OSR block starting at the age of 13.5 months 
(Fig. M-11). Group 2 (NoShock1, NS) underwent all behavior testing but received neither a shock at 5 
months, nor underwent mouse shaker stress (MSS) at 12 months of age. Group 3 (NoShock but MSS, 
NS+MSS) did not receive a shock either, but was subjected to MSS and underwent all behavioral 
testing in parallel to NS. The fourth group (Shock, S) received 2 x 1.5 mA shocks at the age of 5 
months, but no MSS at 12 months, and underwent all behavioral testing. The fifth and last group 
received 2 x 1.5 mA shocks at 5 months and MSS at 12 months and underwent all behavioral testing 
(S+MSS). NS and S+MSS underwent WCM memory-recall test for three days (m-r1 to m-r3) two 
months after initial WCM training. Initial WCM training was done by Gaby Rogel, an experienced 
Post-Doc in the research group of PD Dr. C. T. Wotjak, Department of Stress Neurobiology and 
Neurogenetics, Max Planck Institute of Psychiatry; memory-recall assessment in the WCM and all 
other behavioral testing as well as tissue collection was done by me. Brains and blood of mice of all 5 
groups were collected at the age of 18 months (Fig. M-11). 
 
 
Fig. M-11: Timeline for project (iii) PTSD & Age: 5 groups à 16 C57Bl/6N mice; DL = dark-light box; HC = home cage; MSS = 
mouse shaker stress; NOR = novel object recognition; NS = no shock; OF = open field; PTSD = acoustic startle input/ output 
curve + contextual fear memory assessment + associative (=tone-) fear memory assessment; S = shock; WCM = water cross 
maze.  
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2.6. Statistical Analyses 
All data sets of this study were analyzed either via parametric tests (t-test or Analysis of Variance for 
repeated measures (ANOVA) followed by Tukey Honest Significant Differences-test if applicable) or 
distribution statistics (chi2, χ²) using STATISTICA for Windows (V 5.0 StatSoft, Inc., 1995) or GraphPad 
Prism™ (version 5.0; GraphPad Software Inc.; San Diego, CA, USA). Results were considered 
significant if p ≤ 0.055. If the ANOVA analysis revealed a statistically significant interaction (e.g. SAVA 
OF treatment x time), a post-hoc test (Tukey HSD) was applied. Depending on the behavioral task and 
the experimental groups varying interaction factors were analyzed: e.g. for SAVA: e.g. treatment x 
time or training day: for lacZ e.g. genotype x time or training day; for PTSD & Age: e.g. group x time 
or training day. For all experimental groups tested in the WCM the following criteria were analyzed 
(separately for training week 1 or 2): Latency to reach the platform, Accuracy, number of Wrong 
Platform Visits, number of accurate Learners per group and Learning Score (i.e. mean accuracy per 
training week) per animal. For the sake of clarity and brevity not every individual F- and p- value for 
every test, factor and criterion will be mentioned throughout the description of the results, but the 
most meaningful values per experimental group are stated in the text and the results of all statistical 
analyses are stated in chapter 8.1 Appendix- Statistics (pp. I - XXXI).  
Histological stainings for (i) SAVA were quantified as follows: For SAVA-2 the immunolabeled sections 
of 5 mice per group were analyzed regarding the number of parvalbumin-positive (PV+) neurons in 
infralimbic-, prelimbic and cingulate cortex areas. For SAVA-3 and -4 the sections of 6 mice per group 
were analyzed regarding PV+ cells for all cornu ammonis (CA) regions throughout the dorsal 
hippocampus (a-p -1.4 mm to -2.2. mm from bregma). Experimental groups were compared by 
means of consecutive coronal sections and PV+ neurons were pooled bilaterally per animal. Due to 
massive cellular loss the PV+ content for SAVA-1 could not be adequately quantified (Reichel et al., 
2015b). 
For the analyses of MEMRI scans the data sets of the different groups were either analyzed by 
unpaired Student’s t-test (if only two groups were to be compared) or in case of more than two, 
these groups (e.g. Rosa26-AAV) were first compared to each other via 1way ANOVA using GraphPad 
Prism® 2007 (version 5.0; GraphPad Software Inc.; San Diego, CA, USA) and subsequently analyzed 
using Tukey's Multiple Comparison post hoc test (also performed with GraphPad Prism ® 2007; 
version 5.0; GraphPad Software Inc.; San Diego, CA, USA).  
All results were plotted via GraphPad Prism® 2007 (version 5.0; GraphPad Software Inc.; San Diego, 
CA, USA) with the data presented as mean ± standard error of mean (Mean ± SEM).  
* p ≤ 0.055; ** p < 0.01; *** p < 0.001. 
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3 Results 
 
3.1. (i) SAVA 
The behavioral tests for (i) SAVA were in part carried out by a master student under my supervision 
(SAVA-1; Karola Käfer) and in part with the help of an experienced post-doc of the group of PD Dr. C. 
T. Wotjak (SAVA-2 and parts of SAVA-3; Gabriela Rogel-Salazar, PhD). Acquisition of all behavioral 
data-sets was supervised by me. Histological processing and imaging was carried out by the group of 
Prof. Dr. Wolfgang Härtig at the Paul Flechsig Institute for Brain Research (University of Leipzig). 
Statistical analyses of all data-sets and graph-preparations were done by me. 
Furthermore, at the time point of preparation of this thesis, a manuscript describing the SAVA- 
project was submitted to be published, and has since been accepted by the journal “Frontiers in 
Behavioral Neuroscience”. Thus, the figures and description of results presented here (partly) overlap 
with the published manuscript, which was also prepared by me (Reichel et al., 2015b).  
The goal of the (i) SAVA project was to assess the behavioral consequences of long-term GABAergic 
lesions in the dorsal hippocampus (dHPC) and the prelimbic cortex (PrL) after the injection of 
saporin-conjugated anti vesicular GABA transporter antibodies (SAVAs). We particularly focused on 
the consequences regarding cognitive abilities and with respect to schizophrenia-related behavior 
traits. For the dHPC we furthermore investigated the short-term effects of GABAergic depletion and 
focused here on the distinction between the acquisition and the recall of a spatial memory. 
 
3.1.1. SAVA-1: Consequences of long-term GABAergic depletion in dHPC 
SAVA-1 investigated the behavioral effects of long-term (i.e. > 14 days) GABAergic interneuron 
depletion via saporin-conjugated immuno-toxins in the dHPC (Fig. R-1a+b). GABAergic neuronal loss 
in the dorsal HPC increased the distance traveled in the OF for the last 10 min of testing (Fig. R1c1; 
treatment x time: F10,100 = 3.63, p = 0.0004; Tab. St-1). However, loss of GABAergic neurons in the 
dHPC had diverging effects on rearing behavior in the OF. Rearing frequency (RF) was not affected by 
immunolesioning (Tab. St-1), but rearing duration (RD) was slightly decreased in SAVA-treated 
animals (Fig. R-1c3; treatment effect: F2,20 = 4.09, p = 0.0323; Tab. St-1). In contrast, anxiety-related 
behavior in the dark-light box (DL; Fig. R-1d1-3) and acoustic startle response input/ output (ASR- 
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I/O; Fig. R-1e1) as well as pre-pulse inhibition/- facilitation (PPI/PPF; Fig. R-1e2-4; Tab. St-1) were 
unaffected by long-term GABAergic neuronal loss in the dHPC.  
 
 
 
Subsequent testing for spatial place learning abilities in the WCM revealed marked impairments 
affecting all learning parameters for SAVA-treated mice (Fig. R-1f1-4): SAVA-treated animals 
displayed a higher latency to reach the platform (Fig. R-1f2; treatment x day: F8,80 = 5.12, p < 0.0001), 
Fig. R-1: SAVA-1 – Behavioral 
consequences of long-term GABAergic 
depletion in dorsal hippocampus 
(dHPC): (a) timeline for SAVA-1: 
stereotactic PBS, ucAB or SAVA 
injection at d0, recovery for 14 days, 
basal phenotyping (OF, DL, ASR (I/O 
and PPI/PPF)) d15 to 21 pi; cognitive 
testing (WCM, FC) d22 to 36 pi. Brains 
were collected after transcardial 
perfusion on d37. (b) Injection sites for 
SAVA-1: dHPC, bilateral, 2µl each side 
(l 1.3 mm; a-p -1.8 mm; v 2.0 mm from 
bregma); groups and sample size for 
SAVA-1; (c1-3) OF behavior; (d1-3) DL 
behavior; (e1-4) ASR as basic I/O curve 
and PPI/PPF after 55, 65 or 75 dB SPL 
pre-pulse, respectively, for 5 different 
IPIs; (f1) basic schema of WCM; (f2-4) 
learning parameters in the WCM; (g1) 
timeline for FC: tone- shock pairing on 
d0; testing for contextual and tone 
memory in conditioning and novel 
context on d1; (g2) comparison of 
contextual memory in the different 
contexts with and without tone 
presentation presented as freezing 
behavior over the course of 3 min 
observation periods (%); (g3) tone 
memory presented as freezing 
behavior (%) in novel context before 
and after presentation of tone. ASR = 
acoustic startle response; dB SPL = 
decibel at sound pressure level; DL = 
dark-light box; FC = fear conditioning; 
I/O = input/ output; IPI = inter-pulse 
interval; OF = open field; PBS = 
phosphate-buffered saline; pi = post 
injection; PPI/PPF = pre-pulse 
inhibition/ -facilitation; ucAB = 
unconjugated antibody; WCM = water 
cross maze. All data presented as 
mean ± SEM. ٭ p < 0.05, ٭٭ p < 0.01, 
 p < 0.001 (chi² test or ANOVA ٭٭٭
followed by Tukey HSD post hoc test). 
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and performed less accurately (Fig. R-1f3; treatment x day: F8,80 = 7.46, p < 0.0001) compared to PBS 
and ucAB treated mice. This was also evident at the population level when comparing the number of 
accurate learners between treatment groups at the last day of training (Fig. R-1f4; chi² day 5: p < 
0.0001). However, SAVA treatment of the dHPC did not significantly affect contextual- and auditory 
cued fear memory (Fig. R-1g2+3; Tab. St-1). 
Histopathological analyses revealed a complete absence of parvalbumin positive (PV+) interneurons 
from the dHPC (Fig. R-5a3+4; due to massive cellular loss statistics not applicable).  
 
3.1.2. SAVA-2: Consequences of long-term GABAergic depletion in the PrL 
SAVA-2 analyzed the consequences of long-term (i.e. > 14 days) GABAergic depletion in the prelimbic 
cortex (PrL; Fig. R-2a+b). SAVA administration did not affect the Distance traveled in the OF (Fig. R-
2c1; Tab. St-2), but decreased both RF and RD (Fig. R-2c2+3; RF: treatment x time: F5,90 = 5.67, p = 
0.0001 and RD: F5,90 = 3.24, p = 0.0098). Furthermore, SAVA treatment caused a trend towards a 
decreased latency in the DL (i.e. slightly decreased anxiety related behavior; Fig. R-2d1; p = 0.08), 
without affecting the frequency to enter the light compartment or the duration spend in the light 
compartment (Fig. R-2d2+3; Tab. St-2). SAVA-treated mice displayed unaffected ASR-I/O responses 
(Fig. R-2e1; Tab. St-2), but presented with decreased PPF for pre- pulse intensities of 55 dB and 65 
dB, but not 75 dB (Fig. R-2e2-4; 55 dB: treatment x inter-pulse interval: F4,72 = 5.36, p = 0.0008; 65 dB: 
treatment x inter-pulse interval: F4,72 = 8.02, p < 0.0001; for 75 dB see Tab. St-2). WCM training did 
not reveal any performance differences for SAVA- vs. PBS-treated mice during week 1 of training (i.e. 
acquisition; Fig. R-2f1-4; Tab. St-2). However, during week 2 (i.e. reversal learning) SAVA-treated 
animals displayed a decreased accuracy to re-learn the new platform position (Fig. R-2f3; treatment x 
day: F6,108 = 2.73, p = 0.0165). These treatment effects were again also mirrored at the population 
level when comparing the number of accurate learners at the last training day of each week (Fig. R-
2f4; chi² week 1 day 7: p = 0.5312; chi² week 2 day 7: p = 0.0253; Tab. St-2).   
SAVA treatment in the PrL furthermore resulted in slightly reduced contextual fear memory (Fig. R-
2g2; p = 0.07) and an accelerated decrease in their freezing response over the course of the 3-min re-
exposure to the conditioned tone (Fig. R-2g3; treatment x time: F10,180 = 2.09, p = 0.0273).  
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Histological analyses (Fig. R-5b1-6) revealed a decreased number of PV+ cells in the PrL (p = 0.0294, 
unpaired Student's t- test, one-sided); Fig. R-5b6) and anterior cingulate cortex (p = 0. 0408, unpaired 
Student's t- test, one-sided); Fig. R-5b5) of SAVA treated animals (Tab. St-5). 
 
 
 
Fig. R-2: SAVA-2 – Behavioral 
consequences of long-term GABAergic 
depletion in prelimbic cortex (PrL): (a) 
timeline for SAVA-2: stereotactic PBS or 
SAVA injection at d0, recovery for 14 
days, basal phenotyping (OF, DL, ASR 
(I/O, PPI/PPF)) d15 to 21 pi; cognitive 
testing (WCM, FC) d22 to 36 pi. Brains 
were collected after transcardial 
perfusion on d37. (b) Injection sites for 
SAVA-2: PrL, bilateral, 0.5 µl each side (l 
0.5 mm; a-p +1.9 mm; v 2.5 mm from 
bregma); groups and sample size for 
SAVA-2; (c1-3) OF behavior; (d1-3) DL 
behavior;  (e1-4) ASR as basic I/O curve 
and PPI/PPF after 55, 65 or 75 dB SPL 
pre-pulse, respectively, for 5 different 
IPIs; (f1) basic schema of WCM; (f2-4) 
learning parameters in the WCM; (g1) 
timeline for FC: tone- shock pairing on 
d0; testing for contextual and tone 
memory in conditioning and novel 
context on d1; (g2) comparison of 
contextual memory in the different 
contexts with and without tone 
presentation presented as freezing 
behavior over the course of 3 min 
observation periods (%); (g3) tone 
memory presented as freezing behavior 
(%) in novel context before and after 
presentation of tone. ASR = acoustic 
startle response; dB SPL = decibel at 
sound pressure level; DL = dark-light 
box; FC = fear conditioning; I/O = input/ 
output; IPI = inter-pulse interval; OF = 
open field; PBS = phosphate-buffered 
saline; pi = post injection; PPI/PPF = pre-
pulse inhibition/ -facilitation; WCM = 
water cross maze. All data presented as 
mean ± SEM. ٭ p < 0.05, ٭٭ p < 0.01, 
 p < 0.001 (student’s t-test; chi² test ٭٭٭
or ANOVA followed by Tukey HSD post 
hoc test).  
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3.1.3. SAVA-3: Consequences of short-term GABAergic depletion in dHPC; ACQUISITION 
SAVA-3 investigated the short-term effects (i.e. < 12 days) of GABAergic depletion in the dHPC and 
focused especially on the consequences regarding the acquisition of a spatial memory (Fig. R-3a+b). 
Therefore we implanted guide cannulas into the dHPC, let the animals recover for 12 days and only 
then injected SAVAs or PBS via the cannulas. SAVA treatment did not affect distance traveled, nor the 
rearing behavior in the OF two days after administration (Fig. R-3c1-3; Tab. St-3). However, 10 days 
post injection (pi) SAVA-treated animals displayed a drastically heightened distance traveled in the 
OF (Fig. R-3e1+2; Distance d2 pi vs. d10 pi treatment x day: F1,25 = 31.1914,  p < 0.0001; Distance d10 
pi  treatment effect: F1,25 = 17.15, p = 0.0003), but still only minor changes in rearing behavior (Fig. R-
3e3+4; Tab. St-3). WCM training beginning three days after SAVA injection into the dHPC (d3 pi) once 
again revealed a severe learning impairment for SAVA-treated animals across all learning parameters 
(Fig. R-3d1-4; Tab. St-3): Similar to SAVA-1, SAVA- treated mice again displayed a longer latency to 
find the platform (Fig. R-3d2; treatment x day: F6,150 = 8.28, p < 0.0001), a decreased accuracy to 
swim directly to the platform (Fig. R-3d3; treatment x day: F6,150 = 7.63, p < 0.0001) and lastly, the 
SAVA treated group contained a reduced number of accurate performers at the end of training (i.e. 
Learners, Fig. R-3d4; chi² day 7: p = 0.0012; Tab. St-3).   
Histopathological analyses (Fig. R-5c1-5) revealed a vastly reduced number of PV+ cells in the cornu 
ammonis (CA) regions of the dHPC in SAVA-treated animals (p < 0.0001; Fig. R-5c5¸ Tab. St-5). 
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3.1.4. SAVA-4: Consequences of short-term GABAergic depletion in dHPC; RECALL 
SAVA-4 also investigated the short-term effects of GABAergic neuronal loss in the dHPC, but this time 
focusing on the recall of a spatial memory. Therefore animals were again equipped with guide 
cannulas aimed at the dHPC (analogous to SAVA-3), but were first trained in the WCM until all of 
them had reached the accuracy criterion (Fig. R-4d3+4, Training day 1-7; Tab. St-4). Once all animals 
had acquired the platform position and performed accurately, they were injected with SAVA or PBS 
and subsequently repeatedly tested in OF and WCM (Fig. R-4a+b). In parallel to SAVA-3, SAVA 
treatment once again did not affect OF behavior on day 2 pi (Fig. R-4c1-3; Tab. St-4), but caused an 
increased distance traveled on day 8 pi (Fig. R-4e1+2; Distance d2 pi vs. d8 pi treatment x day: F1,22 = 
10.1958,  p = 0.0042; d8 Distance treatment x time: F5,110 = 4.53, p = 0.0009) as well as a slightly 
increased RF (Fig. R-4e3; treatment effect F1,22 = 5.62, p = 0.027), but no changes regarding RD (Tab. 
St-4).  
 
Fig. R-3: SAVA-3 – Locomotor and 
cognitive consequences of short-
term GABAergic depletion in dorsal 
hippocampus (dHPC) – 
ACQUISITION: (a) timeline for SAVA-
3: stereotactic cannula implantation 
at d0, recovery for 12 days, SAVA 
application = d0 pi; OF testing d2 pi 
+ d10 pi; WCM training d3 pi until d9 
pi; harvesting of brains after 
transcardial perfusion on d11 pi; (b) 
cannula position for SAVA-3: dHPC, 
bilateral, l 1.3 mm; a-p -1.8 mm; v 
1.0 mm from bregma; injection of 
0.5 µl PBS or SAVA per cannula; 
groups and sample size; (c1-3) OF 
behavior d2 pi; (d1) basic schema of 
WCM; (d2-4) learning parameters in 
the WCM; (e1) OF Distance d2 pi vs. 
d10 pi; (e2-4) OF behavior d10 pi. OF 
= open field; PBS = phosphate-
buffered saline; pi = post injection; 
WCM = water cross maze. All data 
presented as mean ± SEM. ٭٭ p < 
 p < 0.001 (chi² test or ٭٭٭ ,0.01
ANOVA followed by Tukey HSD post 
hoc test).  
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Re-exposure to the WCM on day 3+4 pi revealed a treatment-dependent increase in the latency to 
reach the platform (F1,22 = 4.08, p = 0.0558) but no accuracy differences between groups (Fig. R-
4d2+3; Tab. St-4). However, the number of learners in the PBS-treated groups increased from d3 to 
d4 pi (from 60 % to 80 %), whereas it decreased for SAVA-treated animals (from 64 % to 50 %). WCM 
re-testing on day 9+10 pi revealed a significant treatment effect on latency (F1,22 = 15.21, p = 0.0008) 
but only a minor treatment-dependent trend regarding performance accuracy (F1,22 = 3.55, p = 
0.0728). The number of learners was nearly identical between groups on day 9 pi (PBS: 70 %; SAVA: 
64%; chi² day 9 pi : p = 0.7697), but differed significantly on day 10 pi  (PBS: 100 %; SAVA: 64%; chi² 
day 10 pi : p = 0.0337; Fig. R-4d4; Tab. St-4). Thus, initial recall performance was nearly identical for 
both treatment groups at multiple testing time points post injection. However, if the recall day was 
followed by another day of training, PBS-treated animals improved once again regarding their 
accuracy levels and number of accurate learners, whereas SAVA-treated animals stagnated or even 
decreased in WCM performance during re-acquisition. 
 
 
 
Fig. R-4: SAVA-4 –  Locomotor 
and cognitive consequences of 
short-term GABAergic depletion 
in dorsal hippocampus (dHPC) – 
RECALL: (a) timeline for SAVA-4: 
stereotactic cannula 
implantation at d0, recovery for 
12 days, OF testing on d13, WCM 
training d14-20, SAVA 
application = d0 pi, OF testing d2 
pi + d8 pi, WCM recall-training 
d3+4 pi and d9+10 pi, harvesting 
of brains after transcardial 
perfusion on d11 pi; (b) cannula 
position for SAVA-4: dHPC, 
bilateral, l 1.3 mm; a-p -1.8 mm; 
v 1.0 mm from bregma; injection 
of 0.5 µl PBS or SAVA per 
cannula; groups and sample size; 
(c1-3) OF behavior d2 pi; (d1) 
basic schema of WCM; (d2-4) 
learning parameters in the 
WCM; (e1) OF Distance d2 pi vs. 
d10 pi; (e2-4) OF behavior d8 pi. 
OF = open field; PBS = 
phosphate-buffered saline; pi = 
post injection; WCM = water 
cross maze. All data presented as 
mean ± SEM; ٭ p < 0.05, ٭٭٭ p < 
0.001 (chi² test or ANOVA 
followed by Tukey post hoc test).  
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These findings of SAVA-4 corroborate the results of SAVA-3 concerning the (re-)acquisition-abilities 
of a spatial memory following GABAergic depletion in the dHPC via SAVA immuno-toxin, as well as 
the depletion-duration-dependent increase in locomotor activity observed during OF testing.  
Histopathological analyses after GABAergic depletion via SAVA administration (Fig. R-5d1-5) revealed 
a significantly reduced number of PV+ cells in the CA regions of the dHPC for SAVA-treated animals (p 
= 0.019; Fig. R-5d5; Tab. St-5). 
 
 
Fig. R-5: Histology SAVA-1 through SAVA-4: (a1+2 – d1+2) respective locations and extensions of lesions for SAVA-1 
through SAVA-4; (a1-d1) lesion extent: black = smallest occurring lesion, grey = biggest occurring lesion; (a3) representative 
image of CA1 region of a PBS-treated mouse; (a4) representative image of CA1 region of a SAVA-treated mouse; (b3) 
representative image of PrL of a PBS-treated mouse; (b4) representative image of PrL of SAVA-treated mouse; (b5+6) 
quantification of PV+ cells in anterior cingulate cortex and PrL, respectively; (c3) representative image of CA1 region for a 
PBS-treated mouse; (c4) representative image of CA1 region for a SAVA-treated mouse; (c5) quantification of PV+ cells for 
SAVA-3 across all CA sub-regions; (d3) representative image of left dHPC of a PBS-treated mouse; (d4) representative image 
of left dHPC of a SAVA-treated mouse; (d5) quantification of PV+ cells for SAVA-4 across all CA sub-regions; stainings: green 
= PV+; red = VGLUT1; CA = cornu ammonis; dHPC = dorsal hippocampus; PBS = phosphate-buffered saline; PrL = prelimbic 
cortex; PV = parvalbumin. Data presented as mean ± SEM; ٭ p < 0.05, ٭٭ p < 0.01, ٭٭٭ p < 0.001 (Student’s t- test).   
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In summary, GABAergic lesions of the dorsal hippocampus severely impair the acquisition of a spatial 
learning task, independent of the duration of depletion. In contrast, hyperactivity in the open field 
after hippocampal GABAergic depletion can be viewed as a function of time, since an increased 
distance traveled can only be observed beginning approximately 5 days after SAVA administration. 
This hyperactivity-effect increases until at least day 10 after SAVA-treatment, but is diminished again 
on day 15 after SAVA administration. Furthermore, although GABAergic interneurons of the dHPC are 
essential for the acquisition of a spatial learning task, their depletion in the dorsal hippocampus does 
not affect the recall of a spatial memory. GABAergic lesioning of the PrL, in contrast, decreases 
rearing behavior in the OF along with a decrease in anxiety-related behavior in the DL as well as 
diminished PPF-responses and a decline in tone-fear memory. Interestingly, GABAergic depletion in 
the PrL selectively interferes with the reversal learning capabilities of the animals, but not with the 
acquisition of a spatial memory.  
Table R-1: Summary of consequences of GABAergic lesions    
PARAMETER 
dHPC              
(long-term) 
PrL                  
(long-term) 
dHPC (short-
term/ acquisition) 
dHPC (short-
term/ recall) 
OF activity 
    
Anxiety related 
behavior  
              n/a           n/a 
ASR- I/O               n/a           n/a 
ASR- PPI/PPF           
(65 dB) 
              n/a           n/a 
FC –                    
Context freezing 
              n/a           n/a 
FC –                        
Tone freezing 
  
            n/a           n/a 
WCM performance 
(week 1 = acquisition) 
    
WCM performance 
(week 2 = reversal 
learning/ recall) 
         n/a 
 
          n/a 
 
ASR = acoustic startle response; FC = fear conditioning; dHPC = dorsal hippocampus; I/O = input/ output curve; MEMRI = 
manganese-enhanced MRI; n/a = not applicable; OF = open field; PPI/PPF = pre-pulse inhibition/- facilitation; PrL = 
prelimbic cortex; WCM = water cross maze. 
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3.2. Project (ii) lacZ 
The initial characterization of R26R:Nex-Cre mice concerning spatial learning abilities, basal 
locomotor activity and acoustic startle responses, as well as CNS- structural changes and their 
comparison to Nex-Cre mice was first reported in my Diploma Thesis (Reichel, 2011). Behavioral and 
structural assessments of these mouse-lines have since been repeated with independent cohorts and 
extended to additional mouse-lines and more detailed analyses. The results of the repeated and 
extended studies are described below. Furthermore, at the time point of preparation of this thesis a 
manuscript describing in particular the findings of constitutive lacZ expression has been submitted to 
be published and is currently under review. Consequently, some of the figures as well as the 
description of the findings reported here are overlapping with the submitted manuscript (Reichel et 
al., 2015a). The manuscript for publication has also been prepared by me.  
 
3.2.1. Consequences of constitutive lacZ expression 
Transgenic lacZ expression is a widely used marker to visualize genetic manipulations. However, the 
bacterial lacZ sequence codes for β-Galactosidase (β-Gal) and is an analog to senescence-associated 
β-Gal (SA-β-Gal), which is a marker for aged and thus deteriorating tissue. Moreover, the stable 
expression and subsequent accumulation of proteins is a hallmark of neurodegenerative diseases. 
Therefore we asked whether the expression of lacZ would result in consequences similar to 
neurodegenerative or age-related decline regarding cellular functionality, which are ultimately 
resulting in cognitive deficits. 
Constitutive transgenic expression, i.e. expression beginning during embryogenesis, is the most 
widespread application, since it does not require further manipulation during the life-span of the 
animal to induce expression. Therefore and due to the extensive implications of glutamatergic 
principal neurons for learning and memory related behaviors we first analyzed the consequences of 
constitutive lacZ expression in glutamatergic principal neurons.  
 
 
 
 
Results – Project (ii): lacZ  
81 
 
3.2.1.1 R26R:Nex-Cre mice 
Thus, the first lacZ expressing line that underwent in-depth screening was the R26R:Nex-Cre mouse 
line, which, due to its “Nex”-Cre-driver line expresses lacZ in cortical glutamatergic neurons, i.e. 
throughout the cortex, but also particularly in the hippocampus (HPC, Fig. R-6). 
 
 
Fig. R-6: Histology for R26R:Nex-Cre
+
 mice (coronal sections): upper row X-Gal staining for R26R:Nex-Cre
+
 mice; lower row: 
Nissl staining for R26R:Nex-Cre
+
 mice. BlA = basolateral amygdala; Ctx = cortex; HPC = hippocampus; lat. V. = lateral 
ventricles. 
 
R26R:Nex-Cre+ mice underwent a behavioral screen at the age of approximately four months and 
displayed a number of marked differences compared to their Cre-negative (i.e. without lacZ 
expression) littermates that were tested in parallel (Fig. R-7). We observed a drastically heightened 
locomotor activity (i.e. distance traveled) in the OF accompanied by reduced rearing behavior (Fig. R-
7a1-a3; Distance (Genotype): F1,17 = 10.6423; p = 0.0046; Rearing Frequency (Genotype): F1,17 = 
16.7673; p = 0.0008; Rearing Duration (Genotype): F1,17 = 19.8874; p = 0.0003; for further statistical 
analyses (e.g. interaction values etc.) please see Tab. St-6). Anxiety-related measurements in the DL 
revealed a trend towards a reduced latency for the first entrance into the light compartment (Fig. R-
7b1; unpaired student’s t-test: p = 0.0691) and a significantly increased frequency to enter the light 
compartment (Fig. R-7b2; unpaired student’s t-test: p = 0.0066), but no differences between groups 
regarding the time spent in the light compartment (Fig. R-7b3; Tab. St-6).  
Analysis of the acoustic startle response input/ output revealed no significant differences for 
R26R:Nex-Cre+ vs. R26R:Nex-Cre- mice (Fig. R-7c1; Tab. St-6). However, we observed a significant 
genotype x IPI (inter pulse interval) interaction difference for a heightened PPF in R26R:Nex-Cre+ 
mice after a 55 dB pre-pulse (PPI/PPF 55 dB (genotype x IPI): F4,68 = 4.8913; p = 0.0016), but not after 
a 65 or 75 dB pre-pulse (Fig. R-7c2-c3; Tab. St-6).  
HPC lat. V. 
HPC 
HPC 
lat. V. 
HPC 
Ctx 
BlA 
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Fear Conditioning revealed a diminished freezing-response for R26R:Nex-Cre+ mice in the shock 
context 24 h after shock application (Fig. R-7d1; unpaired student’s t-test: 0.0138), but no differences 
for tone-associated fear memory or extinction training (Fig. R-7d2-d4; Tab. St-6). 
 
 
Lastly, WCM training revealed a severe spatial learning impairment for R26R:Nex-Cre+ mice 
compared to Cre-negative littermates across all learning parameters (Fig. R-7e1-e5): R26R:Nex-Cre+ 
displayed an increased latency to reach the platform (Fig. R-7e1; WCM Latency (Genotype): F1,18 = 
Fig. R-7: Behavioral 
consequences of 
constitutive 
glutamatergic lacZ 
expression (R26R:Nex-
Cre): (a1-a3) OF behavior; 
(b1-b3) DL behavior; (c1-
c4) ASR- I/O and PPI/PPF; 
(d1-d4) contextual and 
associative (tone-) fear 
memory and extinction 
training; (e1-e5) WCM 
performance. ASR = 
acoustic startle response; 
DL = dark-light box; I/O = 
input/ output; OF = open 
field; PPI/PPF = pre-pulse 
inhibition/ -facilitation; 
WCM = water cross maze; 
WPV = wrong platform 
visits. All data presented 
as mean ± SEM; ٭ p < 
 > p ٭٭٭ ,p < 0.01 ٭٭ ,0.05
0.001 (Student’s t-test, χ² 
test or ANOVA followed 
by Tukey HSD post hoc 
test). 
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30.0181, p < 0.0001), a severely impaired accuracy to find the platform (Fig. R-7e2; WCM Accuracy 
(Genotype): F1,18 = 73.2025, p < 0.0001), an increased number of wrong platform visits (Fig. R-7e3; 
WCM WPV (Genotype): F1,18 = 96.4193, p < 0.0001), and the R26R:Nex-Cre
+ test group entailed not a 
single accurate learner at the end of training (Fig. R.7e4; Learners day 5 chi²: p = 0.0003).  
In order to determine whether the mice were actively searching for the platform or merely passively 
floating until they were removed from the water, we also analyzed the swim-strategy of the test 
groups and found a strong start-side-bias for R26R:Nex-Cre+ mice, which persisted even after the 
initial training days and indicates that the mice were indeed actively looking for the platform, but 
employed a response-based strategy rather than a place-learning strategy in order to reach the 
platform (Fig. R-7e5; WCM Start-Bias (Genotype): F1,18 = 16.8779, p = 0.0007). 
Following the marked findings of the behavioral screen, R26R:Nex-Cre mice also underwent 
manganese-enhanced magnetic resonance imaging (MEMRI) and the lacZ expressing mice revealed 
once more drastic changes compared to their Cre-negative littermates (Fig. R-8). While the absolute 
whole brain volume of both groups did not differ (Fig. R-8a; Tab. St-6), the normalized hippocampal 
volume of R26R:Nex-Cre+ mice was reduced by approximately 30 % compared to R26R:Nex-Cre- 
littermates (Fig. R-8b; unpaired student’s t-test: p < 0.0001) and the normalized lateral ventricle 
volume of lacZ expressing mice in turn displayed a 2.5 -fold increase compared to lacZ-negative 
littermates (Fig. R-8c; unpaired student’s t-test: p < 0.0001).  
 
 
Fig. R-8: R26R:Nex-Cre MEMRI analyses: (a) absolute whole brain volume of lacZ-positive and lacZ-negative littermates; (b) 
relative hippocampal volume of lacZ-positive and lacZ-negative littermates; (c) relative lateral ventricle volume of lacZ-
positive and lacZ-negative littermates. Hippocampal and ventricle volumes were normalized to whole brain volumes and 
mean lacZ-negative volumes were defined as 100%. All data presented as mean ± SEM; ٭٭٭ p < 0.001 (Student’s t-test). 
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3.2.1.2. Nex-Cre mice 
The drastic changes observed for R26R:Nex-Cre+ mice compared to R26R:Nex-Cre- could have been 
due to the lacZ-expression or the heterozygous Nex-gene locus, since the Cre-recombinase disrupts 
one allele of the gene. Therefore we subsequently analyzed the Nex-Cre driver line itself. The 
behavioral screen was focused on those tests that revealed the strongest effects in R26R:Nex-Cre+ 
mice, i.e. OF and WCM. We observed no significant differences between Nex-Cre+ and Nex-Cre- 
littermates in the OF (Fig. R-9a1-a3; Tab. St-7), but found a slightly impaired WCM performance 
regarding accuracy levels and WPV in week 2 (reversal learning) for Nex-Cre+ mice (Fig. R-9b2+b3; 
WCM Accuracy week 2 (Genotype): F1,17 = 6.9036, p = 0.0176; WCM WPV week 2 (Genotype): F1,17 = 
11.2469, p = 0.0038; Tab. St-7). 
Afterwards, Nex-Cre mice also underwent MEMRI and while Cre-positive littermates displayed a 
decreased absolute whole brain volume (Fig. R-10a; unpaired student’s t-test: p = 0.0002), we found 
no differences regarding normalized hippocampal volumes (Fig. R-10b; Tab. St-7) or normalized 
lateral ventricle volumes (data not shown; Tab. St-7). 
 
 
Fig. R-9: Behavioral consequences of heterozygous Nex-gene locus (Nex-Cre mice): (a1-a3) OF behavior; (b1-b4) WCM 
performance. OF = open field; WCM = water cross maze. All data presented as mean ± SEM; ٭٭ p < 0.01 (ANOVA followed 
by Tukey HSD post hoc test). 
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3.2.1.3. CAG-CAT-EGFP:Nex-Cre mice 
 
The behavioral screen and MEMRI of Nex-Cre mice revealed that the previously observed alterations 
of R26R:Nex-Cre+ mice cannot be ascribed to the heterozygous Nex-gene. Therefore, we next 
analyzed CAG-CAT-EGFP:Nex-Cre+ mice, which express GFP in cortical glutamatergic neurons (Fig. R-
11), in order to assess whether the observed effects were specific to lacZ expression or a general 
consequence of any reporter-protein expression.  
 
   
Fig. R-11: Histology for CAG-CAT-EGFP:Nex-Cre
+
 mice: upper row GFP-staining for CAG-CAT-EGFP:Nex-Cre
+
 mice (dHPC); 
lower row: Nissl staining for CAG-CAT-EGFP:Nex-Cre
+
 mice (dHPC). dHPC = dorsal hippocampus. 
 
The behavioral screen of CAG-CAT-EGFP:Nex-Cre mice was carried out congruent to the screen of 
R26R:Nex-Cre mice and revealed only minor behavioral changes for GFP-expressing vs. Cre-negative 
littermates (Fig. R-12). Distance traveled in the OF was not affected (Fig. R-12a1; Tab. St-8) and 
Fig. R-10: Nex-Cre MEMRI analyses: 
(a) absolute whole brain volume of 
Cre-positive and Cre-negative 
littermates; (b) relative hippocampal 
volume of Cre-positive and Cre-
negative littermates; Hippocampal 
volumes normalized to whole brain 
volume All data presented as mean ± 
SEM; ٭٭٭ p < 0.001 (Student’s t-test). 
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neither was the rearing duration (Fig. R-12a3; Tab. St-8). However, there was a genotype-dependent 
effect regarding rearing frequency (Fig. R-12a2; Rearing Frequency (Genotype): F1,18 = 5.9353; p = 
0.0255) indicating an increased rearing frequency for GFP-expressing littermates.  
 
DL testing revealed no performance differences between littermates (Fig. R-12b1-b2; Tab. St-8) and 
neither did ASR testing (I/O and PPI/PPF; Fig. R-12c1-c4; Tab. St-8). Fear conditioning resulted in a 
slightly enhanced freezing response in the shock context for CAG-CAT-EGFP:Nex-Cre+ mice compared 
to Cre-negative littermates 24 h after shock application (Fig. R-12d1; unpaired student’s t-test: p = 
Fig. R-12: Behavioral 
consequences of 
constitutive  
glutamatergic GFP 
expression (CAG-CAT-
EGFP:Nex-Cre): (a1-a3) OF 
behavior; (b1-b3) DL 
behavior; (c1-c4) ASR- I/O 
and PPI/PPF; (d1-d4) 
contextual and associative 
(tone-) fear memory and 
extinction training; (e1-
e5) WCM performance. 
ASR = acoustic startle 
response; DL = dark-light 
box; I/O = input/ output; 
OF = open field; PPI/PPF = 
pre-pulse inhibition/ -
facilitation; WCM = water 
cross maze. All data 
presented as mean ± SEM; 
-p < 0.05 (Student’s t ٭
test, χ² test or ANOVA). 
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0.07), but revealed no changes regarding associative (i.e. tone-) fear memory or extinction training 
(Fig. R12d2-d4; Tab, St-8). WCM training furthermore revealed slightly enhanced accuracy levels for 
GFP expressing mice during the second week of training (i.e. reversal-training; Fig. R12e2; WCM 
Accuracy week 2 (Genotype): F1,20 = 3.6963, p = 0.0689), but no differences regarding the other 
learning parameters (Fig. R-12e1-e4; Tab. St-8).  
MEMRI analysis of CAG-CAT-EGFP:Nex-Cre mice revealed no significant differences between 
littermates regarding whole brain volume or normalized HPC volume (Fig. R-15; Tab. St-8). 
 
Taken together the results of R26R:Nex-Cre, Nex-Cre and CAG-CAT-EGFP:Nex-Cre mice exposed 
drastic lacZ-expression-dependent effects concerning behavioral alterations, including severe 
cognitive impairments, as well as marked structural changes coinciding with lacZ expression in 
cortical glutamatergic neurons. These effects cannot be attributed to the heterozygous Nex-gene 
since Nex-Cre+ mice displayed only minimal behavioral alterations and no (normalized) structural 
changes. Moreover, glutamatergic GFP expression also led to only minor behavioral modifications 
which furthermore pointed into the opposite direction compared to R26R:Nex-Cre mice. For 
instance, while R26R:Nex-Cre+ mice displayed decreased contextual fear memory, CAG-CAT-
EGFP:Nex-Cre+ mice presented with slightly increased contextual fear memory. In addition, we did 
not find any structural changes following glutamatergic GFP expression. 
Thus, in order to assess whether lacZ expression generally causes such severe consequences or 
whether the specificity of the consequences depends on the affected neuronal population, we 
subsequently analyzed the effects of constitutive lacZ expression in GABAergic forebrain neurons.    
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3.2.1.4. R26R:Dlx5/6-Cre mice 
 
The previous analyses of R26R:Nex-Cre, Nex-Cre and CAG-CAT-EGFP:Nex-Cre mice point towards 
lacZ as the driving force behind the observed phenotypic alterations. In order to test to which extent 
these effects additionally depend on the driving promoter, i.e. the affected neuronal population, we 
subsequently analyzed R26R:Dlx5/6-Cre mice that express lacZ in a contrasting neuronal sub-
population: GABAergic forebrain neurons (e.g. the striatum and the substantia nigra; Fig. R-13). 
 
  
Fig. R-13: Histology for R26R:Dlx
5/6
-Cre
+
 mice (coronal sections): upper row: X-Gal staining for R26R:Dlx-Cre
+
 mice; lower 
row: Nissl staining for R26R:Dlx-Cre
+
 mice. BNST = bed nucleus of the stria terminalis; CP = caudate putamen; DMH = 
dorsomedial hypothalamic nucleus; HPC = hippocampus; LS = lateral septum; OT = olfactory tubercle; PM-/LC = 
posteromedial-/ lateral cortical amygdaloid nucleus; SN = substantia nigra; ST = stria terminalis; VP = ventral pallidum. 
 
The behavioral screen of R26R:Dlx5/6-Cre was again carried out in parallel to the screens of 
R26R:Nex-Cre and CAG-CAT-EGFP:Nex-Cre mice. Similar to R26R:Nex-Ce+ mice, R26R:Dlx5/6-Cre+ 
mice displayed strongly increased locomotor activity (i.e. distance traveled) in the OF as well as an 
increased rearing frequency but no changes in rearing duration (Fig. R-14a1-a3; Distance (Genotype): 
F1,14 = 14.5666; p = 0.0019; Rearing Frequency (Genotype): F1,14 = 16.6784; p = 0.0011; for Rearing 
Duration: please see Tab. St-9) compared to Cre-negative littermates. DL testing revealed an 
increased frequency to enter the light compartment for R26R:Dlx5/6-Cre+ mice (Fig. R-14b2; unpaired 
student’s t-test: p = 0.0335) as well as an increased time spent in the light compartment (Fig. R-14b3; 
unpaired student’s t-test: p = 0.0006), but no changes regarding the latency to enter the light 
compartment (Fig. R-14b1; Tab. St.9). Furthermore, R26R:Dlx5/6-Cre+ mice presented with decreased 
ASR- I/O (Fig. R-14; ASR-I/O (Genotype): F1,14 = 5.4254; p = 0.0353), but no changes for PPI/PPF (Fig. R-
14c2-c4; Tab. St-9). Similarly, fear conditioning also revealed no differences between lacZ-expressing 
and Cre-negative littermates for contextual fear memory, associative (tone-) fear memory or 
extinction training (Fig. R-14d1-d4; Tab. St-9).  
CP 
VP 
BNST 
LS 
OT 
CP 
ST 
DMH 
SN 
PM-/LC 
HPC 
SN 
CP LS 
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Fig. R-14: Behavioral consequences of constitutive GABAergic lacZ expression (R26R:Dlx
5/6
-Cre): (a1-a3) OF behavior; (b1-
b3) DL behavior; (c1-c4) ASR- I/O and PPI/PPF; (d1-d4) contextual and associative (tone-) fear memory and extinction 
training; (e1-e5) WCM performance. ASR = acoustic startle response; DL = dark-light box; I/O = input/ output; OF = open 
field; PPI/PPF = pre-pulse inhibition/ -facilitation; WCM = water cross maze. All data presented as mean ± SEM; ٭ p < 0.05, 
  .(p < 0.001 (Student’s t-test, χ² test or ANOVA followed by Tukey HSD post hoc test ٭٭٭ ,p < 0.01 ٭٭
 
WCM training on the other hand revealed a genotype dependent decrease in accuracy for the first 
week of training for R26R:Dlx5/6-Cre+ mice (without a significant interaction effect; Fig. R-14e2; WCM 
Accuracy week 1 (Genotype): F1,14 = 5.1518, p = 0.0396), mirrored by a reduced learning score for 
R26R:Dlx5/6-Cre+ mice during the first week of WCM training (Fig. R-14e5; unpaired student’s t-test: p 
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= 0.0398). Additional WCM learning parameters were not significantly affected by lacZ expression in 
GABAergic forebrain neurons (Fig. R14e1-e4; Tab. St-9). 
 
3.2.1.5. Comparison of constitutively lacZ expressing lines  
Although glutamatergic and GABAergic constitutive lacZ expression resulted in the strongest 
phenotypic (and structural) alterations, both the heterozygous disruption of the Nex-gene 
locus as well as glutamatergic GFP expression also resulted in slight changes of the mouse-
phenotype. Therefore we cannot conclusively exclude these mechanisms as co-factors of the 
observed changes, but based on the severity of the effects we can conclude that lacZ 
expression has the strongest impact on the phenotypic alterations. Furthermore, given the 
specificity of the alterations when comparing glutamatergic and GABAergic lacZ expression, 
we can also assume a promoter-dependent effect (i.e. a lacZ x promoter interaction), 
“driving” the phenotypic alterations based on the affected neuronal sub-populations. 
A comparison of normalized HPC volumes of R26R:Nex-Cre, Nex-Cre, CAG-CAT-EGFP:Nex-Cre 
and R26R:Dlx5/6-Cre mice (via MEMRI) once more underlines this lacZ x promoter interaction with 
regard to hippocampal volume decrease: neither the heterozygously disrupted Nex-gene locus, nor 
glutamatergic GFP expression or GABAergic lacZ expression caused significant hippocampal volume 
loss, but glutamatergic lacZ expression caused severe  HPC shrinkage (Fig. R-15; unpaired student’s t-
test: p < 0.0001; Tab. St-6 – St-9). 
 
 
Fig. R-15: MEMRI comparison of constitutive lines (HPC): relative hippocampal volumes (normalized to whole brain 
volumes) of R26R:Nex-Cre, Nex-Cre, CAG-CAT-EGFP:Nex-Cre and R26R:Dlx
5/6
-Cre mice, respectively. Data presented as 
mean ± SEM;  ٭٭٭ p < 0.001 (Student’s t-test). 
 
Results – Project (ii): lacZ  
91 
 
In order to better gage what might cause the observed behavioral and structural alterations on a 
cellular level, an immunofluorescent β-gal antibody staining for R26R:Nex-Cre+ and R26R:Dlx5/6-Cre+ 
mice was performed (Fig. R-16). This staining revealed a strong compartmentalization of lacZ-
expression within the soma of the neurons, specifically, very close to the nucleus. No lacZ signal was 
detected in the axons or dendrites of expressing neurons. This distinct localization could hint at an 
interference of lacZ with the “normal/ housekeeping” function of the affected cells.   
 
 
 
 
 
 
 
 
 
 
 
Fig. R-16: β-gal 
antibody staining 
for R26R:Nex-Cre
+
 
(left) and 
R26R:Dlx
5/6
-Cre
+
 
(right) mice: blue = 
DAPI (= nucleus); 
red = β-gal. CA = 
cornu ammonis; DG 
= dentate gyrus. 
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3.2.1.6. Proteomic analysis of R26R:Nex-Cre mice 
 
Immunofluorescent staining did not provide further answers regarding the cellular and molecular 
effects of lacZ expression. Therefore a proteomic analysis of hippocampal micro punches via two-
dimensional-polyacrylamide gel electrophoresis (2D-PAGE) was performed, and revealed three 
differentially expressed proteins in R26R:Nex-Cre+ compared to R26R:Nex-Cre- littermate 
hippocampal punch extracts (Fig. R-17; for full protein lists please see Appendix chapter 8.2.). The 
differentially expressed proteins were HSP60 (heat shock protein 60 kDa), F-actin-capping protein 
subunit alpha-2 (FACP) and L-lactate dehydrogenase (LDH).  
 
 
Fig. R-17: Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) of hippocampal micro-punch extracts from 
R26R:Nex-Cre
-
 and R26R:Nex-Cre
+
 mice: Differentially expressed protein spots 1 – 3 were excised, digested  with trypsin 
and analyzed by tandem mass spectrometry. Spot 1 = HSP60 (heat shock protein 60 kDa; higher expression in Cre- 
littermates); spot 2 = FACP (F-actin-capping protein; higher expression in Cre+ littermates); spot 3 = LDH (L-lactate 
dehydrogenase; higher expression in Cre+ littermates). Images provided by Chi-Ya Kao and Prof. Dr. C. Turck. 
 
Altered LDH expression supports the hypothesis of a “preoccupied” neuron and the increase in FACP 
for lacZ expressing mice is in line with the drastic hippocampal volume decrease in R26R:Nex-Cre+ 
compared to R26R:Nex-Cre- littermate mice. However, so far no causal relationship has been 
established, and the time-point of differential protein expression, i.e. does the differential protein 
expression begin as soon as lacZ expression begins, or is it a consequences of the duration of lacZ-
expression, could also not be resolved so far. 
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Taken together, the analyses of constitutive lacZ-, Cre- and GFP expressing mouse lines have 
revealed a number of marked alterations due to lacZ expression (Tab. R-2). Glutamatergic 
constitutive lacZ expression, for instance, resulted in hyperactivity in the OF, cognitive deficits 
regarding the acquisition of a contextual fear memory and severe cognitive impairments regarding 
the acquisition of spatial learning task in the WCM. Furthermore, glutamatergic constitutive lacZ 
expression caused a 30% reduction in hippocampal volume and a 2.5 –fold increase in lateral 
ventricle volume. Since the heterozygous disruption of the Nex-gene caused merely minor 
impairments during the reversal learning of the spatial learning task in the WCM and a general 
decrease in absolute whole brain volume, we concluded that the strong effects observed in 
R26R:Nex-Cre+ mice are due to the lacZ expression. In order to control for the specificity of the lacZ-
effect – as opposed to a general reporter-protein-effect – we also analyzed glutamatergic GFP 
expression which resulted in slightly heightened rearing activity in the OF and an increased 
contextual fear memory as well as an improved performance in the WCM, confirming the previously 
assumed specificity of the lacZ-effects. Lastly, in order to determine how strongly these effects are 
influenced by the affected neuronal population, we also analyzed GABAergic lacZ expression and 
found once again a hyperactivity in the OF alongside a decreased acoustic startle response and a 
slightly impaired spatial learning performance, underlining the promoter-driven specificity of the 
lacZ-effects. 
Proteomic analysis of hippocampal micro-punches of glutamatergic lacZ expressing mice furthermore 
revealed that the observed structural and behavioral changes are most likely due to a number of 
differentially regulated proteins.  
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Table R-2: Summary of phenotypic alterations observed for constitutive Cre-positive compared to 
Cre-negative littermates     
PARAMETER R26R:Nex-Cre+    Nex-Cre+ CAG-CAT-EGFP:Nex-Cre+ R26R:Dlx5/6-Cre+ 
OF activity   
  
Anxiety related 
behavior  
 
      n/a  
 
ASR- I/O 
 
      n/a  
 
ASR- PPI/PPF           
(65 dB) 
 
      n/a   
FC –                    
Context freezing 
 
      n/a   
FC –                        
Tone freezing 
 
      n/a  
 
WCM performance 
   
 
MEMRI               
Whole Brain 
    
MEMRI - Cortex    
 
MEMRI - total HPC 
 
   
MEMRI – lateral 
ventricles 
    
 
ASR = acoustic startle response; FC = fear conditioning; HPC = hippocampus; I/O = input/ output curve; MEMRI = 
manganese-enhanced MRI; n/a = not applicable; OF = open field; PPI/PPF = pre-pulse inhibition/- facilitation; WCM = water 
cross maze 
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3.2.1.7. Are the consequences of lacZ expression solely developmentally based?  
 
Given the activity of the Nex- and the Dlx5/6- promoter during embryogenesis (E16 and E13, 
respectively (Schwab et al., 1998; Stühmer et al., 2002)), we cannot exclude that the observed effects 
are primarily developmentally derived. 
Therefore we injected ten weeks old R26 reporter mice unilaterally in dorsal and ventral 
hippocampus either with a Cre-coding AAV (pAAV2.1-CMV-Cre-2A-GFP M4; Fig. R18a), a GFP coding 
AAV (pAAV2.1-sc-GFP-pACG-2-M4) or with PBS, and analyzed the effects via MEMRI four months 
after the injections. MEMRI revealed a significant unilateral hippocampal volume reduction following 
Cre-AAV injection (i.e. four months after adult-induced lacZ expression), but not after PBS or GFP 
injection (Fig. R-18b-d; Tab. St-10). Therefore, the structural changes due to lacZ expression are in 
fact inducible in adulthood and not solely developmentally based. 
 
 
 
In summary, constitutive lacZ expression in glutamatergic or GABAergic forebrain neurons causes 
severe behavioral, structural and molecular alterations. Since the Nex- and Dlx5/6 promoter are active 
during embryogenesis we cannot exclude developmental effects as the cause for the observed 
changes. However, Cre-AAV application in adult R26R mice resulted in a distinct volume reduction 
following adult-induced lacZ expression. Thus, at least the structural consequences of lacZ expression 
are not solely based on developmental effects.  
Fig. R-18: AAV induced HPC 
volume loss in R26R mice: (a) 
timeline for unilateral AAV/ PBS 
injection into the left HPC of R26R 
mice and description of AAVs 
used; X-Gal/ GFP-IF staining 4 
weeks after respective AAV 
injections; (b-d) MEMRI results of 
the treated left hippocampus (i.e. 
black bar) in relation to the un-
treated right hippocampus (i.e. 
white bar; control); (b) HPC 
volume 4 months after PBS 
injection; (c) HPC volume 4 
months after GFP-AAV injection; 
(d) HPC volume 4 months after 
Cre-AAV injection. HPC volumes 
normalized to whole brain 
volumes. AAV = adeno-associated 
virus; HPC = hippocampus. Data 
presented as mean ± SEM; ٭٭ p < 
0.01 (Student’s t-test). 
Results – Project (ii): lacZ  
96 
 
3.2.2. Consequences of adult-induced lacZ expression 
Following the observed adult-induced structural effects of lacZ expression and given the increasing 
number of “inducible” transgenic mouse lines, we next asked whether tamoxifen-induced lacZ 
expression in adulthood would result in similar phenotypic alterations as the previously analyzed 
constitutive lacZ expression did. 
 
3.2.2.1. i-R26R:Nex-Cre mice 
To investigate this we first screened the tamoxifen-inducible i-R26R:Nex-Cre mouse line in order to 
facilitate a direct comparison between the effects of constitutive and inducible lacZ expression in 
cortical glutamatergic neurons. X-Gal staining of i-R26R:Nex-Cre+ mice revealed a drastically 
diminished lacZ expression (Fig. R-19) compared to constitutively expressing R26R:Nex-Cre+ mice (cf 
Fig. R-6). Although we could still observe a strong expression pattern throughout the CA regions of 
the hippocampus, particularly for the dorsal hippocampus (Fig. R-19 left and middle), there was very 
little lacZ expression detectable throughout the cortex and a diminished expression-intensity in the 
ventral hippocampus (Fig. R-19 right).  
 
 
Fig. R-19: X-Gal staining for i-R26R:Nex-Cre
+
 mice (hippocampus): X-Gal staining revealed a markedly diminished lacZ 
expression pattern following adult-induction compared to constitutive glutamatergic expression (cf Fig. R-6). Expression 
was still clearly visible throughout the dorsal HPC (left and middle), but less distinct for the ventral HPC (right) and the 
cortex (left and middle). Sections were counterstained with Vector® nuclear fast red counterstain (i.e. light grey background 
staining). CA = cornu ammonis; Ctx = cortex; DG = dentate gyrus; HPC = hippocampus. 
 
The bodyweight of i-R26R:Nex-Cre+ and i-R26R:Nex-Cre- mice increased throughout testing (mice 
were approximately nine to ten months old at the end of testing), but did not differ between groups 
(Fig. R-20; Tab. St-11). 
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i-R26R:Nex-Cre first underwent a shortened basal behavioral screen at the age of 3.5 months (OF + 
ASR) before receiving exclusively tamoxifen-containing food (TAM) for three weeks in order to 
faithfully induce lacZ expression. Four months after the first day of TAM-food these mice underwent 
the extended behavioral screen in parallel to R26R:Nex-Cre, CAG-CAT-EGFP:Nex-Cre and 
R26R:Dlx5/6-Cre mice. We choose an incubation window of four months since we observed structural 
alterations four months after Cre-AAV injections in R26R mice (see above). The activity in the OF 
before TAM already differed significantly between Cre-positive and Cre-negative littermates. There 
was no difference regarding Distance traveled (Fig. R-21a1; Tab. St-11), but the rearing behavior was 
significantly decreased for Cre-positive littermates (Fig. R-21b2 + b3; Rearing Frequency (Genotype): 
F1,19 = 10.6171; p = 0.0041; Rearing Duration (Genotype): F1,19 = 7.0237; p = 0.0158). ASR-I/O did not 
reveal any differences between groups (Fig. R-21b1; Tab. St-11), but there was a significant genotype 
x IPI interaction regarding a heightened PPF after a 55 dB pre-pulse, but not after a 65 or 75 dB pre-
pulse, for Cre-positive littermates (Fig. R-21b2-b4; PPI/PPF 55 dB (genotype x IPI): F4,76 = 3.7929; p = 
0.0073; for 65 and 75 dB please see Tab. St-11). Rearing decrease as well as PPF interaction are 
reminiscent of effects observed in constitutively lacZ expressing mice (R26R:Nex-Cre; cf Fig. R-7). 
 
Fig. R-20: Weight throughout testing for 
i-R26R:Nex-Cre mice: weight 
measurements began the day of the first 
OF testing (i.e. before TAM; age approx. 
3.5 months) and ended the day of 
MEMRI (age approx.. nine months). 
MEMRI = manganese-enhanced MRI; 
MnCl2 = manganese-chloride (-injection); 
OF = open field; TAM = tamoxifen (-food). 
No significant differences detected 
between groups (ANOVA). 
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The observed OF differences were no longer apparent 4 months after TAM-treatment, i.e. after lacZ 
expression was induced (Fig. R-22a1-a3; Tab. St-11). However, lacZ-expressing littermates displayed 
an increased frequency to enter the light compartment during DL testing (Fig. R-22b2; unpaired 
student’s t-test: p = 0.0437) without changes to the light latency or time spent in the light 
compartment (Fig. R-22b1 + b3; Tab. St-11). Since we observed no locomotor effect in the OF (i.e. no 
difference in distance traveled) before and after TAM, the increase in light compartment entries is 
most likely a genuine decrease in anxiety-related behavior. 
ASR-I/O and PPI/PPF revealed no group differences for i-R26R:Nex-Cre mice after TAM-treatment 
(Fig. R-22c1-c4; Tab. St-11). However, fear conditioning revealed a decreased contextual fear-
response of i-R26R:Nex-Cre+ mice in the shock context 24 h after shock application (Fig. R-22d1; 
unpaired student’s t-test: p = 0.0147). Tone-fear memory and extinction training were not affected 
by adult-induced glutamatergic lacZ expression (Fig. R-22d2-d4; Tab. St-11). WCM training also did 
not reveal any group differences across all learning parameters (Fig. R-22e1-e4; Tab. St-11). The 
increased frequency in the DL as well as the decreased contextual fear memory are in accordance 
with the previously observed effects for constitutively lacZ expressing mice (R26R:Nex-Cre; cf Fig. R-
7). 
Fig. R-21: Behavior 
BEFORE Tamoxifen-
treatment for i-
R26R:Nex-Cre mice: (a1-
a3) OF behavior; (b1-b4) 
ASR- I/O and PPI/PPF. 
ASR = acoustic startle 
response; I/O = input/ 
output; OF = open field; 
PPI/PPF = pre-pulse 
inhibition/ -facilitation. 
All data presented as 
mean ± SEM; ٭ p < 0.05, 
 p < 0.01 (ANOVA ٭٭
followed by Tukey HSD 
post hoc test).  
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Following the behavioral screen, i-R26R:Nex-Cre mice also underwent MEMRI in order to analyze 
whether the AAV-induced effects could be replicated by TAM-induced lacZ expression. While the 
absolute whole brain volume again did not differ between groups (Fig. R-23a; Tab. St-11), adult-
induced glutamatergic lacZ expression did result in a significantly reduced normalized hippocampal 
volume (Fig. R-23e1; unpaired student’s t-test: p = 0.0053). This effect was predominantly driven by a 
decrease in dorsal HPC volume (Fig. R-23e2; unpaired student’s t-test: p = 0.0023), whereas the 
ventral HPC did not differ between groups (Fig. R-23e3; unpaired student’s t-test: p = 0.1811).  
Fig. R-22: i-R26R:Nex-
Cre mice behavior 4 
months AFTER 
Tamoxifen-treatment: 
(a1-a3) OF behavior; 
(b1-b3) DL behavior; 
(c1-c4) ASR- I/O and 
PPI/PPF; (d1-d4) 
contextual and 
associative (tone-) fear 
memory and extinction 
training; (e1-e4) WCM 
performance. ASR = 
acoustic startle 
response; DL = dark-
light box; I/O = input/ 
output; OF = open field; 
PPI/PPF = pre-pulse 
inhibition/ -facilitation; 
WCM = water cross 
maze. All data 
presented as mean ± 
SEM; ٭ p < 0.05 
(Student’s t-test or 
ANOVA followed by 
Tukey HSD post hoc 
test). 
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Furthermore we observed a trend towards a decreased caudate putamen volume in i-R26R:Nex-Cre+ 
mice compared to their Cre-negative littermates (Fig. R-22c; unpaired student’s t-test: p = 0.0697), 
but no changes regarding cortex- or lateral ventricle volumes (Fig. R-22b + d; Tab. St-11). There were 
no differences regarding MnCl2 signal-intensity between i-R26R:Nex-Cre
+ and i-R26R:Nex-Cre- 
littermates (Data not shown; for statistical analyses please see Tab. St-11). 
 
 
Fig. R-23: i-R26R:Nex-Cre mice MEMRI analyses 4 months AFTER Tamoxifen-treatment: (a-e4) lacZ-positive and lacZ-
negative littermates are always compared; (a) absolute whole brain volume; (b) relative cortex volume; (c) relative CPu 
volume; (d) relative lateral ventricle volume; (e1-e4) relative hippocampal volume. (b-e4) volumes normalized to whole 
brain volume. (e4) mean lacZ-negative volumes were defined as 100 %. CPu = caudate putamen; d-HPC = dorsal 
hippocampus; HPC = hippocampus; v-HPC = ventral hippocampus; Vol. = volume. All data presented as mean ± SEM; ٭٭ p < 
0.01 (Student’s t-test). 
 
The previous proteomic analysis of dHPC micro punches taken from constitutive R26R:Nex-Cre+ mice 
revealed three differentially expressed proteins (cf R-17). Based on those results and the behavioral 
and structural findings for i-R26R:Nex-Cre+ mice, we decided to specifically analyze selected proteins 
via Western Blot for micro punches of i-R26R:Nex-Cre mice. Due to the involvement of actin (FACP) 
in the differentially regulated proteins we chose vinculin as a control protein (i.e. “housekeeper”) to 
normalize the protein bands to. Subsequently we chose to target structural (Actin), 
neurodegeneration-related (e.g. apoptosis-inducing factor = AIF; CDK5) and learning- and memory 
related proteins (e.g. PP2B = Calcineurin), but failed to observe any significant differences between i-
R26R:Nex-Cre+ and i-R26R:Nex-Cre- littermates (Fig. R-24 and R-25; Tab. St-11). 
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Fig. R-24: i-R26R:Nex-Cre mice Western Blot analyses of dHPC micro-punches: (a) AIF and PP1ß protein bands (= blot 1); 
(b) PP2B, Actin and CDK5 protein bands (= blot 2); AIF = apoptosis inducing factor; C- = Cre-negative samples; C+ = Cre-
positive samples (i.e. with lacZ expression); CDK5 = cyclin-dependent kinase 5; kDa = kilo Dalton; M = marker; PP2B = 
Calcineurin; Vinculin = “housekeeper”. 
 
Based on these western blot results we can conclude that the observed behavioral and structural 
alterations following adult-induced lacZ expression in i-R26R:Nex-Cre+ mice are not due to our 
chosen target-proteins. 
 
 
 
Fig. R-25: Quantification 
of Western Blot 
analyses for i-
R26R:Nex-Cre mice 
(hippocampal micro-
punches): (a1-3) 
quantification for blot 1; 
(b1-4) quantification for 
blot 2. AIF = apoptosis 
inducing factor; CDK5 = 
cyclin-dependent kinase 
5; PP2B = Calcineurin. 
All data presented as 
mean ± SEM. 
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Taken together the analysis of i-R26R:Nex-Cre+ mice revealed that phenotypic alterations driven by 
lacZ expression can – at least in part – also be induced in adulthood and are therefore not solely 
based on developmental effects. The decrease in severity in behavioral and structural alterations 
after adult-induced compared to constitutive glutamatergic lacZ expression indicates a potentiation 
of the consequences of lacZ expression during embryogenesis. Furthermore, the behavioral 
differences observed in i-R26R:Nex-Cre mice before TAM-treatment also hint at a more complex 
relationship between transgenic manipulations and phenotypic consequences and point towards 
pre-lacZ-expression existing phenotypic alterations for i-R26R:Nex-Cre+ mice, possibly due to 
glutamatergic CreERT2 expression and its cytosolic accumulation. 
Nevertheless, behavioral and structural changes due to lacZ expression, albeit attenuated, are 
inducible in adulthood.  
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3.2.2.2. i-R26R:CamKIIα-Cre mice 
 
Given the partially overlapping effects of constitutive vs. adult-induced glutamatergic lacZ 
expression, we subsequently asked whether (1) adult-induced lacZ expression in a larger neuronal 
sub-population would yield different and possibly more extensive promoter driven effects, and 
whether (2) these effects would interact with the duration of the expression (i.e. the age of the 
animals). Therefore we first screened the i-R26R:CamKIIα-Cre mouse line, which enables tamoxifen-
inducible lacZ expression in CamKIIα-positive neurons. 
 
3.2.2.2.1. i-R26R:CamKIIα-Cre mice: repeated testing 4, 12 and 20 months after tamoxifen-
treatment 
 
X-Gal staining of i-R26R:CamKIIα-Cre+ revealed a strong lacZ expression pattern expression 
throughout the hippocampus, the cortex, lateral septal nuclei, the dorsomedial hypothalamic nuclei 
and the dorsal raphe nucleus 4 months after TAM-treatment (Fig. R-26c; Paxinos & Franklin “The 
Mouse Brain in Stereotaxic Coordinates; ©2004). i-R26R:CamKIIα-Cre+ and Cre-negative littermates 
did not differ regarding survival over the course of testing (Fig. R-26a; Tab. St-12), and revealed only 
a slight genotype-dependent trend towards a decreased bodyweight for Cre-positive littermates (Fig. 
R-26b; bodyweight (genotype): F1,9 = 3.573, p = 0.0913). 
 
                     
  
Fig. R-26: Survival rate, weight 
throughout testing and X- Gal 
staining for i-R26R:CamKIIα-Cre 
mice: (a) survival rate until 25 
months of age (= end of testing); (b) 
weight throughout testing; (c) X-Gal 
staining with nuclear fast red 
counterstain for i-R26R:CamKIIα-
Cre
+
 mice 4 months after TAM 
treatment; top row: sagittal 
sections; bottom row: coronal 
sections; red = nuclei; blue = lacZ 
expression. Data presented as mean 
± SEM. Cb = cerebellum; DMH = 
dorsomedial hypothalamic nucleus; 
DR = dorsal raphe nucleus; HPC = 
hippocampus; LS = lateral septal 
nuclei; MnCl2 = manganese-
chloride; OF = open field; TAM = 
tamoxifen. 
Results – Project (ii): lacZ  
104 
 
In parallel to i-R26R:Nex-Cre mice, i-R26R:CamKIIα-Cre mice also underwent the abbreviated 
baseline behavioral screen consisting only of OF and ASR-I/O  at the age of 3.5 months before 
receiving TAM-food, followed by the extended behavioral and structural screen 4 months after TAM-
treatment. This group of i-R26R:CamKIIα-Cre mice furthermore underwent additional behavioral 
testing as well as MEMRI 12 months and again 20 months after TAM-treatment (i.e. at the age of 16 
and 24 months) in order to assess age-dependent effects of lacZ expression. 
Cre-positive and –negative littermates did not differ in OF or ASR- I/O performance before TAM-
treatment (Fig. R-27c-f; Tab. St-12). 
 
 
Fig. R-27: Baseline behavior for i-R26R:CamKIIα-Cre mice BEFORE Tamoxifen- treatment: (a-c) OF behavior; (d) ASR- I/O. 
ASR = acoustic startle response; I/O = input/ output; OF = open field. All data presented as mean ± SEM. No significant 
differences detected (ANOVA). 
 
 
OF performance of i-R26R:CamKIIα-Cre+ and Cre-negative littermates four months after TAM-
treatment differed only slightly regarding an increased rearing frequency for i-R26R:CamKIIα-Cre+ 
mice (Fig. R-28a2; OF RF (genotype x time): F2,42 = 3.7177, p = 0.0326), whereas the other OF 
parameters remained unaffected by lacZ expression (Fig. R-28a1 + a3; Tab. St-12). We observed no 
group differences in OF performance between i-R26R:CamKIIα-Cre+ and Cre-negative littermates 12 
months after TAM-treatment (Fig. R-28b1-b3; Tab. St-12). In contrast, 20 months after TAM-
treatment i-R26R:CamKIIα-Cre+ displayed an increased distance traveled in the OF (Fig. R-28c1; OF 
Distance (genotype x time): F5,70 = 2.8725, p = 0.0204), but still no significant differences regarding 
rearing behavior (Fig. R-28c2 + c3; Tab. St-12). 
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DL performance of i-R26R:CamKIIα-Cre+ and Cre-negative littermates 4 months after TAM-treatment 
did not reveal any group differences regarding latency to enter the light compartment, frequency to 
enter the light compartment or time spent in the light compartment (Fig. R-29a1-a3; Tab. St-12). DL 
testing 20 months after TAM-treatment however, revealed an increased frequency to enter the light 
compartment for i-R26R:CamKIIα-Cre+ compared to i-R26R:CamKIIα-Cre- littermates (Fig. R-29b2; 
unpaired student’s t-test: p = 0.0391). Latency to enter the light compartment and time spent in the 
light compartment were not differentially affected between i-R26R:CamKIIα-Cre groups 20 months 
after TAM-treatment (Fig. R-29b1 + b3; Tab. St-12). The increased frequency to enter the light 
compartment 20 months after TAM-treatment might have been confounded by the increased 
distance traveled in the OF at the same time-point of testing. 
Fig. R-28: Open Field 
behavior 4, 12 and 20 
months AFTER Tamoxifen-
treatment for  
i-R26R:CamKIIα-Cre mice: 
(a1-3) OF 4 months after 
Tamoxifen-treatment; (b1-3) 
OF 12 months after 
Tamoxifen-treatment; (c1-3) 
OF 20 months after 
Tamoxifen-treatment. OF = 
open field. All data presented 
as mean ± SEM. ٭ p < 0.05, 
 p < 0.01 (ANOVA followed ٭٭
by Tukey HSD post hoc test).  
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Fig. R-29: Dark-light box behavior of i-R26R:CamKIIα-Cre mice 4 and 20 months AFTER Tamoxifen-treatment: All data 
presented as mean ± SEM.  ٭ p < 0.05 (Student’s t-test). 
 
Furthermore, ASR- I/O performance did also not differ between i-R26R:CamKIIα-Cre+ and Cre-
negative littermates 4 months after TAM-treatment, but lacZ expressing mice displayed heightened 
PPF for all pre-pulse intensities [Fig. R-30a1-a4; PPI/PPF 55 dB (genotype):  F1,21 = 11.6843, p = 0.0026; 
PPI/PPF 65 dB (genotype):  F1,21 = 10.2456, p = 0.0043; PPI/PPF 75 dB (genotype):  F1,21 = 6.6736, p = 
0.0173; for additional statistical values please see Tab. St-12]. ASR- I/O testing 12 months after TAM-
treatment again revealed no group differences (Fig. R-30b1; Tab. St-12), but PPF responses were still 
differentially affected. However, in contrast to testing 4 months after TAM, PPI/PPF testing with a 
pre-pulse intensity of 55 dB at 12 months post TAM revealed a genotype dependent trend towards a 
decreased PPF response [Fig. R-30b2; PPI/PPF 55 dB (genotype):  F1,18 = 3.4761, p = 0.0787; Tab. St-
12], and presentation of a 65 dB pre-pulse, but not 75 dB, resulted in significantly decreased PPF 
response for i-R26R:CamKIIα-Cre+ littermates [Fig. R-30b1-b4; PPI/PPF 65 dB (genotype):  F1,18 = 
4.6725, p = 0.0444; Tab. St-12].  
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Fig. R-30: Acoustic startle response of i-R26R:CamKIIα-Cre mice 4, 12 and 20 months AFTER Tamoxifen-treatment: (a1-4) 
ASR-I/O and PPI/PPF 4 months after Tamoxifen-treatment;  (b1-4) ASR-I/O and PPI/PPF 12 months after Tamoxifen-
treatment; (c1-4) ASR-I/O and PPI/PPF 20 months after Tamoxifen-treatment; ASR = acoustic startle response; I/O = input/ 
output; PPI/PPF = pre-pulse inhibition/ -facilitation; All data presented as mean ± SEM; ٭ p < 0.05, ٭٭ p < 0.01, ٭٭٭ p < 
0.001 (ANOVA followed by Tukey HSD post hoc test). 
 
ASR- I/O and PPI/PPF assessment at the age of 24 months (i.e. 20 months after TAM-treatment 
began), revealed no group differences. Rather, we observed barely existing startle responses at all 
(independent of genotype; Fig. R-30c1-c4; Tab. St-12), possibly indicating an age-dependent impaired 
perception of the white noise pulses.  
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Fig. R-31: Fear memory of i-R26R:CamKIIα-Cre mice 4, 12 and 20 months AFTER Tamoxifen-treatment: (a1-4) FC 4 months 
after TAM-treatment; (a1-3) contextual and tone fear memory assessed 24 h after FC; (a4) extinction training on d2, 3, 4 
and 11 after fear conditioning; (b1+2) residual contextual and tone fear memory of previous FC [cf (a)] 12 months after 
TAM-treatment; (c1-4) FC 20 months after TAM-treatment; (c1+2) contextual fear memory assessed 24 h after FC; (c3+4) 
tone fear memory assessed 24 h after FC. d = day; FC = fear conditioning; h = hours; TAM = tamoxifen. All data presented as 
mean ± SEM; ٭ p < 0.05, ٭٭ p < 0.01, ٭٭٭ p < 0.001 (Student’s t-test or ANOVA followed by Tukey HSD post hoc test). 
  
Fear conditioning 4 months after TAM-treatment revealed a slightly increased tone-fear memory 
(Fig. R-31a2 + a3; unpaired student’s t-test: p = 0.085; FC Tone (genotype x interval): F10,210 = 2.1552, 
p = 0.0218; Tab. St-12) for i-R26R:CamKIIα-Cre+ mice compared to Cre-negative littermates in the 
novel context, which also resulted in a delayed fear-extinction learning (i.e. repeated exposure to the 
tone in the novel environment; Fig. R-31a4; Extinction training (genotype x day): F10,42 = = 3.5374, p = 
0.038; Tab. St-12). Residual fear memory assessment 12 months after TAM-treatment (without a 
renewed shock-application) revealed a non-existent contextual fear memory independent of 
genotype (Fig. R-31b1; Tab. St-12), and only a slight response to the presentation of the conditioned 
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tone, but again without group differences (Fig. R-31b2; Tab. St-12). Renewed fear conditioning (i.e. 
new shock-application) at the age of 24 months (i.e. 20 months after TAM-treatment) also revealed 
no genotype differences regarding contextual fear memory (Fig. R-31c1 + c2, Tab. St-12). However, 
exposure to the novel context (without tone-exposure) resulted in a decreased baseline-freezing 
response for i-R26R:CamKIIα-Cre+ mice compared to Cre-negative littermates (Fig. R-31c3; unpaired 
student’s t-test: p = 0.0004), without significantly affecting the tone-evoked fear response (Fig. R-
31c3 + c4; Tab. St-12). This decreased baseline freezing response of i-R26R:CamKIIα-Cre+ mice in the 
novel context could once again be confounded by the slight increase in activity in the OF (cf R-28c1). 
i-R26R:CamKIIα-Cre mice also underwent WCM training 4, 12 and 20 months after TAM-treatment 
(Fig. R-32), whereby training at 4 months post-TAM entailed initial acquisition training as well as 
reversal training (i.e. the platform was moved to the opposite arm) and during training at 12 and 20 
months post-TAM the platform was located at the same position as at the end of reversal training. 
We observed no group differences across all performance parameters and testing time-points (Fig. R-
32a-e; Tab. St-12). Interestingly, initial performance of all mice at repeated testing was neither at the 
accuracy-level where training previously ended, nor at the level where training originally began (Fig. 
R-32c). Rather, animals remembered the basic scheme and requirements of the task and displayed 
steeper learning curves 12 and 20 months after TAM-treatment. 
Following each WCM training, i-R26R:CamKIIα-Cre mice also underwent MEMRI, which revealed no 
differences regarding the absolute whole brain volume between groups, but an increase of it over 
time (Fig. R-33a1 - a3; Tab. St-12), as well as an increased relative cortex volume accompanied by a 
decreased relative lateral ventricle volume for i-R26R:CamKIIα-Cre+ mice compared to Cre-negative 
littermates (Fig. R-33b1 + d1; unpaired student’s t-test: Cortex p = 0.0102; lateral ventricles p = 
0.0338). Furthermore, while the whole brain volume increased over time, the relative hippocampal 
volume decreased with progressing age (Fig. R-33c1 - c3; Tab. St-12). Additionally, the initial 
normalized HPC signal intensity was decreased for i-R26R:CamKIIα-Cre+ mice compared to Cre-
negative littermates (Fig. R-33e1).  
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Fig. R-32: Water Cross Maze performance of i-R26R:CamKIIα-Cre mice 4, 12 and 20 months AFTER Tamoxifen-treatment: 
Data presented as mean ± SEM. TAM = tamoxifen. 
 
Taken together, in particular the OF and ASR, but also the MEMRI results of i-R26R:CamKIIα-Cre+ 
mice compared to i-R26R:Nex-Cre+ mice revealed once more an interaction of promoter x lacZ 
expression as the driving force of the behavioral and structural changes, also for the consequences of 
adult-induced lacZ expression. Moreover, the repeated within-subject testing demonstrated that 
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expression-duration and age of the animals are additional factors that further interact and modulate 
the initial changes due to lacZ expression. 
 
 
 
Fig. R-33: MEMRI analyses for i-
R26R:CamKIIα-Cre mice 4, 12 
and 20 months AFTER 
Tamoxifen-treatment:  (a1-3) 
absolute whole brain volumes of 
lacZ-positive and lacZ-negative 
littermates for each time point; 
(b1-3) relative cortex volumes of 
lacZ-positive and lacZ-negative 
littermates for each time point; 
(c1-3) relative HPC volumes of 
lacZ-positive and lacZ-negative 
littermates for each time point; 
(d1-3) relative lateral ventricle 
volumes of lacZ-positive and 
lacZ-negative littermates for each 
time point; (e1-e4) relative HPC 
intensity of lacZ-positive and 
lacZ-negative littermates for each 
time point. All volumes 
normalized to whole brain 
volume. Intensities normalized to 
whole brain intensity. HPC = 
hippocampus; Vol. = volume. All 
data presented as mean ± SEM. ٭ 
p < 0.05 (Student’s t-test). 
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3.2.2.2.2. i-R26R:CamKIIα-Cre mice: repeated testing 2 and 4 months after tamoxifen-treatment 
 
Given the age-and time-dependent effects of lacZ expression we observed for the previous cohort of 
i-R26R:CamKIIα-Cre mice, and the fact that lacZ (co-)expressing mice are often utilized earlier than 4 
months after lacZ-induction, we subsequently asked, whether the behavioral effects could also be 
observed at an earlier time point. Therefore a separate group of i-R26R:CamKIIα-Cre mice 
underwent an abbreviated behavioral screen (OF and ASR) already 2 months and once more 4 
months after TAM-treatment. 
Pre-TAM baseline screening for ASR (I/O and PPI/PPF) as well as the bodyweight of these animals 
throughout testing revealed no group differences (Fig. R-34a-c3; Tab. St-13). 
 
 
Fig. R-34: Weight throughout testing and ASR behavior BEFORE Tamoxifen-treatment for i-R26R:CamKIIα-Cre (2M) mice: 
(a) weight throughout testing; (b) ASR- I/O; (c1-3) ASR- PPI/PPF. ASR = acoustic startle response; I/O = input/ output; OF = 
open field; PPI/PPF = pre-pulse inhibition/ -facilitation. All data presented as mean ± SEM. No significant differences 
detected (ANOVA). 
Baseline measurements 
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OF assessment two months after TAM-treatment again revealed no performance differences for i-
R26R:CamKIIα-Cre+ mice and Cre-negative littermates (Fig. R-35a1 - a3; Tab. St-13). Testing of ASR- 
I/O two months after TAM-treatment also did not reveal any differences between groups (Fig. R-
35b1; Tab. St-13). However, presentation of a pre-pulse of 65 dB resulted in an increased PPF for i-
R26R:CamKIIα-Cre+ mice compared to Cre-negative littermates (Fig. R-35b3; PPI/PPF 65 dB 
(genotype):  F1,20 = 4.7549, p = 0.0413) and presentation of a 75 dB pre-pulse resulted in a significant 
genotype x IPI interaction towards an increased PPF of i-R26R:CamKIIα-Cre+ mice compared to Cre-
negative littermates (Fig. R-35b4; PPI/PPF 75 dB (genotype x IPI):  F4,80 = 3.3786, p = 0.0132). This 
observed increase in PPF for i-R26R:CamKIIα-Cre+ mice two months after TAM-treatment 
recapitulates the findings for the previous cohort of i-R26R:CamKIIα-Cre+ mice four months after 
TAM-treatment (cf Fig. R-30a2 – a4). 
 
Fig. R-35: OF and ASR behavior 2 months AFTER Tamoxifen-treatment for i-R26R:CamKIIα-Cre (2M) mice: (a1-3) OF 2 
months after Tamoxifen-treatment; (b1-4) ASR-I/O and PPI/PPF 2 months after Tamoxifen-treatment. ASR = acoustic startle 
response; I/O = input/ output; OF = open field; PPI/PPF = pre-pulse inhibition/ -facilitation. All data presented as mean ± 
SEM. ٭٭ p < 0.01, ٭٭٭ p < 0.001 (ANOVA followed by Tukey HSD post hoc test). 
 
In order to assess whether the observed phenotypic changes 2 months after TAM-treatment would 
persist or might again invert as previously described when tested 12 months after TAM-treatment (cf 
Fig. R-30b2 – b4), this group of i-R26R:CamKIIα-Cre mice also underwent OF and ASR testing 4 
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months after TAM-treatment. As previously observed, OF testing of i-R26R:CamKIIα-Cre mice 4 
months after TAM-treatment revealed a slightly increased rearing frequency for i-R26R:CamKIIα-Cre+ 
mice compared to Cre-negative littermates (Fig. R-36a2; OF RF (genotype x time): F5,100 = 2.4714, p = 
0.0373), but no differences regarding the distance traveled (cf Fig. R-28 a1 + a2). However, ASR- I/O 
and PPI/PPF testing 4 months after TAM-treatment also revealed no group differences (Fig. R-36b1 – 
b4; Tab. St-13).  
 
  
Fig. R-36: OF and ASR behavior 4 months AFTER Tamoxifen-treatment for i-R26R:CamKIIα-Cre (2M) mice: (a1-3) OF 4 
months after Tamoxifen-treatment; (b1-4) ASR-I/O and PPI/PPF 4 months after Tamoxifen-treatment. ASR = acoustic startle 
response; I/O = input/ output; OF = open field; PPI/PPF = pre-pulse inhibition/ -facilitation. All data presented as mean ± 
SEM. ٭ p < 0.05 (ANOVA followed by Tukey HSD post hoc test). 
 
Therefore we concluded that phenotypic alterations due to inducible lacZ expression can indeed be 
observed already two months after TAM-treatment. However, the progression and persistence of 
these alterations appear to be dependent not only on the promoter x lacZ expression-interaction 
along with expression-duration and age-dependent factors, but seem to be guided by additional, 
possibly inter-individual, factors we did, and could, so far not account for.   
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3.2.2.3. i-R26R:DAT-Cre mice 
 
Given the somewhat enigmatic and peculiar results observed following lacZ expression in CamKII-
positive neurons, we decided to test an additional “inducible” mouse line that would express lacZ in 
a completely separate neuronal sub-population: the i-R26R:DAT-Cre mouse line, which enables 
inducible lacZ expression in neurons positive for the dopamine (active) transporter (DAT).  
 
3.2.2.3.1. i-R26R:DAT-Cre mice: repeated testing 4, 12 and 20 months after tamoxifen-treatment 
 
In parallel to i-R26R:CamKIIα-Cre mice, i-R26R:DAT-Cre mice first underwent the abbreviated pre-
TAM baseline screening regarding OF and ASR behavior at the age of 3.5 months and were 
subsequently extensively tested 4, 12 and 20 months post tamoxifen-treatment. Neither survival nor 
bodyweight were significantly altered by lacZ expression throughout testing (Fig. R-37a + b; Tab. St-
14). X-Gal staining of i-R26R:DAT-Cre+ mice revealed a strong expression pattern distinctly localized 
to the ventral tegmental area (VTA) and the substantia nigra (SN; Fig. R-25c; Paxinos & Franklin “The 
Mouse Brain in Stereotaxic Coordinates; ©2001). 
 
Fig. R-37: Survival rate, weight throughout testing and X- Gal staining for i-R26R:DAT-Cre mice: (a) survival rate until 25 
months of age (= end of testing); (b) weight throughout testing; (c) X-Gal staining (plus nuclear fast red counterstain; black 
& weight image acquisition) for i-R26R:DAT-Cre
+
 mice 4 months after TAM treatment. cp = cerebral peduncle (basal part); 
IF = interfascicular nucleus; IPR = interpeduncular nucleus (rostral part); ML = mammillary nucleus; OF = open field; PN = 
paranigral nucleus; SNC = substantia nigra pars compacta; SNR = substantia nigra pars reticularis; Tamox = tamoxifen; VTA = 
ventral tegmental area. 
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Similarly, neither OF performance nor ASR-I/O responses differed between groups before tamoxifen-
treatment (Fig. R-38a –d; Tab. St-14). 
 
 
Fig. R-38: Behavior BEFORE Tamoxifen-treatment for i-R26R:DAT-Cre mice: (a-c) OF behavior; (d) ASR- I/O. ASR = acoustic 
startle response; I/O = input/ output; OF = open field. All data presented as mean ± SEM. No significant differences 
detected (ANOVA). 
 
 
In contrast, OF testing 4 months after TAM-treatment revealed decreased activity across all 
parameters for i-R26R:DAT-Cre+ mice compared to i-R26R:DAT-Cre- littermates (Fig. R-39a1 – a3; OF 
Distance (genotype): F1,14 = 6.0541, p = 0.0275; OF RF (genotype): F1,14 = 4.027, p = 0.0645; OF RD 
(genotype): F1,14 = 4.5753, p = 0.0505; Tab. St-14). i-R26R:DAT-Cre
+ mice and i-R26R:DAT-Cre- 
littermates did not differ in their performance during OF testing 12 months after TAM-treatment (Fig. 
R-39b1 – b3), but displayed again a trend towards a decreased rearing activity for R26R:DAT-Cre+ 
mice compared to i-R26R:DAT-Cre- littermates when tested 20 months after TAM-treatment  (Fig. R-
39c1 – c3; OF RF (genotype): F1,9 = 4.5379, p = 0.062; OF RD (genotype): F1,9 = 4.0962, p = 0.0737; Tab. 
St-14). However, given the absolute values of their rearing behavior (i.e. ≤ 5) and the often observed 
decreased mobility in age, the lack of statistically significant differences might in fact be attributed to 
a floor effect. 
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Since deficits in locomotor behavior coinciding with SN alterations (i.e. lacZ expression in DAT-
positive neurons) easily prompt a connection to motor disorders such as Parkinson’s Disease (PD), we 
subjected the i-R26R:DAT-Cre mice additionally to a motor-skill learning task: the accelerating 
rotarod. Training began at the age of 12 months (i.e. 8 months after TAM-treatment) in order to 
mimic the often progressed age of PD affected patients. Initial motor-skill acquisition revealed a 
genotype x training day –dependent effect towards a slightly impaired motor learning of R26R:DAT-
Cre+ mice compared to i-R26R:DAT-Cre- littermates (Fig. R40; Rotarod d1 – d6 (genotype x training 
day): F5,65 = 2.3412, p = 0.0513). However, overall motor-performance as well as motor-memory were 
unaffected by lacZ expression in SN and VTA (Fig. R40; Rotarod d1 – d130 (genotype): F1,13 = 0.0438, p 
= 0.8375; Tab. St-14). These rotarod results imply that the decreased OF-activity observed for 
Fig. R-39: Open Field 
behavior 4, 12 and 20 
months AFTER Tamoxifen-
treatment for i-R26R:DAT-
Cre mice: (a1-3) OF 4 
months after Tamoxifen-
treatment; (b1-3) OF 12 
months after Tamoxifen-
treatment; (c1-3) OF 20 
months after Tamoxifen-
treatment. OF = open field. 
All data presented as mean 
± SEM. ٭ p < 0.05 (ANOVA 
followed by Tukey HSD post 
hoc test). 
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R26R:DAT-Cre+ mice compared to i-R26R:DAT-Cre- littermates is not due to impaired motor-skills, 
and may rather be due to a decreased motivation to explore their environment or possibly a 
heightened anxiety-like phenotype. 
 
 
 
However, testing of anxiety-like behavior of i-R26R:DAT-Cre mice in the DL 4 and 20 moths after 
TAM-treatment revealed no anxiety-related behavioral differences between groups across all 
parameters (Fig. R-41a1 – b3; Tab. St- 14). 
 
 
Fig. R-40: Accelerating 
rotarod performance of i-
R26R:DAT-Cre mice beginning 
8 months AFTER Tamoxifen-
treatment (i.e. age = 12 
months): acc. = accelerating. 
Data presented as mean ± 
SEM. 
 
Fig. R-41: Dark-light box 
behavior of i-R26R:DAT-Cre 
mice 4 and 20 months AFTER 
Tamoxifen-treatment: All data 
presented as mean ± SEM. 
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Assessment of the acoustic startle response for i-R26R:DAT-Cre mice revealed a marked increase 
regarding the input/ output curve for i-R26R:DAT-Cre+ mice compared to i-R26R:DAT-Cre- littermates 
four months after TAM-treatment (Fig. R-42a1; ASR I/O (genotype x stimulus intensity): F4,56 = 4.0832, 
p = 0.0057; Tab. St-14). This I/O-increase was accompanied by a genotype-dependent decrease in 
PPF after a 55 dB and a 65 dB, but not a 75 dB pre-pulse presentation (Fig. R-42a2 – a4; PPI/PPF 55 
dB (genotype):  F1,14 = 6.074, p = 0.0273; PPI/PPF 65 dB (genotype): F1,14 = 16.8121, p = 0.0011; Tab. 
St-14). ASR testing 12 months after TAM-treatment revealed no changes regarding input/output 
curve (Fig. R-42b1; Tab. St-14), but revealed an interaction-dependent increase of PPF for i-
R26R:DAT-Cre+ mice compared to i-R26R:DAT-Cre- littermates (Fig. R-42b3; PPI/PPF 65 dB (genotype 
x IPI): F4,48 = 3.8452, p = 0.0086; Tab. St-14). This reversal of PPF responses by lacZ expressing mice 
between testing at 4 months and at 12 months post TAM-treatment has been similarly observed for 
i-R26R:CamKIIα-Cre+ mice, albeit in the opposite direction. 
Once again similar to i-R26R:CamKIIα-Cre+ mice, ASR performance 20 months after TAM-treatment 
revealed a barely existent startle response independent of genotype for i-R26R:DAT-Cre mice (Fig. R-
42c1 –c4; Tab. St-14). 
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Fear conditioning and subsequent fear memory assessment of i-R26R:DAT-Cre mice revealed a minor 
effect 4 months after TAM-treatment: i-R26R:DAT-Cre+ mice displayed a slightly heightened 
baseline-freezing response compared to i-R26R:DAT-Cre- littermates in a novel context before the 
presentation of the conditioned tone (Fig. R-43a2; unpaired student’s t-test: p = 0.0104; Tab. St-14). 
However, once again, this effect might have been confounded by the OF performance of i-R26R:DAT-
Cre+ mice (cf Fig. R-39a1-a3). Neither fear extinction training 4 months after TAM-treatment, nor 
repeated fear conditioning at 12 or 20 months after TAM-treatment (with a renewed tone-shock 
pairing for each time point) resulted in differential fear expression between groups (Fig. R-43a4 – c3; 
Tab. St-14). 
Following fear conditioning, i-R26R:DAT-Cre mice were also trained in the WCM (in parallel to i-
R26R:CamKIIα-Cre mice) 4, 12 and 20 months after TAM-treatment. Animals displayed no group 
differences during initial acquisition of the spatial learning task, but reversal learning (i.e. week 2 four 
Fig. R-42: Acoustic 
startle response of 
i-R26R:DAT-Cre 
mice 4, 12 and 20 
months AFTER 
Tamoxifen-
treatment: (a1-4) 
ASR-I/O and 
PPI/PPF 4 months 
after Tamoxifen-
treatment;  (b1-4) 
ASR-I/O and 
PPI/PPF 12 months 
after Tamoxifen-
treatment; (c1-4) 
ASR-I/O and 
PPI/PPF 20 months 
after Tamoxifen-
treatment; ASR = 
acoustic startle 
response; I/O = 
input/ output; 
PPI/PPF = pre-pulse 
inhibition/ -
facilitation; All data 
presented as mean 
± SEM; ٭ p < 0.05, 
 > p ٭٭٭ ,p < 0.01 ٭٭
0.001 (ANOVA 
followed by Tukey 
HSD post hoc test). 
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months after TAM) revealed an improved performance for i-R26R:DAT-Cre+ mice compared to i-
R26R:DAT-Cre- littermates (Fig. R-44b – e; WCM WPV week 2 (genotype): F1,14 = 6.6012, p = 0.0223; 
WCM Accuracy week 2 (genotype): F1,14 = 4.4859, p = 0.0526; WCM Learners week 2 chi-square (χ
2) 
test: p = 0.0209; WCM Learning Score week 2 unpaired student’s t-test: p = 0.0526; Tab. St-14). 
 
           
Fig. R-43: Fear memory of i-R26R:DAT-Cre mice 4, 12 and 20 months AFTER Tamoxifen-treatment: (a1-4) FC 4 months 
after TAM-treatment; (a1-3) contextual and tone fear memory assessed 24 h after FC; (a4) extinction training on d2, 3, 4 
and 11 after fear conditioning; (b1-3) FC 12 months after TAM-treatment; contextual and tone fear memory assessed 24 h 
after FC; (c1-3) FC 20 months after TAM-treatment; contextual and tone fear memory assessed 24 h after FC. d = day; FC = 
fear conditioning; h = hours; TAM = tamoxifen. All data presented as mean ± SEM; ٭ p < 0.05 (Student’s t-test). 
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Repeated testing in the WCM 12 months after TAM-treatment also resulted in an improved accuracy 
for i-R26R:DAT-Cre+ mice compared to i-R26R:DAT-Cre- littermates (Fig. R-44c; WCM Accuracy 12 
months (genotype x day): F4,52 = 3.4866, p = 0.0135; Tab. St-14). WCM performance 20 months after 
TAM-treatment did not differ statistically significantly between groups, possibly due to the (age-
dependent) decreased number of animals per group (Fig. R-44e; Tab. St-14).  
 
 
Fig. R-44: Water Cross Maze performance of i-R26R:DAT-Cre mice 4, 12 and 20 months AFTER Tamoxifen-treatment.  All 
data presented as mean ± SEM. ٭ p < 0.05, ٭٭ p < 0.01 (Student’s t-test, χ² test or ANOVA followed by Tukey HSD post hoc 
test). 
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Following WCM training, i-R26R:DAT-Cre mice also underwent MEMRI at 4, 12 and 20 months after 
TAM-treatment. In parallel to i-R26R:CamKIIα-Cre mice, absolute whole brain volume of i-R26R:DAT-
Cre mice did not differ between groups, but increased over time. Again similar to i-R26R:CamKIIα-
Cre mice, total relative hippocampal volume of i-R26R:DAT-Cre mice did not differ between groups 
either, but once again decreased over time (Fig. R-45a1 – b3; Tab. St-14). However, in contrast to i-
R26R:CamKIIα-Cre mice, we did observe a genotype-dependent effect regarding an increased dorsal 
hippocampal volume of i-R26R:DAT-Cre+ mice compared to Cre-negative littermates 4 months after 
TAM-treatment (Fig. R-45c1; unpaired student’s t-test: p = 0.0369), but not 12 or 20 months after 
TAM-treatment (Fig. R-44c2 + c3; Tab. St-14). Instead, interestingly, 20 months after TAM-treatment 
we observed a decrease in ventral hippocampal volume of i-R26R:DAT-Cre+ mice compared to Cre-
negative littermates (Fig. R-45c3; unpaired student’s t-test: p = 0.0386).   
VTA volume on the other hand was slightly increased 4 and 12 but not 20 months after TAM-
treatment (Data not shown; unpaired student’s t-test: VTA 4 months: p = 0.0655; VTA 12 months: p = 
0.0694; Tab. St-14). Additionally, we observed a decreased cortex-signal intensity 12 months, but not 
4 or 20 months after TAM-treatment (Fig. R-45d2; unpaired student’s t-test: p = 0.0393; tab. St-14). 
In summary, inducible lacZ expression in the SN and VTA caused decreased locomotor activity in the 
OF, an increased ASR- I/O curve accompanied by reduced PPF as well as an improved WCM 
performance and an increased dorsal hippocampal volume 4 months after induction.  
Thus, i-R26R:DAT-Cre+ mice displayed a distinct and markedly altered phenotype after lacZ 
expression compared to Cre-negative littermates. Once again, the phenotype not just differed with 
respect to the Cre-driver line (CamKIIα vs. DAT), rather, behavioral and structural alterations are also 
subject to time-dependent (i.e. expression-duration-dependent) and age-dependent effects and are 
not constant throughout repeated testing (see also chapter 3.2.2.2.1 i-R26R:CamKIIα-Cre 4, 12 and 
20 months after TAM-treatment mice for similar effects). 
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Fig. R-45: MEMRI analyses for i-R26R:DAT-Cre mice 4, 12 and 20 months AFTER Tamoxifen-treatment: (a1-3) absolute 
whole brain volume of lacZ-positive and lacZ-negative littermates for each time point; (b1-3) relative HPC volume of lacZ-
positive and lacZ-negative littermates for each time point; (c1-3) relative d-HPC and v-HPC volume of lacZ-positive and lacZ-
negative littermates for each time point; (d1-3) relative dorsal Cortex intensity of lacZ-positive and lacZ-negative littermates 
for each time point. All volumes normalized to whole brain volume. Intensities normalized to whole brain intensity. d- = 
dorsal; HPC = hippocampus; v- = ventral; Vol. = volume. All data presented as mean ± SEM. ٭ p < 0.05 (Student’s t-test). 
 
In parallel to i-R26R:CamKIIα-Cre mice, we again asked whether the observed (behavioral) effects 
due to lacZ expression in SN and VTA were also measurable already two months after lacZ induction. 
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3.2.2.3.2. i-R26R:DAT-Cre mice: repeated testing 2, 4 and 12 months after tamoxifen-treatment 
 
Therefore, a separate cohort of i-R26R:DAT-Cre mice underwent a shortened baseline screen before 
TAM-treatment (ASR only) at the age of 3.5 months and was subjected to a condensed behavioral 
screen consisting of OF and ASR I/O and PPI/PPF already 2 months after TAM-treatment. 
Bodyweight throughout testing was not affected by lacZ expression, and pre-TAM behavioral screen 
revealed no differences between groups (Fig. R-46a – c3; Tab. St-15). 
 
 
 
OF testing of i-R26R:DAT-Cre mice two months after TAM-treatment did not reveal any group 
differences (Fig. R-47a1-a3; Tab. St-15), but the rearing activity of i-R26R:DAT-Cre+ mice at 4 months 
after TAM-treatment was again decreased compared to Cre-negative littermates (Fig. R-47b2 + b3; 
OF RF 4 months (genotype): F1,19 = 4.6838, p = 0.0434; OF RD 4 months (genotype): F1,19 = 5.1688, p = 
0.0348; Tab. St-15; cf Fig. R-39a2 + a3). Moreover, rearing duration 12 months after TAM-treatment 
Fig. R-46: Weight 
throughout testing and 
behavior BEFORE 
Tamoxifen-treatment for i-
R26R:DAT-Cre (2M) mice:  
(a) weight throughout 
testing; (b) ASR- I/O; (c1-3) 
ASR- PPI/PPF. ASR = 
acoustic startle response; 
I/O = input/ output; 
PPI/PPF = pre-pulse 
inhibition/ -facilitation. All 
data presented as mean ± 
SEM. 
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was also reduced for i-R26R:DAT-Cre+ mice compared to Cre-negative littermates (Fig. R-47c3; OF RD 
12 months (genotype): F1,13 = 4.2126, p = 0.0608; Tab. St-15). 
 
 
 
Acoustic startle response, however, was only marginally affected in this cohort by lacZ expression in 
DAT-positive neurons 2 or 4 months after TAM-treatment (Fig. R-48a1 – b4; ASR-PPI/PPF 65 dB 2 
months (genotype x IPI): F4,76 = 2.6655, p = 0.0387 (post hoc analysis revealed no significant 
differences); Tab. St-15). However, i-R26R:DAT-Cre+ mice once again displayed an increased startle 
response for the ASR- I/O curve 12 months after TAM-treatment (Fig. R48c1; ASR I/O 12 months 
(genotype x stimulus intensity): F4,52 = 2.7737, p = 0.0365; Tab. St-15). This finding resembles the 
Fig. R-47: Open Field 
behavior 2, 4 & 12 months 
AFTER Tamoxifen-
treatment for i-R26R:DAT-
Cre (2M) mice: (a1-3) OF 2 
months after Tamoxifen-
treatment; (b1-3) OF 4 
months after Tamoxifen-
treatment; (c1-3) OF 12 
months after Tamoxifen-
treatment. OF = open field. 
All data presented as mean 
± SEM. ٭ p < 0.05, ٭٭٭ p < 
0.001 (ANOVA followed by 
Tukey HSD post hoc test). 
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effects observed for the first i-R26R:DAT-Cre cohort (cf Fig. R-42a1) 4months after TAM, but this time 
without affecting pre-pulse inhibition/ -facilitation (Fig. R-48c2 – c4; Tab. St-15).  
 
 
Fig. R-48: ASR behavior 2, 4 & 12 months AFTER Tamoxifen-treatment for i-R26R:DAT-Cre (2M) mice: (a1-4) ASR-I/O and 
PPI/PPF 2 months after Tamoxifen-treatment; (b1-4) ASR-I/O and PPI/PPF 4 months after Tamoxifen-treatment; (c1-4) ASR-
I/O and PPI/PPF 12 months after Tamoxifen-treatment; ASR = acoustic startle response; I/O = input/ output; PPI/PPF = pre-
pulse inhibition/ -facilitation; All data presented as mean ± SEM; ٭ p < 0.05 (ANOVA followed by Tukey HSD post hoc test). 
 
Since the repeated testing of independent cohorts of i-R26R:DAT-Cre mice did not reveal reliably 
reproducible results, and behavioral effects due to the expression and subsequent translocation of 
CreERT2 have been published before and have been observed by us for e.g. i-R26R:Nex-Cre mice, we 
decided to test an additional “inducible” line to account for any possible Cre-translocation effects 
after TAM-treatment as opposed to genuine lacZ-effects. Given the partially contradicting results for 
i-R26R:DAT-Cre mice, we analyzed  i-DAT-Cre mice; i.e. mice expressing Cre-recombinase in DAT-
positive neurons, but no lacZ.  
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3.2.2.4. i-DAT-Cre mice: Cre-translocation control 
 
The i-DAT-Cre mouse line entails the Cre-ERT2 fusion product that translocates into the nucleus upon 
tamoxifen-administration, but does not contain the lacZ-sequence. Any resulting effects can 
therefore be solely ascribed to the Cre-translocation itself.  
Testing of i-DAT-Cre mice, including the pre-tamoxifen baseline screen at 3.5 months, was essentially 
done in parallel to i-R26R:CamKIIα-Cre and i-R26R:DAT-Cre mice, but did not encompass DL testing 
or fear conditioning, since i-R26R:DAT-Cre+ mice displayed only minor (FC) or no (DL) behavioral 
differences for these tasks compared to i-R26R:DAT-Cre- littermates.  
Pre-tamoxifen behavioral screen as well as bodyweight measurements throughout testing did not 
reveal any group differences for i-DAT-Cre mice (Fig. R-49a – d3; Tab. St-16). 
OF performance 4 months after TAM-treatment did not differ between i-DAT-Cre+ and i-DAT-Cre- 
littermates either (Fig. R-50a1 –a3; Tab. St-16). Acoustic startle response- I/O curve was also not 
affected by the Cre-translocation (Fig. R-50b1; Tab. St-16). However, similar to i-R26R:DAT-Cre+ mice, 
pre-pulse facilitation was mildly decreased for i-DAT-Cre+ mice after the presentation of a 65 dB, but 
not of a 55 dB or 75 dB pre-pulse (Fig. R-50b3; PPI/PPF 65dB (genotype): F1,16 = 3.2573, p = 0.09; Tab. 
St-16). 
Moreover and again similar to i-R26R:DAT-Cre+ mice, WCM performance was also slightly improved 
during the first week of training for i-DAT-Cre+ mice compared to i-DAT-Cre- littermates (Fig. R-50c2 – 
c4; WCM Accuracy week 1 (genotype): F1,16 = 3.1208, p = 0.0964; WCM Learners week 1 day 5: chi-
square (χ2) test: p = 0.0704; WCM Learning Score week 1: unpaired student’s t-test: p = 0.0959; tab. 
St-16).  
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Fig. R-49: Weight throughout 
testing and behavior BEFORE 
Tamoxifen-treatment for i-
DAT-Cre mice: (a) weight 
throughout testing; (b) ASR- 
I/O; (c1-3) ASR- PPI/PPF; (d1-
3) OF behavior. ASR = 
acoustic startle response; I/O 
= input/ output; OF = open 
field; PPI/PPF = pre-pulse 
inhibition/ -facilitation. All 
data presented as mean ± 
SEM; no statistical differences 
detected (ANOVA). 
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Fig. R-50: i-DAT-Cre mice behavior 4 months AFTER Tamoxifen-treatment: (a1-a3) OF behavior; (b1-c4) ASR- I/O and 
PPI/PPF; (c1-c4) WCM performance. ASR = acoustic startle response; I/O = input/ output; OF = open field; PPI/PPF = pre-
pulse inhibition/ -facilitation; WCM = water cross maze. All data presented as mean ± SEM. (Student’s t-test, χ² test or 
ANOVA followed by Tukey HSD post hoc test). 
 
Lastly, i-DAT-Cre mice also underwent MEMRI and we observed a significant increase in absolute 
whole brain volume for i-DAT-Cre+ mice compared to i-DAT-Cre- littermates 4 months after TAM-
treatment (Fig. R-51a; unpaired student’s t-test: p = 0.0238; Tab- St-16). We did not find a statistically 
significant difference regarding the normalized total hippocampal volume (Fig. R-51b; Tab. St-16), but 
when differentiating between dorsal and ventral hippocampus we found a reduction of the ventral 
hippocampus of i-DAT-Cre+ mice compared to i-DAT-Cre- littermates 4 months after TAM-treatment 
(Fig. R-51c; unpaired student’s t-test: p = 0.0051; Tab- St-16), similar to i-R26R:DAT-Cre+ mice 20 
months after TAM- treatment (cf Fig. R-45c3). Neither VTA volume nor HPC signal intensity differed 
between groups (data not shown; Tab. St-16). 
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Fig. R-51: i-DAT-Cre MEMRI analyses 4 months AFTER Tamoxifen-treatment: (a) absolute whole brain volume of Cre-
positive and Cre-negative littermates; (b) relative hippocampal volume of Cre-positive and Cre-negative littermates; (c) 
relative dorsal and ventral hippocampal volume of Cre-positive and Cre -negative littermates. Hippocampal volumes 
normalized to whole brain volume. HPC = hippocampus; Vol. = volume. All data presented as mean ± SEM; ٭ p<0.05, ٭٭ 
p<0.01 (Student’s t-test).  
 
 
Admittedly, we did not perform MEMRI before TAM-treatment and therefore cannot exclude a priori 
effects of transgenic Cre-ERT2-expression (and possible cytosolic accumulation) in i-DAT-Cre+ mice 
compared to i-DAT-Cre- littermates. However, we did not observe whole brain volume differences for 
i-R26R:DAT-Cre+ mice compared to Cre-negative littermates, further complicating the interpretation 
of the results for i-DAT-Cre+ mice. 
In summary, inducible lacZ expression definitely causes distinct behavioral and structural alterations 
dependent on the Cre-driving promoter and the duration of expression (Tab. R-3). While these 
“induced” alterations are somewhat attenuated compared to the consequences of constitutive lacZ 
expression, they also at least partly replicate the constitutive lacZ-effects (i.e. R26R:Nex-Cre+ and i-
R26R:Nex-Cre+ mice both display increased DL-frequency, decreased contextual fear memory and a 
decreased hippocampal volume compared to Cre-negative littermates). And although attenuated, 
these induced alterations nonetheless represent significant changes compared to littermate-controls. 
Furthermore, these induced phenotypic changes can at least in part be observed already 2 months 
after the induction of lacZ expression. However, the specificity of effects is not only promoter-
dependent. Rather, the promoter-specificity interacts with the duration of expression as well as the 
age of the animals, and seems to be furthermore mediated by so far unrecognized mechanisms. 
Lastly, the mere expression (and possible cytosolic accumulation) of the Cre-ERT2 fusion product, as 
well as its translocation to the nucleus upon tamoxifen administration cannot be conclusively ruled 
out as an additional phenotypic modulator.  
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Table R-3: Summary of phenotypic alterations observed for i-Cre-positive vs. i-Cre-negative 
littermates (4 months AFTER Tamoxifen-treatment) 
PARAMETER  
(4 MONTHS AFTER TAM) 
i-R26R:Nex-Cre i-R26R:CamKIIα-Cre i-R26R:DAT-Cre i-DAT-Cre 
OF activity 
    
Anxiety related behavior  
 
            n/a 
ASR- I/O     
ASR- PPI/PPF           (65 
dB) 
    
FC –                    Context 
freezing 
             n/a 
FC –                        Tone 
freezing 
             n/a 
WCM performance  
 
  
MEMRI               Whole 
Brain Volume 
    
MEMRI – Cortex Volume     
MEMRI - dorsal HPC 
Volume 
 
   
MEMRI - ventral HPC 
Volume 
    
 
ASR = acoustic startle response; FC = fear conditioning; HPC = hippocampus; I/O = input/ output curve; MEMRI = 
manganese-enhanced MRI; n/a = not applicable; OF = open field; PPI/PPF = pre-pulse inhibition/- facilitation; WCM = water 
cross maze.  
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3.3. Project (iii): PTSD & Age 
 
Given the inconclusive results regarding age-dependent effects of lacZ expression, the third project 
(iii) PTSD & Age investigated the cumulative effects of one or more environmental/ psychological 
traumata in combination with progressed age on the (cognitive) behavior of a mouse model of PTSD. 
Mice were separated into 5 groups, two of which underwent a shock procedure (S). Additionally, one 
group of S –mice and one group of non-shocked (NS) mice were exposed to the mouse shaker stress 
procedure (MSS; see chapter 2.2.7.). The rationale behind this strategy was that exposure to multiple 
traumata would potentiate “age-effects”, e.g. cognitive decline. 
Mice were group housed throughout testing and their weight was monitored throughout testing. We 
observed a group-dependent effect on bodyweight (Weight throughout (group): F4,73 = 3.6638, p = 
0.0089), with the S+MSS group displaying the strongest weight-gain, whereas the NS+MSS displayed 
the smallest weight-gain (Fig. R-52; Tab. St-17).   
 
 
Fig. R-52: Weight throughout testing for PTSD & Age mice. Data presented as mean ± SEM. ٭٭ p < 0.01 (ANOVA)   
 
 
3.3.1. PTSD-like phenotype one month after foot-shock application 
One month after shock application shocked (S) and non-shocked (NS) animals underwent behavioral 
phenotyping to assess their PTSD-related responses, such as hyperarousal and contextual as well as 
associative (tone-) fear memory (Fig. R-53b-c4). In order to control for possibly confounding 
differences in basal activity, we also assessed the basic locomotor behavior in the open field (i.e. 
Distance traveled; Fig. R-53a). We observed no group differences regarding OF behavior (Fig. R-53a; 
Tab. St-17), but S mice displayed strong hyperarousal compared to NS mice (i.e. increased acoustic 
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startle response; Fig. R-53b; ASR – I/O (1; group): F1,62 = 4.9026, p = 0.0305), as well as a marked 
increase in their contextual fear memory (Fig. R-53c1 + c2; unpaired student’s t-test: p < 0.0001; Tab. 
St-17) and their tone-fear memory in a novel context (Fig. R-53c3 + c4; unpaired student’s t-test: p < 
0.0001; Tab. St-17). These increases in contextual and tone-fear memory were accompanied by a 
general increase in freezing behavior in a novel context (before tone presentation; Fig. R-52c4 “Tone 
OFF”; unpaired student’s t-test: p < 0.0001; Tab. St-17). Interestingly, shocked mice displayed a high 
variance regarding their contextual and tone-freezing responses (Fig. R-53c2 + c4), possibly indicating 
inter-individual differences concerning stress-vulnerability and stress-resilience. 
Nevertheless, given the marked group-differences between S and NS mice concerning freezing 
responses, we concluded that the shock application one month prior to these behavioral tests 
induced a PTSD-like phenotype. 
 
 
Fig. R-53: PTSD-like phenotype one month after Shock application (1): (a) Distance traveled in the OF; (b) ASR- I/O; (c1-c4) 
contextual and tone fear memory one month after shock application. ASR = acoustic startle response; I/O = input/ output; 
NS = no shock; OF = open field; S = shock. All data presented as mean ± SEM. ٭ p < 0.05, ٭٭ p < 0.01, ٭٭٭ p < 0.001 
(Student’s t-test or ANOVA followed by Tukey HSD post hoc test).  
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3.3.2. Mouse Shaker Stress (MSS) 
Six months after PTSD-testing half of S and NS mice (respectively) additionally underwent the MSS 
procedure. Immediately before MSS and 30 min after MSS blood samples were taken and later 
analyzed regarding their corticosterone levels (Cort; Fig. R-54). Before MSS, we observed a trend 
towards increased Cort levels for S mice (unpaired student’s t-test: p = 0.0682; Tab. St-17) compared 
to NS mice, which did not persist after MSS. However, Cort levels of both groups were strongly 
increased after MSS (Fig. R-54; unpaired student’s t-test: p < 0.0001; Tab. St-17); hence, MSS 
successfully stressed both groups of mice. 
 
  
 
 
3.3.3. Anxiety-related behavior and PTSD-like phenotype beginning eight months after foot-shock 
application 
One month after MSS, anxiety-related behavior of NS and S mice (with or without MSS) was assessed 
in the DL. All shocked mice (independent of MSS) displayed heightened anxiety behavior regarding 
the latency to enter the light compartment, the time spent in the light compartment and the 
frequency to enter the light compartment (Fig. R-55a1, a1 - c1; unpaired student’s t-test NS vs. S: 
Latency: p = 0.0029; Duration: p = 0.0457; Frequency: p = 0.0925; Tab. St-17). When further 
separated into groups with respect to MSS, S+MSS mice displayed the strongest anxiety phenotype 
compared to NS mice. This additive effect was particularly evident regarding latency and frequency 
to enter the light compartment (Fig. R-55a2 + c2; unpaired student’s t-test NS vs. S+MSS: Latency: p = 
0.0043; Frequency: p = 0.029; Tab. St-17).  
This shows that the original shock application had a persistent (traumatic) effect on these mice (i.e. 
increased anxiety), which was furthermore heightened by the additional stressor of MSS.  
Fig. R-54: Corticosterone 
levels for non-shocked and 
shocked mice before and 
after MSS. Cort = 
corticosterone; MSS = mouse 
shaker stress; NS = no shock; 
S = shock. Data presented as 
mean ± SEM. ٭٭٭ p < 0.001 
(Student’s t-test). 
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Following DL testing, mice underwent a second PTSD-related assessment (in parallel to Fig. R-53). 
This time the home cage group (HC), which had not been previously handled or tested, also 
underwent OF testing (Fig. R-56a), but not ASR-I/O or fear memory testing. This was done in order to 
assess the basic activity level and locomotor behavior of HC mice as a baseline for the subsequent 
tests. Since HC mice did not undergo the shock-procedure, nor were they exposed to the shock-
context, fear-memory assessment in the different contexts and ASR-testing were omitted for these 
mice, since it would not have revealed any relevant information with respect to the question at hand: 
do multiple trauma result in additive cognitive deficits in age? 
We did not observe any group differences regarding the distance traveled in the OF (Fig. R-56a; Tab. 
St-17). ASR-I/O testing also didn’t reveal any persisting group differences regarding hyperarousal, 
independent of shock or MSS (Fig. R-56b; Tab. St-17). Assessment of the contextual fear memory, 
however, revealed a lasting shock-effect regarding an increased freezing response in the shock 
context for S mice compared to non-shocked mice (Fig. R-56c1 – c3; unpaired student’s t-test FC 
Fig. R-55: Anxiety related 
behavior in the Dark-Light Box 
8 months after Shock 
application: left: all S vs. all NS 
animals; right: NS and S groups 
are additionally split with 
respect to MSS; (a1+a2) 
Latency to enter the light 
compartment; (b1+b2) Time 
spent in the light 
compartment; (c1+c2) 
Frequency to enter the light 
compartment. MSS = mouse 
shaker stress; NS = no shock; S 
= shock. All data presented as 
mean ± SEM. ٭ p < 0.05, ٭٭ p < 
 p < 0.001 (Student’s ٭٭٭ ,0.01
t-test). 
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Context (2) NS – S (all): p < 0.0001; Tab. St-17), albeit independent of MSS. Similarly, tone-fear 
memory assessment also revealed a lasting shock effect independent of MSS (Fig. R-56d1 – d3; 
unpaired student’s t-test FC Novel Context (2) NS – S (T; all): p < 0.0001; Tab. St-17). Additionally, S or 
S+MSS mice no longer displayed an increased freezing-response in the novel context before tone 
presentation (i.e. no lasting generalized fear; Fig. R-56d3 “Tone OFF”).  
 
 
Fig. R-56: PTSD-like phenotype nine months after Shock application (2): (a) Distance traveled in the OF; (b) ASR- I/O; (c1-
c3) contextual fear memory nine months after shock application; (d1-d3) tone fear memory nine months after shock 
application. ASR = acoustic startle response; HC = home-cage group (only for OF); I/O = input/ output; MSS = mouse shaker 
stress; NS = no shock; OF = open field; S = shock. All data presented as mean ± SEM. ٭ p < 0.05, ٭٭ p < 0.01, ٭٭٭ p < 0.001 
(Student’s t-test or ANOVA followed by Tukey HSD post hoc test). 
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Nevertheless, given the results of DL and PTSD (2)-testing, shock application and MSS definitely 
caused a lasting cumulative anxiety-phenotype. Moreover, although independent of MSS, shocked 
mice still displayed increased freezing responses in the presence of trauma-reminders (i.e. shock-
context or conditioned tone) nearly nine months after shock application. 
 
3.3.4. Cognitive performance nine months after foot-shock application 
 
Following the PTSD-like phenotype (2) assessment, all mice were tested in the novel-object 
recognition task. For this, the mice were first allowed to explore two objects for 10 min, one of which 
was subsequently replaced by a novel object (for detailed protocol please see chapter 2.2.6.). The 
amount of time spent investigating the new object compared to the old (familiar) object (i.e. 
discrimination index) was taken as an indicator for short-term object memory. Although we did not 
observe any performance differences across groups (Fig. R57b; Tab. St-17), S+MSS mice displayed the 
strongest negative discrimination index (i.e. these mice spent more time with the familiar as opposed 
to the novel object; Fig. R-57c), possibly indicating a novelty-fear effect (i.e. heightened anxiety), 
rather than a genuine deficit regarding short-term memory (Fig. R-57c; Tab. St-17). 
 
 
Fig. R-57: Novel object recognition performance 9 months after shock application: (a) exploration time during sample 
phase; (b) exploration time during choice phase; (c) discrimination index between old and new object. HC = home-cage; L = 
left; MSS = mouse shaker stress; N = new; NS = no shock; O = old; R = right; S = shock. Data presented as mean ± SEM. 
 
Lastly, in order to assess possible hippocampus-dependent cognitive deficits, (iii) PTSD & Age mice 
also underwent WCM training. However, once again, we did not observe any performance 
differences between groups across all learning parameters (Fig. R-58 d1-d7; Tab. St-17). 
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Since age-dependent cognitive decline often presents with a decrease in memory-recall abilities, we 
additionally assessed the recall memory for this spatial learning task of the two most divergent 
“treatment”-groups (i.e. NS and S+MSS). These mice underwent memory-recall (m - r) testing in the 
WCM two months after initial training. Both groups displayed a decreased accuracy compared to the 
end of initial training, however, once again, we did not observe any performance differences 
between groups regarding initial recall memory or re-acquisition (Fig. R-58. Tab. St-17). 
 
 
Fig. R-58: Water Cross Maze performance 10 months after shock application (+ recall memory 2 months later): d = day; 
HC = home-cage; m = recall memory assessment; MSS = mouse shaker stress; NS = no shock; S = shock. Only NS and S+MSS 
underwent m1-m3. Data presented as mean ± SEM. No significant differences detected (ANOVA). 
 
 
3.3.5. Initial fear responses correlate with spatial learning performance in age 
Nonetheless, given the high variance for shocked mice regarding their initial fear memory one month 
after shock application and the variance for WCM performance (i.e. Learning Score; Fig. R-58d), we 
asked whether the possible indication of stress vulnerability/ -resilience represented by the initial 
freezing response was at all correlated with the WCM performance. Indeed, we found a number of 
significant correlations and strong trends between initial freezing levels and WCM performance for 
S+MSS, but not S, mice (Fig. R-59; Tab. St-17). Specifically, the level of contextual fear memory one 
month after shock application was inversely correlated with the learning score for the initial training 
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in the WCM (i.e. d1 – d7; Fig. R-59a; Pearson correlation: p = 0.0496; Tab. St-17). This means that 
those mice displaying the lowest freezing levels performed best in the WCM, whereas those with a 
higher freezing level performed slightly delayed. When dividing the S+MSS mice according to their 
freezing level, it became apparent that this effect was driven by the distribution among low-freezing 
animals (Fig. R-59b+c), since the high-responders are clustered too close together. 
Furthermore, when correlating the initial tone-fear memory of S+MSS mice with their WCM- learning 
score across initial training, we also observed a strong negative trend regarding freezing levels and 
WCM performance (Fig. R-59d; Pearson correlation: p = 0.0649; Tab. St-17), indicating again an 
inverse relationship between initial freezing levels and WCM performance in age. Lastly, when 
comparing the initial contextual fear-responses to the accuracy levels of the first day of memory-
recall training in the WCM, we once more found an inverse correlation between freezing levels and 
WCM performance (Fig. R-59e; Pearson correlation: p = 0.0552; Tab. St-17). 
 
 
Fig. R-59: Correlations between WCM performance and initial freezing response (freezing response as displayed one 
month after shock application; S+MSS group only): (a) correlation between contextual fear memory and WCM LS d1-d7; (b) 
correlation between contextual fear memory (low responders) and WCM LS d1-d7; (c) correlation between contextual fear 
memory (high responders) and WCM LS d1-d7; (d) correlation between tone-fear memory and WCM LS d1-d7; (e) 
correlation between contextual fear memory and WCM Accuracy on day 1 of memory-recall assessment. Ctxt = context (i.e. 
shock context); d = day; LS = learning score; m = recall memory; MSS = mouse shaker stress; NE = novel environment; S = 
shock T = tone; WCM = water cross maze. ٭ p ≤ 0.055; Pearson correlations. 
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Interestingly, all of these correlations are selective to the S+MSS group. Given the group-specificity of 
these correlations, they possibly hint at a relationship between initial stress responses after trauma 
and cognitive performance-levels in aged individuals, especially when further challenged by 
additional stressors throughout the life-span.  
 
In summary, the (iii) PTSD & Age project revealed that two 1.5 mA foot-shocks not only reliably 
induce a PTSD-like phenotype one month after shock application, but that this behavioral phenotype 
largely persists until at least 9 months after shock application. An additional stressor can further 
heighten the persistent anxiety-related behavior, but does not necessarily additionally heighten the 
lastingly increased contextual- and tone-fear responses. Cognitive behavior in age, however, does 
not seem to be directly mediated by a single, albeit lasting, stressor. Additional stressful events might 
enhance a pre-existing distinction between stress-resilient and stress-susceptible animals, whereby 
the stress-susceptible mice – i.e. those animals already displaying a relatively higher freezing 
response one month after shock – are more sensitive to the additional stressor and subsequently 
perform with slight deficits in age when trained in a spatial learning task.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Results – Project (iii): PTSD & Age 
142 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
143 
 
 
4 Discussion 
 
Higher cognitive functions are one of the defining characteristics of mankind, yet, many of 
the underlying neurobiological mechanisms are still unresolved while simultaneously a 
myriad of disease mechanisms and even the progression of age easily disturb overall 
cognitive abilities. 
Therefore, the aim of this work was to explore three distinct disease-related scenarios and 
their consequences on the cognitive abilities of mice. To this end project (i) investigated the 
effects of GABAergic depletion in discrete forebrain structures with particular regards to 
schizophrenia-related behavioral traits and cognitive deficits. Project (ii) analyzed the 
consequences of the transgenic expression of a widely-used reporter protein in mice under 
the control of several different promoters, both for constitutive and adult-inducible 
expression patterns and with or without progressed age as an additional factor. Given that 
protein over-expression and subsequent -accumulation are hallmarks of neurodegenerative 
diseases, the results of project (ii) (i.e. the behavioral, cognitive, structural and molecular 
consequences of transgenic protein expression) were analyzed and interpreted in the 
context of neurodegeneration. Lastly, project (iii) investigated the cumulative effects of life-
time stress exposure and age on the cognitive abilities of a mouse model of PTSD. 
 
4.1. Project (i) SAVA 
Project (i) SAVA investigated the effects of long-term (i.e. > 14 days) GABAergic neuronal depletion 
via saporin-conjugated anti-vesicular GABA transporter antibodies (SAVAs) at the level of the dorsal 
hippocampus (dHPC) and the prelimbic cortex (PrL), as well as the short-term (i.e. < 12 days) 
consequences of GABAergic neuronal depletion in the dHPC. Short-term consequences were 
analyzed with a particular focus on the effects regarding the acquisition or the recall of a spatial 
memory. We observed severe cognitive impairments concerning the acquisition of a spatial memory 
following SAVA administration in the dHPC, independent of incubation period. However, SAVA 
treatment after memory acquisition did not significantly affect the recall of a spatial memory. 
Furthermore, we observed a transient hyperactivity phenotype caused by GABAergic lesioning of the 
dHPC. SAVA application in the PrL, in contrast, revealed decreased sensorimotor-gating abilities and 
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diminished cognitive flexibility, both of which are reminiscent of schizophrenia-related behavior 
traits. 
 
4.1.1. Localized GABAergic depletion – a new model for Schizophrenia? 
The results of project (i) are in so far remarkable, as the rather simplistic approach of diminishing one 
neuronal sub-population in distinct CNS structures of C57Bl6/N mice resulted in marked and specific 
behavioral effects mirroring hallmarks of one of the most complex neuropsychiatric disorders: 
Schizophrenia (i.e. hyperlocomotion; deficits in sensorimotor gating; impaired cognitive abilities 
(Swerdlow and Geyer, 1998; Kuperberg and Heckers, 2000; Powell and Geyer, 2007; Waltz and Gold, 
2007)).  
However, concerning the validity of this approach, there are a variety of limiting factors with respect 
to the development of a new mouse model for schizophrenia. For instance, although there are 
several subclasses of GABAergic interneurons which have been proposed to be differentially involved 
in generating a behavioral phenotype (Markram et al., 2004; Kubota, 2014), SAVA injections do not 
allow for a distinction regarding their specific involvement in the observed behavioral effects. Thus, 
in order to determine the overall extent of the relative GABAergic neuron loss for each target area, 
we chose to visualize parvalbumin containing (PV+) neurons, as they represent a large subclass of 
GABAergic interneurons and have been previously shown to be involved in learning and memory-
related processes (Caillard et al., 2000). Indeed, we observed significant PV+ loss after every SAVA 
injection, but cannot determine the relative influence of PV+ vs. other GABAergic interneurons on 
the observed behavioral alterations. Nonetheless, the relative smaller effect on PV+ interneurons in 
the PrL compared to the dHPC, for instance, is consistent with the hypothesis that a relatively minor 
loss of PV+ neurons in a highly complex area such as the PrL is sufficient to cause significant 
behavioral alterations. Furthermore, differing distributions of GABAergic interneurons throughout 
the cortical layers (Markram et al., 2004) might result in relatively fewer PV+ neurons at this specific 
injection site, but more GABAergic neurons of other subclasses (e.g. Martinotti cells). Although we 
did not specifically account for them, the loss of these “other” GABAergic subclasses may in fact be 
causally related to the observed behavior effects, as has been previously suggested for 
schizophrenia-related behavioral traits (Woo et al., 1997).  
Moreover, considering the histopathological stainings and the lesion extent (cf Fig. R-5b1 – b4), it is 
in fact feasible that we did not lesion the PrL as specific and distinctly as we’d hoped. Rather, it 
appears as if a larger area that includes the PrL and is perhaps best described as medial prefrontal 
cortex (mPFC) was affected by this (prolonged) SAVA treatment. Additional experiments with lower 
injection volumes, shorter incubation times and more extensive histological analyses will have to 
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verify the specificity of the observed effects with regards to the location (ACC, PrL, IL or PFC) and to 
the affected neuronal population: are the observed behavioral effects direct consequences of 
GABAergic depletion or are the effects due to secondary glutamatergic neuronal loss? 
Nonetheless, particularly the altered PPF response after SAVA administration to the PrL/PFC is 
noteworthy. To the best of our knowledge, so far mostly changes in PPI – not PPF – have been 
reported concerning schizophrenia-related animal models, as well as human schizophrenic patients 
(Swerdlow and Geyer, 1998; Geyer et al., 2002). However, it has also been previously shown that 
acoustic startle responses with or without a given pre-pulse are not merely dependent on a possible 
pathology, but also on the genetic background of the employed animals as well as on the set-up itself 
(Paylor and Crawley, 1997; Plappert et al., 2004). For instance, the commonly used intervals 
separating pre-pulse and the main pulse in a pre-pulse inhibition protocol are in the range of 30 to 
500 ms, (Swerdlow et al., 1992), whereas our protocol uses intervals between 5 and 100 ms, based 
on the shorter reaction times in mice compared to humans. Thus, given the fact that the main 
difference for PrL SAVA- vs. PBS-treatment occurred at a 10 ms interval, this might in fact represent a 
cumulative startle response with respect to the pre-pulse and the 115 dB main test pulse. Therefore, 
the observed effect would nonetheless be a gating-deficit that increases the startle response for 
short inter pulse intervals and might decrease pre-pulse inhibition at larger inter pulse intervals. In 
other words, the observed decrease in PPF could be a literal left-shift from a decreased PPI due to 
the genetic background (C57BL/6N) and the specific set-up used in this study.  
Alternatively, it has been reported that PPI and PPF are in fact governed by distinct and somewhat 
independent neurobiological mechanism, whereby PPI is predominantly mediated by the D2-
dopamine receptor whereas PPF is more closely governed by the D1-dopamine receptor (Mansbach 
and Geyer, 1991; Plappert et al., 2004; Swerdlow et al., 2004). Therefore our extensive GABAergic 
depletion in the PrL/PFC could have revealed a hitherto unrecognized PPI-independent sensorimotor-
gating- and thus novel bona fide PPF effect. 
Different types of GABAergic neurons are known to be intricately involved in spatial learning tasks 
(Ruediger et al., 2011; Buetfering et al., 2014). Our findings of intact acquisition but impaired reversal 
learning abilities following SAVA injection into the PrL are concordant with the prominent role 
regarding cognitive flexibility ascribed to this brain structure (Euston et al., 2012). The impairment of 
spatial learning abilities following SAVA injection into the dHPC, in turn, is in line with previous 
findings obtained by excitotoxic lesions of the hippocampus and schizophrenia-related genetic 
manipulations of the HPC (Kleinknecht et al., 2012; Gilani et al., 2014). Noticeably, based on our 
results GABAergic neurons in the dorsal hippocampus are essential for the acquisition of a spatial 
memory, but not for the recall; to the best of our knowledge a previously unrecognized distinction. 
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This finding was additionally challenged by endowing a separate group of C57Bl/6 mice with guide 
cannulas, training them in the WCM and once they had successfully acquired the platform position, 
injecting the exogenous GABAA agonist muscimol bilateral into their dHPC. Since this sub-project was 
neither performed nor supervised by myself, it is not included in the Results-section of this thesis. 
Nonetheless, the administration of muscimol into the dHPC completely prevented the recall of a 
spatial memory, thus (a) proving the involvement of the dorsal HPC in the recall of a spatial memory 
and (b) highlighting the involvement of the endogenous GABAergic signaling for the recall of a spatial 
memory (Reichel et al., 2015b). Moreover, the importance of the HPC for the recall of a spatial 
memory has also been reported elsewhere (Schlesiger et al., 2013). 
In addition to the cognitive effects after SAVA administration at the level of the dHPC, we also 
observed a duration-dependent hyper-locomotor phenotype for these mice. A similarly increased 
locomotor activity after the reduction of PV+ neurons in the dHPC has been previously reported in 
the context of rodent models of schizophrenia (Penschuck et al., 2006). 
Aside from the targeted consequences of SAVA administration on GABAergic interneurons, we also 
had to consider non-specific side effects such as inflammation due to the injection/ cannula 
implantation itself, as well as long-term consequences of GABAergic neuronal loss. Along those lines 
it has been reported that disrupting the integrity of skull and brain as a whole (e.g. via surgery) 
induces an inflammatory response (reviewed in e.g. Wang and Shuaib, 2002), which in turn can cause 
astrocytosis (Eng et al., 1992). An increased inflammatory response can also lead to behavioral 
alterations (Dantzer et al., 2008). Indeed, we did observe an increase in microglia activity in SAVA-
treated animals compared to PBS treated animals (data not shown but previously published in 
(Antonucci et al., 2012)). However, the behavioral effects observed by us, in particular for 
experiments affecting the hippocampus, are so severe (i.e. total ablation of spatial learning abilities) 
and also very specific to the time point of injection (acquisition vs. recall), that they are most likely 
not primarily based on an increased inflammatory response. This holds true in particular for SAVA-
treated animals tested in SAVA-3 (acquisition) and SAVA-4 (recall). The mice in SAVA-3 displayed 
severe place learning impairments already on day five after SAVA administration, whereas animals in 
SAVA-4 showed no effect on recall memory but a strong effect on locomotor activity after the same 
incubation period as SAVA-3. Additionally, these mice were able to acquire the platform position 
before SAVA injection, but after guide-cannula placement. Although surgery, cannulas and injection 
of either PBS or ucAB also cause inflammatory responses, albeit attenuated compared to SAVA 
administration, all PBS-treated groups and the mice that received the unconjugated antibodies 
always performed unaffected by guide-cannula placement and/ or PBS and ucAB injections. Thus, 
while we cannot exclude an inflammatory process caused by guide cannulas and PBS- or SAVA 
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injections as a mediating factor regarding the observed phenotypes, the specificity and the extent of 
these phenotypes are a strong indicator for de facto GABAergic hypo-function effects. Moreover, 
treatment with ucAB and the resulting non-existent altered phenotype once again underlines the 
specificity and functionality of the antibodies, i.e. only when coupled with Saporin do they exert their 
destructive consequences on GABAergic interneurons. 
Additionally, regarding long-term consequences of immuno-toxin-induced loss of GABAergic 
neurons, Antonucci, et al (2012) previously reported a loss of CA1 pyramidal neurons 12 days after 
SAVA treatment. Since basal phenotyping for SAVA-1 and SAVA-2 only started on day 15 after SAVA 
administration, we cannot exclude that non-GABAergic neuronal populations were successively 
affected and contributed to the resulting phenotypes. Given the prominent role of particularly the 
prelimbic cortex in the expression of fear (Vidal-Gonzalez et al., 2006), an extensive GABAergic 
neuronal loss could account for the accelerated fear relief observed upon recall of auditory cued fear 
memory following SAVA administration into the PrL. Alternatively, concerning the extent of the “PrL” 
lesion, a loss of GABAergic neurons in the PrL as well as in the adjacent infralimbic- and anterior 
cingulate cortex could have resulted in an overall increased PFC signaling activity: the loss of the 
inhibitory influence of GABAergic interneurons in the PFC would increase the excitatory output for 
the PFC, and in particular a heightened excitatory output of the IL would in turn inhibit the activity of 
the basolateral amygdala and thus explain the observed decrease in freezing responses after fear 
conditioning (Ashwell and Ito, 2014). Moreover, in combination with the decreased latency to enter 
the light compartment of the dark-light box (i.e. a behavioral marker for decreased anxiety), the 
accelerated decrease of tone-fear expression could also be interpreted as decreased anxiety-related 
behavior, or even as increased risk-taking behavior, as it has been previously described regarding 
Schizophrenia and PFC malfunction (Thomson et al., 2011; Mujica-Parodi et al., 2014). 
Moreover, regarding the secondary or compensatory loss of glutamatergic neurons after prolonged 
SAVA-exposure, for SAVA-3 and SAVA-4 we observed clear and distinctive behavioral effects within 
10 days of SAVA administration, which is again indicative of a predominantly GABAergic driven effect 
as opposed to a secondary glutamatergic-based consequence (Antonucci et al., 2012). Additionally, in 
terms of secondary or compensatory mechanisms, a reduction, albeit delayed, of excitatory neurons 
might in fact be beneficial for a functioning local network, particularly in the hippocampus, since 
extensive and prolonged  inhibitory interneuron loss can lead to epileptiform seizures in animal 
models as well as in humans (de Lanerolle et al., 1989; Wong et al., 2003). However, future studies 
should definitely once again investigate the specific time-course of GABAergic lesions, and in 
particular define at which time GABAergic loss (i.e. after what percentage-loss) causes behavioral 
alterations. 
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Lastly, one major and previously hinted-at additional limiting factor of our approach is the fact that, 
depending on the injection site of SAVAs, GABAergic lesions appear to spread outside of the targeted 
region of interest, which in turn limits the specificity of the observed effects. While this can be 
somewhat contained with lower injection volumes, it can never be completely avoided with this 
method. However, off-target activation or -inhibition of neuronal populations is a common con-
founding factor of many approaches, including transgenic manipulations and optogenetics and can 
be, at least partially, retrospectively controlled for via e.g. (more) extensive histological verifications.  
Furthermore, our straightforward verification approach of GABAergic lesions via the quantification of 
PV+ neurons was an additional limiting factor regarding the interpretation of the results, since we did 
not account for the loss of other GABAergic populations, such as e.g. somatostatin-positive 
interneurons. A quantitative analysis of the extent of several affected GABAergic neuronal 
populations in relation to the observed phenotypes could provide additional insight into the intricate 
functional GABAergic interneuron network.    
Finally, given the competing theories of GABAergic vs. glutamatergic involvement in the etiology of 
Schizophrenia (Elert, 2014), it might be of interest to tag vesicular glutamatergic transporter-
antibodies with Saporin, in order to specifically ablate glutamatergic neurons in the same regions as 
we applied the SAVAs. In particular the verification of the dHPC- GABAergic-specific distinction 
regarding the acquisition and the recall of a spatial memory, but also the PrL effect on PPF and the 
accelerated decrease of the tone-fear response would be intriguing. 
In summary, we found that GABAergic interneurons are not merely a generalized moderating 
influence on cortical network activity and a variety of behavioral phenotypes, but rather that 
GABAergic interneurons have a specific function (e.g. memory acquisition vs. memory recall; learning 
flexibility) within each local neuronal circuitry. Moreover, our direct approach of GABAergic lesioning 
resulted in the development of a number of schizophrenia-related behavior traits. Although our 
approach does not constitute a physiological representation of the complex interactions leading to 
neuropsychiatric disorders associated with aberrations in GABAergic signaling such as Schizophrenia, 
it nonetheless revealed important new insights into the role of GABAergic interneurons regarding the 
development of lesion-duration dependent consequences such as hyperlocomotion, as well as 
specific and strongly schizophrenia-associated behavioral effects such as altered sensorimotor gating 
and cognitive deficits. Given these results, the application of SAVAs might not be the ideal method to 
generate a new mouse model of Schizophrenia, but distinct GABAergic depletions definitely enable 
new insights into the development of phenotypic consequences of GABAergic loss as well as for the 
understanding of the functional connectivity of the entire GABAergic interneuron network, and can 
thereby provide new insights into the development of schizophrenia-related behavioral deficits. 
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4.2. Project (ii) lacZ 
 
Project (ii) lacZ investigated the primarily cognition-related consequences of constitutive or adult-
induced lacZ-expression mediated by several different Cre-driver lines, thus affecting several 
different neuronal sub-populations, and the possibly additive effects of prolonged lacZ-expression/ –
accumulation and progressed age. 
The rationale behind this study was two-fold: on the one hand lacZ is a very commonly employed 
reporter protein that enables the visualization of genetic manipulations with the inherent 
assumption that lacZ expression itself is inert. However, β-Gal, the protein product of lacZ, is also the 
bacterial analog to the mammalian marker for aged and degrading cells: senescence-associated β-
Gal. Moreover, the persistent expression and accumulation of a given protein is one of the hallmarks 
of neurodegenerative diseases. Thus, these apparently contradictory properties of lacZ – (1) inert 
transgenic marker and (2) age-related cellular degradation marker – prompted us to perform in-
depth screenings of the consequences of lacZ expression with a particular focus on the consequences 
for cognitive abilities. Our hypothesis was that we would observe cognitive deficits similar to age-
dependent effects or even neurodegenerative-like cognitive decline.  
We found that constitutive lacZ expression in glutamatergic principal neurons resulted in a 
hyperactive phenotype, severely impaired cognitive abilities and massive structural alterations. In 
contrast, constitutive GABAergic lacZ expression caused again hyperactivity but also distinctly 
decreased startle responses and minor cognitive deficits without marked structural alterations. 
Additionally, hippocampal micro-punches of glutamatergic-lacZ expressing mice revealed several 
differentially expressed proteins, indicating the far-reaching consequences of lacZ expression. 
Moreover, constitutive glutamatergic Cre-expression itself (i.e. in the absence of lacZ) resulted in 
decreased whole brain volumes and minute cognitive alterations. In contrast, constitutive 
glutamatergic GFP-expression caused improved cognitive performances coinciding with slightly 
increased locomotor activity levels. These findings demonstrated that constitutive lacZ expression in 
murine CNS specifically and distinctly (negatively) alters the behavioral, structural and molecular 
phenotype of the affected mice and in particular their cognitive abilities. Nonetheless, both the 
expression of Cre-recombinase as well as the expression of a different reporter protein (GFP) also 
caused significant alterations to the behavioral and structural phenotype of the affected animals. 
Therefore we cannot exclude for instance Cre-expression itself or the heterozygous Nex-gene locus 
(Cre-recombinase was originally knocked-in into one allel of the Nex-gene locus) for glutamatergic 
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Cre- and lacZ expression as confounding phenotype-modulating factors. However, given the 
specificity (glutamatergic vs. GABAergic) and the severity (Cre-expression vs. Cre-mediated lacZ 
expression) of the observed effects, we conclude that they are in fact predominantly driven by the 
lacZ expression. 
Considering the developmentally-early activation of the glutamatergic and the GABAergic gene-
promoters (E13 and E10 respectively (Schwab et al., 1998; Stühmer et al., 2002; Wu et al., 2005; 
Merlo et al., 2007)), as well as the timeline regarding protein-accumulation in neurodegenerative 
diseases (i.e. beginning in adulthood), we subsequently also analyzed the consequences of adult-
induced lacZ expression in order to attempt to distinguish developmentally-caused vs. genuine lacZ-
expression consequences. We found that adult-induced lacZ expression causes partially similar, 
albeit attenuated, behavioral and structural consequences, in particular for glutamatergic expression 
four months after induction. Furthermore, adult-induced CamKIIα- and DAT-driven lacZ expression 
also resulted in distinct and significant behavioral and structural alterations, beginning at least four 
months after induction and lasting throughout the life-time of the animals. Moreover, CamKIIα-
driven lacZ expression already resulted in behavioral alterations two months after induction. 
However, we failed to observe additive age-dependent cognitive deficits both for CamKIIα- and DAT-
driven adult-induced lacZ expression. Lastly – remarkably – adult-induced CreERT2 expression also 
resulted in significant behavioral and structural alterations in the absence of lacZ. 
Taken together we could show that lacZ expression, constitutively expressed or adult-induced, is 
definitely not inert to the behavioral and structural (regarding CNS) phenotype of mice and thus our 
findings provide a strong caveat against the use of lacZ co-expression for behavioral, structural and 
molecular phenotyping studies in mice. Furthermore, concomitant effects due to Cre-expression 
have to be carefully controlled for, and the expression of other reporter-proteins (e.g. GFP) can also 
result in undesirable side-effects. 
 
4.2.1. lacZ expression- developmental toxicity, neurodegeneration or premature ageing? 
Given the wide-spread use of lacZ our findings are surprising, to say the least. However, aside from 
the above summarized detrimental – but specific – consequences of lacZ expression, possibly the 
most alarming finding of this study is the fact that we found phenotypic alterations for EVERY 
genetically manipulated mouse line we tested. While the cognitive deficits observed for constitutive 
Cre expression in glutamatergic principal neurons are minor compared to lacZ expression, and 
glutamatergic GFP expression in fact resulted in improved cognitive performances, these findings 
nonetheless constitute a significant alteration compared to their Cre-negative littermates. Moreover, 
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while the effects of constitutive Cre and/ or lacZ expression in glutamatergic neurons can certainly at 
least partially be accounted for by developmental effects, adult-induced glutamatergic, CamKIIα- or 
DAT-driven lacZ and/ or Cre-expression also caused significant behavioral and structural alterations, 
which are independent of developmental effects.  
Cre-mediated side-effects have been reported before (Giusti et al., 2014), and given the direct 
comparison between adult-induced DAT- mediated Cre- and lacZ- expression, the question arises, 
how much of the assumed lacZ consequences are in fact caused by Cre expression itself. For 
instance, i-R26R:DAT-Cre+ mice displayed an increased startle amplitude (ASR-I/O) and what 
appeared to be a consequential decrease in PPF. However, i-DAT-Cre+ mice also displayed slightly 
reduced PPF, but without alterations to ASR-I/O. Similarly, i-R26R:DAT-Cre+ mice performed clearly 
better in the WCM than their Cre-negative littermates (cf Fig. R-44), but i-DAT-Cre+ mice also 
performed slightly better than their control-counterparts. On the other hand, DAT-specific Cre 
expression, but not lacZ expression, resulted in an increased whole brain volume and a decreased 
ventral HPC volume four months after induction. In contrast, DAT-Cre mediated adult-induced lacZ 
expression caused an increased dorsal HPC volume four months after induction and a decreased 
ventral HPC volume only 20 months after induction (as opposed to four months after induction as 
observed for i-DAT-Cre+; cf Fig. R-45 and R-51). Thus, the question now becomes whether Cre- and 
lacZ expression are causing partially contradictory effects at first that are overtaken by prolonged 
lacZ expression. Similarly, constitutive glutamatergic Cre-expression caused a decrease in whole 
brain volume, whereas constitutive glutamatergic lacZ-expression resulted in markedly decreased 
(total) HPC volume. Admittedly, we only analyzed selected behavioral test for constitutively 
glutamatergic Cre-expressing mice, which did not result in such severe behavioral alterations as 
constitutive glutamatergic lacZ-expression did. Nevertheless, we can conclude that transgenic Cre 
expression is also not inert, albeit to a lesser extent than lacZ expression.  
Correspondingly, several previous studies have also reported significant secondary effects or hitherto 
unrecognized accompanying consequences of genetic manipulations employing the Cre/loxP or the 
tet-ON/tet-OFF and other transgenic model systems, which extended to transgenic GFP expression 
and the genetic background of the animals employed for each study (Chan et al., 2012; Han et al., 
2012; Ciesielska et al., 2013; White et al., 2013; Czajkowski et al., 2014; Giusti et al., 2014). Especially 
considering the recent efforts to establish international “mouse-knockout-consortia” (e.g. EUCOMM 
or IKMC) with the goal to provide genome-spanning transgenic mice that are proposed to carry the 
lacZ sequence as an efficacy marker, our findings warrant a re-evaluation of this approach (Skarnes 
et al., 2011; White et al., 2013). Particularly White et al. (2013) already noted that nearly all genetic 
manipulations, more often than not, lead to unexpectedly altered phenotypes. Furthermore, White 
Discussion 
 
152 
 
et al. (2013) and we observed an additional unsolicited consequence of genetic manipulations: 
erratic genetic distribution across the progeny. For instance, homozygous lacZ expression or lacZ-
tagged alleles that were constitutively active resulted in a markedly decreased number of progeny, 
and the genetic distribution was no longer according to the generally accepted Mendelian 
inheritance rules. Specifically, breeding of lacZ-homozygous R26 reporter mice to the constitutively 
active glutamatergic Cre-driver line resulted in approximately 25 % rather than 50 % lacZ-carrying 
offspring.  
Hence, although the goal to target and categorize every protein-coding gene (in the mouse) in order 
to facilitate and standardize future genetic studies is a noble one, the usage of lacZ-tagged alleles 
might in fact provoke the opposite effect (i.e. misinterpretation and contradictory results) and can 
thus only be discouraged based on our results.  
 
Nevertheless, the initial rationale behind this study was to assess the cognitive effects of lacZ 
expression with respect to neurodegenerative-like and age-dependent effects. And while we did 
observe severe cognitive impairments following constitutive glutamatergic lacZ expression, and 
attenuated cognitive deficits as a consequence of adult-induced glutamatergic lacZ expression, we 
failed to observe negative cognitive effects for other adult-induced lacZ expressing lines. In fact, 
adult-induced DAT-Cre mediated lacZ expression improved cognitive performance in the WCM. Thus 
we can conclude that lacZ expression does not generally impair cognitive abilities, rather, the Cre-
driver line and thus the affected neuronal population and the location of lacZ expression determine 
the behavioral and structural consequences.  
However, in particular for constitutive glutamatergic lacZ expression it would be intriguing to further 
ascertain the extent of the cognitive decline. For instance, these mice displayed marked impairments 
for spatial learning and contextual fear memory, but not for tone-fear memory (or extinction 
training). Moreover, these mice presented with both increased locomotor activity in the OF and an 
increased frequency to enter the light compartment in the dark-light test. Since adult-inducible 
glutamatergic lacZ expression also resulted in increased DL-frequency, but did not alter the distance 
traveled in the OF, this indicates a genuine decrease in anxiety-related behavior as a result of 
glutamatergic lacZ expression. Additionally this increased frequency could also be an indication for a 
short-term memory deficit, similarly to one observed by employing a spontaneous alteration task in 
e.g. a Y-maze. Hence, future studies might broaden the cognitive assessment from fear conditioning 
and WCM to short-term memory tasks via e.g. Y-maze-testing.  
Interestingly, while in particular both lacZ expressing lines affecting glutamatergic neurons displayed 
decreased contextual fear responses, their tone-fear memories were unaffected, as were their 
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extinction learning abilities; indicating that contextual- and tone-fear memories are predominantly 
governed by distinct neurobiological mechanisms. Although hippocampus and amygdala are both 
undoubtedly intricately involved in the acquisition and the expression of a conditioned fear memory 
(Herry et al., 2008; Plendl and Wotjak, 2010; Raybuck and Lattal, 2011), our findings underline the 
functional distinction between contextual- and tone-fear memory. Especially noteworthy along those 
lines is the fact that constitutively glutamatergic-lacZ expressing mice not only displayed a marked 
lacZ expression pattern for the HPC, but also the amygdala (cf Fig. R-6). However, these mice only 
performed impaired regarding contextual-, and not tone-fear memory. This is particularly surprising 
given their severe cognitive deficits observed for WCM training, without any effect on tone-fear 
memory or extinction training. Conversely, adult-induced glutamatergic lacZ expression appeared to 
be somewhat limited to the HPC with no apparent lacZ expression in the amygdala, and resulted in 
decreased contextual fear memory, without affecting tone-fear memory, extinction training or 
spatial learning in the WCM. Additionally, while adult-induced lacZ expression in CamKIIα-positive 
neurons also revealed a marked expression pattern throughout the HPC, but not the amygdala (cf 
Fig. R-26c), this resulted in an unaltered contextual fear memory and an increased tone-fear 
memory. This increased tone-fear response subsequently also led to slightly delayed extinction 
learning, which was apparent at the second day of training, but absent at the end of training. Thus, 
adult-induced lacZ expression in the HPC affects either contextual- or tone-fear memory, depending 
on the specific nature of the affected neuronal population. This finding is in line with previous studies 
elegantly demonstrating the importance of the HPC for the generation of a contextual fear memory 
and the subsequent activation of the amygdala by the HPC (Ramirez et al., 2013).  
Given the proposed close relationship between CamKII-expression and glutamatergic signaling as 
well as learning and memory and synaptic plasticity, it is rather surprising that CamKIIα-dependent 
lacZ expression only resulted in relatively minor cognitive alterations. However, this might be due to 
the fact that CamKII has several isoforms that are coded for by at least four different gene sequences 
and is present throughout the entire neuron (with a bias towards the dendrites) as opposed to being 
restricted to the cell soma (i.e. where lacZ appears to accumulate). Thus, the alteration of the 
expression- or activity level of one CamKII-isoform can most likely, at least partially, be compensated 
for by other CamKII-isoforms (Silva et al., 1992; Colbran and Brown, 2004; Robison, 2014). 
Nevertheless, the increased tone-freezing response following adult-induced lacZ expression in 
CamKIIα-positive neurons, the increased PPF responses and increased cortex volumes were the main 
findings for this mouse line. Besides the HPC, these mice expressed lacZ also for instance in the 
lateral septal nucleus (cf R-26), which in turn has been implicated in the generation of PPI/PPF 
responses (Decker et al., 1995; Koch, 1999). Interestingly, the increased PPF response four months 
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after expression-induction was inverted to a decreased PPF response 12 months after induction, 
without altering the PPI response and thus further hinting at two neurobiologically independent 
mechanisms for PPI and PPF responses (Mansbach and Geyer, 1991; Koch, 1999; Plappert et al., 
2004; Swerdlow et al., 2004). Likewise, this inversion between 4 and 12 months after lacZ-induction 
could indicate a genuine lacZ-expression x age interaction-effect. This means that it is feasible that 
lacZ-expression at an earlier age (i.e. 8 months old) has a different effect on cellular function than at 
a later time-point (i.e. 16 months old). Additionally, we observed a similar effect for adult-induced 
DAT-driven lacZ-expression. Also for these mice PPF responses were inverted between 4 and 12 
months after lacZ-induction without affecting PPI. These mice presented with lacZ expression in the 
SN and the VTA (cf R-37), and in particular the VTA has also been shown to be involved in the 
generation of a startle response, including PPI/PPF (Borowski and Kokkinidis, 1996). Although the 
decreased PPF response four months after DAT-lacZ induction is possibly confounded by the 
increased ASR-I/O response, we observed no group differences regarding ASR-I/O 12 months after 
induction, but again a near-significantly different (between genotypes) PPF response. This PPF 
response 12 months after DAT-driven lacZ expression was again inverted compared to the PPF 
response 4 months after lacZ induction without (differentially) altering PPI responses for either time-
point, once more indicating somewhat independent or at least supplementary neurobiological 
mechanisms for ASR-I/O, PPI and PPF responses. A functional segregation between startle, PPI and 
PPF is further supported by recent studies selectively inactivating dopaminergic N-Methyl-D-
aspartate receptors (NMDAR) and their subsequent assessment of (fear potentiated) startle and PPI 
(Zweifel et al., 2011). The disruption of NMDARs was chosen since the activity level of dopaminergic 
neurons depends to a large extent on glutamatergic signaling via NMDARs and dopaminergic output 
is a major modulator of the startle response (Zweifel et al., 2008; Zweifel et al., 2009). Following the 
genetic inactivation of dopaminergic NMDARs, Zweifel et al. (2011) found that the knockout mice 
displayed a markedly increased startle response after fear conditioning (but not before) compared to 
littermate controls, but without altering the PPI responses (Zweifel et al., 2011). The heightened 
startle response was context-independent for NMDAR-knockout mice, additionally indicating a deficit 
regarding the integration of contextual information, which is predominately mediated by 
dopaminergic signaling of the nucleus accumbens (NAcc). In either case, this work and our findings 
both indicate distinct neurobiological mechanisms regarding the generation of startle, PPI and PPF 
responses. 
We observed opposing PPF effects following adult-induced CamKIIα- or DAT-driven lacZ expression. 
CamKIIα-driven lacZ expression resulted in increased PPF responses four months after induction 
while DAT-driven lacZ expression lead to decreased PPF responses four months after induction (cf 
Fig. R-30 and R-42). Accordingly, different lesion studies have reported opposing influencing effects 
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for the lateral septal nuclei and the VTA regarding startle responses (Decker et al., 1995; Borowski 
and Kokkinidis, 1996). Considering the intercellular consequences of lacZ expression, it is possible 
that lacZ-expression at early time-points over-activates the affected neurons and thereby increases 
their output, which, assuming ASR-I/O and PPF responses are governed somewhat independently, 
would result in decreased PPF responses if the VTA was affected (as observed for DAT-driven lacZ 
expression), and increased PPF if the lateral septal nuclei are affected. In contrast, at later time-
points lacZ expression may have exhausted the cellular functionality and thus decreases the neuronal 
output of the affected cells and thereby causes inverted startle responses (Decker et al., 1995; 
Borowski and Kokkinidis, 1996; Koch, 1999). However, unfortunately we were not able to replicate 
these inversion-effects for CamKIIα- or DAT-driven lacZ expression, and in a separate cohort of 
CamKIIα-driven lacZ expressing mice only observed an altered PPF response already two months 
after induction. Testing of a second cohort of DAT-driven lacZ expressing mice revealed merely an 
increased ASR-I/O response for Cre-positive mice compared to littermates 12 months after induction, 
but overall no group differences regarding PPI/PPF responses. Nonetheless, also for these additional 
cohorts and repeated startle-tests we observed again an age dependent change in PPF responses for 
CamKIIα- and DAT-groups, albeit independent of lacZ expression.  
Aside from the altered ASR-I/O and PPF responses following DAT-driven lacZ expression, the main 
findings for these mice were a decreased OF activity, an improved WCM performance and an 
increased dorsal HPC volume. Although VTA/ SN manipulation (via lacZ expression) and decreased 
mobility in the OF easily prompt a connection to motoric disorders, training on the rotarod as well as 
their impeccable performance in the WCM indicate that these mice in fact do not exhibit motoric 
deficits. Rather, the decreased activity in the OF could point towards a decreased motivation to 
explore their environment. This, in turn, would again be in accordance with VTA-amygdaloid 
dysfunctions as e.g. observed for early stages of Parkinson’s disease and further highlights the close 
functional relationship between VTA and amygdala as well as the importance of the symptom cluster 
of depression/ apathy with respect to PD (Borowski and Kokkinidis, 1996; Lieberman, 2006; Bennett 
and Thomas, 2014; Berg et al., 2014; de la Riva et al., 2014). 
Likewise, the decreased motivation to explore a new environment could also account for the 
observed increased freezing levels for i-R26R:DAT-Cre+ mice in the novel environment before the 
presentation of the conditioned tone. Considering that this freezing response was measured 24 h 
after FC it should not represent an increased generalized fear response (Pamplona et al., 2011). 
Although heightened generalized fear after fear conditioning has been reported following the 
disruption of VTA dopaminergic signaling (Zweifel et al., 2011), we observed no differences for DL 
behavior, and therefore conclude that DAT-lacZ expression might alter motivational behavior 
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(possibly via NAcc modulation), but most likely does not induce a heightened anxiety-related 
phenotype. 
As mentioned above, MEMRI revealed a volume increase for the dorsal HPC four months and a 
volume increase for the ventral HPC 20 months after lacZ induction for these mice. The increased 
dHPC volume might be related to the improved WCM performance observed for DAT-lacZ expressing 
mice, although this improvement was only visible for the second week of training (i.e. reversal 
training) at the initial testing-time point, which is generally more closely associated to a heightened/ 
improved activity of the PFC, rather than the dHPC (see above SAVA-2 and (Baker and Ragozzino, 
2014)). However, VTA dopaminergic neurons project to both HPC and the PFC and might therefore 
also influence PFC activity (Sesack and Carr, 2002). Moreover, the nucleus accumbens (NAcc) also 
receives dopaminergic input from the VTA and has, in turn, been shown to not only integrate PFC 
and HPC activity, but also to additionally modulate their activity via dopamine release (Chronister et 
al., 1980; Grace et al., 2007; Goto and Grace, 2008). Along the lines of the previously mentioned 
hypothesis that early-time point lacZ expression over-excites affected neurons, VTA-lacZ expression 
could therefore result in an over-activation of the PFC, either directly or indirectly via the NAcc, 
which could be beneficial for the reversal learning of a spatial strategy. Regarding the improved 
performance of i-R26R:DAT-Cre+ mice in the WCM at the second test-time point (i.e. 12 months post 
induction/ 16 months of age), the successful recall or re-acquisition of the spatial learning task would 
in fact require a well-functioning HPC (see above SAVA-1, SAVA-3 and SAVA-Muscimol). Since we 
have not established a timeline how long the proposed lacZ-induced over-activation persists, it is 
feasible, that lacZ-expressing VTA neurons still enhance the activity of either HPC or NAcc (or both) at 
this later time point and therefore again improve the WCM performance of DAT-lacZ expressing 
mice. However, at 12 months post induction we did not observe a dHPC volume increase, rather we 
observed a decrease in cortex-signal-intensity for this time point (cf Fig. R-45).  
The MEMRI signal-intensity measurement is used to gauge the activity level of a given brain structure 
as the signal intensity is proposed to increase with increasing neuronal activity of a chosen target 
area (Grünecker et al., 2013). Furthermore it has been previously shown via local knockdown of 
Cav1.2 channels (L-type voltage-gated calcium channels) or toxic disruption of axonal transport that 
manganese is actively and anterogradely transported through the axon and most likely accumulates 
in the axon terminals (Sloot and Gramsbergen, 1994; Langwieser et al., 2010; Bedenk, 2014). 
However, although it has also been shown that both Cav1.2 channels as well as N-Methyl-D-aspartate 
receptors (NMDAR) account for a large portion of manganese uptake and thus MEMRI signal 
intensity (Itoh et al., 2008), it is still not conclusively resolved how MnCl2 is transported through the 
CNS, and is therefore difficult to ascertain whether a higher signal intensity indeed equals a higher 
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neuronal activity in that specific location, or whether it in fact represents a decreased neuronal 
activity. In either case, given the proposed accumulation in the axon terminals, both scenarios would 
additionally imply that a change in MnCl2 accumulation and thus in MEMRI signal intensity for a 
specific region of interest might not necessarily reflect an activity change for that specific region, but 
rather would represent the activity change of a neuron, the soma of which might be located 
elsewhere. Given these complex characteristics of MnCl2 accumulation and –transportation, Figure D-
1 is trying to illustrate the two contradictory possibilities of MEMRI-signal interpretations: depending 
on the transport of MnCl2 throughout the CNS, it is possible that (a) high neuronal activity in location 
A would increase the accumulation of MnCl2 (i.e. signal intensity) in that active neuron (most likely in 
the axon terminal, see above), whereas low neuronal activity would result in low MnCl2 accumulation 
(Fig. D-1a). Conversely, it is also feasible, that (b) due to high neuronal activity in neuron A, MnCl2 
would be transported out of the nerve terminals to a larger extent than for low neuronal activity, and 
thus high neuronal activity would in fact result in low MnCl2 accumulation and low neuronal activity 
would lead to higher MnCl2 accumulation (Fig. D-1b). Moreover, in either case the activity level of an 
intermediate neuron B might be unaffected itself, but due to its proximity to the axon terminals of 
neuron A or B, the MEMRI signal intensity in that location might be altered and subsequently 
misinterpreted as a change in the neuronal activity of neuron B.    
 
 
Fig. D-1: MEMRI Signal Intensity contemplation: scheme illustrating different levels of MnCl2 accumulation. (a) high 
neuronal activity for neuron A increases MnCl2 accumulation in terminal of neuron A (and thus increases MEMRI signal 
intensity), whereas there is lower activity and subsequently less accumulation for neuron C; (b) conversely, high neuronal 
activity in neuron A lowers MnCl2 accumulation in nerve terminal of neuron A, and low activity of neuron C leads to 
increased MnCl2 accumulation. The activity of intermediate neuron B might be unchanged in either case, but MnCl2 signal 
intensity at this location could be altered due to the activity changes of adjacent neurons. MnCl2 = manganese-chloride. 
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Given the improved WCM performance of i-R26R:DAT-Cre+ mice 12 months after lacZ-induction and 
the undoubted involvement for the dorsal cortex (i.e. visual- and somatosensory cortex) for this task, 
a decrease in signal intensity for that area at that time point might in fact point towards the second 
explanation, wherein high neuronal activity equals low MEMRI signal intensities and vice versa. 
Likewise, lacZ expression in CamKIIα-positive neurons resulted in increased tone-fear memory 
responses four months after induction, which I previously ascribed to hippocampal over-activation 
due to lacZ expression, and this also coincides with a decrease in HPC MEMRI signal intensity at this 
time point. Thus it seems likely that in fact a decrease in MEMRI signal intensity represents an 
increase in neuronal activity for that area. 
However, we did not observe differences in MEMRI signal intensities for adult-induced glutamatergic 
lacZ expression- neither for the cortex nor the HPC; therefore it is not possible to conclusively 
interpret these results across test-groups based on the current data. 
 
The structural data acquired by MEMRI were only slightly more consistent across test groups. 
Constitutive glutamatergic lacZ expression caused a 30 % reduction of HPC volume, whereas 
constitutive GABAergic lacZ expression did not cause HPC volume changes. However, this can be 
accounted for by the differential distribution of glutamatergic vs. GABAergic neurons throughout the 
HPC. There are approximately ten-times more glutamatergic than GABAergic neurons in the dorsal 
HPC and still about five-times as many glutamatergic compared to GABAergic neurons in the ventral 
HPC (Jinno and Kosaka, 2010). Additionally, the previous investigation of constitutive glutamatergic 
lacZ expression via Golgi staining revealed an apparent decrease in dendritic arborization in the HPC 
of these mice, which would at least partially account for the observed hippocampal volume loss 
(Reichel, 2011). Moreover, this apparent contradicting consequence of glutamatergic vs. GABAergic 
lacZ expression might result from the involvement of glutamatergic, but not GABAergic, neurons in 
adult neurogenesis in the SGZ of the HPC. In other words, adult neurogenesis in the HPC generates 
glutamatergic but not GABAergic neurons. Yet, lacZ expression in glutamatergic neurons might 
selectively interfere with this process, which in turn could result in a volume decrease for these mice 
(Hevner et al., 2006; Hodge et al., 2012). Furthermore, although the decrease of hippocampal 
dendritic arborization has been previously reported, particularly in the context of increased stress 
levels, it has also been shown that neuronal dendrites account for approximately 26 % of grey matter 
and thus even a total loss of dendritic processes could most likely not account for the hippocampal 
volume loss of ca. 30 % as observed following constitutive glutamatergic lacZ expression (Vyas et al., 
2002; Kassem et al., 2013). Thus, this severe hippocampal volume loss might in fact represent the 
cumulative consequences of a heightened number of glutamatergic and therefore affected neurons 
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in the hippocampus (compared to the number of GABAergic interneurons in the HPC), impaired adult 
neurogenesis and decreased dendritic arborization. Additionally, developmental deficits due to the 
early activation of the Nex-promoter cannot be excluded. 
Especially when comparing these consequences of constitutive glutamatergic lacZ expression with 
the adult-induced effects, additional developmental mechanisms appear likely, since adult-induced 
lacZ expression only caused a HPC volume decrease of approximately 8 % (cf Fig. R-8b vs. Fig. R-
23e4).    
However, although adult-induced glutamatergic lacZ expression in the HPC caused a volume 
decrease, adult-induced CamKIIα-driven lacZ expression did not affect HPC volume four months after 
induction (although clearly present in the HPC (Fig. R-26)), but instead resulted in an increased cortex 
volume, where we also observed CamKIIα-driven lacZ expression. Similarly, adult-induced DAT-driven 
lacZ expression increased VTA volume four months after induction. Thus, the location where lacZ is 
expressed is directly structurally affected by it, although again in a distinct fashion for CamKIIα vs. 
glutamatergic HPC neurons. This is most likely again due to the involvement of glutamatergic, but not 
CamKIIα-positive, neurons in adult neurogenesis (see above). In order to determine whether the HPC 
volume loss after adult-induced glutamatergic lacZ expression is indeed the result of a decreased 
number of neurons and/or decreased dendritic arborization, further stereological and histological 
(i.e. Golgi staining) analyses will be necessary.  
Alternatively, the initial volume increase for lacZ expressing structures in i-R26R:CamKIIα-Cre+ and i-
R26R:DAT-Cre+ mice might in fact be due to different stages of inflammatory processes as observed 
for e.g. hepatocytes following lacZ expression (Akagi et al., 1997). Thus, these structures should be 
further analyzed regarding the (aberrant) presence of inflammatory markers (e.g. cytokines or 
microglia). 
In contrast, partially based on the previous proteomics results for constitutive glutamatergic lacZ 
expression, and partially guided by the behavioral alterations specific to adult-induced glutamatergic 
lacZ expression, (i.e. decreased contextual fear memory), as well as our original hypothesis regarding 
neurodegenerative mechanisms due to lacZ expression, we focused our protein analysis of 
hippocampal punches from adult-induced glutamatergic lacZ expressing mice on the structural 
marker actin, the learning and memory-related Calcineurin (PP2B) and CDK5 as well as the 
neurodegenerative/cell-death-related apoptosis-inducing factor (AIF) and PP1β (Mansuy et al., 1998; 
Garcia et al., 2003; Lopes and Agostinho, 2011; Cheung and Ip, 2012). Unfortunately, we were unable 
to detect any differences in protein levels between adult-induced glutamatergic lacZ expressing mice 
and their Cre-negative littermates. Nevertheless, this in fact further supports the probable 
inflammatory mechanisms involved in structural and behavioral alterations. This holds particularly 
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true, considering the number of studies investigating the aging process and neurodegenerative 
diseases that have highlighted the involvement and the consequences of aberrant immune-system 
activity and increased cytokine- and microglia levels with respect to the development of cognitive 
deficits and other behavioral alterations (Dantzer et al., 2008; Dilger and Johnson, 2008; Villeda and 
Wyss-Coray, 2008; Zhang et al., 2013). Bearing in mind the specific location of β-Gal accumulation in 
the cells, i.e. in the neuron-soma close to the nucleus (cf Fig. R-16), it is possible that this evokes a 
cellular rescue-response ultimately resulting in increased inflammatory responses, as it has been 
similarly reported for AAV9-mediated transfection (Ciesielska et al., 2013). However, since we have 
not further investigated the mechanisms behind the volume alterations this remains highly 
speculative. Nevertheless, we observed a mostly dendritic accumulation for GFP expression (cf Fig. R-
11), as opposed to the soma-exclusive lacZ location, which could further explain why lacZ-, but not 
GFP-, expression results in such severe and detrimental consequences for the structural and 
behavioral phenotype of the analyzed mice.  
Future western blot studies investigating adult induced glutamatergic lacZ expression should first 
verify the differentially expressed proteins as detected by proteomic analysis for constitutive 
glutamatergic lacZ expression (i.e. HSP60, FACP and LDH), and then attempt to ascertain whether 
there are indeed increased levels of inflammatory markers present. Subsequently, any findings could 
and should once more be verified for e.g. VTA micro-punches of DAT-driven lacZ expressing mice or 
HPC micro-punches of CAMKIIα-driven lacZ expressing mice. However, since glutamatergic and 
CamKIIα-driven lacZ expression already resulted in diverging effects regarding their (cognitive) 
behavior and HPC volume, the results of protein analyses for these two lines might also be 
contradictory. One additional approach to ascertain the cellular and molecular consequences of lacZ 
expression could also be a TUNEL assay. The TUNEL (terminal deoxynucleotidyl transferase dUTP nick 
end labeling) method labels apoptotic cells (Kuang et al., 2014), and could thus further indicate 
whether lacZ is indeed a cellular toxin ultimately leading to cell death. However, while glutamatergic 
lacZ expression always resulted in a volume reduction of HPC, CamKIIα- or DAT-driven (adult-
induced) lacZ expression coincided with volume increases in cortex and VTA, respectively. A volume 
increase is contradictory to an increased apoptotic cell death, but would be in line with increased 
necrotic cell death (Barros et al., 2001). 
Nonetheless, the (speculative) hypothesis that lacZ expression causes an inflammatory response is in 
fact consistent with our original hypothesis that lacZ expression might induce neurodegenerative-like 
effects. A number of studies have previously reported inflammatory and infectious-like mechanisms 
involved in neurodegenerative disease etiology (Perry et al., 2007; Dilger and Johnson, 2008; De 
Chiara et al., 2012). Moreover it has been suggested that, similar to prion-disease progression, 
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neurodegenerative diseases such as AD or PD also underlie infectious disease mechanisms that cause 
for instance the spread of lewy bodies or a-beta plaques throughout the brain (Luk et al., 2012b; Luk 
et al., 2012a; Morales et al., 2012).   
Regardless of inflammatory mechanisms we observed markedly diverging consequences of 
constitutive vs. adult-induced glutamatergic lacZ expression. When comparing the expression 
patterns for these two lines, we observed notable differences regarding extent and intensity (i.e. 
amount) of lacZ signal (i.e. X-Gal staining). This vast variance between constitutive and adult-induced 
activity pattern of many gene-promoters has been observed before (Montoliu et al., 2000). However, 
the conclusion of Montoliu et al. (2000) was that due to the decreased adult-induced promoter 
activity and subsequently decreased lacZ signal, this transgenic manipulation approach should be 
predominantly employed for developmental studies and hence advertised the use of constitutively 
expressing Cre-driver lines. Based on our findings we cannot concur and strongly discourage the use 
of constitutive Cre-driver lines that facilitate lacZ expression.     
The tamoxifen-induced CreERT2 system has been under investigation as well, and while tamoxifen-
treatment itself was found to have negligible consequences for the behavioral phenotype of mice 
(Vogt et al., 2008), CreERT2 expression and the inherent Cre-translocation have been found to 
significantly affect the phenotype of mice, sometimes even before tamoxifen treatment  (see above 
and (Giusti et al., 2014)). 
Concerning our initial hypothesis that lacZ expression might induce a prematurely aged phenotype 
involving accelerated neurodegenerative mechanisms and cognitive decline, we have to admit that 
there is no unequivocal answer. We only found obvious cognitive deficits following constitutive 
glutamatergic lacZ expression and minor cognitive deficits for constitutive GABAergic and adult-
induced glutamatergic lacZ expression. The consequences for constitutive expression are almost 
certainly – at least partially –  attributable to the developmentally early activation of both promoters, 
and thus the early interference of lacZ with the normal cellular function (Liu et al., 1997; Schwab et 
al., 1998; Eisenstat et al., 1999; Stühmer et al., 2002). The adult-induced effects in turn are most 
likely closely related to impaired neurogenesis (Clelland et al., 2009; Deng et al., 2010; Burghardt et 
al., 2012). 
In striking contrast to constitutive expression of lacZ in glutamatergic and GABAergic neurons, adult-
induced lacZ expression for CamKIIα- or DAT-positive neurons rather enhanced than impaired 
cognition. Interestingly, improved cognitive abilities have in fact also been reported for prodromal 
Huntington’s disease patients and have been linked to glutamatergic over-activation, i.e. excitotoxic 
mechanisms (Beste et al., 2012). This once again supports the hypothesis that lacZ expression 
increases the activity of affected neurons at early expression time points and thus facilitates 
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cognitive enhancement. Moreover, progressed age also did not negatively affect the cognitive 
abilities of lacZ- expressing mice compared to Cre-negative littermates. The age-dependent 
behavioral alterations we observed were concomitant for both genotypes: overall decrease of 
acoustic startle responses and decreased locomotor activity. We also found an age-dependent, but 
genotype-independent body weight gain for all test cohorts accompanied by increasing whole-brain 
volumes. While similar findings regarding body weight and whole brain volume increase have been 
previously reported, it has also been described that the hippocampal volume increases in parallel to 
the whole brain volume, and merely the percentage of neurons compared to e.g. glia cells in the HPC 
decreases beginning at the end of adolescence (Mortera and Herculano-Houzel, 2012). However, in 
contrast, our results indicate that relative hippocampal volume (i.e. normalized to whole brain 
volume) is largely unaffected by age, considering that if whole brain mass increases but HPC volume 
remains the same, relative HPC volume appears decreased (cf Fig. R-33c1-c3 and Fig. R-45b1-b3).  
Since we did not further decipher whole brain and HPC volume changes, it might also be possible 
that HPC volume marginally decreases over time. Yet, whether this is due to a de facto decrease in 
neuron-number as described in Mortera and Herculano-Houzel (2012), an overall cell loss in HPC or 
in fact represents a changes in e.g. dendritic arborization cannot be resolved based on our data. 
Nonetheless, particularly a volume loss for HPC has been previously described in the context of aged 
rodents as well as for aged humans and has been especially reported as a consequence to 
Alzheimer’s disease (Fjell and Walhovd, 2010; Fjell et al., 2014). 
Similarly, age-dependent decreases of locomotor activity and decreasing responses to acoustic 
stimuli have been observed across species (Brooks and Faulkner, 1994; Ludewig et al., 2003; 
McFadden et al., 2010). 
As mentioned above, one possibly genuine lacZ x age interaction might have been the switch in PPF 
responses for both CamKIIα- and DAT-driven lacZ expression between 8 and 16 months of age (i.e. 4 
and 12 months post lacZ induction). However, we were unable to replicate this finding and can 
therefore not conclusively interpret these effects. Additionally, both age-dependent U-shaped 
responses of PPI/ PPF have been reported (similar to our findings), but also age-independent PPI/PPF 
responses have been described, further complicating the interpretation of the observed altered PPF 
responses coinciding with prolonged lacZ expression (Ellwanger et al., 2003; Ludewig et al., 2003). 
Interestingly, all animals tested for the acoustic startle response and PPI/PPF at the age of 24 months 
(independent of genotype) displayed a nearly non-existing startle response and subsequently also 
displayed no discernible PPI/PPF responses. Since the same mice clearly responded to a 9 kHz tone 
during fear conditioning at the same testing time point, we can exclude that the mice were deaf. 
However, startle impulses consist of white noise bursts, which might be differentially processed, 
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compared to the 9 kHz tone. Furthermore, aged mice presented with increased bodyweight, thus 
possibly confounding the results measured by the piezoelectric sensor, i.e. due to their increased 
bodyweight, baseline responses might have already been increased and the non-existent response-
increase to the acoustic stimuli might therefore represent a ceiling effect. Lastly, the acoustic startle 
response is a reflex mediated by a distinct neuronal network (Koch, 1999), the connectivity and 
activity of which could be degraded as a function of time and age. 
Regarding the absence of age-dependent cognitive deficits, one mediating factor might have been 
the repeated testing, which on the one hand decreases anxiety levels of the animals. On the other 
hand it does not allow, for instance, for genuine de novo acquisition analyses in the WCM, since the 
animals had previously learned to navigate the set-up. Although animals never performed as well on 
the first day of a new test point as they did the last day of the previous test point, they also never 
again performed as “badly” as on the very first day of WCM training. Thus indicating that the mice in 
fact remembered the set-up and therefore did not need to acquire again the entire procedure, but 
rather “refresh” their memory. Furthermore, repeated testing can be equated to a cognitively active 
and trained life-style for humans, which in turn has put forward the theory of cognitive reserve 
(Stern, 2012; O'Shea et al., 2014). This theory states that if neuronal networks are continuously used 
throughout the life time, and thus are trained, they are less likely to degrade with age and therefore 
constitute additional neurons that are functional in age. In combination with the previously stated 
theory that lacZ expression (over-) activates affected neurons, this could in fact represent a cellular 
training effect at early expression time points, thus prepare and support the survival of the neurons 
in age and hence mask age-dependent cognitive decline. Moreover, we did not investigate prolonged 
adult-induced glutamatergic lacZ expression. Given their cognitive deficits (i.e. decreased contextual 
fear memory) at the early testing time point, these mice might in fact develop more pronounced 
deficits in age and present with additive impairments. However, these effects might again only be 
visible if the animals are not repeatedly tested, since repeated testing, in addition to building a 
cognitive reserve, could also constitute an “enriched environment”. Enriched environments in turn 
have been shown to increase neurogenesis and subsequent survival of the newborn neurons and 
thus once again could mask the lacZ-expression- or age-dependent negative consequences on 
cognitive abilities (Kempermann et al., 1997; Kempermann et al., 1998). 
Finally, given the failure to replicate our findings for DAT- and CamKIIα-driven adult-induced lacZ 
expression in independent cohorts, we also have to consider a statistics-dependent analysis-error, 
known as “α-error inflation”. Given a p-value of 0.05, five out of 100 tests (i.e. 5 %) will erroneously 
result in a significant difference between test groups, even if there is no “real” biologically significant 
difference. Given the large number of analyses for the same test group (i.e. the repeated testing of 
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DAT- and CamKIIα-driven adult-induced lacZ expression until the age of 24 months), we cannot 
exclude that some of the reported significant findings are in fact based on α-inflation. This in turn 
could explain why we failed to replicate some of the findings in independent cohorts. Conversely, it 
underlines the extreme spatial learning impairments we observed following constitutive 
glutamatergic lacZ expression, as we were able to replicate this finding in three independent cohorts 
(see above and (Reichel, 2011)). This statistical limitation could be minimized by defining a stricter p-
value of e.g. 0.01. In this case only one out of 100 tests would result in a “false-positive”. However, 
this in turn increase the number of β-errors, i.e. the number of unrecognized biologically relevant 
differences, e.g. due to a too small number of animals per group. In either case, we cannot exclude 
statistical errors concerning the failure to reproduce certain (previously) significant findings.  
 
In summary, neither the expression of Cre nor of CreERT2, nor of the widely used transgenic reporter 
protein lacZ are inert. Constitutive lacZ expression causes severe, most likely developmentally 
mediated, behavioral and structural alterations specific to the Cre-driver line. These effects can also 
be partially induced in adulthood but do not necessarily cause cognitive deficits. Therefore lacZ 
expression appears to be developmentally toxic and possibly changes the activation patterns of 
affected neuron when its expression is induced in adulthood. Moreover, lacZ expression might result 
in aberrant inflammatory responses leading to structural alterations that should be further 
investigated. However, lacZ expression does not appear to cause general additive age-related 
impairments, but seems to differentially affect startle and PPI/PPF responses over time.  
Thus, lacZ expression does not represent a reliable new approach to generate novel 
neurodegenerative-related or prematurely-aged-like mouse models displaying cognitive 
impairments. However, lacZ expression is nonetheless certainly not suitable as a “silent” marker to 
visualize a given transgenic manipulation. In general, all transgenic models and manipulations should 
be carefully controlled (for), in order to avoid similarly unaccountable results as Bennett et al. (2009) 
described for faulty (ex vivo) imaging analyses in e.g. salmons (Bennett et al., 2009).  
Finally, the specific function of the mammalian senescence-associated β-Gal is still not conclusively 
resolved and it is not known whether it is actively involved in developing a senescent cellular 
phenotype or whether it is a passive consequence of age-related lysosomal expansion (Dimri et al., 
1995; Lee et al., 2006; Geng et al., 2010; Kuilman et al., 2010). Thus, its bacterial analog which is 
coded for by the lacZ sequence might in fact not be connected to senescence-related processes at all, 
but exerts its consequences due to its exogenous expression: lacZ is not supposed to be expressed in 
(mouse-) neurons and thus alters the cellular functionality simply because it is present (Ciesielska et 
al., 2013). 
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4.3. Project (iii) PTSD & Age 
 
Project (iii) PTSD & Age investigated the cumulative effects of life-time environmental stressors on 
the cognitive abilities of mice in age. The animals received one or two trauma-like stressors at five or 
12 months of age, respectively. Subsequently, their short-term memory and spatial learning abilities 
were assessed at the age of 14 to 16 months of age. As the initial stressor we employed an 
established procedure of two foot shocks of 1.5 mA conditioned to a 9 kHz tone that has been shown 
to induce PTSD-like behavioral traits, i.e. hyper-arousal as well as increased contextual and 
generalized fear responses (Siegmund and Wotjak, 2007; Pamplona et al., 2011). Indeed, the mice 
displayed a strong PTSD-like phenotype one month after shock application. The second stressor was 
an etiological relevant “earthquake-like” procedure that has been shown to induce lasting stress-
responses (mouse shaker stress; MSS (Bernatova et al., 2002; Farinelli et al., 2012)), and we did in 
fact observe heightened corticosterone levels in the blood of the test-animals following MSS, 
confirming the stressful nature of this procedure (Hashiguchi et al., 1997). One month after MSS 
animals underwent again anxiety- and PTSD-related phenotyping and we found an increased anxiety-
like phenotype for all stressed mice and a particularly strong effect for doubly stressed mice. 
Furthermore, even without intermittent trauma reminders, contextual- and tone-fear responses of 
shocked mice were still increased upon re-exposure to the shock context or the conditioned stimulus 
(i.e. tone) compared to non-shocked animals; thus representing a persistent fear memory. However, 
we did no longer observe hyper-arousal for these mice, indicating a strong memory-trace rather than 
persistent fear. Moreover, the lasting (fear) memory was displayed by all previously shocked mice, 
independent of the additional MSS procedure. Subsequent short-term memory and spatial learning 
testing revealed no overt cognitive difference between groups. Nevertheless, we found a number of 
interesting correlations between the initial contextual fear responses (i.e. one month after shock 
application) and the performance in the WCM for doubly stressed mice. Although these correlations 
were not blatantly obvious, their specificity (i.e. only for twice-stressed mice) and their within 
consistency (i.e. one month contextual- and tone freezing correlated with WCM learning score day 1 
to day 7 and one month contextual freezing correlated with WCM recall accuracy day 1) indicate a 
distinct relationship between initial freezing levels and later-in-life cognitive performances. Given the 
distribution regarding the intensity of initial freezing responses, the correlative relationship regarding 
freezing levels and WCM performance could furthermore hint at inherent stress-susceptibility and 
stress-resiliency endophenotypes (Zannas and West, 2014). The distinction of stress-susceptibility 
and –resiliency is used to describe why for instance only approximately 10 % of trauma-exposed 
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people develop PTSD (Breslau et al., 1991; Kessler et al., 1995; Santiago et al., 2013). There are 
several factors mediating an individual’s stress-susceptibility, including genetic predispositions, 
epigenetic, developmental and environmental factors (Cohen et al., 2007; Ressler et al., 2011; 
Schmidt et al., 2011; Marquez et al., 2013; Zannas and West, 2014). Depending on the constellation 
of these mediating factors one is proposed to be able to cope better or worse with heightened stress 
levels. Additionally heightened stress-vulnerability has in fact been linked to prematurely aged 
phenotypes (O'Donovan et al., 2013). Although C57Bl/6N mice (i.e. the strain used for this 
investigation) constitute an in-breed strain and all mice were reared and housed under the same 
conditions, considering the epigenetic contributions it is quite likely that there were stress-
susceptible and –resilient mice present across all test-groups (i.e. also for non-shocked mice). 
However, only upon exposure to a second stressor this distinction became behaviorally evident. This 
is further supported by the fact that the distribution regarding the initial fear response was measured 
before MSS was performed. Therefore, a distribution of stress-susceptibility and –resilience can be 
observed after one stressor, and a behavioral consequence of this distribution can be observed after 
an additional stressor. Moreover, it is feasible that we would have observed stronger behavioral 
consequences after two stressors, if the mice had been even older at the testing time-point, thereby 
possibly evoking stronger additive effects of age and trauma exposure.  
Furthermore, although we did not observe a cognitive deficit for one- or two-time stressed mice in 
the novel object recognition test, we did observe the strongest negative discrimination index for 
doubly stressed mice, which means that these mice spent more time with the familiar as opposed to 
the novel object. This test was intentionally done without a habituation phase to the exploration 
arena and at a light level of 10 lux instead of red-light. These parameters were chosen in order to 
evoke heightened stress-levels and thus possibly foster stress-dependent cognitive deficits (Schwabe 
et al., 2010; Liston et al., 2013). While we did not observe de facto cognitive deficits, the strong 
negative discrimination index for two-time stressed mice nonetheless indicates an anxiety-driven and 
possibly novelty-fear-related effect (Misslin and Cigrang, 1986). In contrast, the slightly positive 
discrimination index for shock-only mice could represent an initial beneficial effect of a single 
stressor and bell curve-like consequences of stress-exposure (Schmidt, 2011; Santarelli et al., 2014). 
However, it could also be argued that the test itself produced sub-optimal results and which hinder a 
genuine distinction regarding cognitive performance between groups. In other words, all groups 
spent relatively little time exploring the objects at sample- and choice-time points; hence, the results 
could depict a floor-effect. Future studies perhaps should include a habituation phase to the 
exploration arena after all, and possibly “artificially” stress the animals via odor cues, e.g. spray the 
arena with 70 % EtOH (i.e. the same odor-cue as for the fear conditioning context), which should 
increase the anxiety-level of all animals but particularly affect previously shocked mice and thus 
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facilitate the investigation of additive/ heightened stress effects. Based on our results we can only 
conclude that one or two stressors most likely do not result in lasting short-term memory 
impairments, but two stressors might increase novelty-fear-related behavior. 
Considering the bell curve-like consequences of stress exposure, the mice here have been 
intentionally exposed to the stressor at a time point of solidified adulthood. This time point 
eliminates early-life stress-related influences and the persistent anxiety-related phenotype is thus in 
accordance to the “mismatch-hypothesis” (Schmidt, 2011; Santarelli et al., 2014). This hypothesis 
states, across species, that if exposed to heightened stress levels early in life, the individual will be 
able to cope better with equally heightened stress levels later in life. However, if the individual is 
sheltered from stress early on but exposed to extreme stress later in life, he/she will not be able to 
cope as well. Thus, it would be interesting to analyze whether the here employed stressors, when 
applied at an earlier time-point, would still result in such strong and lasting anxiety-like phenotypes. 
In summary, PTSD-relevant stressors applied in adulthood induce strong and long-lasting trauma-
related fear memories that are distributed according to stress-susceptibility levels. An additional 
environmental stressor furthermore induces a lasting heightened anxiety phenotype that 
subsequently might affect the performance in a short-term memory task and appears to modulate 
the acquisition of a spatial learning paradigm.  
 
4.3.1. Cognitive performance in age: a remembrance of (stressful-) things passed? 
 
The fact that we did not observe a discrete cognitive decline as a consequence to one or multiple 
stressors is in line with previous studies, as for instance PTSD patients do not commonly present with 
major cognitive impairments, and rather display attention- or task switching deficits (Brandes et al., 
2002; Qureshi et al., 2011). In contrast, the fact that we failed to observe cumulative stressor x age-
related cognitive decline is most likely due to the study design, as many studies have previously 
reported a close connection between mood disorders and accelerated cognitive decline in age 
(Gualtieri and Johnson, 2008; Yaffe et al., 2010; Kohler et al., 2013). Based on these studies a 
hypothesis has recently been brought forward that stress-related psychiatric disorders such as PTSD 
or major depressive disorder are in fact the first step towards neurodegeneration and 
neurodegenerative diseases, and particularly depression has been named as a major prodromal 
symptom of Alzheimer’s and Parkinson’s disease (Lieberman, 2006; Potter and Steffens, 2007; 
Gualtieri and Johnson, 2008; Tobe, 2012; Almeida et al., 2014; Bennett and Thomas, 2014; Berg et 
al., 2014; de la Riva et al., 2014). Furthermore, other neuropsychiatric disorders such as 
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schizophrenia have also been associated to a prematurely aged phenotype and additive cognitive 
decline (Anthes, 2014). 
With regards to our study and considering the average life span of 24 months for mice, testing at 14- 
16 months was most likely too early (Yeoman et al., 2012), although cognitive decline and structural 
alterations have also been observed for middle-aged men and mice (Mortera and Herculano-Houzel, 
2012; Ferreira et al., 2014). Moreover, while it has been shown in humans that life-time stress 
exposure and neuropsychiatric diseases such as depression increase the risk of cognitive deficits 
related to neurodegeneration in age (and vice versa; see above), this has not been sufficiently 
replicated in mice. Thus, while future studies aiming to investigate the relationship of stress exposure 
and cognitive abilities in age can rely on the lasting effects of the stressors as shown here, it would 
be advisable to analyze cognitive abilities at later test points and possibly employ additional short-
term memory test, e.g. via spontaneous alternation in the T- or Y-maze in order to distinguish 
anxiety-mediated performance differences and genuine cognitive decline (Deacon and Rawlins, 
2006). Furthermore, an additional confounding factor of our study might again be the repeated 
handling and testing, as mentioned for repeated testing of lacZ expressing mice (see above). 
Repeated testing might have once again constituted an enriched-environment-like effect, thus 
increased neurogenesis and therefore masked subtle cognitive effects (Kempermann et al., 1997; 
Burghardt et al., 2012). However, since the phenotype of the animals has to be assessed in order to 
determine whether they e.g. indeed display a PTSD-like phenotype, this confounding factor might be 
difficult to control for. 
Additionally, the mice of this study have been group housed, which has also been shown to affect 
cognitive and general behavior of mice (Kulesskaya et al., 2014), thus, future studies might control 
for these effects by employing group- as well as singly housed animals.  
Moreover, it would be interesting for future studies to investigate the effects of cognitive reserve on 
stress-induced accelerated cognitive decline. As mentioned above, cognitive reserve describes the 
beneficial effects of cognitive training throughout the life span on late-in-life cognitive abilities, due 
to a proposed strengthening and thus compensatory or even protective effect of continuous 
neuronal activity against age-related neuronal loss and cognitive decline. However, it has also been 
stated that once a certain threshold of neuronal loss is crossed, no amount of training can 
compensate the functional loss. Additionally, the more cognitively trained and active an individual is 
throughout life, the more apparent the cognitive decline in age becomes (Stern, 2012; O'Shea et al., 
2014). Thus, for instance, animals could be trained in several cognitive tasks throughout their (early) 
life-span and at middle age be exposed to extreme stressors. Subsequently the mice could be 
assessed in different (i.e. new) cognitive tasks at aged time points and their performance could be 
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compared to animals that did not receive cognitive training prior to the stressor. Any potentially 
improved performances for previously trained animals could be ascribed to protective “cognitive-
reserve-like” effects and could be verified e.g. either histologically or via imaging techniques (Grady, 
2012). 
Here, we observed different (minor) deficit-levels regarding the performances in NOR and WCM that 
can be accounted for by the varying predominant involvement of different brain structures for each 
test. For instance, the HPC is intricately involved in spatial learning (O'Keefe, 1976; Morris, 1984; 
Ferbinteanu et al., 2003; Foster and Knierim, 2012), whereas the PFC is additionally closely 
associated with short-term memory abilities (Euston et al., 2012). Both HPC and PFC are major hubs 
for the feedback control of the HPA axis (Sapolsky et al., 1986; Sapolsky et al., 2000; Wingenfeld and 
Wolf, 2011) and their functionality can thus be affected by increased stress levels. Increased anxiety 
levels during NOR can be relatively easily attenuated by the animals themselves by displaying a bias 
towards the familiar object. In contrast, due to the exposure to water the incentive to quickly find 
and reach the platform in the WCM is much stronger and cannot be this easily (actively) modulated 
by the mice themselves. Thus, anxiety-related performance deficits, as opposed to de facto cognitive 
impairments, are most likely easily masked during WCM training, due to the inherent requirements 
and strong motivational aspects of this set-up. 
Nonetheless we can conclude that cognitive performances in age are modulated – to an extent – by 
life-time (stressful) events. However, the specific consequences of the stressors on cognitive abilities 
depend on a number of variables, including time point and frequency of stress (cf mismatch), genetic 
predispositions, cognitive activity throughout the life-time and the specific time point of testing 
(cognitive reserve) as well as the inherent stress-susceptibility of mice and men. In particular the 
level of individual stress-susceptibility is of high interest and impact on todays research as the 
etiology of many neuropsychiatric disorders have been closely linked to individual stress-vulnerability 
(de Kloet et al., 2005).Given the increasingly stressful life-style of many western civilizations as well 
as the increasing life-span of the human population and the seemingly inevitable age-related 
cognitive decline, the possibilities of cognitive reserve and possible protective mechanisms against 
the consequences of stressful life-events should be of the utmost priority among neurobiological 
investigations.  
While we were not able to detect obvious cognitive deficits in middle aged mice after severe stress 
exposure, we could show that the stressor itself causes lasting anxiety-related effects and multiple 
stressors at least interact with cognitive performances in age. Thus, if refined, this approach might in 
fact be very useful for future studies regarding the cognitive abilities of stressed and (appropriately) 
aged mice. 
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4.4. Behavioral testing in mice- the proper tests for complex questions? 
 
Behavioral testing in animal studies is a broad and varied field that can reveal tremendous new 
insights into neurobiological mechanisms or be easily and grossly misinterpreted. Thus it is important 
to know and control the many confounding factors of behavioral test and analyze them without bias 
(Sousa et al., 2006). 
For instance in the case of the above described studies the general activity level of the mice was 
always assessed by using the open field test under red-light conditions. By doing this e.g. altered 
frequencies to enter the light side in the dark-light box test or altered freezing levels in a novel 
context before tone presentation could be either accounted for (i.e. these changes were due to 
changes in general activity levels) or be recognized as genuine e.g. anxiety-related effects. Without 
the OF control such distinction would not be easily possible. However, when looking in particular at 
the rearing behavior observed in the OF (throughout this work), there are almost always differences 
between groups. Hence, in particular the rearing behavior appears to be a rather vulnerable 
behavioral trait in mice. Rearing has been related to exploratory, anxiety-related and in particular 
hippocampal-dependent learning and memory-related (“spatial mapping”) behavior (Lever et al., 
2006) and has been reportedly affected by hippocampal lesioning (Kleinknecht et al., 2012). Given 
the manipulation of the HPC in many test groups throughout this work either by direct lesioning 
(SAVA) or local lacZ expression/ projections of lacZ expressing neuronal populations to the HPC, this 
could in fact explain the commonly observed alterations of the rearing behavior. Moreover, many 
Alzheimer`s studies report coinciding hyperlocomotion in the OF and spatial learning deficits due to 
hippocampal malfunction (Edwards et al., 2014). Conversely, it has also been noted that OF and dark-
light testing produce rather inconsistent findings across studies and therefore have to be very 
carefully controlled and the procedure has to be minutely standardized in order to produce reliable 
results (Ennaceur, 2014).  
In contrast, regarding spatial learning abilities in the WCM it appears that only major hippocampal 
manipulations (i.e. ablation of GABAergic neurons or 30 % volume loss of the HPC), resulted in 
obvious and distinct learning impairments. Likewise, Kleinknecht et al. (2012) previously reported 
that a remaining HPC volume of merely 50% is sufficient to successfully solve the WCM. The findings 
here furthermore indicate that not just the overall volume of the remaining HPC but the functionality 
of distinct neuronal populations (e.g. GABAergic vs. glutamatergic) is important in order to acquire 
the task. Interestingly, for some test groups (i.e. adult induced glutamatergic lacZ expression) we 
observed deficits for HPC-dependent contextual fear memory, but not for spatial learning, which 
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have been similarly described for Alzheimer’s related mouse models (Gerlai et al., 2002). Conversely 
we observed the opposite effect (i.e. spatial but not contextual learning deficits) for other test 
groups (SAVA-1 long-term dorsal HPC and constitutive GABAergic lacZ expression). Since the latter 
two both constitute GABAergic manipulations this indicates a further functional distinction of 
GABAergic and glutamatergic HPC neurons, whereby, surprisingly, GABAergic interneurons appear to 
be more closely associated to spatial learning abilities and glutamatergic HPC neurons appear to be 
more closely related to contextual fear memory learning. In contrast, CamKIIα-positive hippocampal 
neurons do not appear to be closely associated to spatial learning abilities at all, as adult-induced 
CamKIIα-driven lacZ expression did not affect WCM performance. Lastly, a proposed increased input 
from DAT-positive neurons (cf initial lacZ expression might over-activate affected neurons) appears 
to have a beneficial effect on spatial learning abilities. 
However, only CamKIIα-positive lacZ expression affected (i.e. increased) tone-fear memory 
expression and thus slightly delayed extinction learning. None of the other test groups presented 
with alterations regarding tone-fear memory or extinction learning, again underlining distinct 
neuronal networks (HPC – PFC – Amygdala) and different neuronal sub-populations as the driving 
force behind different cognitive parameters. The lack of effect on tone-fear memory and extinction 
learning was especially surprising for constitutive glutamatergic lacZ expression, as these mice clearly 
presented with lacZ expression in the amygdala which is closely connected to the acquisition of a 
tone-fear memory, in particular the lateral amygdala (Roozendaal et al., 2009; Salzman and Fusi, 
2010; Ghosh et al., 2013; Bergstrom and Johnson, 2014). Therefore our results highlight the 
functional distinction of neuronal sub-populations in distinct neuronal networks – such as the 
amygdala; i.e. it appears that glutamatergic neurons in the amygdala (or the HPC) are not entirely 
indispensable concerning the acquisition and subsequent extinction of a tone-fear memory.  
 
One WCM-related observation we made for all test groups was the Accuracy-drop between the last 
initial training day and the first day of recall training- whether recall training be four days (SAVA-4 
short-term HPC; recall), two months (PTSD & Age) or eight months (lacZ) later. While this drop was 
more pronounced as a function of time, it never dropped back to the level of naïve (i.e. never before 
tested in the WCM) mice. Thus mice always remembered at least the basic requirements of the maze 
(e.g. find the platform) and therefore only had to relearn the details (where is the platform), which 
they usually also acquired faster upon repeated training than for initial acquisition. Consequently, 
although the WCM constitutes an interesting approach to assess cognitive abilities, the main 
drawback remains that it seems as if only major hippocampal malfunctions results in clearly 
discernible deficits when trained in the spatial learning paradigm. Therefore it might be worthwhile 
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to reduce extra-maze cues in order to complicate the acquisition of the platform position. However, 
it also should not be made too difficult either, as this could induce anxiety-like states which in turn 
have been shown to nearly prevent HPC-dependent learning (Packard and Wingard, 2004). 
Regarding overall behavioral testing it is also important to control for (decreased) effects due to 
repeated testing. For instance, repeated testing in the WCM for lacZ expressing lines prevented the 
analysis of de novo spatial learning in age and might thus have masked possible subtle deficits. This is 
particularly regrettable as it has been previously described that it is easier in age to assess or refine 
previously coded information than to generate or store new information, i.e. to acquire new learning 
tasks (Wilson et al., 2006). Given our study design of repeated testing in the same set-up, it is 
therefore very difficult to discern age-related cognitive decline. Moreover it has been argued that the 
HPC is primarily involved in the recall of recent memories and only to a lesser extent in the recall of 
remote memories (Maviel et al., 2004). However, in the case of remote-memory recall it has also 
been proposed that the HPC might be necessary for the renewed acquisition of task details and 
would hence once again be required for the successful task completion (Maviel et al., 2004; 
Schlesiger et al., 2013). Regardless of the specific involvement of the HPC for the recall of remote vs. 
recent memories, the HPC is a primary target for age-dependent functionality changes and it would 
therefore be very interesting to refine the study design in order to facilitate the documentation of 
age-dependent HPC-related cognitive decline.  
Furthermore, during initial testing mice are often more stressed than upon repeated testing due to 
habituation. Thus effects observed during initial testing might always be additionally strongly 
influenced by heightened stress levels and therefore result in increased performance differences 
(Magarinos and McEwen, 1995; Wingard and Packard, 2008; Packard, 2009; Schwabe et al., 2010; 
Marquez et al., 2013). Additionally, as mentioned above, repeated testing can induce cognitive-
reserve-like or environmental enrichment-like effects and thereby increase neurogenesis and mask 
or attenuate possible cognitive deficits (Kempermann et al., 1997; Snyder et al., 2011; Stern, 2012; 
O'Shea et al., 2014). Likewise it has been reported that the exposure to novel environments 
decreases contextual fear levels through a number of molecular mechanisms including e.g. NMDAR 
modulations (de Carvalho Myskiw et al., 2014). It is thus feasible that repeated testing (in the WCM 
and otherwise) not only decreases anxiety levels due to habituation or passively increases 
neurogenesis, but actively modulates hippocampal functionality. 
Therefore we can conclude that cognitive abilities can not only be externally manipulated by the 
chosen experimental approach (e.g. GABAergic lesioning, lacZ expression or environmental 
stressors), but can also be “internally” or passively modulated by e.g. the experimental set-ups (e.g. 
with or without light) or the study design (time point/ frequency of testing). Thus, while many 
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behavioral tests have been specifically developed in order to assess cognitive function and can 
provide fantastic insight into the neurobiological mechanisms underlying the specific learning 
paradigm (e.g. WCM vs. fear conditioning), it is nonetheless paramount to be aware of the “internal” 
mediating factors in order to ascertain genuine cognitive effects mediated by distinct study-related 
“external” manipulations. 
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5 Conclusion & Outlook 
 
The work presented here highlights the importance of (i) GABAergic interneurons for the acquisition, 
but not the recall of a spatial memory; and, particularly for GABAergic interneurons in the PFC, we 
underlined their close involvement in the development of Schizophrenia-related behavioral traits.  
We employed immuno-toxin-tagged antibodies to ablate GABAergic interneurons and hence did not 
model the actual disease-physiology. Nonetheless, this approach proved very useful in the analyses 
of distinct GABAergic networks and their influence on cognitive abilities. Thus this approach 
represents a valuable tool for future studies and could be used to further discern local GABAergic 
network functionality. However, it would be advisable to employ guide cannulas in order to ascertain 
distinctly GABAergic effects and possibly employ decreased injection volumes in order to prevent the 
manipulation of neighboring networks. Particularly a functional distinction of prelimbic vs. infralimbic 
GABAergic neurons would be of interest with regards to PPF and tone-fear memory. However, these 
structures might in fact be too closely connected to achieve genuinely distinct results via SAVA 
injections. A possibly better suited area might thus be the VTA or the substantia nigra. The results of 
this lesion study could then be compared to both GABAergic and DAT-driven lacZ expression, as both 
promoters caused expression patterns visible in the VTA. Additionally, it would be of particular 
interest to investigate whether a saporin-tagged glutamatergic (e.g. VGLUT) antibody-application 
(e.g. in the HPC) would result in similar effects as glutamatergic lacZ expression. Moreover, 
GABAergic depletion and simultaneous glutamatergic blockade should conceal the effects observed 
by us and in fact reveal further functional distinctions for other neuronal populations, e.g. CamKIIα-
positive neurons. Subsequent to any neuronal depletion, histological verification should again be 
carried out. However in particular following GABAergic depletion additional markers to parvalbumin 
(e.g. somatostatin or calretinin) should be employed in order to correlate distinct GABAergic 
populations with the observed cognitive phenotypes. Especially with regard to Schizophrenia and the 
PFC the differential involvement of several GABAergic subclasses has been previously reported (Woo 
et al., 1997; Blum and Mann, 2002). 
Furthermore this work emphasizes the (ii) importance of extensive controls for genetically 
manipulated animals and strongly discourages the use of lacZ as an “inert” transgenic marker. 
Moreover, lacZ expression in different neuronal subpopulations highlighted again their distinct 
functionalities regarding contextual fear memory, tone-fear memory and spatial learning- in 
particular for the hippocampus. Although we can conclude that lacZ expression is not inert and is in 
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fact most likely a cellular toxin, particularly when expressed during embryogenesis, we could not 
define the mechanism or pathways by which it exerts its detrimental effects. Therefore, future 
studies should focus on immune-related changes of protein expression levels, e.g. increased 
expression levels of cytokines in expression-affected areas. Additionally, histological analyses could 
focus on the visualization of astrocytes and microglia in affected brain structures, particularly for 
CamKIIα- and DAT-driven lacZ expression, since we observed a volume increase for some of the 
affected structures for both lines (i.e. cortex and VTA). Immune-related changes might also be of 
particular interest with regards to prolonged lacZ expression, i.e. in aged animals; and might possibly 
after all reveal a prematurely senescent-like cellular phenotype. 
In addition, future Golgi stainings could resolve the question whether glutamatergic lacZ expression 
causes de facto neuronal loss or primarily a decrease in dendritic arborization.  
The possible increase in inflammatory markers should also be investigated for aged and/or stressed 
animals, as increased stress has been reported to modulate immune responses and a prematurely 
aged phenotype (McEwen, 2007; Moreno-Villanueva et al., 2013; Oglodek et al., 2014).  
The last project furthermore revealed that (iii) repeated stress exposure during (early) adulthood 
appears to modulate cognitive performances in middle- and therefore possibly also in old age. These 
stress affects might be attenuated by a cognitively and physically active life-style (before and after 
the stressor). Follow-up studies should further investigate the specific effects of these mediating 
influences, e.g. to which extent do they protect against age- and stress-dependent cognitive decline 
(cf mismatch and cognitive reserve). 
 
Summarizing the results of all three projects, it appears that cognitive abilities are readily (negatively) 
affected by specific molecular manipulations, both on a cellular and a structural level, but are rather 
resistant and resilient towards environmental stressors and, surprisingly, regarding progressed age. 
The specific extent of the cognitive deficits, as well as of possible other phenotypic alterations, is 
always dependent on the distinct location of the manipulations (e.g. SAVA-HPC vs. SAVA-PrL or 
CamKIIα-dependent vs. DAT-dependent lacZ expression). However, the HPC was seemingly always 
affected by our manipulations (with the possible exception of SAVA-PrL), either directly or via e.g. 
dopaminergic projections from the VTA and subsequently appeared to differentially modulate 
cognitive abilities; thus replicating previous findings regarding the importance of the HPC with 
respect to cognitive functions. Furthermore, also within the HPC the functionality of several neuronal 
sub-populations is important for the successful solution to a task (e.g. memory acquisition vs. recall 
(i.e. GABAergic neurons); glutamatergic vs. CamKIIα-positive neurons (i.e. contextual fear memory)). 
Moreover, we found that the neurodegenerative hallmark of aberrant protein expression and 
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accumulation, which so often leads to severe cognitive impairments for afflicted patients, also leads 
to marked phenotypic alterations in mice – regarding cognitive abilities but also concerning basic 
exploratory behavior and CNS structure – even when this protein is a supposedly inert transgenic 
marker. Accordingly, although lacZ expression is most likely not a genuine model for 
neurodegeneration, we could recapitulate the severe effects of aberrant protein expression and once 
more underline the common principle of neurodegenerative diseases. Additionally, we were able to 
provide a strong caveat against the use of lacZ-co-expression for any behavioral, structural or 
molecular phenotyping study. 
Lastly, rather surprisingly, we were not able to observe genuine and overt age-dependent cognitive 
deficits in our mice; neither coinciding with lacZ expression nor following multiple traumata. This 
might in fact be an inert deficit of mice, the specific strain of mice we employed (all groups were on a 
C57Bl/6N genetic background and these mice might be particularly resilient to life-time stressors or 
age-effects) or due to the cognitive tests we used. And although there are many studies employing 
aged and cognitively impaired mice (Yeoman et al., 2012; Villeda and Wyss-Coray, 2013), possibly the 
better rodent-model to assess cognitive decline might in fact be rats (Rapp and Gallagher, 1996; 
Gallagher et al., 2011). Age-dependent cognitive decline does not result in an overall loss of cognitive 
abilities, rather, it presents as the progressive worsening of cognitive abilities. Hence, due to their 
increased cognitive abilities compared to mice, conceivably rats present better possibilities to 
recapitulate the nuances and sometimes minute progression of age-dependent cognitive decline.  
Especially considering the previously mentioned aging society and the close bidirectional relationship 
between life-time stress, aging, neurodegeneration and cognition, it is extremely important to 
further our understanding of the multitude of factors that finally yield the “aged phenotype” (Grady, 
2012). Moreover, aging is a gradual process exerting its (negative) consequences already at middle 
age (Ferreira et al., 2014). If we understood these mechanisms, we might be able to slow down their 
progression and thus delay the onset of age-dependent cognitive deficits. This in turn might also 
benefit patients of neurodegenerative diseases and could help to further elucidate the 
neurobiological mechanisms underlying many neuropsychiatric afflictions.  
Concerning neuropsychiatric disorders, the recent publication of the revised “Diagnostic and 
Statistical Manual of Mental Disorders” (DSM-V; (American Psychiatric Association: Diagnostic and 
Statistical Manual of Mental Disorders, 2013)) has brought forth a lively debate regarding the 
usefulness of this manual. The basis of the argument arises from the fact that the DSM-V is still highly 
descriptive and based on patient interviews as opposed to underlying neurobiological malfunctions. 
However, this is not due to any fault of the authors, rather, animal studies investigating 
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neuropsychiatric disorders have largely failed to produce consistent and reliable results that could be 
applied for the diagnosis of neuropsychiatric disorders, such as e.g. biomarkers (Nestler and Hyman, 
2010). This fact once again underlines the necessity to further our understanding of the 
neurobiological mechanisms of cognition in health and disease in order to identify for instance 
diagnosis-relevant biomarkers. However, such endeavors can only be successful if the appropriately 
controlled animal models and the proper corresponding tests are employed. This rings particularly 
true for studies employing transgenic animals. No matter how elegant the study design or the 
genetic manipulation, one has to be certain about the specificity of the observed effects. 
Finally, one also has to be aware that the (cognitive) phenotype of an animal model is not solely 
defined by a distinct genetic sequence, but is in fact the product of a multi-factorial design. Rather 
fittingly, White et al. (2013) phrased this sentiment as follows: “… [these results] reveal our collective 
inability to predict phenotypes based on [DNA-] sequence or expression pattern alone.” (White et al., 
2013). Thus, the alteration of any one of the above mentioned factors via e.g. transgenic 
manipulations, inflammatory responses or multiple testing can cause unforeseen consequences that 
have to be minutely controlled for in order to produce e.g. reliable biomarkers for neuropsychiatric 
disorders or to decode the mechanism of neurodegenerative diseases. 
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8.1. Statistics 
 
Significance level used throughout statistical analyses: p ≤ 0.055 
 
 
 
8.1.1. (i) SAVA statistics 
 
Abbreviations used for (i) SAVA statistics: 
 
ACC  =  anterior cingulate cortex 
ASR  =  acoustic startle response 
CA  =  cornu ammonis  
d   =   day 
dHPC  =   dorsal hippocampus 
dB   =   decibel 
DL  =   dark-light box 
FC  =   fear conditioning 
I/O  =  input/ output 
OF  =   open field  
pi  =   post injection  
PPI/F     =   pre-pulse inhibition/ facilitation 
PrL  =   prelimbic cortex 
WCM   =  water cross maze 
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Table St-1: SAVA-1 – Behavioral consequences of long-term GABAergic depletion in dHPC 
Parameter Treatment Repeated Measure T x RM 
OF - Distance 
F2,20 = 2.2322,  
p = 0.1333 
F5,100 = 1.6187,  
p = 0.162 
F10,100 = 3.6262,  
p = 0.0004 
OF – Rearing 
Frequency 
F2,20 = 2.9071,  
p = 0.0779 
F5,100 = 5.2120,  
p = 0.0003 
F10,100 = 1.0640,  
p = 0.3971 
OF – Rearing 
Duration 
F2,20 = 4.0964,  
p = 0.0323 
F5,100 = 5.481,  
p = 0.0002 
F10,100 = 0.243,  
p = 0.9909 
DL - Latency 
1way ANOV.A:  
F2,20 = 0.2846,  
p = 0.7553 
    
DL - Frequency 
1way ANOV.A:  
F2,20 = 0.0186,  
p = 0.9816 
    
DL - Duration 
1way ANOV.A:  
F2,20 = 1.022,  
p = 0.3780 
    
ASR - I/O 
F2,20 = 0.30554,  
p = 0.7401 
F4,80 = 52.08575,  
p < 0.0001 
F8,80 = 0.62428,  
p = 0.7551 
ASR - PPI/F 55 dB 
F2,20 = 0.23655,  
p = 0.7915 
F4,80 = 48.84858,  
p < 0.0001 
F8,80 = 1.00313,  
p = 0.4404 
ASR - PPI/F 65 dB 
F2,20 = 0.4347,  
p = 0.6534 
F4,80 = 66.5850,  
p < 0.0001 
F8,80 = 0.8667,  
p = 0.5480 
ASR - PPI/F 75 dB 
F2,20 = 0.1921,  
p = 0.8267 
F4,80 = 57.8451,  
p < 0.0001 
F8,80 = 0.4880,  
p = 0.8614 
WCM - Latency 
F2,20 = 8.3476,  
p = 0.0023 
F4,80 = 70.3987,  
p < 0.0001 
F8,80 = 5.1227,  
p < 0.0001 
WCM - Accuracy 
F2,20 = 12.5932,  
p = 0.0003 
F4,80 = 33.8868,  
p < 0.0001 
F8,80 = 7.4616,  
p < 0.0001 
WCM - Learners d5 
chi-square (χ
2
) test:  
p < 0.0001 
    
FC - Shock Context 
1way ANOV.A:  
F2,20 = 0.8554,  
p = 0.4401 
    
FC - Novel Context 
1way ANOV.A:  
F2,20 = 1.358,  
p = 0.2799 
    
FC - Novel Context 
+ Tone 
1way ANOV.A:  
F2,20 = 1.136,  
p = 0.3411 
    
FC - Tone – 20 sec 
F2,20 = 0.6482,  
p = 0.5336 
F10,200 = 22.2197,  
p < 0.0001 
F20,200 = 1.8456,  
p = 0.0183 
 
Values described in this table refer to the results as depicted in Figure R-1: SAVA-1 – Behavioral 
consequences of long-term GABAergic depletion in dorsal hippocampus (dHPC); p. 72. 
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Table St-2 – SAVA-2 – Behavioral consequences of long-term GABAergic depletion in PrL 
Test 
Treatment 
Repeated 
Measure 
T x RM 
OF - Distance 
F1,18 = 2.9485,  
p = 1.1031 
F5,90 = 10.5843,  
p < 0.0001 
F5,90 = 1.6739,  
p = 0.1490 
OF – Rearing 
Frequency 
F1,18 = 7.3052,  
p = 0.0146 
F5,90 = 2.7139,  
p = 0.0249 
F5,90 = 5.6707,  
p = 0.0001 
OF – Rearing 
Duration 
F1,18 = 4.5949,  
p = 0.0460 
F5,90 = 2.4165,  
p = 0.0419 
F5,90 = 3.2415,  
p = 0.0098 
DL - Latency 
unpaired Student's 
t- test: p = 0.0807 
    
DL - Frequency 
unpaired Student's 
t- test: p = 0.4056 
    
DL - Duration 
unpaired Student's 
t- test: p = 0.5522 
    
ASR - I/O 
F1,18 = 1.1295,  
p = 0.3019 
F4,72 = 71.6169,  
p < 0.0001 
F4,72 = 0.9898,  
p = 0.4187 
ASR - PPI/F 55 dB 
F1,18 = 5.7611,  
p = 0.0274 
F4,72 = 41.5333,  
p < 0.0001 
F4,72 = 5.3639,  
p = 0.0008 
ASR - PPI/F 65 dB 
F1,18 = 1.3957,  
p = 0.2528 
F4,72 = 101.9713,  
p < 0.0001 
F4,72 = 8.0160,  
p < 0.0001 
ASR - PPI/F 75 dB 
F1,18 = 0.1440,  
p = 0.7088 
F4,72 = 71.6887,  
p < 0.0001 
F4,72 = 0.5916,  
p = 0.6698 
WCM - Latency 
week 1 
F1,18 = 1.22,  
p = 0.2839 
F6,108 = 38.3621,  
p < 0.0001 
F6,108 = 2.5682,  
p = 0.0230 
WCM - Latency 
week 2 
F1,18 = 1.4359,  
p = 0.2463 
F6,108 = 59.7205,  
p < 0.0001 
F6, 108 = 0.5540,  
p = 0.7659 
WCM - Accuracy 
week 1 
F1,18 = 0.4287,  
p = 0.5209 
F6,108 = 47.0675,  
p < 0.0001 
F6,108 = 3.6442,  
p = 0.0025 
WCM - Accuracy 
week 2 
F1,18 = 3.4820,  
p = 0.0784 
F6,108 = 33.9837,  
p < 0.0001 
F6,108 = 2.7302,  
p = 0.0165 
WCM - Learners 
week 1 – day 7 
chi-square (χ
2
) test:  
p = 0.5312 
    
WCM - Learners 
week 2 – day 7 
chi-square (χ
2
) 
test:  
p = 0.0253 
    
FC - Shock 
Context 
unpaired Student's 
t- test: p = 0.0703 
    
FC - Novel 
Context 
unpaired Student's 
t- test: p = 0.0768 
    
FC - Novel 
Context (Tone) 
unpaired Student's 
t- test: p = 0.1226 
    
FC - Tone - 20 sec 
F1,18 = 4.5827,  
p = 0.0462 
F10,180 = 42.4614,  
p < 0.0001 
F10,180 = 2.0910,  
p = 0.0273 
 
Values described in this table refer to the results as depicted in Figure R-2: SAVA-2 – Behavioral 
consequences of long-term GABAergic depletion in prelimbic cortex (PrL); p. 74. 
 
 
Appendix – (i): SAVA Statistics 
V 
 
Table St-3: SAVA-3 – Locomotor and cognitive consequences of short-term GABAergic depletion in 
dorsal hippocampus (dHPC) – ACQUISTION 
Test Treatment 
Repeated 
Measure T x RM 
OF d2 pi – 
Distance  
F1,25 = 2.4355,  
p = 0.1312 
F5,125 = 18.2919,  
p < 0.0001 
F5,125 = 1.0034,  
p = 0.4186 
OF d2 pi –  
Rearing Frequency 
F1,25 = 1.1315,  
p = 0.297618 
F5,125 = 8.1155,  
p < 0.0001 
F5,125 = 0.9180,  
p = 0.4717 
OF d2 pi –  
Rearing Duration 
F1,25 = 1.7261,  
p = 0.2008 
F5,125 = 17.0018,  
p < 0.0001 
F5,125 = 2.2159,  
p = 0.056753 
WCM - Latency 
F1,25 = 27.9789,  
p < 0.0001 
F6,150 = 29.5358,  
p < 0.0001 
F6,150 = 8.2756,  
p < 0.0001 
WCM - Accuracy 
F1,25 = 17.6819,  
p = 0.0003 
F6,150 = 30.1111,  
p < 0.0001 
F6,150 = 7.6333,  
p < 0.0001 
WCM - Learners 
d7 
chi-square (χ
2
) 
test:  
p = 0.0012 
    
OF d10 pi - 
Distance 
F1,25 = 17.1451,  
p = 0.0003 
F5,125 = 7.5580,  
p < 0.0001 
F5,125 = 0.7078,  
p = 0.618620 
OF d2 pi V.s.      
d10 pi – Distance 
F1,25 = 3.7493,          
p = 0.0642 
F1,25 = 2.6097,                
p = 0.1188 
F1,25 = 31.1914,                 
p < 0.0001 
OF d10 pi –  
Rearing 
Frequency 
F1,25 = 3.3974,  
p = 0.0772 
F5,125 = 10.6345,  
p < 0.0001 
F5,125 = 1.2968,  
p = 0.2695 
OF d10 pi –  
Rearing Duration 
F1,25 = 0.8604,  
p = 0.3625 
F5,125 = 11.4098,  
p < 0.0001 
F5,125 = 4.1256,  
p = 0.0017 
 
Values described in this table refer to the results as depicted in Figure R-3: SAVA-3 – Locomotor and 
cognitive consequences of short-term GABAergic depletion in dorsal hippocampus (dHPC) – 
ACQUISTION; p. 76. 
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Table St-4: SAVA-4 – Locomotor and cognitive consequences of short-term GABAergic depletion in 
dorsal hippocampus (dHPC) – RECALL 
Test 
Treatment 
Repeated 
Measure T x RM 
OF d2 pi - Distance 
F1,22 = 2.5025,  
p = 0.1279 
F5,110 = 49,9363,  
p < 0.0001 
F5,110 = 0.1301,  
p = 0.9852 
OF d2 pi –  
Rearing Frequency 
F1,22 = 1.6716,  
p = 0.2095 
F5,110 = 0.9407,  
p = 0.4577 
F5,110 = 0.5215,  
p = 0.7595 
OF d2 pi –  
Rearing Duration 
F1,22 = 2.6685,  
p = 0.1166 
F5,110 = 0.6666,  
p = 0.6496 
F5,110 = 0.3768,  
p = 0.8637 
WCM - Latency    
d1 - d7 
F1,22 = 1.2036,  
p = 0.2845 
F6,132 = 125.4741,  
p < 0.0001 
F6,132 = 0.4104,  
p = 0.8711 
WCM - Accuracy  
d1 - d7 
F1,22 = 0.0044,  
p = 0.9480 
F6,132 = 66.4122,  
p < 0.0001 
F6,132 = 0.3785,  
p = 0.8916 
WCM - Learners 
d7 
100% of both 
groups have 
learned --> chi² (χ
2
) 
test not possible 
    
WCM - Latency   
d3 + d4 pi  
F1,22 = 4.0781,  
p = 0.0558 
F1,22 = 1.4397,  
p = 0.2430 
F1,22 = 0.04,  
p = 0.8433 
WCM - Accuracy   
d3  + d4 pi  
F1,22 = 1.2498,  
p = 0.2757 
F1,22 = 0.1602,  
p = 0.6928 
F1,22 = 0.1602,  
p = 0.6928 
WCM - Learners  
d3 pi 
chi-square test:  
p = 0.8307 
    
WCM – Learners 
d4 pi 
chi-square (χ
2
) 
test:  
p = 0.1345 
    
WCM - Latency    
d9 + d10 pi  
F1,22 = 15.2054,  
p = 0.0008 
F1,22 = 4.3048,  
p = 0.0499 
F1,22 = 0.0050,  
p = 0.9443 
WCM - Accuracy  
d9 + d10 pi 
F1,22 = 3.5496,  
p = 0.0728 
F1,22 = 2.3697,  
p = 0.1380 
F1,22 = 0.1526,  
p = 0.6999 
WCM - Learners  
d9 pi 
chi-square (χ
2
) 
test:  
p = 0.7697 
    
WCM - Learners 
d10 pi 
chi-square test:  
p = 0.0337 
    
OF d8 pi - 
Distance 
F1,22 = 8.5375,  
p = 0.0079 
F5,110 = 7.2454,  
p < 0.0001 
F5,110 = 4.5288,  
p = 0.0009 
OF d2 pi V.s.        
d8 pi –  Distance 
F1,22 = 2.9861, 
p = 0.0980 
F1,22 = 19.6827,  
p = 0.0002 
F1,22 = 10.1958,  
p = 0.0042 
OF d8 pi –  
Rearing 
Frequency 
F1,22 = 5.6168,  
p = 0.0270 
F5,110 = 4.5372,  
p = 0.0008 
F5,110 = 1.7347,  
p = 0.1326 
OF d8 pi –  
Rearing Duration 
F1,22 = 0.7573,  
p = 0.3936 
F5,110 = 5.8102,  
p < 0.0001 
F5,110 = 0.7080,  
p = 0.618682 
 
Values described in this table refer to the results as depicted in Figure R-4: SAVA-4 – Locomotor and 
cognitive consequences of short-term GABAergic depletion in dorsal hippocampus (dHPC) – RECALL; 
p. 77. 
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Table St-5: SAVA Histology 
Group/ Brain region 
unpaired Student's t- test 
(one-sided) 
SAVA-2: ACC p = 0.0408 
SAVA-2: PrL p = 0.0294 
SAVA-3: CA 1-3 p < 0.0001 
SAVA-4: CA 1-3 p = 0.0096 
 
Values described in this table refer to the results as depicted in Figure R-5: Histology SAVA-1 through 
SAVA-4; p. 78. 
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8.1.2. (ii) lacZ statistics 
 
Abbreviations used for (ii) lacZ statistics: 
 
AAV   =   adeno-associated virus 
ASR  =  acoustic startle response 
dB   =   decibel 
DL  =   dark-light box 
FC  =   fear conditioning 
HPC  =   hippocampus (dHPC = dorsal; vHPC = ventral) 
I/O  =  input/ output 
Int.  =  intensity 
MEMRI =   manganese-enhanced magnetic resonance imaging 
OF  =   open field  
PBS  =   phosphate-buffered saline 
PP2B  =  calcineurin 
PPI/F      =   pre-pulse inhibition/ facilitation 
RD   =   rearing duration 
rel.   =  relative 
RF  =   rearing frequency 
Tam  =   tamoxifen 
V.   =   volume 
VTA   =   ventral tegmental area 
WCM   =  water cross maze 
WPV  =   wrong platform visits 
 
 
 
 
 
Appendix – (ii):  lacZ Statistics 
IX 
 
Table St-6: R26R:Nex-Cre 
Test 
Genotype 
Repeated 
Measure 
G x RM 
OF - Distance 
F1,17 = 10.6423,  
p = 0.0046 
F2,34 = 1.5671,  
p = 0.2234 
F2,34 = 0.5551,  
p = 0.9852 
OF – Rearing 
Frequency 
F1,17 = 16.7673,  
p = 0.0008 
F2,34 = 16.129,  
p < 0.0001 
F2,34 = 1.957,  
p = 0.1569 
OF – Rearing 
Duration 
F1,17 = 19.8874,  
p = 0.0003 
F2,34 = 13.7687,  
p < 0.0001 
F2,34 = 7.7104,  
p = 0.0017 
DL - Latency 
unpaired Student's 
t- test: p = 0.0691 
  
DL - Frequency 
unpaired Student's 
t- test: p = 0.0066 
  
DL - Duration 
unpaired Student's 
t- test: p = 0.7098 
  
ASR - I/O 
F1,17 = 0.7551,  
p = 0.397 
F4,68 = 27.1714,  
p < 0.0001 
F4,68 = 1.6286,  
p = 0.1771 
ASR - PPI/F 55 dB 
F1,17 = 0.6459,  
p = 0.4327 
F4,68 = 66.0874,  
p < 0.0001 
F4,68 = 4.8913,  
p = 0.0016 
ASR - PPI/F 65 dB 
F1,17 = 0.3396,  
p = 0.5677 
F4,68 = 98.5123,  
p < 0.0001 
F4,68 = 0.838,  
p = 0.5058 
ASR - PPI/F 75 dB 
F1,17 = 0.4783,  
p = 0.4985 
F4,68 = 32.6285,  
p < 0.0001 
F4,68 = 0.0756 
p = 0.9894 
FC - Shock 
Context 
unpaired Student's 
t- test: p = 0.0138 
  
FC - Novel 
Context (Tone) 
unpaired Student's 
t- test: p = 0.3439 
  
FC - Novel 
Context (Tone; 
sec 160 – sec 360) 
F1,17 = 0.746,  
p = 0.3998 
F10,170 = 35.2626,  
p < 0.0001 
F10,140 = 0.6451,  
p = 0.7736 
Extinction training 
F1,17 = 0.0031,  
p = 0.9562 
F3,51 = 31.4273,  
p < 0.0001 
F3,51 = 1.1083 
p = 0.3544 
WCM - Latency  
F1,18 = 30.0181,  
p < 0.0001 
F4,72 = 68.8014,  
p < 0.0001 
F4,72 = 2.38611,  
p = 0.059 
WCM - Accuracy  
F1,18 = 73.2025,  
p < 0.0001 
F4,72 = 16.9775,  
p < 0.0001 
F4,72 = 8.9387,  
p < 0.0001 
WCM – WPV  
F1,18 = 96.4193,  
p < 0.0001 
F4,72 = 8.5013,  
p < 0.0001 
F4,72 = 4.0529,  
p = 0.0051 
WCM – Learners 
day 5 
chi-square (χ
2
) 
test:  
p = 0.0003 
  
WCM – Start-Bias 
F1,18 = 16.8779,  
p = 0.0007 
F4,72 = 4.6547,  
p < 0.0001 
F4,72 = 2.3558,  
p = 0.0617 
MEMRI - Whole 
Brain (V.) 
unpaired Student's 
t- test: p = 0.6026 
  
MEMRI – HPC  
(rel. V.) 
unpaired Student's 
t- test: p < 0.0001 
  
MEMRI – lateral 
ventricle (rel. V.) 
unpaired Student's 
t- test: p < 0.0001 
   
Values described in this table refer to the consequences of constitutive glutamatergic lacZ expression 
as depicted in Figure R-7, Figure R-8 and Figure R-15; pp. 82, 83 and 90. 
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Table St-7: Nex-Cre 
Test 
Genotype 
Repeated 
Measure 
G x RM 
OF - Distance 
F1,17 = 0.1072,  
p = 0.7473 
F2,34 = 5.3155,  
p = 0.0098 
F2,34 = 0.0624,  
p = 0.9396 
OF – Rearing 
Frequency 
F1,17 = 1.4209,  
p = 0.2496 
F2,34 = 9.5155,  
p = 0.0005 
F2,34 = 0.5335,  
p = 0.5914 
OF – Rearing 
Duration 
F1,17 = 3.0654,  
p = 0.0980 
F2,34 = 27.462,  
p < 0.0001 
F2,34 = 0.9852,  
p = 0.3838 
WCM - Latency 
(week 1) 
F1,17 = 1.8124,  
p = 0.1959 
F4,68 = 21.2646,  
p < 0.0001 
F4,68 = 0.5052,  
p = 0.732 
WCM - Accuracy 
(week 1) 
F1,17 = 0.1952,  
p = 0.6642 
F4,68 = 36.0061,  
p < 0.0001 
F4,68 = 0.2391,  
p = 0.9153 
WCM – WPV  
(week 1)  
F1,17 = 0.1.3865,  
p = 0.2552 
F4,68 = 27.4631,  
p < 0.0001 
F4,68 = 0.9299,  
p = 0.4519 
WCM - Learners 
(week 1) – day 5 
100% of both 
groups have 
learned --> chi-
square (χ
2
) test not 
possible 
  
WCM - Latency 
(week 2) 
F1,17 = 0.54475  
p = 0.4705 
F4,68 = 78.4601,  
p < 0.0001 
F2,68 = 1.9502,  
p = 0.1121 
WCM - Accuracy 
(week 2) 
F1,17 = 6.9036 
p = 0.0176 
F4,68 = 68.7098,  
p < 0.0001 
F2,68 = 0.9775,  
p = 0.4257 
WCM - WPV  
(week 2)  
F1,17 = 11.2469 
p = 0.0038 
F4,68 = 156.8253,  
p < 0.0001 
F2,68 = 3.968,  
p = 0.0059 
WCM - Learners 
(week 2) – day 5 
chi-square (χ
2
) test:  
p = 0.3684 
  
MEMRI - Whole 
Brain (V.) 
unpaired Student's 
t- test: p = 0.0002 
  
MEMRI – HPC   
(rel. V.) 
unpaired Student's 
t- test: p = 0.3221 
  
MEMRI – lateral 
ventricle (rel. V.) 
unpaired Student's 
t- test: p = 0.2542 
  
 
Values described in this table refer to the consequences of constitutive glutamatergic Cre expression 
as depicted in Figure R-9, Figure R-10 and Figure R-15; pp. 84, 85 and 90. 
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Table St-8: CAG-CAT-EGFP:Nex-Cre 
Test 
Genotype 
Repeated 
Measure 
G x RM 
OF - Distance 
F1,18 = 3.4632,  
p = 0.0792 
F2,36 = 10.1935,  
p = 0.0003 
F2,36 = 0.1498,  
p = 0.8615 
OF – Rearing 
Frequency 
F1,18 = 5.9353,  
p = 0.0255 
F2,36 = 2.4773,  
p = 0.09818 
F2,36 = 0.5353,  
p = 0.5901 
OF – Rearing 
Duration 
F1,18 = 2.1293,  
p = 0.1617 
F2,36 = 4.2743,  
p = 0.0216 
F2,36 = 0.1082,  
p = 0.8977 
DL - Latency 
unpaired Student's 
t- test: p = 0.5488 
  
DL - Frequency 
unpaired Student's 
t- test: p = 0.2792 
  
DL - Duration 
unpaired Student's 
t- test: p = 0.3323 
  
ASR - I/O 
F1,18 = 1.4244,  
p = 0.2482 
F4,27 = 30.2386,  
p < 0.0001 
F4,72 = 1.183,  
p = 0.3256 
ASR - PPI/F 55 dB 
F1,18 = 0.9645,  
p = 0.3391 
F4,72 = 38.069,  
p < 0.0001 
F4,72 = 0.7359,  
p = 0.5705 
ASR - PPI/F 65 dB 
F1,18 = 0.0667,  
p = 0.7992 
F4,72 = 95.2497,  
p < 0.0001 
F4,72 = 0.1147,  
p = 0.9769 
ASR - PPI/F 75 dB 
F1,18 = 0.314,  
p = 0.5821 
F4,72 = 54.6151,  
p < 0.0001 
F4,72 = 0.6068,  
p = 0.659 
FC - Shock 
Context 
unpaired Student's 
t- test: p = 0.0713 
  
FC - Novel 
Context (+ Tone) 
unpaired Student's 
t- test: p = 0.2694 
  
Extinction training 
F1,18 = 0.1695,  
p = 0.6854 
F3,54 = 15.871,  
p < 0.0001 
F3,54 = 0.5228,  
p = 0.6685 
WCM - Latency 
(week 1) 
F1,20 = 0.0378,  
p = 0.8478 
F4,80 = 122.2573,  
p < 0.0001 
F4,80 = 0.6437,  
p = 0.6329 
WCM - Accuracy 
(week 1) 
F1,20 = 1.3209,  
p = 0.264 
F4,80 = 45.3354,  
p < 0.0001 
F4,80 = 1.841,  
p = 0.1291 
WCM - WPV  
(week 1)  
F1,20 = 1.7762,  
p = 0.1976 
F4,80 = 49.4319,  
p < 0.0001 
F4,80 = 1.9524,  
p = 0.1098 
WCM - Learners 
(week 1) – day 5 
chi-square (χ
2
) test:  
p = 0.6827 
  
WCM - Latency 
(week 2) 
F1,20 = 0.4313,  
p = 0.5188 
F4,80 = 106.4069,  
p < 0.0001 
F4,80 = 1.754,  
p = 0.1464 
WCM - Accuracy 
(week 2) 
F1,20 = 3.6963,  
p = 0.0689 
F4,80 = 62.0817,  
p < 0.0001 
F4,80 = 2.3065,  
p = 0.0653 
WCM - WPV  
(week 2)  
F1,20 = 0.8753,  
p = 0.3607 
F4,80 = 140.1676,  
p < 0.0001 
F4,80 = 0.3167,  
p = 0.8661 
WCM – Learning 
Score (week 2)  
unpaired Student's 
t- test: p = 0.0689 
  
WCM – Learners   
(week 2) – day 5 
chi-square (χ
2
) test:  
p = 0.3233 
  
MEMRI – Whole 
Brain (V.) 
unpaired Student's 
t- test: p = 0.209 
  
MEMRI – HPC   
(rel. V.) 
unpaired Student's 
t- test: p = 0.4133 
  
MEMRI – HPC 
dorsal (rel. V.) 
unpaired Student's 
t- test: p = 0.9179 
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MEMRI – HPC  
ventral (rel. V.) 
unpaired Student's 
t- test: p = 0.0742 
  
 
Values described in this table refer to the consequences of constitutive glutamatergic GFP expression 
as depicted in Figure R-12 and Figure R-15; pp. 86 and 90. 
 
 
 
 
Table St-9: R26R:Dlx5/6-Cre 
Test 
Genotype 
Repeated 
Measure 
G x RM 
OF - Distance 
F1,14 = 14.5666,  
p = 0.0019 
F2,28 = 0.1628,  
p = 0.8506 
F2,28 = 5.5891,  
p = 0.0091 
OF – Rearing 
Frequency 
F1,14 = 16.6784,  
p = 0.0011 
F2,28 = 20.3025,  
p < 0.0001 
F2,28 = 8.3126,  
p = 0.0015 
OF – Rearing 
Duration 
F1,14 = 0.2688,  
p = 0.6123 
F2,28 = 7.2488,  
p = 0.0029 
F2,28 = 1.0402,  
p = 0.3667 
DL - Latency 
unpaired Student's 
t- test: p = 0.2093 
  
DL - Frequency 
unpaired Student's 
t- test: p = 0.0335 
  
DL - Duration 
unpaired Student's 
t- test: p = 0.0006 
  
ASR - I/O 
F1,14 = 5.4254,  
p = 0.0353 
F4,56 = 36.4687,  
p < 0.0001 
F4,56 = 3.0788,  
p = 0.0231 
ASR - PPI/F 55 dB 
F1,14 = 2.2784,  
p = 0.1534 
F4,56 = 30.3338,  
p < 0.0001 
F4,56 = 0.3345,  
p = 0.8536 
ASR - PPI/F 65 dB 
F1,14 = 1.8129,  
p = 0.1996 
F4,56 = 50.1614,  
p < 0.0001 
F4,56 = 1.1264,  
p = 0.3534 
ASR - PPI/F 75 dB 
F1,14 = 0.3416,  
p = 0.5682 
F4,56 = 37.3307,  
p < 0.0001 
F4,56 = 2.0571,  
p = 0.0987 
FC - Shock 
Context 
unpaired Student's 
t- test: p = 0.3154 
  
FC - Novel 
Context (Tone; 
sec 160 – sec 360) 
F1,14 = 1.2867,  
p = 0.2757 
F10,140 = 28.62314,  
p < 0.0001 
F10,140 = 0.29046,  
p = 0.9824 
Extinction training 
F1,12 = 0.2212,  
p = 0.6466 
F3,36 = 18.8413,  
p < 0.0001 
F3,36 = 1.7956,  
p = 0.1655 
WCM - Latency 
week 1 
F1,14 = 0.3145,  
p = 0.5838 
F4,56 = 29.7887,  
p < 0.0001 
F4,56 = 0.6784,  
p = 0.6098 
WCM - Accuracy 
week 1 
F1,14 = 5.1518,  
p = 0.0396 
F4,56 = 33.0018,  
p < 0.0001 
F4,56 = 1.0567,  
p = 0.3865 
WCM - WPV 
week 1  
F1,14 = 1.5669,  
p = 0.2312 
F4,56 = 21.1086,  
p < 0.0001 
F4,56 = 0.8803,  
p = 0.4817 
WCM - Learners 
week 1 – day 5 
chi-square (χ
2
) test:  
p = 0.2482 
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WCM – Learning 
Score (week 1)  
unpaired Student's 
t- test: p = 0.0398 
  
WCM - Latency 
week 2 
F1,14 = 0.6272,  
p = 0.4416 
F4,56 = 39.3929,  
p < 0.0001 
F4,56 = 0.9075,  
p = 0.466 
WCM - Accuracy 
week 2 
F1,14 = 2.1261,  
p = 0.1669 
F4,56 = 18.6792,  
p < 0.0001 
F4,56 = 1.1081,  
p = 0.3618 
WCM - WPV  
week 2 
F1,14 = 2.4729,  
p = 0.1381 
F4,56 = 53.7224,  
p < 0.0001 
F4,56 = 0.591,  
p = 0.6706 
WCM - Learners 
week 2 – day 5 
chi-square (χ
2
) test:  
p = 0.3173 
  
WCM – Learning 
Score (week 2)  
unpaired Student's 
t- test: p = 0.1671 
  
MEMRI - Whole 
Brain (V.) 
unpaired Student's 
t- test: p = 0.515 
  
MEMRI – HPC   
(rel. V.) 
unpaired Student's 
t- test: p = 0.4315 
  
MEMRI – HPC 
dorsal (rel. V.) 
unpaired Student's 
t- test: p = 0.8581 
  
MEMRI – HPC 
ventral (rel. V.) 
unpaired Student's 
t- test: p = 0.2779 
  
 
Values described in this table refer to the consequences of constitutive GABAergic lacZ expression as 
depicted in Figure R-14 and Figure R-15; pp. 89 and 90. 
 
 
 
 
Table St-10: R26R – AAV (MEMRI) 
Region of interest 
Statistical 
analyses 
Whole Brain V.                  
(for all groups; absolute) 
1way ANOVA 
F1,3 = 0.7927,  
p = 0.4733 
PBS: left vs. right HPC      
(rel. V.) 
paired Student's        
t- test: p = 0.4441 
GFP-AAV: left vs. right HPC 
(rel. V.) 
paired Student's       
t- test: p = 0.1146 
Cre-AAV: left vs. right HPC 
(rel. V.) 
paired Student's       
t- test: p = 0.0090 
 
Values described in this table refer to the results as depicted in Figure R-18: AAV induced HPC 
volume loss in R26R mice; p. 95. 
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Table St-11: i-R26R:Nex-Cre 
Test 
Genotype 
Repeated 
Measure 
G x RM 
Weight 
throughout 
F1,18 = 0.1355,  
p = 0.7171 
F9,162 = 175.4038,  
p < 0.0001 
F9,162 = 0.7537,  
p = 0.6592 
BEFORE TAM       
OF – Distance  
F1,19 = 0.4671,  
p = 0.5026 
F5,95 = 30.1344,  
p < 0.0001 
F5,95 = 0.3997,  
p = 0.8479 
BEFORE TAM       
OF – RF 
F1,19 = 10.6171,  
p = 0.0041 
F5,95 = 8.5602,  
p < 0.0001 
F5,95 = 1.3537,  
p = 0.2488 
BEFORE TAM       
OF – RD 
F1,19 = 7.0237,  
p = 0.0158 
F5,95 = 14.4915,  
p < 0.0001 
F5,95 = 1.4892,  
p = 0.2006 
BEFORE TAM      
ASR – I/O   
F1,18 = 0.0997,  
p = 0.7558 
F4,72 = 23.9623,  
p < 0.0001 
F4,72 = 0.259,  
p = 0.9032 
BEFORE TAM       
PPI/PPF 55dB 
F1,19 = 0.2836,  
p = 0.6005 
F4,76 = 40.2701,  
p < 0.0001 
F4,76 = 3.7929,  
p = 0.0073 
BEFORE TAM       
PPI/PPF 65dB 
F1,19 = 0.228,  
p = 0.6385 
F4,76 = 35.6057,  
p < 0.0001 
F4,76 = 0.4307,  
p = 0.7861 
BEFORE TAM       
PPI/PPF 75dB 
F1,19 = 2.4221,  
p = 0.1361 
F4,76 = 28.1091,  
p < 0.0001 
F4,76 = 1.4724,  
p = 0.2189 
4 months post 
TAM 
4 months post 
TAM 
4 months post TAM 4 months post TAM 
OF – Distance  
F1,18 = 2.3727,  
p = 0.1409 
F5,90 = 3.7832,  
p = 0.0037 
F5,90 = 1.0996,  
p = 0.3663 
OF – RF 
F1,18 = 0.4465,  
p = 0.5125 
F5,90 = 16.7535,  
p < 0.0001 
F5,90 = 0.2705,  
p = 0.9281 
OF – RD 
F1,18 = 0.9967,  
p = 0.3313 
F5,90 = 17.211,  
p < 0.0001 
F5,90 = 1.6089,  
p = 0.1658 
DL - Latency 
unpaired Student's 
t- test: p = 0.2286 
  
DL - Frequency 
unpaired 
Student's t- test: p 
= 0.0437 
  
DL - Duration 
unpaired Student's 
t- test: p = 0.8642 
  
ASR – I/O   
F1,16 = 0.2073,  
p = 0.655 
F4,64 = 25.9161,  
p < 0.0001 
F4,64 = 1.0721,  
p = 0.3777 
PPI/PPF 55dB 
F1,18 = 0.1094,  
p = 0.7447 
F4,72 = 34.3117,  
p < 0.0001 
F4,72 = 2.1385,  
p = 0.0847 
PPI/PPF 65dB 
F1,18 = 0.0245,  
p = 0.8774 
F4,72 = 37.4058,  
p < 0.0001 
F4,72 = 0.4915,  
p = 0.742 
PPI/PPF 75dB 
F1,18 = 0.2298,  
p = 0.6375 
F4,72 = 28.103,  
p < 0.0001 
F4,72 = 0.3012,  
p = 0.8762 
FC - Shock 
Context 
F1,18 = 7.2788,  
p = 0.0147 
F8,144 = 4.3703,  
p < 0.0001 
F8,144 = 0.7137,  
p = 0.6792 
FC - Shock 
Context 
unpaired 
Student's t- test: p 
= 0.0147 
  
FC - Novel Context 
(Tone; sec 160 – 
sec 360) 
F1,18 = 0.3422,  
p = 0.5658 
F10,180 = 30.9099,  
p < 0.0001 
F10,180 = 0.7035,  
p = 0.7204 
FC - Novel Context 
(Tone) 
unpaired Student's 
t- test: p = 0.543 
  
Extinction training 
F1,18 = 0.0233,  
p = 0.8803 
F3,54 = 30.9454,  
p < 0.0001 
F3,54 = 0.2932,  
p = 0.8301 
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WCM - Latency 
(week 1) 
F1,18 = 0.4195,  
p = 0.5254 
F4,72 = 166.5491,  
p < 0.0001 
F4,72 = 0.0838,  
p = 0.9872 
WCM - Accuracy 
(week 1) 
F1,18 = 0.1093,  
p = 0.7447 
F4,72 = 37.7317,  
p < 0.0001 
F4,72 = 1.273,  
p = 0.2886 
WCM – WPV  
(week 1) 
F1,18 = 0.0087,  
p = 0.9267 
F4,72 = 21.3993,  
p < 0.0001 
F4,72 = 1.1563,  
p = 0.3374 
WCM - Learners 
(week 1) – day 5 
chi-square (χ
2
) 
test:  
p = 1.0 
  
WCM – Learning 
Score (week 1)  
unpaired Student's 
t- test: p = 0.7188 
  
WCM - Latency 
(week 2) 
F1,18 = 0.0314,  
p = 0.8613 
F4,72 = 45.3401,  
p < 0.0001 
F4,72 = 1.0547,  
p = 0.3853 
WCM - Accuracy 
(week 2) 
F1,18 = 1.0656,  
p = 0.3156 
F4,72 = 44.6456,  
p < 0.0001 
F4,72 = 0.4177,  
p = 0.7953 
WCM – WPV  
(week 2) 
F1,18 = 0.1531,  
p = 0.7002 
F4,72 = 63.2836,  
p < 0.0001 
F4,72 = 0.7202,  
p = 0.5809 
WCM - Learners 
(week 2) – day 5 
chi-square (χ
2
) 
test:  
p = 0.2636 
  
WCM – Learning 
Score (week 2)  
unpaired Student's 
t- test: p = 0.3240 
  
MEMRI - Whole 
Brain (V.) 
unpaired Student's 
t- test: p = 0.121 
  
MEMRI – HPC   
(rel. V.) 
unpaired 
Student's t- test: p 
= 0.0053 
  
MEMRI – dorsal 
HPC (rel. V.) 
unpaired 
Student's t- test: p 
= 0.0023 
  
MEMRI – ventral 
HPC (rel. V.) 
unpaired Student's 
t- test: p = 0.1811 
  
MEMRI – CPu    
(rel. V.) 
unpaired Student's 
t- test: p = 0.0697 
  
MEMRI – dorsal 
Cortex (rel. V.) 
unpaired Student's 
t- test: p = 0.2339 
  
MEMRI – lateral 
ventricles (rel. V.) 
unpaired Student's 
t- test: p = 0.5959 
  
MEMRI – Whole 
Brain (Intensity) 
unpaired Student's 
t- test: p = 0.4725 
  
MEMRI – HPC (rel. 
Intensity) 
unpaired Student's 
t- test: p = 0.5588 
  
MEMRI – dorsal 
Cortex (rel. 
Intensity) 
unpaired Student's 
t- test: p = 0.3299 
  
Western Blot (1) 
vinculin 
unpaired Student's 
t- test: p = 0.1703 
  
Western Blot (1) 
AIF/ vinculin 
unpaired Student's 
t- test: p = 0.2280 
  
Western Blot (1) 
PP1ß/ vinculin 
unpaired Student's 
t- test: p = 0.2642 
  
Western Blot (2) 
vinculin 
unpaired Student's 
t- test: p = 0.7258 
  
Western Blot (2) 
PP2B/ vinculin 
unpaired Student's 
t- test: p = 0.4532 
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Western Blot (2) 
Actin/ vinculin 
unpaired Student's 
t- test: p = 0.6083 
  
Western Blot (2) 
CDK5/ vinculin 
unpaired Student's 
t- test: p = 0.2817 
  
Values described in this table refer to the consequences of adult-induced glutamatergic lacZ 
expression as depicted in Figure R-20 through Figure R-25; pp. 97 - 101. 
 
 
Table St-12: i-R26R:CamKIIα-Cre 
Test 
Genotype 
Repeated 
Measure 
G x RM 
Survival 
throughout 
Mantel-Cox test/ 
chi-square (χ
2
) test: 
p = 0.3712 
  
Weight 
throughout 
F1,9 = 3.573,  
p = 0.0913 
F9,81 = 15.7867,  
p < 0.0001 
F9,81 = 0.7218,  
p = 0.6875 
BEFORE TAM      
OF – Distance  
F1,25 = 1.2356,  
p = 0.2769 
F2,50 = 26.5996,  
p < 0.0001 
F2,50 = 2.1951,  
p = 0.122 
BEFORE TAM      
OF – RF 
F1,25 = 0.0147,  
p = 0.9044 
F2,50 =6.2178,  
p < 0.0001 
F2,50 = 3.112,  
p = 0.0532 
BEFORE TAM      
OF – RD 
F1,25 = 0.0804,  
p = 0.7792 
F2,50 = 18.722,  
p < 0.0001 
F2,50 = 1.0384,  
p = 0.3615 
BEFORE TAM      
ASR – I/O   
F1,25 = 1.0094,  
p = 0.3247 
F4,100 = 30.5486,  
p < 0.0001 
F4,100 = 0.5056,  
p = 0.7317 
4 months post 
TAM 
4 months post 
TAM 
4 months post TAM 4 months post TAM 
OF – Distance  
F1,21 = 0.4474,  
p = 0.5108 
F2,42 = 0.9763,  
p = 0.3851 
F2,42 = 0.4503,  
p = 0.6405 
OF – RF 
F1,21 = 0.2288,  
p = 0.6374 
F2,42 = 26.0340,  
p < 0.0001 
F2,42 = 3.7177,  
p = 0.0326 
OF – RD 
F1,21 = 0.773,  
p = 0.3893 
F2,42 = 30.7188,  
p < 0.0001 
F2,42 = 0.6561,  
p = 0.5241 
DL - Latency 
unpaired Student's 
t- test: p = 0.4868 
  
DL - Frequency 
unpaired Student's 
t- test: p = 0.6055 
  
DL - Duration 
unpaired Student's 
t- test: p = 0.1569 
  
ASR – I/O   
F1,21 = 0.6953,  
p = 0.4137 
F4,84 = 50.5958,  
p < 0.0001 
F4,84 = 0.7694,  
p = 0.5481 
PPI/PPF 55dB 
F1,21 = 11.6843,  
p = 0.0026 
F4,84 = 41.9511,  
p < 0.0001 
F4,84 = 7.5545,  
p < 0.0001 
PPI/PPF 65dB 
F1,21 = 10.2456,  
p = 0.0043 
F4,84 = 106.1034,  
p < 0.0001 
F4,84 = 10.0296,  
p < 0.0001 
PPI/PPF 75dB 
F1,21 = 6.6736,  
p = 0.0173 
F4,84 = 50.1953,  
p < 0.0001 
F4,84 = 4.1696,  
p = 0.004 
FC - Shock 
Context 
F1,21 = 2.7139,  
p = 0.1144 
F8,168 = 4.3702,  
p < 0.0001 
F8,168 = 0.7241,  
p = 0.67 
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FC - Shock 
Context 
unpaired Student's 
t- test: p = 0.1144 
  
FC - Novel 
Context (Tone; 
sec 160 – sec 360) 
F1,21 = 3.2384,  
p = 0.0863 
F10,210 = 34.6489,  
p < 0.0001 
F10,210 = 2.1552,  
p = 0.0218 
FC - Novel 
Context (Tone) 
unpaired Student's 
t- test: p = 0.0854 
  
Extinction 
training 
F1,21 = 1.4811,  
p = 0.2371 
F10,42 = 23.9357,  
p < 0.0001 
F10,42 = 3.5374,  
p = 0.038 
WCM - Latency 
(week 1) 
F1,21 = 0.2469,  
p = 0.6244 
F4,84 = 156.9715,  
p < 0.0001 
F4,84 = 0.7021,  
p = 0.5927 
WCM - Accuracy 
(week 1) 
F1,21 = 0.0899,  
p = 0.7672 
F4,84 = 45.7573,  
p < 0.0001 
F4,84 = 0.9558,  
p = 0.4362 
WCM – WPV 
(week 1) 
F1,21 = 0.0205,  
p = 0.8876 
F4,84 = 24.5865,  
p < 0.0001 
F4,84 = 0.4984,  
p = 0.737 
WCM - Learners 
(week 1) – day 5 
chi-square (χ
2
) test:  
p = 0.2826 
  
WCM – Learning 
Score (week 1)  
unpaired Student's 
t- test: p = 0.7643 
  
WCM - Latency 
(week 2) 
F1,21 = 0.2924,  
p = 0.5944 
F4,84 = 61.7096,  
p < 0.0001 
F4,84 = 0.2672,  
p = 0.8983 
WCM - Accuracy 
(week 2) 
F1,21 = 0.0671,  
p = 0.7982 
F4,84 = 48.5917,  
p < 0.0001 
F4,84 = 0.274,  
p = 0.894 
WCM – WPV 
(week 2) 
F1,21 = 0.6827,  
p = 0.418 
F4,84 = 73.933,  
p < 0.0001 
F4,84 = 0.8769,  
p = 0.4814 
WCM - Learners 
(week 2) – day 5 
chi-square (χ
2
) test:  
p = 0.5518 
  
WCM – Learning 
Score (week 2)  
unpaired Student's 
t- test: p = 0.7982 
  
MEMRI - Whole 
Brain (V.) 
unpaired Student's 
t- test: p = 0.9338 
  
MEMRI – HPC   
(rel. V.) 
unpaired Student's 
t- test: p = 0.0959 
  
MEMRI – dorsal 
Cortex (rel. V.) 
unpaired Student's 
t- test: p = 0.0102 
  
MEMRI – lateral 
ventricles (rel. V.) 
unpaired Student's 
t- test: p = 0.0338 
  
MEMRI – Whole 
Brain (Int.) 
unpaired Student's 
t- test: p = 0.9878 
  
MEMRI – HPC  
(rel. Int.) 
unpaired Student's 
t- test: p = 0.0451 
  
MEMRI – dorsal 
Cortex (rel. Int.) 
unpaired Student's 
t- test: p = 0.7389 
  
12 months post 
TAM 
12 months post 
TAM 
12 months post TAM 12 months post TAM 
OF – Distance  
F1,18 = 2.0899,  
p = 0.1655 
F5,90 = 10.6214,  
p < 0.0001 
F5,90 = 0.7979,  
p = 0.554 
OF – RF 
F1,18 = 1.922,  
p = 0.1826 
F5,90 = 17.9618,  
p < 0.0001 
F5,90 = 1.0419,  
p = 0.3981 
OF – RD 
F1,18 = 2.0907,  
p = 0.1654 
F5,90 = 29.9003,  
p < 0.0001 
F5,90 = 0.6876,  
p = 0.6341 
ASR – I/O   
F1,18 = 1.771,  
p = 0.1999 
F4,72 = 25.8731,  
p < 0.0001 
F4,72 = 1.6286,  
p = 0.1764 
PPI/PPF 55dB 
F1,18 = 3.4761,  
p = 0.0787 
F4,72 = 24.7695,  
p < 0.0001 
F4,72 = 0.4877,  
p = 0.7447 
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PPI/PPF 65dB 
F1,18 = 4.6725,  
p = 0.0444 
F4,72 = 49.0419,  
p < 0.0001 
F4,72 = 3.5408,  
p < 0.0108 
PPI/PPF 75dB 
F1,18 = 2.3708,  
p = 0.141 
F4,72 = 39.2496,  
p < 0.0001 
F4,72 = 1.9241,  
p = 0.1156 
FC - Shock 
Context 
F1,17 = 0.0101,  
p = 0.921 
F8,136 = 3.0414,  
p = 0.0035 
F8,136 = 0.8144,  
p = 0.5911 
FC - Novel 
Context (Tone; 
sec 160 – sec 360) 
F1,18 = 1.6041,  
p = 0.2215 
F10,180 = 18.9005,  
p < 0.0001 
F10,180 = 1.1808,  
p = 0.3065 
WCM - Latency  
F1,18 = 0.7816,  
p = 0.38832 
F4,72 = 61.0448,  
p < 0.0001 
F4,72 = 0.0498,  
p = 0.9952 
WCM - Accuracy  
F1,18 = 0.0747,  
p = 0.7878 
F4,72 = 18.2823,  
p < 0.0001 
F4,72 = 0.2637,  
p = 0.9003 
WCM – WPV  
F1,18 = 0.0,  
p = 0.1 
F4,72 = 21.1298,  
p < 0.0001 
F4,72 = 0.4572,  
p = 0.7668 
WCM – Learners  
day 5 
chi-square (χ
2
) test:  
p = 0.1360 
  
WCM – Learning 
Score   
unpaired Student's 
t- test: p = 0.7887 
  
MEMRI - Whole 
Brain (V.) 
unpaired Student's 
t- test: p = 0.7482 
  
MEMRI – HPC   
(rel. V.) 
unpaired Student's 
t- test: p = 0.5050 
  
MEMRI – dorsal 
Cortex (rel. V.) 
unpaired Student's 
t- test: p = 0.5339 
  
MEMRI – lateral 
ventricles (rel. V.) 
unpaired Student's 
t- test: p = 0.0141 
  
MEMRI – Whole 
Brain (Int.) 
unpaired Student's 
t- test: p = 0.6829 
  
MEMRI – HPC 
(rel. Int.) 
unpaired Student's 
t- test: p = 0.2737 
  
MEMRI – dorsal 
Cortex (rel. Int.) 
unpaired Student's 
t- test: p = 0.4162 
  
20 months post 
TAM 
20 months post 
TAM 
20 months post TAM 20 months post TAM 
OF – Distance  
F1,14 = 2.1789,  
p = 0.1621 
F5,70 = 6.0289,  
p = 0.0001 
F5,70 = 2.8725,  
p = 0.0204 
OF – RF 
F1,14 = 0.6384,  
p = 0.4376 
F5,70 = 13.9468,  
p < 0.0001 
F5,70 = 1.3196,  
p = 0.2659 
OF – RD 
F1,14 = 0.6629,  
p = 0.4292 
F5,70 = 14.6628,  
p < 0.0001 
F5,70 = 0.2592,  
p = 0.9337 
DL - Latency 
unpaired Student's 
t- test: p = 0.6007 
  
DL - Frequency 
unpaired Student's 
t- test: p = 0.0391 
  
DL - Duration 
unpaired Student's 
t- test: p = 0.8802 
  
ASR – I/O   
F1,14 = 0.2393,  
p = 0.6326 
F4,56 = 7.6347,  
p < 0.0001 
F4,56 = 1.1526,  
p = 0.3415 
PPI/PPF 55dB 
F1,14 = 8.2372,  
p = 0.0124 
F4,56 = 0.4781,  
p = 0.7516 
F4,56 = 0.6511,  
p = 0.6285 
PPI/PPF 65dB 
F1,14 = 2.9613,  
p = 0.1073 
F4,56 = 3.7915,  
p = 0.0085 
F4,56 = 1.7373,  
p = 0.1547 
PPI/PPF 75dB 
F1,14 = 2.7699,  
p = 0.1183 
F4,56 = 2.6957,  
p = 0.0399 
F4,56 = 1.4978,  
p = 0.2153 
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FC - Shock 
Context 
F1,13 = 0.0347,  
p = 0.855 
F8,104 = 0.8891,  
p = 0.5285 
F8,104 = 0.796,  
p = 0.6073 
FC - Shock 
Context 
unpaired Student's 
t- test: p = 0.855 
  
FC - Novel 
Context (Tone; 
sec 160 – sec 360) 
F1,13 = 1.8968,  
p = 0.1917 
F10,130 = 9.6903,  
p < 0.0001 
F10,130 = 0.8854,  
p = 0.5487 
FC - Novel 
Context 
(baseline; NO 
tone) 
unpaired Student's 
t- test: p = 0.0004 
  
FC - Novel 
Context (Tone) 
unpaired Student's 
t- test: p = 0.2465 
  
WCM - Latency  
F1,12 = 0.1331,  
p = 0.7216 
F4,48 = 25.0941,  
p < 0.0001 
F4,48 = 1.8526,  
p = 0.1342 
WCM - Accuracy  
F1,12 = 1.0869,  
p = 0.3177 
F4,48 = 22.6341,  
p < 0.0001 
F4,48 = 1.6488,  
p = 0.1775 
WCM – WPV  
F1,12 = 2.2296,  
p = 0.1612 
F4,48 = 8.7452,  
p < 0.0001 
F4,48 = 0.6593,  
p = 0.6233 
WCM – Learners  
day 5 
chi-square (χ
2
) test:  
p = 0.3472 
  
WCM – Learning 
Score  
unpaired Student's 
t- test: p = 0.3177 
  
MEMRI - Whole 
Brain (V.) 
unpaired Student's 
t- test: p = 0.7042 
  
MEMRI – HPC   
(rel. V.) 
unpaired Student's 
t- test: p = 0.5367 
  
MEMRI – dorsal 
Cortex (rel. V.) 
unpaired Student's 
t- test: p = 0.0582 
  
MEMRI – lateral 
ventricles (rel. V.) 
unpaired Student's 
t- test: p = 0.6453 
  
MEMRI – Whole 
Brain (Int.) 
unpaired Student's 
t- test: p = 0.1023 
  
MEMRI – HPC   
(rel. Int.) 
unpaired Student's 
t- test: p = 0.0907 
  
MEMRI – dorsal 
Cortex (rel. Int.) 
unpaired Student's 
t- test: p = 0.8022 
  
Values described in this table refer to the consequences of adult-induced CamKIIα-driven lacZ 
expression (repeated testing until the age of 24 months) as depicted in Figure R-26 through Figure R-
33; pp. 103 - 111. 
 
 
 
 
 
 
 
Appendix – (ii):  lacZ Statistics 
XX 
 
Table St-13: i-R26R:CamKIIα-Cre (2 M) 
Test 
Genotype 
Repeated 
Measure 
G x RM 
Weight 
throughout 
F1,13 = 8.4995,  
p = 0.012 
F6,78 = 180.0353,  
p < 0.0001 
F6,78 = 0.8413,  
p = 0.5419 
BEFORE TAM      
ASR – I/O   
F1,19 = 1.415,  
p = 0.2489 
F4,76 = 49.9942,  
p < 0.0001 
F4,76 = 0.8582,  
p = 0.493 
BEFORE TAM       
PPI/PPF 55dB 
F1,19 = 0.42,  
p = 0.5247 
F4,76 = 33.2342,  
p < 0.0001 
F4,76 = 1.1101,  
p = 0.358 
BEFORE TAM       
PPI/PPF 65dB 
F1,19 = 0.8729,  
p = 0.3619 
F4,76 = 67.138,  
p < 0.0001 
F4,76 = 2.0732,  
p = 0.0926 
BEFORE TAM       
PPI/PPF 75dB 
F1,19 = 0.0008,  
p = 0.9774 
F4,76 = 43.921,  
p < 0.0001 
F4,76 = 1.0058,  
p = 0.4099 
2 months post 
TAM 
2 months post 
TAM 
2 months post TAM 2 months post TAM 
OF – Distance  
F1,20 = 0.8218,  
p = 0.3755 
F5,100 = 35.8268,  
p < 0.0001 
F5,100 = 0.923,  
p = 0.4694 
OF – RF 
F1,20 = 0.0822,  
p = 0.7772 
F5,100 = 2.192,  
p = 0.061 
F5,100 = 1.9324,  
p = 0.0956 
OF – RD 
F1,20 = 0.0025,  
p = 0.961 
F5,100 = 17.6165,  
p < 0.0001 
F5,100 = 2.7191,  
p = 0.024 
ASR – I/O   
F1,20 = 0.0806,  
p = 0.7794 
F4,80 = 39.6687,  
p < 0.0001 
F4,80 = 0.3824,  
p = 0.8206 
PPI/PPF 55dB 
F1,20 = 1.3823,  
p = 0.2535 
F4,80 = 53.0367,  
p < 0.0001 
F4,80 = 0.1968,  
p = 0.9394 
PPI/PPF 65dB 
F1,20 = 4.7549,  
p = 0.0413 
F4,80 = 73.9914,  
p < 0.0001 
F4,80 = 2.6915,  
p = 0.0368 
PPI/PPF 75dB 
F1,20 = 3.8126,  
p = 0.065 
F4,80 = 56.7721,  
p < 0.0001 
F4,80 = 3.3786,  
p = 0.0132 
4 months post 
TAM 
4 months post 
TAM 
4 months post TAM 4 months post TAM 
OF – Distance  
F1,20 = 0.1641,  
p = 0.6897 
F5,100 = 5.1982,  
p = 0.0003 
F5,100 = 0.7526,  
p = 0.5861 
OF – RF 
F1,20 = 1.0041,  
p = 0.3283 
F5,100 = 9.7747,  
p < 0.0001 
F5,100 = 2.4714,  
p = 0.0373 
OF – RD 
F1,20 = 2.3289,  
p = 0.1427 
F5,100 = 13.4694,  
p < 0.0001 
F5,100 = 1.7436,  
p = 0.1316 
ASR – I/O   
F1,19 = 0.0055,  
p = 0.9415 
F4,76 = 41.0405,  
p < 0.0001 
F4,76 = 0.1225,  
p = 0.974 
PPI/PPF 55dB 
F1,18 = 0.7074,  
p = 0.4113 
F4,72 = 47.0134,  
p < 0.0001 
F4,72 = 0.133,  
p = 0.9698 
PPI/PPF 65dB 
F1,18 = 2.4988,  
p = 0.1313 
F4,72 = 68.0795,  
p < 0.0001 
F4,72 = 1.9212,  
p = 0.1161 
PPI/PPF 75dB 
F1,18 = 0.1396,  
p = 0.713 
F4,72 = 41.2855,  
p < 0.0001 
F4,72 = 1.9897,  
p = 0.1052 
Values described in this table refer to the consequences of adult-induced CamKIIα-driven lacZ 
expression (first assessment two months after tamoxifen-treatment) as depicted in Figure R-34 
through Figure R-36; pp. 112 - 114. 
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Table St-14: i-R26R:DAT-Cre 
Test 
Genotype 
Repeated 
Measure 
G x RM 
Survival 
throughout 
Mantel-Cox test:     
p = 0.2276 
  
Survival at end of 
testing 
chi-square (χ
2
) test: 
p = 0.1376 
  
Weight 
throughout 
F1,6 = 0.0114,  
p = 0.9184 
F8,48 = 9.1558,  
p < 0.0001 
F8,48 = 0.5768,  
p = 0.7918 
BEFORE TAM      
OF – Distance  
F1,16 = 0.1897,  
p = 0.669 
F2,32 = 3.875,  
p = 0.0311 
F2,32 = 0.7761,  
p = 0.4686 
BEFORE TAM      
OF – RF 
F1,16 = 0.5468,  
p = 0.4703 
F2,32 = 0.9881,  
p = 0.3834 
F2,32 = 2.458,  
p = 0.1016 
BEFORE TAM      
OF – RD 
F1,16 = 0.0855,  
p = 0.7737 
F2,32 = 1.6051,  
p = 0.2166 
F2,32 = 1.7294,  
p = 0.1936 
BEFORE TAM      
ASR – I/O   
F1,15 = 1.4031,  
p = 0.2546 
F4,60 = 13.7066,  
p < 0.0001 
F4,60 = 1.1422,  
p = 0.3455 
4 months post 
TAM 
4 months post 
TAM 
4 months post TAM 4 months post TAM 
OF – Distance  
F1,14 = 6.0541,  
p = 0.0275 
F5,70 = 7.6943,  
p < 0.0001 
F5,70 = 0.6077,  
p = 0.6942 
OF – RF 
F1,14 = 4.027,  
p = 0.0645 
F5,70 = 6.489,  
p < 0.0001 
F5,70 = 0.1552,  
p = 0.9778 
OF – RD 
F1,14 = 4.5753,  
p = 0.0505 
F5,70 = 14.4918,  
p < 0.0001 
F5,70 = 2.9216,  
p = 0.0188 
DL - Latency 
unpaired Student's 
t- test: p = 0.5624 
  
DL - Frequency 
unpaired Student's 
t- test: p = 0.1238 
  
DL - Duration 
unpaired Student's 
t- test: p = 0.5361 
  
ASR – I/O   
F1,14 = 3.6813,  
p = 0.0756 
F4,56 = 29.398,  
p < 0.0001 
F4,56 = 4.0832,  
p = 0.0057 
PPI/PPF 55dB 
F1,14 = 6.074,  
p = 0.0273 
F4,56 = 47.0182,  
p < 0.0001 
F4,56 = 1.6525,  
p = 0.174 
PPI/PPF 65dB 
F1,14 = 16.8121,  
p = 0.0011 
F4,56 = 120.074,  
p < 0.0001 
F4,56 = 5.529,  
p = 0.0008 
PPI/PPF 75dB 
F1,14 = 3.1837,  
p = 0.0961 
F4,56 = 40.1081,  
p < 0.0001 
F4,56 = 1.0453,  
p = 0.3922 
FC - Shock 
Context 
unpaired Student's 
t- test: p = 0.9085 
  
FC - Novel 
Context 
(Baseline) 
unpaired Student's 
t- test: p = 0.0104 
  
FC - Novel 
Context (Tone) 
unpaired Student's 
t- test: p = 0.2190 
  
FC - Novel 
Context (Tone; 
sec 160 – sec 360) 
F1,14 = 2.1388,  
p = 0.1657 
F10,140 = 25.893,  
p < 0.0001 
F10,140 = 0.2195,  
p = 0.9942 
Extinction training 
F1,14 = 1.0313,  
p = 0.3271 
F3,42 = 15.0493,  
p < 0.0001 
F3,42 = 1.0449,  
p = 0.3827 
WCM - Latency 
(week 1) 
F1,14 = 9.4827,  
p = 0.0082 
F4,56 = 85.0966,  
p < 0.0001 
F4,56 = 1.0,  
p = 0.4153 
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WCM - Accuracy 
(week 1) 
F1,14 = 0.0066,  
p = 0.9365 
F4,56 = 29.7679,  
p < 0.0001 
F4,56 = 0.2038,  
p = 0.9353 
WCM – WPV 
(week 1) 
F1,14 = 1.7534,  
p = 0.2067 
F4,56 = 19.6106,  
p < 0.0001 
F4,56 = 0.1596,  
p = 0.9578 
WCM - Learners 
(week 1) – day 5 
chi-square (χ
2
) test:  
p = 0.5218 
  
WCM – Learning 
Score (week 1)  
unpaired Student's 
t- test: p = 0.9391 
  
WCM - Latency 
(week 2) 
F1,14 = 0.0037,  
p = 0.9526 
F4,56 = 130.1484,  
p < 0.0001 
F4,56 = 0.8863,  
p = 0.4782 
WCM - Accuracy 
(week 2) 
F1,14 = 4.4859,  
p = 0.0526 
F4,56 = 86.582,  
p < 0.0001 
F4,56 = 1.582,  
p = 0.1918 
WCM – WPV 
(week 2) 
F1,14 = 6.6012,  
p = 0.0223 
F4,56 = 123.393,  
p < 0.0001 
F4,56 = 2.4743,  
p = 0.0546 
WCM - Learners 
(week 2) – day 5 
chi-square (χ
2
) 
test:  
p = 0.0209 
  
WCM – Learning 
Score (week 2)  
unpaired Student's 
t- test: p = 0.0526 
  
Rotarod d1 – d6 
F1,13 = 0.1033,  
p = 0.753 
F5,65 = 7.2006,  
p < 0.0001 
F5,65 = 2.3412,  
p = 0.0513 
Rotarod d1 – 
d130 
F1,13 = 0.0438,  
p = 0.8375 
F13,169 = 3.0289,  
p = 0.0005 
F13,169 = 0.7442,  
p = 0.7174 
MEMRI - Whole 
Brain (V.) 
unpaired Student's 
t- test: p = 0.5257 
  
MEMRI – HPC   
(rel. V.) 
unpaired Student's 
t- test: p = 0.1525 
  
MEMRI – dorsal 
HPC (rel. V.) 
unpaired Student's 
t- test: p = 0.0369 
  
MEMRI – ventral 
HPC (rel. V.) 
unpaired Student's 
t- test: p = 0.5815 
  
MEMRI – VTA   
(rel. V.) 
unpaired Student's 
t- test: p = 0.0655 
  
MEMRI – lateral 
ventricles (rel. V.) 
unpaired Student's 
t- test: p = 0.2609 
  
MEMRI – dorsal 
Cortex (rel. V.) 
unpaired Student's 
t- test: p = 0.6122 
  
MEMRI – whole 
brain (rel. Int.) 
unpaired Student's 
t- test: p = 0.0129 
  
MEMRI – dHPC 
(rel. Int.) 
unpaired Student's 
t- test: p = 0.402 
  
MEMRI – vHPC 
(rel. Int.) 
unpaired Student's 
t- test: p = 0.8386 
  
MEMRI – VTA   
(rel. Int.) 
unpaired Student's 
t- test: p = 0.37 
  
MEMRI – dorsal 
Cortex (rel. Int.) 
 
unpaired Student's 
t- test: p = 0.3368 
 
  
 
12 months post 
TAM 
 
12 months post 
TAM 
 
12 months post TAM 
 
12 months post TAM 
 OF – Distance  
F1,13 = 0.3591,  
p = 0.5593 
F5,65 = 3.3136,  
p = 0.0099 
F5,65 = 2.0579,  
p = 0.0821 
OF – RF 
F1,13 = 1.8771,  
p = 0.1939 
F5,65 = 10.1187,  
p < 0.0001 
F5,65 = 1.6046,  
p = 0.1714 
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OF – RD 
F1,13 = 1.7182,  
p = 0.2126 
F5,65 = 5.4686,  
p = 0.0003 
F5,65 = 1.3766,  
p = 0.2447 
ASR – I/O   
F1,13 = 0.4632,  
p = 0.5081 
F4,52 = 6.4778,  
p = 0.0003 
F4,52 = 0.6074,  
p = 0.6591 
PPI/PPF 55dB 
F1,12 = 0.6037,  
p = 0.4522 
F4,48 = 21.7362,  
p < 0.0001 
F4,48 = 1.96,  
p = 0.1157 
PPI/PPF 65dB 
F1,12 = 0.2458,  
p = 0.629 
F4,48 = 74.2032,  
p < 0.0001 
F4,48 = 3.8452,  
p = 0.0086 
PPI/PPF 75dB 
F1,12 = 0.0111,  
p = 0.9178 
F4,48 = 32.7846,  
p < 0.0001 
F4,48 = 0.8127,  
p = 0.5233 
FC - Shock 
Context 
unpaired Student's 
t- test: p = 0.537 
  
FC - Novel 
Context (Baseline) 
unpaired Student's 
t- test: p = 0.3307 
  
FC - Novel 
Context (Tone) 
unpaired Student's 
t- test: p = 0.2696 
  
FC - Novel 
Context (Tone; 
sec 160 – sec 360) 
F1,13 = 1.2961,  
p = 0.2755 
F10,130 = 19.038,  
p < 0.0001 
F10,130 = 0.771,  
p = 0.6564 
WCM - Latency  
F1,13 = 1.0164,  
p = 0.3318 
F4,52 = 66.4581,  
p < 0.0001 
F4,52 = 0.3161,  
p = 0.8659 
WCM - Accuracy  
F1,13 = 3.8901,  
p = 0.0702 
F4,52 = 26.3245,  
p < 0.0001 
F4,52 = 3.4866,  
p = 0.0135 
WCM – WPV  
F1,13 = 6.6999,  
p = 0.0225 
F4,52 = 19.4761,  
p < 0.0001 
F4,52 = 4.3029,  
p = 0.0044 
WCM - Learners 
day 5 
chi-square (χ
2
) test:  
p = 0.2685 
  
WCM – Learning 
Score  
unpaired Student's 
t- test: p = 0.0702 
  
MEMRI - Whole 
Brain (V.) 
unpaired Student's 
t- test: p = 0.0847 
  
MEMRI – HPC   
(rel. V.) 
unpaired Student's 
t- test: p = 0.2244 
  
MEMRI – dorsal 
HPC  (rel. V.) 
unpaired Student's 
t- test: p = 0.4937 
  
MEMRI – ventral 
HPC  (rel. V.) 
unpaired Student's 
t- test: p = 0.9327 
  
MEMRI – VTA   
(rel. V.) 
unpaired Student's 
t- test: p = 0.0694 
  
MEMRI – lateral 
ventricles (rel. V.) 
unpaired Student's 
t- test: p = 0.0564 
  
MEMRI – dorsal 
Cortex  (rel. V.) 
unpaired Student's 
t- test: p = 0.8529 
  
MEMRI – whole 
brain (rel. Int.) 
unpaired Student's 
t- test: p = 0.5662 
  
MEMRI – dHPC 
(rel. Int.) 
unpaired Student's 
t- test: p = 0.9257 
  
MEMRI – vHPC 
(rel. Int.) 
unpaired Student's 
t- test: p = 0.6879 
  
MEMRI – VTA   
(rel. Int.) 
unpaired Student's 
t- test: p = 0.1226 
  
MEMRI – dorsal 
Cortex (rel. Int.) 
unpaired Student's 
t- test: p = 0.0393 
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20 months post 
TAM 
20 months post 
TAM 
20 months post TAM 20 months post TAM 
OF – Distance  
F1,9 = 0.8255,  
p = 0.3873 
F5,45 = 1.0127,  
p = 0.4214 
F5,45 = 0.2022,  
p = 0.9599 
OF – RF 
F1,9 = 4.5379,  
p = 0.062 
F5,45 = 3.8853,  
p = 0.0052 
F5,45 = 1.3538,  
p = 0.2596 
OF – RD 
F1,9 = 4.0962,  
p = 0.0737 
F5,45 = 4.7354,  
p = 0.0015 
F5,45 = 1.8327,  
p = 0.1256 
DL - Latency 
unpaired Student's 
t- test: p = 0.5645 
  
DL - Frequency 
unpaired Student's 
t- test: p = 0.6877 
  
DL - Duration 
unpaired Student's 
t- test: p = 0.8286 
  
ASR – I/O   
F1,9 = 1.0448,  
p = 0.3334 
F4,36 = 3.1514,  
p = 0.0255 
F4,36 = 0.8031,  
p = 0.5313 
PPI/PPF 55dB 
F1,9 = 0.2885,  
p = 0.6042 
F4,36 = 1.291,  
p = 0.2918 
F4,36 = 0.0869,  
p = 0.986 
PPI/PPF 65dB 
F1,9 = 1.1591,  
p = 0.3097 
F4,36 = 1.5189,  
p = 0.2173 
F4,36 = 0.4593,  
p = 0.765 
PPI/PPF 75dB 
F1,9 = 0.1279,  
p = 0.7289 
F4,36 = 3.2065,  
p = 0.0238 
F4,36 = 1.486,  
p = 0.2268 
FC - Shock 
Context 
unpaired Student's 
t- test: p = 0.6325 
  
FC - Shock 
Context 
F1,9 = 0.245,  
p = 0.6325 
F8,72 = 3.869,  
p = 0.0008 
F8,72 = 1.1789,  
p = 0.3238 
FC - Novel 
Context (no Tone) 
unpaired Student's 
t- test: p = 0.082 
  
FC - Novel 
Context (Tone) 
unpaired Student's 
t- test: p = 0.1258 
  
FC - Novel 
Context (Tone; 
sec 160 – sec 360) 
F1,9 = 3.3123,  
p = 0.1021 
F10,90 = 8.5428,  
p = 0.0008 
F10,90 = 1.462,  
p = 0.1669 
WCM - Latency  
F1,8 = 0.285,  
p = 0.6079 
F4,32 = 29.224,  
p < 0.0001 
F4,32 = 0.5756,  
p = 0.6823 
WCM - Accuracy  
F1,8 = 1.0516,  
p = 0.3351 
F4,32 = 9.3647,  
p < 0.0001 
F4,32 = 0.549,  
p = 0.7010 
WCM – WPV  
F1,8 = 0.5215,  
p = 0.4908 
F4,32 = 3.443,  
p = 0.0189 
F4,32 = 0.6634,  
p = 0.622 
WCM – Learners 
– day 5 
chi-square (χ
2
) test:  
p = 0.091 
  
WCM – Learning 
Score  
unpaired Student's 
t- test: p = 0.3351 
  
MEMRI - Whole 
Brain (V.) 
unpaired Student's 
t- test: p = 0.4318 
  
MEMRI – HPC   
(rel. V.) 
unpaired Student's 
t- test: p = 0.4472 
  
MEMRI – dorsal 
HPC (rel. V.) 
unpaired Student's 
t- test: p = 0.8267 
  
MEMRI – ventral 
HPC (rel. V.) 
unpaired Student's 
t- test: p = 0.0386 
  
MEMRI – VTA   
(rel. V.) 
unpaired Student's 
t- test: p = 0.3358 
  
MEMRI – lateral 
ventricles (rel. V.) 
unpaired Student's 
t- test: p = 0.1281 
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MEMRI – dorsal 
Cortex (rel. V.) 
unpaired Student's 
t- test: p = 0.5963 
  
MEMRI – whole 
brain (rel. Int.) 
unpaired Student's 
t- test: p = 0.2674 
  
MEMRI – dHPC 
(rel. Int.) 
unpaired Student's 
t- test: p = 0.1674 
  
MEMRI – vHPC 
(rel. Int.) 
unpaired Student's 
t- test: p = 0.2075 
  
MEMRI – VTA   
(rel. Int.) 
unpaired Student's 
t- test: p = 0.1545 
  
MEMRI – dorsal 
Cortex (rel. Int.) 
unpaired Student's 
t- test: p = 0.9377 
  
 
Values described in this table refer to the consequences of adult-induced DAT-driven lacZ expression 
(repeated testing until the age of 24 months) as depicted in Figure R-37 through Figure R-45; pp. 115 
- 124. 
 
 
Table St-15: i-R26R:DAT-Cre (2 M) 
Test 
Genotype 
Repeated 
Measure 
G x RM 
Weight 
throughout 
F1,13 = 1.2756,  
p = 0.2791 
F6,78 = 35.0651,  
p < 0.0001 
F6,78 = 0.475,  
p = 0.8249 
BEFORE TAM      
ASR – I/O   
F1,19 = 0.9877,  
p = 0.3328 
F4,76 = 34.7513,  
p < 0.0001 
F4,76 = 0.4823,  
p = 0.7487 
BEFORE TAM       
PPI/PPF 55dB 
F1,19 = 0.0221,  
p = 0.8833 
F4,76 = 37.9042,  
p < 0.0001 
F4,76 = 0.1333,  
p = 0.9697 
BEFORE TAM       
PPI/PPF 65dB 
F1,19 = 0.0424,  
p = 0.839 
F4,76 = 48.3128,  
p < 0.0001 
F4,76 = 1.0719,  
p = 0.3764 
BEFORE TAM       
PPI/PPF 75dB 
F1,19 = 1.1018,  
p = 0.307 
F4,76 = 40.0038,  
p < 0.0001 
F4,76 = 1.5458,  
p = 0.1975 
2 months post 
TAM 
2 months post 
TAM 
2 months post TAM 2 months post TAM 
OF – Distance  
F1,19 = 0.2599,  
p = 0.6161 
F5,95 = 29.1,  
p < 0.0001 
F5,95 = 0.4867,  
p = 0.7854 
OF – RF 
F1,19 = 2.1966,  
p = 0.1547 
F5,95 = 6.8729,  
p < 0.0001 
F5,95 = 0.6184,  
p = 0.6861 
OF – RD 
F1,19 = 2.3868,  
p = 0.1389 
F5,95 = 22.4351,  
p < 0.0001 
F5,95 = 0.4598,  
p = 0.8052 
ASR – I/O   
F1,19 = 1.4841,  
p = 0.238 
F4,76 = 40.6194,  
p < 0.0001 
F4,76 = 1.1076,  
p = 0.3592 
PPI/PPF 55dB 
F1,19 = 0.7671,  
p = 0.392 
F4,76 = 43.8423,  
p < 0.0001 
F4,76 = 0.6968,  
p = 0.5965 
PPI/PPF 65dB 
F1,19 = 0.475,  
p = 0.499 
F4,76 = 55.2023,  
p < 0.0001 
F4,76 = 2.6655,  
p = 0.0387 (no post hoc 
significance) 
PPI/PPF 75dB 
F1,19 = 0.1381,  
p = 0.7143 
F4,76 = 11.7809,  
p < 0.0001 
F4,76 = 0.3929,  
p = 0.8131 
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4 months post 
TAM 
4 months post 
TAM 
4 months post TAM 4 months post TAM 
OF – Distance  
F1,19 = 0.0648,  
p = 0.8018 
F5,95 = 7.0307,  
p < 0.0001 
F5,95 = 3.3869,  
p = 0.0074 (no post hoc 
significance) 
OF – RF 
F1,19 = 4.6838,  
p = 0.0434 
F5,95 = 21.5145,  
p < 0.0001 
F5,95 = 0.8206,  
p = 0.538 
OF – RD 
F1,19 = 5.1688,  
p = 0.0348 
F5,95 = 38.2574,  
p < 0.0001 
F5,95 = 2.5291,  
p = 0.034 
ASR – I/O   
F1,19 = 1.6084,  
p = 0.22 
F4,76 = 49.0303,  
p < 0.0001 
F4,76 = 1.2016,  
p = 0.3171 
PPI/PPF 55dB 
F1,19 = 1.1132,  
p = 0.3046 
F4,76 = 41.5202,  
p < 0.0001 
F4,76 = 0.3967,  
p = 0.8104 
PPI/PPF 65dB 
F1,19 = 2.3231,  
p = 0.1439 
F4,76 = 41.0444,  
p < 0.0001 
F4,76 = 0.3185,  
p = 0.8648 
PPI/PPF 75dB 
F1,19 = 1.8241,  
p = 0.1927 
F4,76 = 30.5231,  
p < 0.0001 
F4,76 = 0.3882,  
p = 0.8164 
12 months post 
TAM 
12 months post 
TAM 
12 months post TAM 12 months post TAM 
OF – Distance  
F1,13 = 0.111,  
p = 0.7443 
F5,65 = 7.2016,  
p < 0.0001 
F5,65 = 0.6297,  
p = 0.6777 
OF – RF 
F1,13 = 2.235,  
p = 0.1588 
F5,65 = 7.3622,  
p < 0.0001 
F5,65 = 1.7122,  
p = 0.1443 
OF – RD 
F1,13 = 4.2126,  
p = 0.0608 
F5,65 = 14.7483,  
p < 0.0001 
F5,65 = 0.9849,  
p = 0.4338 
ASR – I/O   
F1,13 = 2.0395,          
p = 0.1768 
F4,52 = 18.3591,                
p < 0.0001 
F4,52 = 2.7737,                   
p = 0.0365 
PPI/PPF 55dB 
F1,13 = 0.0116,  
p = 0.9159 
F4,52 = 25.1996,  
p < 0.0001 
F4,52 = 0.5134,  
p = 0.7262 
PPI/PPF 65dB 
F1,13 = 0.7662,  
p = 0.3973 
F4,52 = 51.5481,  
p < 0.0001 
F4,52 = 0.1061,  
p = 0.9799 
PPI/PPF 75dB 
F1,13 = 1.1325,  
p = 0.3066 
F4,52 = 29.1374,  
p < 0.0001 
F4,52 = 0.1562,  
p = 0.9594 
 
Values described in this table refer to the consequences of adult-induced DAT-driven lacZ expression 
(first assessment two months after tamoxifen-treatment) as depicted in Figure R-46 through Figure 
R-48; pp. 125 - 127. 
 
 
 
 
 
 
Appendix – (ii):  lacZ Statistics 
XXVII 
 
Table St-16: i-DAT-Cre 
Test 
Genotype 
Repeated 
Measure 
G x RM 
Weight 
throughout 
F1,16 = 0.0256,  
p = 0.8748 
F5,80 = 98.4216,  
p < 0.0001 
F5,80 = 0.9411,  
p = 0.4591 
BEFORE TAM      
OF – Distance  
F1,17 = 0.3715,  
p = 0.5503 
F5,85 = 23.724,  
p < 0.0001 
F5,85 = 1.3796,  
p = 0.2401 
BEFORE TAM      
OF – RF 
F1,17 = 0.1427,  
p = 0.7103 
F5,85 = 3.1809,  
p = 0.0111 
F5,85 = 0.5857,  
p = 0.7109 
BEFORE TAM      
OF – RD 
F1,17 = 0.0518,  
p = 0.8227 
F5,85 = 6.0059,  
p < 0.0001 
F5,85 = 2.0002  
p = 0.0868 
BEFORE TAM      
ASR – I/O   
F1,16 = 0.2186,  
p = 0.6464 
F4,64 = 53.3645,  
p < 0.0001 
F4,64 = 0.5261,  
p = 0.7169 
BEFORE TAM       
PPI/PPF 55dB 
F1,17 = 0.0747,  
p = 0.7879 
F4,68 = 36.836,  
p < 0.0001 
F4,68 = 0.6538,  
p = 0.6262 
BEFORE TAM       
PPI/PPF 65dB 
F1,17 = 0.5723,  
p = 0.4597 
F4,68 = 48.5333,  
p < 0.0001 
F4,68 = 1.8578,  
p = 0.1279 
BEFORE TAM       
PPI/PPF 75dB 
F1,17 = 0.8537,  
p = 0.3684 
F4,68 = 30.4654,  
p < 0.0001 
F4,68 = 0.8693,  
p = 0.487 
4 months post 
TAM 
4 months post 
TAM 
4 months post TAM 4 months post TAM 
OF – Distance  
F1,16 = 1.6972,  
p = 0.2111 
F5,80 = 29.1096,  
p < 0.0001 
F5,80 = 0.3926,  
p = 0.8526 
OF – RF 
F1,16 = 0.0136,  
p = 0.9086 
F5,80 = 6.4694,  
p < 0.0001 
F5,80 = 1.7282,  
p = 0.1376 
OF – RD 
F1,16 = 0.2311,  
p = 0.6372 
F5,80 = 17.1688,  
p < 0.0001 
F5,80 = 0.2732,  
p = 0.9265 
ASR – I/O   
F1,16 = 0.5752,  
p = 0.4592 
F4,64 = 49.7213,  
p < 0.0001 
F4,64 = 0.9638,  
p = 0.4336 
PPI/PPF 55dB 
F1,16 = 2.6933,  
p = 0.1203 
F4,64 = 51.1624,  
p < 0.0001 
F4,64 = 0.6594,  
p = 0.6225 
PPI/PPF 65dB 
F1,16 = 3.2573,  
p = 0.09 
F4,64 = 138.4445,  
p < 0.0001 
F4,64 = 2.0091,  
p = 0.1038 
PPI/PPF 75dB 
F1,16 = 0.8795,  
p = 0.3623 
F4,64 = 102.4374,  
p < 0.0001 
F4,64 = 1.1943,  
p = 0.3219 
WCM - Latency 
(week 1) 
F1,16 = 0.0948,  
p = 0.7622 
F4,64 = 99.5433,  
p < 0.0001 
F4,64 = 0.8141,  
p = 0.5208 
WCM – Accuracy 
(week 1) 
F1,16 = 3.1208,          
p = 0.0964 
F4,64 = 39.648,                
p < 0.0001 
F4,64 = 0.2641,                   
p = 0.8999 
WCM – WPV 
(week 1) 
F1,16 = 0.143,  
p = 0.7103 
F4,64 = 41.2757,  
p < 0.0001 
F4,64 = 1.1891,  
p = 0.3241 
WCM - Learners 
(week 1) – day 5 
chi-square (χ
2
) test:  
p = 0.0704 
  
WCM – Learning 
Score (week 1) 
unpaired Student's 
t- test: p = 0.0959 
  
WCM - Latency 
(week 2) 
F1,16 = 0.8137,  
p = 0.3804 
F4,64 = 95.7352,  
p < 0.0001 
F4,64 = 2.1944,  
p = 0.0795 
WCM - Accuracy 
(week 2) 
F1,16 = 0.1876,  
p = 0.6707 
F4,64 = 55.5152,  
p < 0.0001 
F4,64 = 1.046  
p = 0.3906 
WCM – WPV 
(week 2) 
F1,16 = 1.4779,  
p = 0.2417 
F4,64 = 80.456,  
p < 0.0001 
F4,64 = 1.755,  
p = 0.1489 
WCM - Learners 
(week 2) – day 5 
chi-square (χ
2
) test:  
p = 0.7324 
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WCM – Learning 
Score (week 2 d5) 
unpaired Student's 
t- test: p = 0.6707 
  
MEMRI - Whole 
Brain (V.) 
unpaired Student's 
t- test: p = 0.0238 
  
MEMRI – HPC   
(rel. V.) 
unpaired Student's 
t- test: p = 0.5867 
  
MEMRI – dorsal 
HPC (rel. V.) 
unpaired Student's 
t- test: p = 0.3702 
  
MEMRI – ventral 
HPC (rel. V.) 
unpaired Student's 
t- test: p = 0.0051 
  
MEMRI – dorsal 
Cortex (rel. V.) 
unpaired Student's 
t- test: p = 0.2365 
  
MEMRI – lateral 
ventricles (rel. V.) 
unpaired Student's 
t- test: p = 0.2582 
  
MEMRI – VTA   
(rel. V.) 
unpaired Student's 
t- test: p = 0.2641 
  
MEMRI – HPC   
(rel. Intensity) 
unpaired Student's 
t- test: p = 0.2219 
  
MEMRI – VTA   
(rel. Intensity) 
unpaired Student's 
t- test: p = 0.2489 
  
Values described in this table refer to the consequences of adult-induced DAT-driven Cre expression 
(i.e. Cre-translocation control) as depicted in Figure R-49 through Figure R-51; pp. 129 - 131. 
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8.1.3. (iii) PTSD & Age statistics 
 
Abbreviations used for (iii) PTSD & Age statistics: 
 
(1)   =   one month after shock 
(2)   =   eight to nine months after shock 
ASR  =  acoustic startle response 
Cort   =   corticosterone level 
d  =  day 
DL  =   dark-light box 
F   =   freezing 
FC  =   fear conditioning 
I/O  =  input/ output 
LS   =   learning score 
m   =  memory (WCM – recall) 
MSS   =   mouse shaker stress 
NS  =   no shock 
OF  =   open field  
PPI/F     =   pre-pulse inhibition/ facilitation 
S   =   shock 
WCM   =  water cross maze 
WPV  =   wrong platform visits 
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Table St-17: PTSD & Age 
Test Group Repeated Measure G x RM 
Weight throughout 
F4,73 = 3.6638,  
p = 0.0089 
F2,146 = 186.2033,  
p < 0.0001 
F8,146 = 0.8679,  
p = 0.5452 
ASR – I/O (1) 
F1,62 = 4.9026,  
p = 0.0305 
F4,248 = 161.7626,  
p < 0.0001 
F4,248 = 5.3816,  
p = 0.0004 
FC - Shock Context (1) 
F1,62 = 259.7375,  
p < 0.0001 
F8,496 = 2.7332,  
p = 0.0059 
F8,496 = 3.7898,  
p = 0.0002 
FC - Shock Context (1)  
unpaired Student's t- 
test: p < 0.0001   
FC - Novel Context      
(sec 20 - 360; 1) 
F1,62 = 57.5281,  
p < 0.0001 
F17,1054 = 38.6663,  
p < 0.0001 
F17,1054 = 29.417,  
p < 0.0001 
FC - Novel Context      
(sec 160 - 360; 1) 
F1,62 = 75.706,  
p < 0.0001 
F10,620 = 30.3437,  
p < 0.0001 
F10,620 = 24.2529,  
p < 0.0001 
FC - Novel Context    
(Baseline; 1) 
unpaired Student's t- 
test: p < 0.0001   
FC - Novel Context    
(Tone; 1) 
unpaired Student's t- 
test: p < 0.0001   
OF – Distance (1) 
F1,62 = 1.4579,  
p = 0.2319 
F5,310 = 39.3324,  
p < 0.0001 
F5,310 = 0.9222,  
p = 0.4667 
Cort before – after MSS 
unpaired Student's t- 
test: p < 0.0001   
Cort before MSS: NS – S 
unpaired Student's t- 
test: p < 0.0682   
Cort after MSS: NS – S  
unpaired Student's t- 
test: p < 0.2033   
DL – Latency NS – S (all) 
unpaired Student's t- 
test: p < 0.0029   
DL – Latency NS vs. NS + 
MSS 
unpaired Student's t- 
test: p < 0.2028   
DL – Latency NS vs. S 
unpaired Student's t- 
test: p < 0.0165   
DL – Latency NS vs. S + 
MSS 
unpaired Student's t- 
test: p < 0.0043   
DL – Duration NS – S (all) 
unpaired Student's t- 
test: p < 0.0457   
DL – Duration NS vs. NS + 
MSS 
unpaired Student's t- 
test: p < 0.0046   
DL – Duration NS vs. S 
unpaired Student's t- 
test: p < 0.0031   
DL – Duration NS vs. S + 
MSS 
unpaired Student's t- 
test: p < 0.0144   
DL – Frequency NS – S 
(all) 
unpaired Student's t- 
test: p < 0.0925   
DL – Frequency NS vs. NS 
+ MSS 
unpaired Student's t- 
test: p < 0.8423 
  
DL – Frequency NS vs. S 
unpaired Student's t- 
test: p < 0.5209   
 
DL – Frequency NS vs. S + 
MSS 
 
unpaired Student's t- 
test: p < 0.029 
  
OF – Distance (2) 
F4,73 = 0.7433,  
p = 0.5656 
F5,365 = 56.5694,  
p < 0.0001 
F20,365 = 0.9405,  
p = 0.5356 
ASR – I/O (2) NS vs. S (all) 
F1,58 = 0.5715,  
p = 0.4527 
F4,232 = 144.4399,  
p < 0.0001 
F4,232 = 0.7492,  
p = 0.5594 
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ASR – I/O (2) S vs. S+MSS 
F1,28 = 2.2603,  
p = 0.1439 
F4,112 = 78.4201,  
p < 0.0001 
F4,112 = 1.4373,  
p = 0.2264 
FC - Shock Context (2) 
F3,58 = 15.5615,  
p < 0.0001 
F8,464 = 11.0527,  
p < 0.0001 
F24,464 = 1.5262,  
p = 0.0539 
FC - Shock Context (2)    
NS vs. S (all)  
unpaired Student's t- 
test: p < 0.0001   
FC - Shock Context (2)     
NS vs. NS + MSS 
unpaired Student's t- 
test: p = 0.9047   
FC - Shock Context (2)    
NS vs. S  
unpaired Student's t- 
test: p = 0.0004   
FC - Shock Context (2)    
NS vs. S + MSS 
unpaired Student's t- 
test: p < 0.0001   
FC - Shock Context (2)        
S vs. S + MSS 
unpaired Student's t- 
test: p = 0.1651   
FC - Novel Context      
(sec 20 - 360; 2) 
F3,58 = 3.5834,  
p = 0.019 
F17,986 = 38.3693,  
p < 0.0001 
F51,986 = 2.7387,  
p < 0.0001 
FC - Novel Context          
(2; Tone)  NS – S (all)  
unpaired Student's t- 
test: p < 0.0001   
FC - Novel Context            
(2; Tone)  NS vs. NS + MSS 
unpaired Student's t- 
test: p < 0.8323   
FC - Novel Context          
(2; Tone)  NS vs. S  
unpaired Student's t- 
test: p = 0.0041   
FC – Novel Context          
(2; Tone)  NS vs. S + MSS 
unpaired Student's t- 
test: p = 0.0101   
Object Spatial 
Recognition sample left – 
right  
1way ANOV.A:  
F9,146 = 0.4049,  
p = 0.9309 
  
Object Spatial 
Recognition choice old – 
new  
1way ANOV.A:  
F9,146 = 0.3551,  
p = 0.9542 
  
Object Spatial 
Recognition 
discrimination index 
1way ANOV.A:  
F9,146 = 1.16,  
p = 0.3354 
  
WCM - Latency d1 – d7 
F4,73 = 2.0559,  
p = 0.0954 
F6,438 = 186.4304,  
p < 0.0001 
F24,438 = 1.0543,  
p = 0.3943 
WCM - Accuracy d1 – d7 
F4,73 = 0.1739,  
p = 0.9511 
F6,438 = 180.1221,  
p < 0.0001 
F24,438 = 1.3409,  
p = 0.1314 
WCM - Learners  – day 7 
100% of all groups have 
learned --> chi-square 
(χ
2
) test not possible 
  
WCM – Learning Score    
d1 – d7  
1way ANOV.A:  
F4,73 = 0.1733   
p = 0.9118 
  
WCM - Latency  m1 – m3 
(NS vs. S+MSS) 
F1,29 = 0.3007,  
p = 0.5876 
F2,58 = 16.4682,  
p < 0.0001 
F2,58 = 0.1543,  
p = 0.8573 
WCM - Accuracy rm1 – 
m3 (NS vs. S+MSS) 
F1,29 = 0.3487,  
p = 0.5594 
F2,58 = 24.3602,  
p < 0.0001 
F2,58 = 0.2951,  
p = 0.7456 
 
WCM - Learners  – m3   
(NS vs. S+MSS) 
 
chi-square (χ
2
) test:  
p = 0.9449 
  
WCM – Learning Score     
m1 – m3 (NS vs. S+MSS) 
unpaired Student's t- 
test: p = 0.5587   
Correlation Context 
Freezing vs. WCM LS d1-7 
(S+MSS) 
Pearson r² = 0.2481, 
P = 0.0496   
Correlation Context Pearson r² = 0.452,   
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Freezing vs. WCM LS d1-7 
(S+MSS; high responder) 
P = 0.0678 
Correlation Context 
Freezing vs. WCM LS d1-7 
(S+MSS; low responder) 
Pearson r² = 0.09, 
P = 0.2228   
Correlation Tone Freezing 
vs. WCM LS d1-7 (S+MSS) 
Pearson r² = 0.09, 
P = 0.0649   
Correlation Context F vs. 
WCM Accuracy m1 
(S+MSS) 
Pearson r² = 0.238, 
P = 0.0552   
 
Values described in this table refer to the consequences of one or two stressful life-events on 
cognitive performances in (middle) age as depicted in Figure R-52 through Figure R-59; pp. 133 - 140. 
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8.2. 2D-PAGE Proteomic analyses of R26R:Nex-Cre mice (dHPC micro punches) 
 
The following tables list the proteins that the differentially expressed spots (detected via 2D-PAGE) 
could entail. Proteins are ordered according to their likelihood to represent the spot (i.e. protein 
score). Customarily, only the first protein-hit (highest protein score = highest likelihood) is considered 
per spot for further investigations. Proteomic lists were provided by Chi-Ya Kao (PhD student) & Prof. 
Dr. C. Turck (Group leader Proteomics and Biomarkers) at the Max Planck Institute of Psychiatry. 
 
Table P-1: Spot 1: higher expression in R26R:Nex-Cre- mice (R26R:Nex-Cre- > R26R:Nex-Cre+) 
Protein 
Hit 
Number 
Protein 
Abbreviation 
Protein description 
Protein 
Score 
Protei
n Mass 
Protein 
Matches 
Protein 
Cover 
1 CH60_MOUSE 
60 kDa heat shock protein, mitochondrial OS=Mus 
musculus GN=Hspd1 PE=1 SV=1 
5526 61088 249 50,4 
2 HSP7C_MOUSE 
Heat shock cognate 71 kDa protein OS=Mus 
musculus GN=Hspa8 PE=1 SV=1 
1130 71055 36 39,5 
3 AINX_MOUSE 
Alpha-internexin OS=Mus musculus GN=Ina PE=1 
SV=2 
947 55879 38 50,8 
4 KPYM_MOUSE 
Pyruvate kinase isozymes M1/M2 OS=Mus musculus 
GN=Pkm2 PE=1 SV=4 
630 58378 19 29 
5 PP2BA_MOUSE 
Serine/threonine-protein phosphatase 2B catalytic 
subunit alpha isoform OS=Mus musculus GN=Ppp3ca 
PE=1 SV=1 
550 59291 21 27,6 
6 UBP14_MOUSE 
Ubiquitin carboxyl-terminal hydrolase 14 OS=Mus 
musculus GN=Usp14 PE=1 SV=3 
510 56422 15 24,1 
7 GDIA_MOUSE 
Rab GDP dissociation inhibitor alpha OS=Mus 
musculus GN=Gdi1 PE=1 SV=3 
384 51059 13 29,1 
8 VATA_MOUSE 
V-type proton ATPase catalytic subunit A OS=Mus 
musculus GN=Atp6v1a PE=1 SV=2 
326 68625 17 20,3 
9 HNRPK_MOUSE 
Heterogeneous nuclear ribonucleoprotein K OS=Mus 
musculus GN=Hnrnpk PE=1 SV=1 
325 51230 15 27,4 
10 TCPQ_MOUSE 
T-complex protein 1 subunit theta OS=Mus musculus 
GN=Cct8 PE=1 SV=3 
311 60088 12 21,4 
11 CPNE6_MOUSE Copine-6 OS=Mus musculus GN=Cpne6 PE=1 SV=1 305 62597 12 19,2 
12 UAP1L_MOUSE 
UDP-N-acetylhexosamine pyrophosphorylase-like 
protein 1 OS=Mus musculus GN=Uap1l1 PE=2 SV=1 
302 57319 16 28,4 
13 TBA4A_MOUSE 
Tubulin alpha-4A chain OS=Mus musculus 
GN=Tuba4a PE=1 SV=1 
291 50634 11 19,6 
14 MPP6_MOUSE 
MAGUK p55 subfamily member 6 OS=Mus musculus 
GN=Mpp6 PE=1 SV=1 
279 62877 16 21,5 
15 TBA1B_MOUSE 
Tubulin alpha-1B chain OS=Mus musculus 
GN=Tuba1b PE=1 SV=2 
267 50804 11 19,5 
16 TBA1A_MOUSE 
Tubulin alpha-1A chain OS=Mus musculus 
GN=Tuba1a PE=1 SV=1 
264 50788 11 19,5 
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17 ACTB_MOUSE 
Actin, cytoplasmic 1 OS=Mus musculus GN=Actb 
PE=1 SV=1 
256 42052 11 27,7 
18 GRP75_MOUSE 
Stress-70 protein, mitochondrial OS=Mus musculus 
GN=Hspa9 PE=1 SV=2 
251 73768 7 11,2 
19 PP2BB_MOUSE 
Serine/threonine-protein phosphatase 2B catalytic 
subunit beta isoform OS=Mus musculus GN=Ppp3cb 
PE=2 SV=2 
243 59820 10 14,9 
20 SYT1_MOUSE 
Synaptotagmin-1 OS=Mus musculus GN=Syt1 PE=1 
SV=1 
242 47730 9 19,7 
21 CAP2_MOUSE 
Adenylyl cyclase-associated protein 2 OS=Mus 
musculus GN=Cap2 PE=1 SV=1 
242 53114 10 16,6 
22 SF3A3_MOUSE 
Splicing factor 3A subunit 3 OS=Mus musculus 
GN=Sf3a3 PE=2 SV=2 
165 59147 7 11 
23 PAK1_MOUSE 
Serine/threonine-protein kinase PAK 1 OS=Mus 
musculus GN=Pak1 PE=1 SV=1 
148 61041 6 7,2 
24 ACTBL_MOUSE 
Beta-actin-like protein 2 OS=Mus musculus 
GN=Actbl2 PE=2 SV=1 
130 42319 7 15,7 
25 IF4B_MOUSE 
Eukaryotic translation initiation factor 4B OS=Mus 
musculus GN=Eif4b PE=1 SV=1 
127 68970 4 6,5 
26 DPYL2_MOUSE 
Dihydropyrimidinase-related protein 2 OS=Mus 
musculus GN=Dpysl2 PE=1 SV=2 
126 62638 8 11,7 
27 CPNE1_MOUSE Copine-1 OS=Mus musculus GN=Cpne1 PE=1 SV=1 116 59591 4 6,7 
28 NPTXR_MOUSE 
Neuronal pentraxin receptor OS=Mus musculus 
GN=Nptxr PE=2 SV=1 
100 52822 4 5,1 
29 COR1C_MOUSE Coronin-1C OS=Mus musculus GN=Coro1c PE=1 SV=2 87 53771 5 9,5 
30 PAK3_MOUSE 
Serine/threonine-protein kinase PAK 3 OS=Mus 
musculus GN=Pak3 PE=1 SV=2 
79 62701 5 6,8 
31 PERI_MOUSE Peripherin OS=Mus musculus GN=Prph PE=1 SV=2 70 54349 6 11,2 
32 RN181_MOUSE 
RING finger protein 181 OS=Mus musculus 
GN=Rnf181 PE=2 SV=1 
48 19487 7 10,3 
33 SEPT8_MOUSE Septin-8 OS=Mus musculus GN=Sept8 PE=1 SV=4 30 50123 4 7,7 
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Table P-2: Spot 2: higher expression in R26R:Nex-Cre+ mice (R26R:Nex-Cre+ > R26R:Nex-Cre-) 
Protein 
Hit 
Number 
Protein 
Abbreviation 
Protein description 
Protein 
Score 
Protei
n Mass 
Protein 
Matches 
Protein 
Cover 
1 CAZA2_MOUSE 
F-actin-capping protein subunit alpha-2 OS=Mus 
musculus GN=Capza2 PE=1 SV=3 
1966 33118 69 46,2 
2 LDHB_MOUSE 
L-lactate dehydrogenase B chain OS=Mus musculus 
GN=Ldhb PE=1 SV=2 
1096 36834 57 47 
3 DDAH1_MOUSE 
N(G) N(G)-dimethylarginine 
dimethylaminohydrolase 1 OS=Mus musculus 
GN=Ddah1 PE=1 SV=3 
720 31760 34 52,3 
4 GBB2_MOUSE 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-2 OS=Mus musculus GN=Gnb2 PE=1 
SV=3 
341 38048 13 27,4 
5 GBB1_MOUSE 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-1 OS=Mus musculus GN=Gnb1 PE=1 
SV=3 
335 38151 13 21,8 
6 CRYM_MOUSE 
Mu-crystallin homolog OS=Mus musculus GN=Crym 
PE=1 SV=1 
294 33673 9 22 
7 CRYL1_MOUSE 
Lambda-crystallin homolog OS=Mus musculus 
GN=Cryl1 PE=2 SV=3 
257 35585 14 33,5 
8 PP1B_MOUSE 
Serine/threonine-protein phosphatase PP1-beta 
catalytic subunit OS=Mus musculus GN=Ppp1cb 
PE=1 SV=3 
239 37961 11 23,2 
9 PP1A_MOUSE 
Serine/threonine-protein phosphatase PP1-alpha 
catalytic subunit OS=Mus musculus GN=Ppp1ca 
PE=1 SV=1 
224 38257 11 21,2 
10 ODPB_MOUSE 
Pyruvate dehydrogenase E1 component subunit 
beta  mitochondrial OS=Mus musculus GN=Pdhb 
PE=1 SV=1 
215 39254 7 20,3 
11 PP1G_MOUSE 
Serine/threonine-protein phosphatase PP1-gamma 
catalytic subunit OS=Mus musculus GN=Ppp1cc 
PE=1 SV=1 
207 37701 10 18,6 
12 KCD12_MOUSE 
BTB/POZ domain-containing protein KCTD12 
OS=Mus musculus GN=Kctd12 PE=1 SV=1 
197 36155 6 20,2 
13 G3P_MOUSE 
 lyceraldehyde-3-phosphate dehydrogenase 
OS=Mus musculus GN=Gapdh PE=1 SV=2 
177 36072 5 16,5 
14 PDXK_MOUSE 
Pyridoxal kinase OS=Mus musculus GN=Pdxk PE=1 
SV=1 
174 35278 9 25,6 
15 LDHA_MOUSE 
L-lactate dehydrogenase A chain OS=Mus musculus 
GN=Ldha PE=1 SV=3 
171 36817 4 8,7 
16 IDH3A_MOUSE 
Isocitrate dehydrogenase [NAD] subunit alpha 
mitochondrial OS=Mus musculus GN=Idh3a PE=1 
SV=1 
167 40069 8 17,5 
17 RLA0_MOUSE 
60S acidic ribosomal protein P0 OS=Mus musculus 
GN=Rplp0 PE=1 SV=3 
130 34366 6 15,1 
18 NRBF2_MOUSE 
Nuclear receptor-binding factor 2 OS=Mus 
musculus GN=Nrbf2 PE=1 SV=1 
125 32595 8 20,6 
19 MDHC_MOUSE 
Malate dehydrogenase  cytoplasmic OS=Mus 
musculus GN=Mdh1 PE=1 SV=3 
115 36659 5 11,4 
20 STX1B_MOUSE 
Syntaxin-1B OS=Mus musculus GN=Stx1b PE=1 
SV=1 
111 33452 6 19,1 
21 IPYR2_MOUSE 
Inorganic pyrophosphatase 2 mitochondrial 
OS=Mus musculus GN=Ppa2 PE=2 SV=1 
109 38546 4 10,3 
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22 PP2AA_MOUSE 
Serine/threonine-protein phosphatase 2A catalytic 
subunit alpha isoform OS=Mus musculus 
GN=Ppp2ca PE=1 SV=1 
97 36156 6 15,9 
23 TALDO_MOUSE 
Transaldolase OS=Mus musculus GN=Taldo1 PE=1 
SV=2 
81 37534 4 10,7 
24 VDAC2_MOUSE 
Voltage-dependent anion-selective channel protein 
2 OS=Mus musculus GN=Vdac2 PE=1 SV=2 
79 32340 4 12,9 
25 EIF3I_MOUSE 
Eukaryotic translation initiation factor 3 subunit I 
OS=Mus musculus GN=Eif3i PE=1 SV=1 
77 36837 4 13,8 
26 MDHM_MOUSE 
Malate dehydrogenase mitochondrial OS=Mus 
musculus GN=Mdh2 PE=1 SV=3 
61 36045 4 11,5 
27 ACTA_MOUSE Actin 58 42381 4 10,6 
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Table P-3: Spot 3: higher expression in R26R:Nex-Cre+ mice (R26R:Nex-Cre+ > R26R:Nex-Cre-) 
Protein 
Hit 
Number 
Protein 
Abbreviation 
Protein description 
Protein 
Score 
Protei
n Mass 
Protein 
Matches 
Protein 
Cover 
1 LDHB_MOUSE 
L-lactate dehydrogenase B chain OS=Mus musculus 
GN=Ldhb PE=1 SV=2 
6637 36834 320 50,6 
2 LDHA_MOUSE 
L-lactate dehydrogenase A chain OS=Mus musculus 
GN=Ldha PE=1 SV=3 
1093 36817 49 8,7 
3 GBB1_MOUSE 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-1 OS=Mus musculus GN=Gnb1 PE=1 
SV=3 
456 38151 16 30,6 
4 KCD12_MOUSE 
BTB/POZ domain-containing protein KCTD12 
OS=Mus musculus GN=Kctd12 PE=1 SV=1 
327 36155 9 34,9 
5 CRYM_MOUSE 
Mu-crystallin homolog OS=Mus musculus GN=Crym 
PE=1 SV=1 
325 33673 11 25,2 
6 G3P_MOUSE 
Glyceraldehyde-3-phosphate dehydrogenase 
OS=Mus musculus GN=Gapdh PE=1 SV=2 
320 36072 10 32,4 
7 ODPB_MOUSE 
Pyruvate dehydrogenase E1 component subunit 
beta, mitochondrial OS=Mus musculus GN=Pdhb 
PE=1 SV=1 
308 39254 10 28,7 
8 DDAH1_MOUSE 
N(G),N(G)-dimethylarginine 
dimethylaminohydrolase 1 OS=Mus musculus 
GN=Ddah1 PE=1 SV=3 
305 31760 14 37,9 
9 GBB2_MOUSE 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) 
subunit beta-2 OS=Mus musculus GN=Gnb2 PE=1 
SV=3 
295 38048 12 21,8 
10 TBB2A_MOUSE 
Tubulin beta-2A chain OS=Mus musculus 
GN=Tubb2a PE=1 SV=1 
283 50274 11 25,6 
11 PDXK_MOUSE 
Pyridoxal kinase OS=Mus musculus GN=Pdxk PE=1 
SV=1 
280 35278 10 31,1 
12 CAZA2_MOUSE 
F-actin-capping protein subunit alpha-2 OS=Mus 
musculus GN=Capza2 PE=1 SV=3 
276 33118 14 32,9 
13 PP1G_MOUSE 
Serine/threonine-protein phosphatase PP1-gamma 
catalytic subunit OS=Mus musculus GN=Ppp1cc 
PE=1 SV=1 
272 37701 12 23,5 
14 PP1B_MOUSE 
Serine/threonine-protein phosphatase PP1-beta 
catalytic subunit OS=Mus musculus GN=Ppp1cb 
PE=1 SV=3 
265 37961 12 23,9 
15 TBB2C_MOUSE 
Tubulin beta-2C chain OS=Mus musculus 
GN=Tubb2c PE=1 SV=1 
263 50255 10 24,3 
16 PP1A_MOUSE 
Serine/threonine-protein phosphatase PP1-alpha 
catalytic subunit OS=Mus musculus GN=Ppp1ca 
PE=1 SV=1 
258 38257 11 22,1 
17 TALDO_MOUSE 
Transaldolase OS=Mus musculus GN=Taldo1 PE=1 
SV=2 
223 37534 10 28,2 
18 TBB5_MOUSE 
Tubulin beta-5 chain OS=Mus musculus GN=Tubb5 
PE=1 SV=1 
219 50095 9 20,3 
19 CRYL1_MOUSE 
Lambda-crystallin homolog OS=Mus musculus 
GN=Cryl1 PE=2 SV=3 
198 35585 8 25,4 
20 PPP6_MOUSE 
Serine/threonine-protein phosphatase 6 catalytic 
subunit OS=Mus musculus GN=Ppp6c PE=2 SV=1 
187 35821 9 27,5 
21 MDHC_MOUSE 
Malate dehydrogenase, cytoplasmic OS=Mus 
musculus GN=Mdh1 PE=1 SV=3 
184 36659 11 24,9 
22 TBB3_MOUSE Tubulin beta-3 chain OS=Mus musculus GN=Tubb3 182 50842 8 20,2 
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PE=1 SV=1 
23 PP2AA_MOUSE 
Serine/threonine-protein phosphatase 2A catalytic 
subunit alpha isoform OS=Mus musculus 
GN=Ppp2ca PE=1 SV=1 
169 36156 6 20,7 
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